ID	Title	Ab class	Reference(s)	Feature type	Mab(s)	position	Env feature(s)	HXB2 AA	Entropy M	Entropy B	Entropy C	Experimental method(s)	Annotation
1	CD4 contacts		Wu2011, Zhou2010	Env feature		124	gp120	P	0.047	0.018	0.029	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		125	gp120	L	0.107	0.153	0.058	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		126	gp120, Cys 126 linked to Cys 196	C	0.018	0.028	0.008	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		127	gp120	V	0.093	0.112	0.093	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		196	gp120, Cys 126 linked to Cys 196, V2 loop end	C	0.043	0.034	0.038	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		198	gp120	T	0.458	0.264	0.469	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		279	gp120, Loop D	D	0.860	0.850	0.898	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		369	gp120, CD4 binding loop	P	1.021	0.591	0.470	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		374	gp120, CD4 binding loop	H	0.159	0.277	0.029	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		425	gp120, beta20/beta21	N	0.405	0.138	0.177	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		426	gp120, beta20/beta21	M	0.598	0.866	0.274	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		427	gp120, beta20/beta21	W	0.052	0.061	0.038	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		428	gp120, beta20/beta21	Q	0.052	0.053	0.054	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		429	gp120, beta20/beta21	K	1.406	0.961	1.308	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		430	gp120, beta20/beta21	V	0.397	0.080	0.073	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		431	gp120, beta20/beta21	G	0.072	0.036	0.039	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		432	gp120, beta20/beta21	K	1.137	0.339	0.564	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		457	gp120, beta23	D	0.059	0.054	0.043	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		458	gp120, beta23	G	0.097	0.045	0.095	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		472	gp120	G	0.034	0.012	0.043	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		473	gp120	G	0.031	0.033	0.029	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		474	gp120	D	0.719	0.681	0.752	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		475	gp120	M	0.281	0.092	0.106	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		476	gp120	R	0.699	0.615	0.711	X-ray crystallography	CD4 binding site
1	CD4 contacts		Wu2011, Zhou2010	Env feature		477	gp120	D	0.167	0.112	0.249	X-ray crystallography	CD4 binding site
2	CD4 independence, intrinsic reactivity		Haim2011	Env feature		66	gp120	H	0.019	0.017	0.000		H66N reduces spontaneous exposure of the Coreceptor binding site and reduced Env binding of C34-Ig (C34-Ig corresponds to HR2 and interacts with the HR1 coiled coil of the six-helix bundle). Did not impact CD4bs antibody or 2F5 sensitivity.
2	CD4 independence, intrinsic reactivity		Haim2011	Env feature		197	gp120	N	0.111	0.082	0.109		197N: Loss of glycosylation site caused Ada strain to become CD4 independent, and increased CCR5 binding to gp120 in the absence of CD4. Like changes in gp41 at 625, 626 and 674, the change increased the formation/exposure of the HR1 coiled coil on gp41, promoting the infection of CD4-negative cells expressing CCR5. Increases neutralization sensitivity to CD4i antibodies, but not to CD4bs antibody b12, which interacts in this region.
2	CD4 independence, intrinsic reactivity		Haim2011	Env feature		375	gp120	S	0.790	0.753	0.372		S375W increases spontaneous sampling of the CD4 bound conformation, and exposure of the Corecptor binding site, but does not effect the formation/exposure of the HR1 coiled coil, and did not impact the ability of HIV to infect CD4- cells. Did not impact CD4bs antibody or 2F5 sensitivity, but increases sensitivity to sCD4 and CD4i MAb 17b.
2	CD4 independence, intrinsic reactivity		Haim2011	Env feature		625	gp41	H	0.220	0.185	0.214		NM625/626HT and D674N (AD8 to HXB2 mutations) additively increase CD4-independent infection, and together explained most of the contribution of the HXBc2 ectodomain to this phenotype. These changes (and 197) increase the formation/exposure of the HR1 coiled coil on gp41, promoting the infection of CD4-negative cells expressing CCR5. Increases neutralization sensitivity to CD4i antibodies, and CD4bs antibody b12.
2	CD4 independence, intrinsic reactivity		Haim2011	Env feature		626	gp41	T	0.226	0.201	0.303		NM625/626HT and D674N (AD8 to HXB2 mutations) additively increase CD4-independent infection, and together explained most of the contribution of the HXBc2 ectodomain to this phenotype. These changes (and 197) increase the formation/exposure of the HR1 coiled coil on gp41, promoting the infection of CD4-negative cells expressing CCR5. Increases neutralization sensitivity to CD4i antibodies, and CD4bs antibody b12.
2	CD4 independence, intrinsic reactivity		Haim2011	Env feature		674	gp41	N	1.182	1.029	1.344		NM625/626HT and D674N (AD8 to HXB2 mutations) additively increase CD4-independent infection, and together explained most of the contribution of the HXBc2 ectodomain to this phenotype. Increases neutralization sensitivity to CD4i antibodies, and CD4bs antibody b12.
3	Mutations associated with RV144 vaccine efficacy		Rolland2012	Env feature		169	gp120, V2	V	1.974	1.770	1.344	sequence analysis	K169 (present in vaccine sequence) associated with uninfected status in preventive vaccine trial
3	Mutations associated with RV144 vaccine efficacy		Rolland2012	Env feature		181	gp120, V2	I	0.968	0.929	0.855	sequence analysis	I181 (not present in vaccine sequence) associated with uninfected status in preventive vaccine trial
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	308	gp120, V3 loop	R	0.108	0.091	0.127	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	309	gp120, V3 loop	I	0.921	0.359	0.965	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	312	gp120, V3 loop	G	0.189	0.362	0.008	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	313	gp120, V3 loop	P	0.307	0.424	0.078	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	314	gp120, V3 loop	G	0.053	0.095	0.014	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	315	gp120, V3 loop	R	1.120	1.028	0.196	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	316	gp120, V3 loop	A	1.151	0.736	0.966	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	317	gp120, V3 loop	F	0.758	1.090	0.223	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	318	gp120, V3 loop	V	0.574	0.691	0.507	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	319	gp120, V3 loop	T	0.995	0.913	0.339	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
5	PGT121 epitope defined by competition with 10-188	V3-glycan	Mouquet2012a	binding	PGT121	320	gp120, V3 loop	I	0.720	0.564	0.782	ELISA	binding of PGT121 is competed by binding of 10-188 (epitope NIGPGGRALYTT spanning 308-320)
6	PGT121-123, 125-128, 130, 131 sites important for neutralization	V3-glycan	Walker2011	neutralization	PGT121, PGT122, PGT123, PGT125, PGT126, PGT127, PGT128, PGT130, PGT131	301	gp120, V3 loop	N	0.261	0.176	0.104		N-linked glycans in positions 332 and/or 301 were important for neutralization by PGT MAbs 125-128, 130, and 131.
6	PGT121-123, 125-128, 130, 131 sites important for neutralization	V3-glycan	Walker2011	neutralization	PGT121, PGT122, PGT123, PGT125, PGT126, PGT127, PGT128, PGT130, PGT131	332	gp120	N	0.904	0.491	0.693		N-linked glycans in positions 332 and/or 301 were important for neutralization by PGT MAbs 125-128, 130, and 131; glycan 332 is also critcal for PGT 121-123.
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	301	gp120, V3 loop	N	0.261	0.176	0.104		PGT128 contacts are in V3 at high mannose glycans at 301 and 332, with 301 being a secondary contact.
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	303	gp120, V3 loop	T	0.297	0.190	0.202		PGT128 contact
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	304	gp120, V3 loop	R	0.287	0.390	0.141		PGT128 contact
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	323	gp120, V3 loop	I	0.575	0.531	0.263		PGT128: V3 loop beta strand contacts
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	324	gp120, V3 loop	G	0.088	0.056	0.092		PGT128: V3 loop beta strand contacts
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	325	gp120, V3 loop	N	0.653	0.622	0.622		PGT128: V3 loop beta strand contacts
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	326	gp120, V3 loop	M	0.188	0.143	0.116		PGT128 contact
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	327	gp120, V3 loop	R	0.118	0.066	0.073		PGT128 contact
7	PGT127, PGT128 contacts	V3-glycan	Moore2012, Pejchal2011	contacts	PGT127, PGT128	332	gp120	N	0.904	0.491	0.693		PGT128 contacts are in V3 at high mannose glycans at 301 and 332, with 332 being the primary contact. Also, Moore2012: under-represented in transmitted C's, confers PGT128 sensitivity. Antibodies in early infection initially targeted virus with no glycan at 332, the glycosylation site shifted to 332 to escape the early response, and new antibodies arose that targeted the new mannose epitope.
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	97	gp120	K	0.433	0.421	0.511		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	123	gp120	T	0.033	0.028	0.038		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	128	gp120	S	0.188	0.339	0.088		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	129	gp120	L	0.048	0.056	0.029		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	276	gp120, Loop D	N	0.120	0.063	0.169		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	278	gp120, Loop D	T	0.657	0.715	0.481		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	279	gp120, Loop D	D	0.860	0.850	0.898		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	280	gp120, Loop D	N	0.117	0.090	0.170		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	281	gp120, Loop D	A	1.081	0.814	1.357		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	282	gp120, Loop D	K	0.260	0.337	0.297		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	283	gp120, Loop D	T	0.992	1.091	0.474		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	427	gp120, beta20/beta21	W	0.052	0.061	0.038		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	428	gp120, beta20/beta21	Q	0.052	0.053	0.054		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	429	gp120, beta20/beta21	K	1.406	0.961	1.308		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	430	gp120, beta20/beta21	V	0.397	0.080	0.073		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	455	gp120, beta23	T	0.670	0.426	0.972		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	456	gp120, beta23	R	0.196	0.079	0.323		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	457	gp120, beta23	D	0.059	0.054	0.043		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	458	gp120, beta23	G	0.097	0.045	0.095		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	464	gp120, V5-hypervariable, V5 loop	E	2.371	2.269	2.299		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	472	gp120	G	0.034	0.012	0.043		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	473	gp120	G	0.031	0.033	0.029		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	474	gp120	D	0.719	0.681	0.752		VRC01 contact
8	VRC01 contacts	CD4BS	Wu2011, Zhou2010	contacts	VRC01	476	gp120	R	0.699	0.615	0.711		VRC01 contact
9	3BNC60 contacts	CD4BS	Scheid2011	contacts	3BNC60	278	gp120, Loop D	T	0.657	0.715	0.481		3BNC60 contact
9	3BNC60 contacts	CD4BS	Scheid2011	contacts	3BNC60	280	gp120, Loop D	N	0.117	0.090	0.170		3BNC60 contact
9	3BNC60 contacts	CD4BS	Scheid2011	contacts	3BNC60	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		3BNC60 salt bridge
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	97	gp120	K	0.433	0.421	0.511		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	123	gp120	T	0.033	0.028	0.038		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	124	gp120	P	0.047	0.018	0.029		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	198	gp120	T	0.458	0.264	0.469		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	199	gp120	S	0.086	0.108	0.068		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	257	gp120	T	0.024	0.024	0.015		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	276	gp120, Loop D	N	0.120	0.063	0.169		VRC03 light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	278	gp120, Loop D	T	0.657	0.715	0.481		VRC03 light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	279	gp120, Loop D	D	0.860	0.850	0.898		VRC03 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	280	gp120, Loop D	N	0.117	0.090	0.170		VRC03 heavy chain interaction and light chain interaction (hydrogen bonding); calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	281	gp120, Loop D	A	1.081	0.814	1.357		VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	282	gp120, Loop D	K	0.260	0.337	0.297		VRC03 heavy chain interaction, salt bridge; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	283	gp120, Loop D	T	0.992	1.091	0.474		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		VRC03 heavy chain interaction, hydrogen bonding and salt bridge; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	370	gp120, CD4 binding loop	E	0.035	0.017	0.055		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	375	gp120	S	0.790	0.753	0.372		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	425	gp120, beta20/beta21	N	0.405	0.138	0.177		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	426	gp120, beta20/beta21	M	0.598	0.866	0.274		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	427	gp120, beta20/beta21	W	0.052	0.061	0.038		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	429	gp120, beta20/beta21	K	1.406	0.961	1.308		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	430	gp120, beta20/beta21	V	0.397	0.080	0.073		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	431	gp120, beta20/beta21	G	0.072	0.036	0.039		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	455	gp120, beta23	T	0.670	0.426	0.972		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	456	gp120, beta23	R	0.196	0.079	0.323		VRC03 heavy chain and light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	457	gp120, beta23	D	0.059	0.054	0.043		VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	458	gp120, beta23	G	0.097	0.045	0.095		VRC03 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		VRC03 heavy chain interaction and light chain interaction (hydrogen bonding); calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		VRC03 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		VRC03 heavy chain and light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		VRC03 heavy chain and light chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		VRC03 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	472	gp120	G	0.034	0.012	0.043		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	473	gp120	G	0.031	0.033	0.029		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	474	gp120	D	0.719	0.681	0.752		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	475	gp120	M	0.281	0.092	0.106		VRC03 heavy chain interaction; calculated on the EBI PISA server
10	VRC03 contacts	CD4BS	Wu2011	contacts	VRC03	776	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction	L	0.265	0.197	0.214		VRC03 light chain interaction; calculated on the EBI PISA server
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	97	gp120	K	0.433	0.421	0.511		Env 97K interacts with NIH45-46 heavy chain 99cD, distance 3.95
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	98	gp120	N	0.034	0.045	0.022		Env 98N interacts with NIH45-46 heavy chain 99bR, distance 3.98
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	99	gp120	D	1.169	0.830	0.366		Env 99D interacts with NIH45-46 heavy chain 99bR, distance 2.74
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	102	gp120	E	0.792	0.522	0.426		Env 102E interacts with NIH45-46 heavy chain 99bR, distance 3.42
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	122	gp120	L	0.120	0.101	0.121		Env 122L interacts with NIH45-46 heavy chain 74Y, distance 3.11
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	123	gp120	T	0.033	0.028	0.038		Env 123T interacts with NIH45-46 heavy chain 74Y, distance 3.9
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	124	gp120	P	0.047	0.018	0.029		Env 124G interacts with NIH45-46 heavy chain 74Y, distance 3.41
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	276	gp120, Loop D	N	0.120	0.063	0.169		Env 276N interacts with NIH45-46 light chain 89Y, distance 3.5 ; NIH45-46, VRC01 light chains interact with carbohydrate
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	278	gp120, Loop D	T	0.657	0.715	0.481		Env 278T interacts with NIH45-46 light chain 89Y, distance 3.47
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	279	gp120, Loop D	D	0.860	0.850	0.898		Env 279N interacts with NIH45-46 heavy chain 100Y 3.72 ; interacts with NIH45-46 heavy chain 102W, distance 2.83 ; interacts with NIH45-46 light chain 89Y, distance 3.63 ; NIH45-46G54W, D279A or D279K may confer resistance
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	280	gp120, Loop D	N	0.117	0.090	0.170		Env 280N interacts with NIH45-46 heavy chain 102W, distance 3.34 ; interacts with NIH45-46 heavy chain 47W, distance 3.97 ; interacts with NIH45-46 heavy chain 50W, distance 2.71 ; interacts with NIH45-46 heavy chain 58N, distance 3.75 ; interacts with NIH45-46 light chain 90E, distance 3.12 ; NIH45-46G54W, N280S may confer resistance
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	281	gp120, Loop D	A	1.081	0.814	1.357		Env 281A interacts with NIH45-46 heavy chain 50W, distance 3.8 ; interacts with NIH45-46 heavy chain 52K, distance 3.74; interacts with NIH45-46 heavy chain 99dY, distance 2.9
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	282	gp120, Loop D	K	0.260	0.337	0.297		Env 282K interacts with NIH45-46 heavy chain 99dY, distance 3.04 ; NIH45-46G54W, K282Y may confer resistance, but this change is tolerated by VRC01
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		Env 365S interacts with NIH45-46 heavy chain 57V, distance 3.76 ; interacts with NIH45-46 heavy chain 59Y, distance 3.83 ; water median H bond network, also VRC03
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		Env 366G interacts with NIH45-46 heavy chain 57V, distance 3.67 ; water median H bond network, also VRC03, CD4 has a direct contact
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		Env 367G interacts with NIH45-46 heavy chain 54G, distance 3.72 ; interacts with NIH45-46 heavy chain 55G, distance 3.19
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		Env 368D interacts with NIH45-46 heavy chain 54G, distance 2.8 ; interacts with NIH45-46 heavy chain 71R, distance 2.79 ; main chain H bond, also for CD4 and VRC03
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		Env 371I interacts with NIH45-46 heavy chain 53R, distance 3.83 ; interacts with NIH45-46 heavy chain 54G, distance 3.24 ; interacts with NIH45-46 heavy chain 55G, distance 3.94 ; interacts with NIH45-46 heavy chain 56A, distance 3.49
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	427	gp120, beta20/beta21	W	0.052	0.061	0.038		Env 427W interacts with NIH45-46 heavy chain 53R, distance 3.9
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	430	gp120, beta20/beta21	V	0.397	0.080	0.073		Env 430T interacts with NIH45-46 heavy chain 30L, distance 3.9 ; interacts with NIH45-46 heavy chain 74Y, distance 3.7
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	431	gp120, beta20/beta21	G	0.072	0.036	0.039		Env 431G interacts with NIH45-46 heavy chain 74Y, distance 3.2
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	432	gp120, beta20/beta21	K	1.137	0.339	0.564		Env 432Q interacts with NIH45-46 heavy chain 74Y, distance 3.79
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	455	gp120, beta23	T	0.670	0.426	0.972		Env 455T interacts with NIH45-46 heavy chain 58N, distance 3.53
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	456	gp120, beta23	R	0.196	0.079	0.323		Env 456R interacts with NIH45-46 heavy chain 58N, distance 2.77 ; NIH45-46G54W, R456S or R456W may confer resistance
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	457	gp120, beta23	D	0.059	0.054	0.043		Env 457D interacts with NIH45-46 heavy chain 58N, distance 3.86; interacts with NIH45-46 heavy chain 64Q, distance 2.61
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	458	gp120, beta23	G	0.097	0.045	0.095		Env 458G interacts with NIH45-46 heavy chain 47W, distance 3.79 ; interacts with NIH45-46 heavy chain 58N, distance 3.15 ; interacts with NIH45-46 heavy chain 59Y, distance 3.6 ; interacts with NIH45-46 heavy chain 60A, distance 3.12 ; interacts with NIH45-46 heavy chain 61R, distance 3.49 ; NIH45-46G54W, G458 to other amino acids may confer resistance
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		Env 459G interacts with NIH45-46 light chain 90E, distance 3.13 ; NIH45-46G54W, G459 to other amino acids may confer resistance
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		Env 460A interacts with NIH45-46 heavy chain 61R, distance 3.67
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		Env 461N interacts with NIH45-46 light chain 3V, distance 3.41
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		Env 465N interacts with NIH45-46 heavy chain 61R, distance 3.12
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239		Env 466E interacts with NIH45-46 heavy chain 61R, distance 3.55
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870		Env 467T interacts with NIH45-46 heavy chain 61R, distance 3.05
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		Env 469R interacts with NIH45-46 heavy chain 64Q, distance 3.33
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	474	gp120	D	0.719	0.681	0.752		Env 474N interacts with NIH45-46 heavy chain 53R, distance 3.41
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	476	gp120	R	0.699	0.615	0.711		Env 476K interacts with NIH45-46 heavy chain 99aA, distance 3.8
11	NIH45-46 contacts	CD4BS	Diskin2011	contacts	NIH45-46	480	gp120	R	0.050	0.047	0.049		Env 480R interacts with NIH45-46 heavy chain 99bR, distance 3.82
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	199	gp120	S	0.086	0.108	0.068	neutralization assay	S199A enhances PGV04, VRC01, CD4-IgG, and b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	262	gp120	N	0.029	0.029	0.028	neutralization assay	The N276 glycan forms contacts with VRC01, but VRC01 increases potency when it is absent, suggesting VRC01 has evolved to avoid obstruction by the N276 glycan.
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	276	gp120, Loop D	N	0.120	0.063	0.169	neutralization assay	N276A reduces PGV04 neutralization, enhances VRC01, no impact on CD4-IgG or b12
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	279	gp120, Loop D	D	0.860	0.850	0.898	neutralization assay	D279A reduces PGV04, VRC01, CD4-IgG neutralization, no impact on b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	307	gp120, V3 loop	I	0.067	0.030	0.111	neutralization assay	I307A reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	309	gp120, V3 loop	I	0.921	0.359	0.965	neutralization assay	I309A reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	317	gp120, V3 loop	F	0.758	1.090	0.223	neutralization assay	F317A reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	318	gp120, V3 loop	V	0.574	0.691	0.507	neutralization assay	Y318A reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	420	gp120	I	0.068	0.049	0.078	neutralization assay	I420A reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423A reduces PGV04 and VRC01 neutralization, enhances CD4-IgG and b12 neutralization
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	neutralization assay	N461A enhances PGV04 and VRC01 neutralization, no impact on CD4-IgG and b12
12	Mutation affects PGV04, b12, VRC01, CD4-IgG neutralization	CD4BS	Falkowska2012	neutralization	b12, VRC01, VRC-PG04	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	neutralization assay	S463A enhances PGV04 and VRC01 neutralization, no impact on CD4-IgG and b12
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	256	gp120	S	0.095	0.070	0.078		CH103: H bond
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	279	gp120, Loop D	D	0.860	0.850	0.898		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	280	gp120, Loop D	N	0.117	0.090	0.170		CH103: H bond
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	364	gp120, CD4 binding loop	S	0.982	0.588	1.191		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		CH103: H bond
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		CH103: H bond
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		CH103: H bond/salt bridge
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	369	gp120, CD4 binding loop	P	1.021	0.591	0.470		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	370	gp120, CD4 binding loop	E	0.035	0.017	0.055		CH103: H bond/salt bridge
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	455	gp120, beta23	T	0.670	0.426	0.972		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	457	gp120, beta23	D	0.059	0.054	0.043		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	458	gp120, beta23	G	0.097	0.045	0.095		CH103: H bond
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		CH103: H bond/salt bridge
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	471	gp120, beta24	G	0.879	0.888	0.866		CH103 contact
13	CH103 contacts	CD4BS	Liao2013	contacts	CH103	472	gp120	G	0.034	0.012	0.043		CH103 contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	256	gp120	S	0.095	0.070	0.078	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	257	gp120	T	0.024	0.024	0.015	X-ray crystallography	b12 main chain contact and side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	X-ray crystallography	b12 side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	X-ray crystallography	b12 main chain contact and side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	X-ray crystallography	b12 main chain contact and side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	X-ray crystallography	b12 side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	373	gp120, CD4 binding loop	T	0.953	0.872	0.371	X-ray crystallography	b12 side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	384	gp120	Y	0.075	0.124	0.023	X-ray crystallography	b12 main chain contact and side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	417	gp120, V4 loop	P	0.836	0.736	0.922	X-ray crystallography	b12 main chain contact and side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	418	gp120, Cys 385 linked to Cys 418	C	0.052	0.038	0.059	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	419	gp120	R	0.516	0.341	0.500	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	430	gp120, beta20/beta21	V	0.397	0.080	0.073	X-ray crystallography	b12 main chain contact and side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	431	gp120, beta20/beta21	G	0.072	0.036	0.039	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	432	gp120, beta20/beta21	K	1.137	0.339	0.564	X-ray crystallography	b12 side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	453	gp120, beta23	L	0.494	0.517	0.199	X-ray crystallography	b12 side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	b12 side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	457	gp120, beta23	D	0.059	0.054	0.043	X-ray crystallography	b12 main chain contact and side chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	458	gp120, beta23	G	0.097	0.045	0.095	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	470	gp120, beta24	P	0.043	0.039	0.037	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	472	gp120	G	0.034	0.012	0.043	X-ray crystallography	b12 main chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	473	gp120	G	0.031	0.033	0.029	X-ray crystallography	b12 main chain contact
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	474	gp120	D	0.719	0.681	0.752	X-ray crystallography	b12 main chain contact and side chain contact; H bond
14	b12 contacts	CD4BS	Zhou2007	contacts	b12	475	gp120	M	0.281	0.092	0.106	X-ray crystallography	b12 main chain contact and side chain contact
15	17b contacts	CD4i	Kwong1998	contacts	17b	419	gp120	R	0.516	0.341	0.500		17b contact
15	17b contacts	CD4i	Kwong1998	contacts	17b	421	gp120, beta20/beta21	K	0.312	0.374	0.203		17b contact
15	17b contacts	CD4i	Kwong1998	contacts	17b	422	gp120, beta20/beta21	Q	0.054	0.046	0.031		17b contact
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	156	gp120, V1	N	0.217	0.220	0.224		PG9 glycan contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	160	gp120, V2	N	0.401	0.452	0.358		PG9 glycan contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	165	gp120, V2	I	1.321	1.292	1.011		PG9 contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	167	gp120, V2	G	0.601	1.122	0.185		PG9 contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	168	gp120, V2	K	0.547	0.666	0.396		PG9 contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	169	gp120, V2	V	1.974	1.770	1.344		PG9 contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	170	gp120, V2	Q	1.458	1.423	1.428		PG9 contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	171	gp120, V2	K	1.239	0.957	1.413		PG9 contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
16	PG9-like contacts	V2-apex	McLellan2011	contacts	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	173	gp120, V2	Y	1.165	0.808	1.158		PG9 contact; PG9-like class includes PG16, PGT141, 145, CH01-CH04
17	Mutation affects PG9-like Ab sensitivity	V2-apex	Doria-RoseNA2012, Wang2018a	neutralization	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	Loss of glycan confers resistance to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 (Doria-Rose2012). Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16 (Wang2018a).
17	Mutation affects PG9-like Ab sensitivity	V2-apex	Doria-RoseNA2012, Wang2018a	neutralization	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 (Doria-Rose2012). Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16 (Wang2018a).
17	Mutation affects PG9-like Ab sensitivity	V2-apex	Doria-RoseNA2012, Wang2018a	neutralization	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	171	gp120, V2	K	1.239	0.957	1.413	neutralization assay	169/171 neg charge (E) resistant, pos charge (K) sensitive; PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 (Doria-Rose2012). Mutations at position 160, 169, 171 were associated with resistance to PG9 and PG16 (Wang2018a).
17	Mutation affects PG9-like Ab sensitivity	V2-apex	Doria-RoseNA2012, Wang2018a	neutralization	CH01, CH02, CH03, CH04, PG16, PG9, PGT141, PGT145	173	gp120, V2	Y	1.165	0.808	1.158	neutralization assay	Y increases sensitivity to PG9-like class, which includes PG16, PGT141, 145, CH01-CH04 (Doria-Rose2012).
18	10E8 contacts	MPER	Huang2012a	contacts	10E8	671	gp41	N	0.779	0.669	0.885		10E8 N671 structure and neutralization: key epitope position.
18	10E8 contacts	MPER	Huang2012a	contacts	10E8	672	gp41	W	0.017	0.023	0.014		10E8 W672 structure and neutralization: key epitope position.
18	10E8 contacts	MPER	Huang2012a	contacts	10E8	673	gp41	F	0.058	0.065	0.073		10E8 F673 structure and neutralization: key epitope position.
18	10E8 contacts	MPER	Huang2012a	contacts	10E8	676	gp41	T	0.683	0.610	0.674		10E8 T676 structure and binding: key epitope position.
18	10E8 contacts	MPER	Huang2012a	contacts	10E8	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081		10E8 W680 structure and neutralization: key epitope position.
18	10E8 contacts	MPER	Huang2012a	contacts	10E8	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569		10E8 K/R683 structure: key epitope position.
19	2F5 contacts	MPER	Ofek2004	contacts	2F5	662	gp41	E	1.024	0.874	0.369		2F5 contact site
19	2F5 contacts	MPER	Ofek2004	contacts	2F5	663	gp41	L	0.094	0.094	0.053		2F5 contact site
19	2F5 contacts	MPER	Ofek2004	contacts	2F5	664	gp41	D	0.197	0.156	0.346		2F5 contact site
19	2F5 contacts	MPER	Ofek2004	contacts	2F5	665	gp41	K	0.986	0.656	0.879		2F5 contact site
19	2F5 contacts	MPER	Ofek2004	contacts	2F5	666	gp41	W	0.003	0.000	0.000		2F5 contact site
19	2F5 contacts	MPER	Ofek2004	contacts	2F5	667	gp41	A	1.332	0.545	1.537		2F5 contact site
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	671	gp41	N	0.779	0.669	0.885		4E10 core epitope residue (Brunel2006); 4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	672	gp41	W	0.017	0.023	0.014		4E10 core epitope residue (Brunel2006); 4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	673	gp41	F	0.058	0.065	0.073		4E10 core epitope residue (Brunel2006); 4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	674	gp41	N	1.182	1.029	1.344		4E10 core epitope residue (Brunel2006)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	675	gp41	I	0.050	0.059	0.069		44E10 core epitope residue (Brunel2006); 4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	676	gp41	T	0.683	0.610	0.674		4E10 core epitope residue (Brunel2006); 4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	677	gp41	N	1.187	1.199	1.100		4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008		4E10 core epitope residue (Brunel2006); 4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081		4E10 core epitope residue (Brunel2006); 4E10 contact (Zhang2019a)
20	4E10 contacts	MPER	Brunel2006, Zhang2019a	contacts	4E10	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036		4E10 contact (Zhang2019a)
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	668	gp41	S	0.842	0.596	0.758		Z13e1 contact site
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	669	gp41	L	0.020	0.023	0.000		Z13e1 contact site
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	670	gp41	W	0.026	0.028	0.035		Z13e1 contact site
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	671	gp41	N	0.779	0.669	0.885		Z13e1 contact site; crucial binding residue
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	672	gp41	W	0.017	0.023	0.014		Z13e1 contact site
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	673	gp41	F	0.058	0.065	0.073		Z13e1 contact site
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	674	gp41	N	1.182	1.029	1.344		Z13e1 contact site; crucial binding residue
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	675	gp41	I	0.050	0.059	0.069		Z13e1 contact site
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	676	gp41	T	0.683	0.610	0.674		Z13e1 contact site
21	Z13e1 contacts	MPER	Nelson2007	contacts	Z13, Z13e1	677	gp41	N	1.187	1.199	1.100		Z13e1 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	332	gp120	N	0.904	0.491	0.693		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	334	gp120	S	0.780	0.501	0.890		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	388	gp120, V4 loop	T	0.864	0.778	0.701		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	392	gp120, V4 loop	N	0.561	0.454	0.804		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	394	gp120, V4 loop	T	1.078	0.715	1.439		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	448	gp120	N	0.648	0.448	0.927		2G12 contact site
22	2G12 contacts	glycan	Trkola1996	contacts	2G12	450	gp120	T	0.023	0.018	0.022		2G12 contact site
26	VRC03 signature predictions	CD4BS	West2013	signature	VRC03	19	Signal peptide	T	1.319	1.111	0.600	computational prediction	VRC03: V19 is associated with increased susceptibility to neutralization; intermediate quality of support.
26	VRC03 signature predictions	CD4BS	West2013	signature	VRC03	106	gp120	E	0.705	0.218	0.326	computational prediction	VRC03: T106 is associated with increased susceptibility to neutralization; intermediate quality of support.
27	10E8 signature predictions	MPER	West2013	signature	10E8	231	gp120	K	0.797	0.578	0.780	computational prediction	10E8: E231 is associated with increased resistance to neutralization; intermediate quality of support.
27	10E8 signature predictions	MPER	West2013	signature	10E8	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	10E8: glycosylation at N301 is associated with increased resistance to neutralization; intermediate quality of support.
27	10E8 signature predictions	MPER	West2013	signature	10E8	693	gp41, gp41 transmembrane, Gly-xxx-Gly motif (GGLVG) important for self-association of transmembrane domain	V	0.480	0.700	0.067	computational prediction	10E8: V693 is associated with increased susceptibility to neutralization; intermediate quality of support.
28	4E10 signature predictions	MPER	West2013	signature	4E10	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	computational prediction	4E10: K683 is associated with increased susceptibility to neutralization; high quality of support.
30	12A12 signature predictions	CD4BS	West2013	signature	12A12	155	gp120, V1	K	0.854	0.423	0.831	computational prediction	12A12: Q155 is associated with increased resistance to neutralization; intermediate quality of support.
30	12A12 signature predictions	CD4BS	West2013	signature	12A12	238	gp120	P	0.830	1.065	0.131	computational prediction	12A12: P238 is associated with increased resistance to neutralization; intermediate quality of support.
30	12A12 signature predictions	CD4BS	West2013	signature	12A12	357	gp120	K	1.086	0.868	0.941	computational prediction	12A12: K357 is associated with increased susceptibility to neutralization; high quality of support.
30	12A12 signature predictions	CD4BS	West2013	signature	12A12	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	12A12: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
30	12A12 signature predictions	CD4BS	West2013	signature	12A12	719	gp41, gp41 cytoplasmic tail	T	0.258	0.187	0.085	computational prediction	12A12: I719 is associated with increased susceptibility to neutralization; intermediate quality of support.
31	10-1074 signature predictions	V3-glycan	West2013	signature	10-1074	240	gp120	T	1.789	1.338	1.717	computational prediction	10-1074: S240 is associated with increased resistance to neutralization; marginal quality of support.
31	10-1074 signature predictions	V3-glycan	West2013	signature	10-1074	332	gp120	N	0.904	0.491	0.693	computational prediction	10-1074: glycosylation at N332 is associated with increased susceptibility to neutralization; high quality of support.
31	10-1074 signature predictions	V3-glycan	West2013	signature	10-1074	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	computational prediction	10-1074: I369 is associated with increased resistance to neutralization; marginal quality of support.
31	10-1074 signature predictions	V3-glycan	West2013	signature	10-1074	843	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	I	0.506	0.250	0.859	computational prediction	10-1074: V843 is associated with increased resistance to neutralization; marginal quality of support.
32	2F5 signature predictions	MPER	West2013	signature	2F5	350	gp120	R	1.744	1.273	1.912	computational prediction	2F5: R350 is associated with increased resistance to neutralization; high quality of support.
32	2F5 signature predictions	MPER	West2013	signature	2F5	518	gp41, fusion peptide	L	1.201	1.110	0.718	computational prediction	2F5: M518 is associated with increased susceptibility to neutralization; intermediate quality of support.
32	2F5 signature predictions	MPER	West2013	signature	2F5	640	gp41	S	2.068	1.971	1.834	computational prediction	2F5: S640 is associated with increased susceptibility to neutralization; intermediate quality of support.
32	2F5 signature predictions	MPER	West2013	signature	2F5	665	gp41	K	0.986	0.656	0.879	computational prediction	2F5: K665 is associated with increased susceptibility to neutralization; high quality of support.
32	2F5 signature predictions	MPER	West2013	signature	2F5	667	gp41	A	1.332	0.545	1.537	computational prediction	2F5: A667 is associated with increased susceptibility to neutralization; high quality of support.
33	2G12 signature predictions	glycan	West2013	signature	2G12	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	2G12: glycosylation at N295 is associated with increased susceptibility to neutralization; intermediate quality of support.
33	2G12 signature predictions	glycan	West2013	signature	2G12	332	gp120	N	0.904	0.491	0.693	computational prediction	2G12: glycosylation at N332 is associated with increased susceptibility to neutralization; intermediate quality of support.
33	2G12 signature predictions	glycan	West2013	signature	2G12	339	gp120	N	1.157	1.082	1.026	computational prediction	2G12: glycosylation at N339 is associated with increased susceptibility to neutralization; intermediate quality of support.
34	3BNC117 signature predictions	CD4BS	West2013	signature	3BNC117	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	3BNC117: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
34	3BNC117 signature predictions	CD4BS	West2013	signature	3BNC117	471	gp120, beta24	G	0.879	0.888	0.866	computational prediction	3BNC117: E471 is associated with increased resistance to neutralization; marginal quality of support.
35	3BNC55 signature predictions	CD4BS	West2013	signature	3BNC55	92	gp120	N	1.062	1.058	0.458	computational prediction	3BNC55: E92 is associated with increased susceptibility to neutralization; intermediate quality of support.
35	3BNC55 signature predictions	CD4BS	West2013	signature	3BNC55	279	gp120, Loop D	D	0.860	0.850	0.898	computational prediction	3BNC55: D279 is associated with increased susceptibility to neutralization; high quality of support.
36	8ANC195 signature predictions	gp120/gp41 interface	West2013	signature	8ANC195	230	gp120	N	0.954	0.896	0.544	computational prediction	8ANC195: glycosylation at N230 is associated with increased resistance to neutralization; high quality of support.
36	8ANC195 signature predictions	gp120/gp41 interface	West2013	signature	8ANC195	234	gp120	N	0.584	0.757	0.341	computational prediction	8ANC195: glycosylation at N234 is associated with increased susceptibility to neutralization; high quality of support.
36	8ANC195 signature predictions	gp120/gp41 interface	West2013	signature	8ANC195	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	8ANC195: glycosylation at T276 is associated with increased susceptibility to neutralization; intermediate quality of support.
37	b12 signature predictions	CD4BS	West2013	signature	b12	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	computational prediction	IGg1b12: D185 is associated with increased susceptibility to neutralization; intermediate quality of support.
37	b12 signature predictions	CD4BS	West2013	signature	b12	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	computational prediction	IGg1b12: S364 is associated with increased susceptibility to neutralization; intermediate quality of support.
37	b12 signature predictions	CD4BS	West2013	signature	b12	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	computational prediction	IGg1b12: L369 is associated with increased resistance to neutralization; intermediate quality of support.
37	b12 signature predictions	CD4BS	West2013	signature	b12	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	computational prediction	IGg1b12: glycosylation at N386 is associated with increased resistance to neutralization; intermediate quality of support.
38	NIH45-46 signature predictions	CD4BS	West2013	signature	NIH45-46	234	gp120	N	0.584	0.757	0.341	computational prediction	NIH45-46: glycosylation at N234 is associated with increased resistance to neutralization; high quality of support.
38	NIH45-46 signature predictions	CD4BS	West2013	signature	NIH45-46	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	NIH45-46: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
39	NIH45-46(G54W) signature predictions	CD4BS	West2013	signature	NIH45-46G54W	456	gp120, beta23	R	0.196	0.079	0.323	computational prediction	NIH45-46(G54W): R456 is associated with increased susceptibility to neutralization; intermediate quality of support.
39	NIH45-46(G54W) signature predictions	CD4BS	West2013	signature	NIH45-46G54W	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	NIH45-46(G54W): G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
39	NIH45-46(G54W) signature predictions	CD4BS	West2013	signature	NIH45-46G54W	651	gp41	N	1.168	0.818	1.387	computational prediction	NIH45-46(G54W): S651 is associated with increased susceptibility to neutralization; marginal quality of support.
40	PG16 signature predictions	V2-apex	West2013	signature	PG16	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	PG16: glycosylation at N160 is associated with increased susceptibility to neutralization; intermediate quality of support.
40	PG16 signature predictions	V2-apex	West2013	signature	PG16	171	gp120, V2	K	1.239	0.957	1.413	computational prediction	PG16: K171 is associated with increased susceptibility to neutralization; high quality of support.
41	PG9 signature predictions	V2-apex	West2013	signature	PG9	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	PG9: N160 is associated with increased susceptibility to neutralization; intermediate quality of support.
41	PG9 signature predictions	V2-apex	West2013	signature	PG9	171	gp120, V2	K	1.239	0.957	1.413	computational prediction	PG9: K171 is associated with increased susceptibility to neutralization; high quality of support.
41	PG9 signature predictions	V2-apex	West2013	signature	PG9	732	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.890	0.262	0.816	computational prediction	PG9: G732 is associated with increased resistance to neutralization; high quality of support.
42	PGT121 signature predictions	V3-glycan	West2013	signature	PGT121	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	PGT121: M184 is associated with increased resistance to neutralization; marginal quality of support.
42	PGT121 signature predictions	V3-glycan	West2013	signature	PGT121	332	gp120	N	0.904	0.491	0.693	computational prediction	PGT121: glycosylation at N332 is associated with increased susceptibility to neutralization; high quality of support.
42	PGT121 signature predictions	V3-glycan	West2013	signature	PGT121	442	gp120	Q	2.193	1.699	0.964	computational prediction	PGT121: E442 is associated with increased resistance to neutralization; marginal quality of support.
42	PGT121 signature predictions	V3-glycan	West2013	signature	PGT121	702	gp41, gp41 cytoplasmic tail	L	0.416	0.497	0.316	computational prediction	PGT121: L702 is associated with increased susceptibility to neutralization; intermediate quality of support.
42	PGT121 signature predictions	V3-glycan	West2013	signature	PGT121	843	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	I	0.506	0.250	0.859	computational prediction	PGT121: V843 is associated with increased resistance to neutralization; intermediate quality of support.
43	sCD4 signature predictions		West2013	signature		364	gp120, CD4 binding loop	S	0.982	0.588	1.191	computational prediction	sCD4: P364 is associated with increased resistance to neutralization; intermediate quality of support.
44	VRC01 signature predictions	CD4BS	West2013	signature	VRC01	106	gp120	E	0.705	0.218	0.326	computational prediction	VRC01: T106 is associated with increased susceptibility to neutralization; intermediate quality of support.
44	VRC01 signature predictions	CD4BS	West2013	signature	VRC01	234	gp120	N	0.584	0.757	0.341	computational prediction	VRC01: glycosylation at N234 is associated with increased resistance to neutralization; high quality of support.
44	VRC01 signature predictions	CD4BS	West2013	signature	VRC01	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	computational prediction	VRC01: H364 is associated with increased resistance to neutralization; intermediate quality of support.
44	VRC01 signature predictions	CD4BS	West2013	signature	VRC01	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	VRC01: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
45	VRC02 signature predictions	CD4BS	West2013	signature	VRC02	106	gp120	E	0.705	0.218	0.326	computational prediction	VRC02: T106 is associated with increased susceptibility to neutralization; intermediate quality of support.
45	VRC02 signature predictions	CD4BS	West2013	signature	VRC02	403	gp120, V4-hypervariable, V4 loop	E	2.442	2.430	2.183	computational prediction	VRC02: T403 is associated with increased resistance to neutralization; intermediate quality of support.
45	VRC02 signature predictions	CD4BS	West2013	signature	VRC02	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	VRC02: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
45	VRC02 signature predictions	CD4BS	West2013	signature	VRC02	706	gp41, gp41 cytoplasmic tail	N	0.469	0.312	0.722	computational prediction	VRC02: N706 is associated with increased susceptibility to neutralization; intermediate quality of support.
45	VRC02 signature predictions	CD4BS	West2013	signature	VRC02	772	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	R	0.200	0.270	0.126	computational prediction	VRC02: R772 is associated with increased resistance to neutralization; intermediate quality of support.
46	VRC-CH31 signature predictions	CD4BS	West2013	signature	VRC-CH31	640	gp41	S	2.068	1.971	1.834	computational prediction	VRC-CH31: G640 is associated with increased resistance to neutralization; marginal quality of support.
46	VRC-CH31 signature predictions	CD4BS	West2013	signature	VRC-CH31	798	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking, Prohibin 1/2	N	0.684	0.336	0.870	computational prediction	VRC-CH31: S798 is associated with increased resistance to neutralization; intermediate quality of support.
47	VRC-PG04 signature predictions	CD4BS	West2013	signature	VRC-PG04	106	gp120	E	0.705	0.218	0.326	computational prediction	VRC-PG04: E106 is associated with increased resistance to neutralization; high quality of support.
47	VRC-PG04 signature predictions	CD4BS	West2013	signature	VRC-PG04	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	VRC-PG04: glycosylation at T276 is associated with increased susceptibility to neutralization; intermediate quality of support.
47	VRC-PG04 signature predictions	CD4BS	West2013	signature	VRC-PG04	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	computational prediction	VRC-PG04: H364 is associated with increased resistance to neutralization; intermediate quality of support.
47	VRC-PG04 signature predictions	CD4BS	West2013	signature	VRC-PG04	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	computational prediction	VRC-PG04: S365 is associated with increased susceptibility to neutralization; intermediate quality of support.
47	VRC-PG04 signature predictions	CD4BS	West2013	signature	VRC-PG04	403	gp120, V4-hypervariable, V4 loop	E	2.442	2.430	2.183	computational prediction	VRC-PG04: T403 is associated with increased resistance to neutralization; intermediate quality of support.
48	VRC-PG04b signature predictions	CD4BS	West2013	signature	VRC-PG04b	85	gp120	V	2.208	1.797	1.418	computational prediction	VRC-PG04b: Y85 is associated with increased resistance to neutralization; intermediate quality of support.
48	VRC-PG04b signature predictions	CD4BS	West2013	signature	VRC-PG04b	232	gp120	T	1.649	1.451	0.426	computational prediction	VRC-PG04b: T232 is associated with increased resistance to neutralization; high quality of support.
48	VRC-PG04b signature predictions	CD4BS	West2013	signature	VRC-PG04b	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	VRC-PG04b: glycosylation at T276 is associated with increased susceptibility to neutralization; intermediate quality of support.
48	VRC-PG04b signature predictions	CD4BS	West2013	signature	VRC-PG04b	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	computational prediction	VRC-PG04b: H364 is associated with increased resistance to neutralization; intermediate quality of support.
48	VRC-PG04b signature predictions	CD4BS	West2013	signature	VRC-PG04b	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	computational prediction	VRC-PG04b: S365 is associated with increased susceptibility to neutralization; intermediate quality of support.
49	45-46m2 signature predictions	CD4BS	West2013	signature	45-46m2	456	gp120, beta23	R	0.196	0.079	0.323	computational prediction	45-46m2: R456 is associated with increased susceptibility to neutralization; intermediate quality of support.
49	45-46m2 signature predictions	CD4BS	West2013	signature	45-46m2	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	45-46m2: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
50	45-46m7 signature predictions	CD4BS	West2013	signature	45-46m7	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	45-46m7: G459 is associated with increased susceptibility to neutralization; intermediate quality of support.
51	10-996 signature predictions	V3-glycan	West2013	signature	10-996	49	gp120	T	1.652	0.958	0.335	computational prediction	10-996: D49 is associated with increased susceptibility to neutralization; intermediate quality of support.
51	10-996 signature predictions	V3-glycan	West2013	signature	10-996	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	10-996: H330 is associated with increased susceptibility to neutralization; high quality of support.
51	10-996 signature predictions	V3-glycan	West2013	signature	10-996	332	gp120	N	0.904	0.491	0.693	computational prediction	10-996: glycosylation at N332 is associated with increased susceptibility to neutralization; high quality of support.
51	10-996 signature predictions	V3-glycan	West2013	signature	10-996	444	gp120	R	1.754	1.507	0.494	computational prediction	10-996: S444 is associated with increased susceptibility to neutralization; intermediate quality of support.
52	35O22 contacts	gp120/gp41 interface	Huang2014	contacts	35O22	88	gp120	N	0.053	0.041	0.048	X-ray crystallography	35O22 Heavy chain contact
52	35O22 contacts	gp120/gp41 interface	Huang2014	contacts	35O22	89	gp120	V	0.111	0.081	0.117	X-ray crystallography	35O22 Heavy chain contact
52	35O22 contacts	gp120/gp41 interface	Huang2014	contacts	35O22	90	gp120	T	0.073	0.063	0.051	X-ray crystallography	35O22 Heavy chain contact
52	35O22 contacts	gp120/gp41 interface	Huang2014	contacts	35O22	230	gp120	N	0.954	0.896	0.544	X-ray crystallography	35O22 Heavy chain contact
52	35O22 contacts	gp120/gp41 interface	Huang2014	contacts	35O22	241	gp120	N	0.169	0.183	0.134	X-ray crystallography	35O22 Heavy chain contact
52	35O22 contacts	gp120/gp41 interface	Huang2014	contacts	35O22	625	gp41	H	0.220	0.185	0.214	X-ray crystallography	35O22 Heavy chain contact
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	X-ray crystallography	The glycan at N295 in JRCSF is a contact residue for PGT135; N295A diminishes neutralization sensitivity in a strain specific way.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	330	gp120, V3 loop	H	0.743	0.559	0.655	X-ray crystallography	Contact residue for PGT135. H330A in JRCSF confers neutralization resistance.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	332	gp120	N	0.904	0.491	0.693	X-ray crystallography	The glycan at N332 in JRCSF is a key contact residue for PGT135; N332A confers neutralization resistance in all strains tested.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	373	gp120, CD4 binding loop	T	0.953	0.872	0.371	X-ray crystallography	M373 in JRCSF is a contact residue for PGT135.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	384	gp120	Y	0.075	0.124	0.023	X-ray crystallography	Y384 in JRCSF is a contact residue for PGT135.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	X-ray crystallography	The glycan at N386 in JRCSF is a contact residue for PGT135; N386A diminishes neutralization sensitivity, but in another context it abrogates activity, so its impact is strain specific.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	389	gp120, V4 loop	Q	2.091	1.567	2.120	X-ray crystallography	Q389 in JRCSF is a contact residue for PGT135.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	392	gp120, V4 loop	N	0.561	0.454	0.804	X-ray crystallography	The glycan at N392 in JRCSF is a contact residue for PGT135; N392A confers neutralization resistance, and the glycan has a large contact region with long PGT135 CDR H3 loops.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	409	gp120, V4-hypervariable, V4 loop	E	1.240	1.527	0.670	X-ray crystallography	E409 in JRCSF is a contact residue for PGT135.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	415	gp120, V4 loop	T	0.846	0.760	0.656	X-ray crystallography	T415 in JRCSF is a contact residue for PGT135; T415A diminishes diminishes neutralization sensitivity.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	417	gp120, V4 loop	P	0.836	0.736	0.922	X-ray crystallography	P417 in JRCSF is a contact residue for PGT135; T415A diminishes neutralization sensitivity.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	418	gp120, Cys 385 linked to Cys 418	C	0.052	0.038	0.059	X-ray crystallography	C418 in JRCSF is a contact residue for PGT135, and is conserved among all HIVs.
54	PGT135 contacts	V3-glycan	Kong2013	contacts	PGT135	419	gp120	R	0.516	0.341	0.500	X-ray crystallography	R419 in JRCSF is a contact residue for PGT135; R419A diminishes diminishes neutralization sensitivity.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	132	gp120, V1-hypervariable, V1	T	1.450	0.849	1.573		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	133	gp120, V1-hypervariable, V1	D	1.456	1.052	1.360		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	141	gp120, V1-hypervariable, V1	N	2.221	2.077	2.148		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	143	gp120, V1-hypervariable, V1	S	2.014	1.990	1.810		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	144	gp120, V1-hypervariable, V1	S	2.255	2.072	2.207		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	145	gp120, V1-hypervariable, V1	G	2.331	2.228	2.255		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	146	gp120, V1-hypervariable, V1	R	2.697	2.583	2.629		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	147	gp120, V1-hypervariable, V1	M	2.618	2.513	2.375		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	148	gp120, V1-hypervariable, V1	I	2.707	2.671	2.548		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	149	gp120, V1-hypervariable, V1	M	2.457	2.375	2.256		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	150	gp120, V1-hypervariable, V1	E	2.374	2.019	2.328		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966		CH103: Insertions in the V1 hypervariable region arose very early in the subject CH505, and drove escape from early members of the CH103 lineage; these forms were recognized by later members of the lineage; these forms carried potential N-linked glycosylation sites.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	275	gp120, Loop D	V	1.034	1.420	0.535		CH103 and CH235: E275K + 279 + 281 mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 mAB lineage, that was present simultaneously in the infected donor, CH505. 275 is a contact residue for the CH103 light chain.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	279	gp120, Loop D	D	0.860	0.850	0.898		CH103 and CH235: N279K increased sensitivity to the bNAb CH103 lineage, but was an escape mutations from the autologous neutralizing CH235 mAb lineage, that was present simultaneously in the infected donor, CH505. 279 is a contact residue for the CH103 light chain.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	280	gp120, Loop D	N	0.117	0.090	0.170		CH103 and CH235: N280S + V281 mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 mAB lineage, that was present simultaneously in the infected donor, CH505.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	281	gp120, Loop D	A	1.081	0.814	1.357		CH103 and CH235: V281A, V281G or V281D mutations increased sensitivity to the bNAb CH103 lineage, but were escape mutations from the autologous neutralizing CH235 lineage, that was present simultaneously in the infected donor, CH505. 281 is a contact residue for the CH103 light chain.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	464	gp120, V5-hypervariable, V5 loop	E	2.371	2.269	2.299		CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
55	CH103 and CH235 evolution	CD4BS	Gao2014	neutralization	CH103, CH235	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		CH103: Insertions in the V5 hypervariable region conferred resistance to emerging members of the CH103 lineage.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	56	gp120	S	0.023	0.017	0.022		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	57	gp120	D	0.206	0.198	0.275		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	58	gp120	A	0.024	0.036	0.029		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	59	gp120	K	0.216	0.243	0.130		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	60	gp120	A	0.530	0.461	0.396		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	61	gp120	Y	0.465	0.299	0.148		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	62	gp120	D	1.442	1.302	0.706		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	63	gp120	T	1.295	0.663	1.217		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	75	gp120	V	0.013	0.006	0.008		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	76	gp120	P	0.007	0.012	0.000		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	77	gp120	T	0.042	0.088	0.020		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	78	gp120	D	0.063	0.081	0.059		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	79	gp120	P	0.016	0.017	0.008		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	80	gp120	N	0.634	0.695	0.562		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	81	gp120	P	0.010	0.023	0.008		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	82	gp120	Q	0.287	0.200	0.268		Predicted C1 regional interactions with LCDR1 of PGT151.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	262	gp120	N	0.029	0.029	0.028		Glycan contact of PGT151, but loss of the glycan does not impact PGT151 neutralization.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	448	gp120	N	0.648	0.448	0.927		Glycan contact, but loss of the glycan does not impact PGT151 neutralization; complex patterns of reactivity suggest isolate specific interactions with glycans at N611 and N637.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	490	gp120	K	1.270	0.943	0.157		K490F mutation in BG505 SOSIP.664 reduces PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	499	gp120	T	0.239	0.203	0.161		T499A mutation in BG505 SOSIP.664 reduces PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	500	gp120	K	1.609	0.816	1.832		R500K mutation in BG505 SOSIP.664 reduces PGT151 binding, R500S + R503S abrogates binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	501	gp120	A	0.102	0.017	0.221		A501T in a LAI background diminishes sensitivity and % maximum neutralization.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	502	gp120	K	0.553	0.512	0.348		K502A mutation in BG505 SOSIP.664 reduces PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	503	gp120	R	0.016	0.012	0.020		R503S mutation in BG505 SOSIP.664 abrogates PGT151 binding, as does R500S + R503S.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	504	gp120	R	0.224	0.049	0.216		R504S mutation in BG505 SOSIP.664 modestly reduces PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	505	gp120	V	0.074	0.091	0.064		V505K mutation in BG505 SOSIP.664 modestly reduces PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	588	gp41, Leu/Ile zipper-like sequence	K	1.087	1.197	0.871		R588F mutation in BG505 SOSIP.664 does not impact PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	607	gp41	A	1.317	1.190	1.219		N607K mutation in BG505 SOSIP.664 reduces PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	611	gp41	N	0.050	0.039	0.054		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure. N611Q mutation in BG505 SOSIP.664 reduces PGT151 binding; N611Q+N637Q abrogates PGT151 binding; N611A and N611D reduces neutralization sensitivity and maximum neutralization, to different levels depending on the strain.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	612	gp41	A	1.453	1.525	1.055		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	613	gp41	S	0.379	0.207	0.216		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure. S613A + N616Q mutations in BG505 SOSIP.664 reduces PGT151 binding; S613A reduces neutralization sensitivity and maximum neutralization in JR-CSF.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	614	gp41	W	0.029	0.033	0.015		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	615	gp41	S	0.098	0.111	0.110		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	616	gp41	N	0.226	0.238	0.269		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure. S613A + N616Q mutations in BG505 SOSIP.664 reduces PGT151 binding.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	617	gp41, gp41 fusion domain (595,602,603,617)	K	0.498	0.526	0.500		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	618	gp41	S	0.742	0.725	0.780		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	619	gp41	L	1.866	1.312	1.871		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	620	gp41	E	2.000	1.701	2.182		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	621	gp41	Q	1.713	2.097	1.208		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	622	gp41	I	0.078	0.088	0.053		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	623	gp41	W	0.068	0.066	0.043		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
58	PGT151-PGT158 sites of interaction	gp41 fusion domain	Blattner2014, Falkowska2014	binding	PGT151, PGT152, PGT153, PGT154, PGT155, PGT156, PGT157, PGT158	624	gp41	N	1.565	1.592	1.486		611-624 are predicted to be in the contact region of the HR2 domain of PGT151 based on modeling and an EM structure.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	44	gp120	V	0.058	0.023	0.039		8ANC195: V44 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	45	gp120	W	0.015	0.018	0.028		8ANC195: W45 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	46	gp120	K	0.832	0.269	1.022		8ANC195: K46 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	47	gp120	E	0.647	0.335	0.323		8ANC195: D47 contact, in the buried surface area at the interface, and forms a hydrogen bond with the bNAb.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	89	gp120	V	0.111	0.081	0.117		8ANC195: V89 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	90	gp120	T	0.073	0.063	0.051		8ANC195: T90 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	91	gp120	E	0.029	0.033	0.023		8ANC195: E91 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	92	gp120	N	1.062	1.058	0.458		8ANC195: N92 contact, in the buried surface area at the interface and forms a hydrogen bond with the bNAb.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	93	gp120	F	0.050	0.074	0.015		8ANC195: F93 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	94	gp120	N	0.221	0.217	0.076		8ANC195: N94 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	97	gp120	K	0.433	0.421	0.511		8ANC195: K97 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	234	gp120	N	0.584	0.757	0.341		8ANC195: The glycan at N234 is in contact with 8ANC195 bound to the CRF01_AE 93TH057 gp120 core, N234 is in the buried surface area at the interface, and there is extensive hydrogen bonding with the glycan at this site.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	236	gp120	T	0.762	1.013	0.551		8ANC195 T236 contact, buried surface area at interfaces, part of the critical glycosylation site at 234.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	237	gp120	G	0.048	0.072	0.008		8ANC195: G237 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	238	gp120	P	0.830	1.065	0.131		8ANC195: P238 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	240	gp120	T	1.789	1.338	1.717		8ANC195: K240 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	275	gp120, Loop D	V	1.034	1.420	0.535		8ANC195: E275 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	276	gp120, Loop D	N	0.120	0.063	0.169		8ANC195: The glycan at N276 is in contact with 8ANC195 bound to the CRF01_AE 93TH057 gp120 core; N276 is in buried surface area at the interface, and there is extensive hydrogen bonding with the glycan at this site.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	277	gp120, Loop D	F	1.193	0.669	0.582		8ANC195: L277 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	278	gp120, Loop D	T	0.657	0.715	0.481		8ANC195: T278 is a loop D contact with 8ANC195 bound to CRF01_AE 93TH057 gp120 core, T278 is in buried surface area at the interfaces and forms a hydrogen bond with the bNAb.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	352	gp120	Q	1.680	0.842	1.079		8ANC195: H352 is an outer domain contact with 8ANC195 in a structure with CRF01_AE 93TH057 gp120; it is in buried surface area at the interfaces and forms a hydrogen bond with the bNAb.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	353	gp120	F	0.759	0.735	0.488		8ANC195: F353 is in the buried surface area at 8ANC195 interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	354	gp120	G	2.149	1.918	1.123		8ANC195: N354 is an outer domain contact with 8ANC195 in a structure with CRF01_AE 93TH057 gp120, in buried surface area at 8ANC195 interfaces and forms a hydrogen bond with the bNAb.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	357	gp120	K	1.086	0.868	0.941		8ANC195: K357 is in 8ANC195 buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	456	gp120, beta23	R	0.196	0.079	0.323		8ANC195: R456 is a V5 region contact with 8ANC195 bound to CRF01_AE 93TH057 gp120 core; in buried surface area at interfaces, and forms a hydrogen bond with the bNAb.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		8ANC195: T463 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239		8ANC195: E466 contact, buried surface area at interfaces.
60	8ANC195 contacts	gp120/gp41 interface	Scharf2014	contacts	8ANC195	487	gp120	K	0.020	0.012	0.043		8ANC195: K487 contact, buried surface area at the interface and forms a hydrogen bond with the bNAb.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	93	gp120	F	0.050	0.074	0.015		8ANC195: F93 is ranked 6th among the 10 highest in terms of co-variation with potency and structural proximity to 8ANC195 epitope.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	96	gp120	W	0.054	0.091	0.020		8ANC195: W96 is ranked 2nd among the 10 highest in terms of co-variation with potency and structural proximity to 8ANC195 epitope.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	233	gp120	F	0.065	0.055	0.028		8ANC195: F233 is ranked 3rd among the 10 highest in terms of co-variation and structural proximity.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	234	gp120	N	0.584	0.757	0.341		8ANC195: N234 is ranked 10th among the 10 highest in terms of co-variation with potency and structural proximity to 8ANC195 epitope.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	236	gp120	T	0.762	1.013	0.551		8ANC195: T236 is ranked 4th among the 10 highest in terms of co-variation with potency and structural proximity.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	276	gp120, Loop D	N	0.120	0.063	0.169		8ANC195: N276 is ranked 8th among the 10 highest in terms of co-variation with potency and structural proximity.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	279	gp120, Loop D	D	0.860	0.850	0.898		8ANC195: T279 is ranked 9th among the 10 highest in terms of co-variation with potency and structural proximity.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	280	gp120, Loop D	N	0.117	0.090	0.170		8ANC195: N280 is ranked 5th among the 10 highest in terms of co-variation with potency and structural proximity.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	456	gp120, beta23	R	0.196	0.079	0.323		8ANC195: R456 is ranked 1st among the 10 highest in terms of co-variation with potency and structural proximity.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239		8ANC195: E466 is ranked 7th among the 10 highest in terms of co-variation with potency and structural proximity.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	625	gp41	H	0.220	0.185	0.214		A glycan at 625 was predicted by modeling to be in contact with 8ANC195.
61	8ANC195 residue prediction	gp120/gp41 interface	Chuang2013, Chuang2014	signature	8ANC195	637	gp41	N	0.223	0.168	0.186		Predicted by modeling to be in contact with 8ANC195, however a mutant YU2 pseudovirus N637Q did not show decreased sensitivity to 8ANC195.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	160	gp120, V2	N	0.401	0.452	0.358		PG9: N160 is ranked first among the 10 highest in terms of co-variation with PG9 potency
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	161	gp120, V2	I	1.565	0.964	1.568		PG9: I161 is ranked 7th among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	162	gp120, V2	S	0.289	0.445	0.179		PG9: T162 is ranked third among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	163	gp120, V2	T	0.360	0.638	0.154		PG9: T163 is ranked 5th among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	164	gp120, V2	S	1.660	1.925	0.453		PG9: E164 is ranked 9th among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	167	gp120, V2	G	0.601	1.122	0.185		PG9: D167 is ranked 10th among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	168	gp120, V2	K	0.547	0.666	0.396		PG9: K168 is ranked 8th among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	169	gp120, V2	V	1.974	1.770	1.344		PG9: K169 is ranked second among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	170	gp120, V2	Q	1.458	1.423	1.428		PG9: Q170 is ranked fourth among the 10 highest in terms of co-variation with PG9 potency.
62	PG9 residue prediction	V2-apex	Chuang2013, Chuang2014	signature	PG9	171	gp120, V2	K	1.239	0.957	1.413		PG9: K171 is ranked 6th among the 10 highest in terms of co-variation with PG9 potency.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	279	gp120, Loop D	D	0.860	0.850	0.898		VRC01: N279 is ranked 9th in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	280	gp120, Loop D	N	0.117	0.090	0.170		VRC01: N280 is ranked 2nd among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	353	gp120	F	0.759	0.735	0.488		VRC01: F353 is ranked 10th in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	456	gp120, beta23	R	0.196	0.079	0.323		VRC01: R456 is ranked first among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	457	gp120, beta23	D	0.059	0.054	0.043		VRC01: D457 is ranked 5th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	458	gp120, beta23	G	0.097	0.045	0.095		VRC01: G458 is ranked 3rd among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		VRC01: G459 is ranked 7th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		VRC01: A460 is ranked 8th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		VRC01: S461 is ranked 6th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
63	VRC01 residue prediction	CD4BS	Chuang2013, Chuang2014	signature	VRC01	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239		VRC01: E466 is ranked 4th among the 10 highest in terms of co-variation with CD4bs bNAb VRC01 and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	671	gp41	N	0.779	0.669	0.885		10E8: N671 is ranked 6th among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	672	gp41	W	0.017	0.023	0.014		10E8: W672 is ranked 2nd among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	673	gp41	F	0.058	0.065	0.073		10E8: F673 is ranked 3rd among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	674	gp41	N	1.182	1.029	1.344		10E8: D674 is ranked 9th among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	675	gp41	I	0.050	0.059	0.069		10E8: I675 is ranked 8th among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	676	gp41	T	0.683	0.610	0.674		10E8: T676 is ranked 1st among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	677	gp41	N	1.187	1.199	1.100		10E8: N677 is ranked 4th among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008		10E8: N679 is ranked 7th among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081		10E8: W680 is ranked 5th among the 10 highest in terms of co-variation with potency and structure.
64	10E8 residue prediction	MPER	Chuang2013, Chuang2014	signature	10E8	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569		10E8: R683 is ranked 10th among the 10 highest in terms of co-variation with potency and structure.
65	3BC176 binding	CD4i	Klein2012	binding	3BC176	160	gp120, V2	N	0.401	0.452	0.358	binding assay	3BC176 and 3BC315: N160K reduces binding
65	3BC176 binding	CD4i	Klein2012	binding	3BC176	420	gp120	I	0.068	0.049	0.078	binding assay	3BC176 and 3BC315: I420R slightly enhances binding
66	Stabilizing glycans in structure of glycosylated gp120		Kong2015	Env feature		262	gp120	N	0.029	0.029	0.028		Highly conserved glycan, buried in the cleft of gp120. Its location indicates a role in stability and folding, bridging the inner and outer domains of gp120. It is not involved with bNAb interactions.
66	Stabilizing glycans in structure of glycosylated gp120		Kong2015	Env feature		332	gp120	N	0.904	0.491	0.693		Dense packing of glycans in an oligomannose patch is centered on Asn332.
67	Mutation affects 2F5 binding	MPER	Montero2012	binding	2F5	664	gp41	D	0.197	0.156	0.346	binding assay	Mutation to Ala decreases binding of 2F5.
67	Mutation affects 2F5 binding	MPER	Montero2012	binding	2F5	665	gp41	K	0.986	0.656	0.879	binding assay	Mutation to Ala decreases binding of 2F5.
67	Mutation affects 2F5 binding	MPER	Montero2012	binding	2F5	666	gp41	W	0.003	0.000	0.000	binding assay	Mutation to Ala decreases binding of 2F5.
67	Mutation affects 2F5 binding	MPER	Montero2012	binding	2F5	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.010	0.018	0.008	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
67	Mutation affects 2F5 binding	MPER	Montero2012	binding	2F5	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.033	0.042	0.041	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
67	Mutation affects 2F5 binding	MPER	Montero2012	binding	2F5	685	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	F	0.036	0.029	0.020	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
68	Mutation affects 4E10 binding	MPER	Montero2012	binding	4E10	672	gp41	W	0.017	0.023	0.014	binding assay	Mutation to Ala decreases binding of 4E10.
68	Mutation affects 4E10 binding	MPER	Montero2012	binding	4E10	673	gp41	F	0.058	0.065	0.073	binding assay	Mutation to Ala decreases binding of 4E10.
68	Mutation affects 4E10 binding	MPER	Montero2012	binding	4E10	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.010	0.018	0.008	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
68	Mutation affects 4E10 binding	MPER	Montero2012	binding	4E10	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.033	0.042	0.041	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
68	Mutation affects 4E10 binding	MPER	Montero2012	binding	4E10	685	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	F	0.036	0.029	0.020	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
69	Mutation affects Z13e1 binding	MPER	Montero2012	binding	Z13e1	674	gp41	N	1.182	1.029	1.344	binding assay	Mutation to Ala decreases binding of Z13e1.
69	Mutation affects Z13e1 binding	MPER	Montero2012	binding	Z13e1	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.010	0.018	0.008	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
69	Mutation affects Z13e1 binding	MPER	Montero2012	binding	Z13e1	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.033	0.042	0.041	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
69	Mutation affects Z13e1 binding	MPER	Montero2012	binding	Z13e1	685	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	F	0.036	0.029	0.020	binding assay	Mutation to Ala increases binding of MPER NAbs 2F5, 4E10, and Z13e1.
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	124	gp120	P	0.047	0.018	0.029		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	198	gp120	T	0.458	0.264	0.469		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	207	gp120	K	0.043	0.029	0.029		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	275	gp120, Loop D	V	1.034	1.420	0.535		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	276	gp120, Loop D	N	0.120	0.063	0.169		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	278	gp120, Loop D	T	0.657	0.715	0.481		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	279	gp120, Loop D	D	0.860	0.850	0.898		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	280	gp120, Loop D	N	0.117	0.090	0.170		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	281	gp120, Loop D	A	1.081	0.814	1.357		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	282	gp120, Loop D	K	0.260	0.337	0.297		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	308	gp120, V3 loop	R	0.108	0.091	0.127		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	318	gp120, V3 loop	V	0.574	0.691	0.507		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	428	gp120, beta20/beta21	Q	0.052	0.053	0.054		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	429	gp120, beta20/beta21	K	1.406	0.961	1.308		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	430	gp120, beta20/beta21	V	0.397	0.080	0.073		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	455	gp120, beta23	T	0.670	0.426	0.972		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	456	gp120, beta23	R	0.196	0.079	0.323		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	457	gp120, beta23	D	0.059	0.054	0.043		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	458	gp120, beta23	G	0.097	0.045	0.095		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		3BNC117 contact (Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
72	3BNC117 contacts	CD4BS	Caskey2015, Scheid2016, Zhou2013a	contacts	3BNC117	473	gp120	G	0.031	0.033	0.029		3BNC117 contact (Zhou2013a,Caskey2015,Scheid2016)
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	148	gp120, V1-hypervariable, V1	I	2.707	2.671	2.548	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	171	gp120, V2	K	1.239	0.957	1.413	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	187	gp120, V2-hypervariable, V2	D	1.817	1.813	1.638	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	268	gp120	E	1.220	0.886	1.275	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	280	gp120, Loop D	N	0.117	0.090	0.170	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	306	gp120, V3 loop	R	0.732	0.860	0.338	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	339	gp120	N	1.157	1.082	1.026	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	360	gp120	I	2.172	1.624	2.270	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	394	gp120, V4 loop	T	1.078	0.715	1.439	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	412	gp120, V4 loop	D	2.190	2.094	2.182	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	429	gp120, beta20/beta21	K	1.406	0.961	1.308	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	455	gp120, beta23	T	0.670	0.426	0.972	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	sequence analysis	Statistically significant sequence change in 1/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	sequence analysis	Statistically significant sequence change in 2/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	sequence analysis	Statistically significant sequence change in 2/5 patients following VRC01 infusion.
73	Sequence changes after immunotherapy with VRC01	CD4BS	Lynch2015	immunotherapy	VRC01	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517	sequence analysis	Statistically significant sequence change in 2/5 patients following VRC01 infusion.
75	PG9-like antibodies require N160 for neutralization	V2-apex	Doria-Rose2016	neutralization	CH01, PG16, PG9, PGT145	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	Deletion of N160 abrogates neutralization by PG9, PG16, CH01, and PGT145.
76	VRC26.25 neutralization associated sites	V2-apex	Doria-Rose2016	neutralization	VRC26.25	164	gp120, V2	S	1.660	1.925	0.453		Amino acids D or E associated with sensitivity to VRC26.25 neutralization.
76	VRC26.25 neutralization associated sites	V2-apex	Doria-Rose2016	neutralization	VRC26.25	166	gp120, V2	R	1.127	1.398	0.772		Amino acids G, I, Q, S, or T associated with resistance to VRC26.25 neutralization.
76	VRC26.25 neutralization associated sites	V2-apex	Doria-Rose2016	neutralization	VRC26.25	167	gp120, V2	G	0.601	1.122	0.185		Amino acids T or G associated with resistance to VRC26.25 neutralization.
76	VRC26.25 neutralization associated sites	V2-apex	Doria-Rose2016	neutralization	VRC26.25	169	gp120, V2	V	1.974	1.770	1.344		Amino acids R or K associated with sensitivity to VRC26.25 neutralization. Amino acids E or V associated with resistance to VRC26.25 neutralization.
77	CAP256-VRC26 lineage neutralization-associated sites	V2-apex	Doria-Rose2014, Doria-Rose2016	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A decreases neutralization sensitivity for most CAP256-VRC26 lineage antibodies; the antibody evolved away from dependency on this glycan.
77	CAP256-VRC26 lineage neutralization-associated sites	V2-apex	Doria-Rose2014, Doria-Rose2016	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	The CAP256-VRC26 lineage appears to have initially responded to a superinfecting virus that had T162; the earlier founder virus had I162, so it lacked the glycan at 160, and was resistant to this lineage of antibodies.
77	CAP256-VRC26 lineage neutralization-associated sites	V2-apex	Doria-Rose2014, Doria-Rose2016	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	166	gp120, V2	R	1.127	1.398	0.772	neutralization assay	R166A decreases neutralization sensitivity for all 33 CAP256-VRC26 lineage antibodies.
77	CAP256-VRC26 lineage neutralization-associated sites	V2-apex	Doria-Rose2014, Doria-Rose2016	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	167	gp120, V2	G	0.601	1.122	0.185	neutralization assay	D167N decreases neutralization sensitivity for most CAP256-VRC26 lineage antibodies.
77	CAP256-VRC26 lineage neutralization-associated sites	V2-apex	Doria-Rose2014, Doria-Rose2016	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	168	gp120, V2	K	0.547	0.666	0.396	neutralization assay	K168A decreases neutralization sensitivity for most CAP256-VRC26 lineage antibodies.
77	CAP256-VRC26 lineage neutralization-associated sites	V2-apex	Doria-Rose2014, Doria-Rose2016	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	K169E decreases neutralization sensitivity for all 33 CAP256-VRC26 lineage antibodies.
79	179NC75 binding-associated sites	CD4BS	Freund2015	binding	179NC75	276	gp120, Loop D	N	0.120	0.063	0.169	binding assay	Mutation N276D abolishes binding of 179NC75.
79	179NC75 binding-associated sites	CD4BS	Freund2015	binding	179NC75	280	gp120, Loop D	N	0.117	0.090	0.170	binding assay	Double mutation D368R + N280Y substantially impairs binding of 179NC75.
79	179NC75 binding-associated sites	CD4BS	Freund2015	binding	179NC75	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	binding assay	Double mutation D368R + N280Y substantially impairs binding of 179NC75.
80	HJ16 binding requires N276	CD4BS	Balla-Jhagjhoorsingh2013	binding	HJ16	276	gp120, Loop D	N	0.120	0.063	0.169		Glycan N276 is required for binding of HJ16.
81	375S affects CD4 binding		Li2016	Env feature		375	gp120	S	0.790	0.753	0.372	binding assay, neutralization assay	Substitution of 375S by M, H, Y, F or W led to higher binding affinity to human and rhesus CD4, but without affecting Ab-mediated neutralization sensitivity.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	141	gp120, V1-hypervariable, V1	N	2.221	2.077	2.148	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	187	gp120, V2-hypervariable, V2	D	1.817	1.813	1.638	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	344	gp120	Q	1.728	1.306	1.923	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	347	gp120	S	2.083	2.161	1.508	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	398	gp120, V4-hypervariable, V4 loop	S	1.863	1.469	2.098	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	400	gp120, V4-hypervariable, V4 loop	W	2.263	1.985	2.290	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	401	gp120, V4-hypervariable, V4 loop	S	2.719	2.459	2.574	sequence analysis	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	402	gp120, V4-hypervariable, V4 loop	T	2.419	2.234	2.207	sequence analysis	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	403	gp120, V4-hypervariable, V4 loop	E	2.442	2.430	2.183	sequence analysis	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	404	gp120, V4-hypervariable, V4 loop	G	2.186	2.199	1.740	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	405	gp120, V4-hypervariable, V4 loop	S	2.165	2.388	1.715	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	410	gp120, V4-hypervariable, V4 loop	G	2.415	2.263	2.179	sequence analysis	Site under significant selection in 3 of 9 patients sequenced following 3BNC117 immunotherapy; not a known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	sequence analysis	Patient 2C5 selected for the G459D mutation following 3BNC immunotherapy; this mutation was previously shnown to alter the CD4 binding site and result in resistance to 3BNC117; known 3BNC117 contact site.
82	Sites selected during 3BNC117 immunotherapy	CD4BS	Caskey2015, Schoofs2016	immunotherapy	3BNC117	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	sequence analysis	Site under significant selection in 4 of 9 patients sequenced following 3BNC117 immunotherapy; known 3BNC117 contact site.
83	CAP256-VRC26 lineage epitope	V2-apex	Doria-Rose2016	binding	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	160	gp120, V2	N	0.401	0.452	0.358	binding assay	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
83	CAP256-VRC26 lineage epitope	V2-apex	Doria-Rose2016	binding	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	161	gp120, V2	I	1.565	0.964	1.568	binding assay	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
83	CAP256-VRC26 lineage epitope	V2-apex	Doria-Rose2016	binding	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	162	gp120, V2	S	0.289	0.445	0.179	binding assay	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
83	CAP256-VRC26 lineage epitope	V2-apex	Doria-Rose2016	binding	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	163	gp120, V2	T	0.360	0.638	0.154	binding assay	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
83	CAP256-VRC26 lineage epitope	V2-apex	Doria-Rose2016	binding	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	164	gp120, V2	S	1.660	1.925	0.453	binding assay	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
83	CAP256-VRC26 lineage epitope	V2-apex	Doria-Rose2016	binding	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	165	gp120, V2	I	1.321	1.292	1.011	binding assay	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
83	CAP256-VRC26 lineage epitope	V2-apex	Doria-Rose2016	binding	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	166	gp120, V2	R	1.127	1.398	0.772	binding assay	Epitope for CAP256-VRC26 lineage mAbs located at 160-166
84	Electrostatic interactions with D368	CD4BS	Bonsignori2016	binding	CH235.12, CH235.9, VRC01	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		D368 contacts the CDR H2 loop of VRC01, CH235.9, and CH235.12 by electrostatic interactions.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	4	Signal peptide	K	1.292	1.114	1.115		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	130	gp120	K	1.274	0.883	1.495		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	132	gp120, V1-hypervariable, V1	T	1.450	0.849	1.573		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	144	gp120, V1-hypervariable, V1	S	2.255	2.072	2.207		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	145	gp120, V1-hypervariable, V1	G	2.331	2.228	2.255		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	147	gp120, V1-hypervariable, V1	M	2.618	2.513	2.375		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	234	gp120	N	0.584	0.757	0.341		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	275	gp120, Loop D	V	1.034	1.420	0.535		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	279	gp120, Loop D	D	0.860	0.850	0.898		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	281	gp120, Loop D	A	1.081	0.814	1.357		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	300	gp120, V3 loop	N	1.159	0.738	1.054		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	302	gp120, V3 loop	N	0.245	0.215	0.157		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	325	gp120, V3 loop	N	0.653	0.622	0.622		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	330	gp120, V3 loop	H	0.743	0.559	0.655		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	332	gp120	N	0.904	0.491	0.693		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	334	gp120	S	0.780	0.501	0.890		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	347	gp120	S	2.083	2.161	1.508		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	356	gp120	N	1.011	0.741	0.894		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	398	gp120, V4-hypervariable, V4 loop	S	1.863	1.469	2.098		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	412	gp120, V4 loop	D	2.190	2.094	2.182		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	413	gp120, V4 loop	T	1.440	1.451	1.561		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	417	gp120, V4 loop	P	0.836	0.736	0.922		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	464	gp120, V5-hypervariable, V5 loop	E	2.371	2.269	2.299		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	471	gp120, beta24	G	0.879	0.888	0.866		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	620	gp41	E	2.000	1.701	2.182		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	640	gp41	S	2.068	1.971	1.834		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
85	Antibody-driven selection in donor CH505	CD4BS	Hraber2015	neutralization	CH103, CH235, CH235.12, CH235.9	756	gp41, gp41 cytoplasmic tail, Luman interaction	I	1.267	0.791	0.849		Site associated with at least 80% loss of transmitted-founder sequence in CH505 (donor of mAbs CH103 - CH106 and CH235 lineage); these sites are likely to represent antibody-driven selection.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	158	gp120, V2	S	0.297	0.185	0.291	neutralization assay	S158A abrogates neutralization by PCDN 33A, 38A, 38B.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	159	gp120, V2	F	0.165	0.034	0.038	neutralization assay	F159A abrogates neutralization by PCDN 33A, 38A, 38B.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	301	gp120, V3 loop	N	0.261	0.176	0.104	neutralization assay	Loss of glycosylation site at N301 knocks out PCDN mAb neutralization; N301A abrogates neutralization by PCDN 33A, 38A, 38B.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	303	gp120, V3 loop	T	0.297	0.190	0.202	neutralization assay	T303A abrogates neutralization by PCDN 33A, 38A, 38B.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	307	gp120, V3 loop	I	0.067	0.030	0.111	neutralization assay	I307A abrogates neutralization by PCDN 38A, 38B.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	328	gp120, V3 loop	Q	1.001	0.816	0.882	neutralization assay	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	332	gp120	N	0.904	0.491	0.693	neutralization assay	Loss of glycosylation site at N332 knocks out PCDN mAb neutralization; N332A abrogates neutralization by PCDN 33A, 38A, 38B.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	334	gp120	S	0.780	0.501	0.890	neutralization assay	S334A abrogates neutralization by PCDN 33A, 38A, 38B.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	335	gp120	R	1.840	1.758	1.937	neutralization assay	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
86	Sites affecting neutralization of PCDN lineage mAbs	V3-glycan	MacLeod2016	neutralization	16A, 16B, 22A, 27A, 27B, 27C, 27D, 33A, 38A, 38B	337	gp120	K	2.008	1.862	2.151	neutralization assay	Early E328K or later A328K, along with deletion of glycan site at N335 by mutating T337A, causes sensitivity to PCDN antibodies.
87	Mutation affects trimer formation		deTaeye2015	Env feature		535	gp41	M	1.200	1.414	0.742		I535 and V535 are unfavorable to trimer formation; SOSIP trimers form more efficiently with M535.
87	Mutation affects trimer formation		deTaeye2015	Env feature		543	gp41, Leu/Ile zipper-like sequence	Q	0.529	0.768	0.202		L543 is unfavorable to trimer formation; SOSIP trimers form more efficiently with N543 or Q543.
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	280	gp120, Loop D	N	0.117	0.090	0.170		HJ16 heavy chain contact; light chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	281	gp120, Loop D	A	1.081	0.814	1.357		HJ16 heavy chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	283	gp120, Loop D	T	0.992	1.091	0.474		HJ16 heavy chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	362	gp120	K	1.874	1.265	1.997		HJ16 heavy chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	457	gp120, beta23	D	0.059	0.054	0.043		HJ16 heavy chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	458	gp120, beta23	G	0.097	0.045	0.095		HJ16 heavy chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		HJ16 light chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		HJ16 heavy chain contact; light chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		HJ16 light chain contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	471	gp120, beta24	G	0.879	0.888	0.866		HJ16 heavy chain contact; salt bridge contact
88	HJ16 contacts	CD4BS	Zhou2015	contacts	HJ16	474	gp120	D	0.719	0.681	0.752		HJ16 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	96	gp120	W	0.054	0.091	0.020	X-ray crystallography	VRC13 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	275	gp120, Loop D	V	1.034	1.420	0.535	X-ray crystallography	VRC13 salt bridge contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	VRC13 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	VRC13 heavy chain contact; salt bridge contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	VRC13 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	VRC13 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	VRC13 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	VRC13 heavy chain contact; salt bridge contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	421	gp120, beta20/beta21	K	0.312	0.374	0.203	X-ray crystallography	VRC13 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	VRC13 heavy chain contact
89	VRC13 contacts	CD4BS	Zhou2015	contacts	VRC13	473	gp120	G	0.031	0.033	0.029	X-ray crystallography	VRC13 heavy chain contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	281	gp120, Loop D	A	1.081	0.814	1.357		VRC16 heavy chain contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	282	gp120, Loop D	K	0.260	0.337	0.297		VRC16 heavy chain contact; salt bridge contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	283	gp120, Loop D	T	0.992	1.091	0.474		VRC16 heavy chain contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		VRC16 heavy chain contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		VRC16 light chain contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		VRC16 heavy chain contact; salt bridge contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	431	gp120, beta20/beta21	G	0.072	0.036	0.039		VRC16 heavy chain contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	457	gp120, beta23	D	0.059	0.054	0.043		VRC16 light chain contact
90	VRC16 contacts	CD4BS	Zhou2015	contacts	VRC16	474	gp120	D	0.719	0.681	0.752		VRC16 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	279	gp120, Loop D	D	0.860	0.850	0.898		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	280	gp120, Loop D	N	0.117	0.090	0.170		VRC18 heavy chain contact; light chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	282	gp120, Loop D	K	0.260	0.337	0.297		VRC18 salt bridge contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		VRC18 heavy chain contact; salt bridge contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	428	gp120, beta20/beta21	Q	0.052	0.053	0.054		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	456	gp120, beta23	R	0.196	0.079	0.323		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	458	gp120, beta23	G	0.097	0.045	0.095		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		VRC18 light chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		VRC18 heavy chain contact
91	VRC18 contacts	CD4BS	Zhou2015	contacts	VRC18	473	gp120	G	0.031	0.033	0.029		VRC18 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	122	gp120	L	0.120	0.101	0.121		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	279	gp120, Loop D	D	0.860	0.850	0.898		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	280	gp120, Loop D	N	0.117	0.090	0.170		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		VRC27 heavy chain contact; salt bridge contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	427	gp120, beta20/beta21	W	0.052	0.061	0.038		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	432	gp120, beta20/beta21	K	1.137	0.339	0.564		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	455	gp120, beta23	T	0.670	0.426	0.972		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	456	gp120, beta23	R	0.196	0.079	0.323		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	457	gp120, beta23	D	0.059	0.054	0.043		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	458	gp120, beta23	G	0.097	0.045	0.095		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		VRC27 light chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		VRC27 heavy chain contact
92	VRC27 contacts	CD4BS	Zhou2015	contacts	VRC27	476	gp120	R	0.699	0.615	0.711		VRC27 salt bridge contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	275	gp120, Loop D	V	1.034	1.420	0.535		1B2530 heavy chain contact; salt bridge contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	276	gp120, Loop D	N	0.120	0.063	0.169		1B2530 light chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	278	gp120, Loop D	T	0.657	0.715	0.481		1B2530 light chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	279	gp120, Loop D	D	0.860	0.850	0.898		1B2530 light chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	280	gp120, Loop D	N	0.117	0.090	0.170		1B2530 heavy chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	281	gp120, Loop D	A	1.081	0.814	1.357		1B2530 heavy chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	282	gp120, Loop D	K	0.260	0.337	0.297		1B2530 heavy chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		1B2530 heavy chain contact; salt bridge contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	427	gp120, beta20/beta21	W	0.052	0.061	0.038		1B2530 heavy chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		1B2530 light chain contact
93	1B2530 contacts	CD4BS	Zhou2015	contacts	1B2530	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		1B2530 light chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	102	gp120	E	0.792	0.522	0.426		8ANC131 heavy chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	276	gp120, Loop D	N	0.120	0.063	0.169		light chain interaction
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	278	gp120, Loop D	T	0.657	0.715	0.481		8ANC131 light chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	279	gp120, Loop D	D	0.860	0.850	0.898		heavy chain interaction
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	280	gp120, Loop D	N	0.117	0.090	0.170		8ANC131 heavy chain contact; light chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	281	gp120, Loop D	A	1.081	0.814	1.357		8ANC131 heavy chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	282	gp120, Loop D	K	0.260	0.337	0.297		8ANC131 heavy chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		8ANC131 heavy chain contact; salt bridge contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	426	gp120, beta20/beta21	M	0.598	0.866	0.274		8ANC131 heavy chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	430	gp120, beta20/beta21	V	0.397	0.080	0.073		8ANC131 heavy chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	431	gp120, beta20/beta21	G	0.072	0.036	0.039		8ANC131 heavy chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	456	gp120, beta23	R	0.196	0.079	0.323		8ANC131 heavy chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		8ANC131 light chain contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	474	gp120	D	0.719	0.681	0.752		8ANC131 heavy chain contact; salt bridge contact
94	8ANC131 contacts	CD4BS	Gristick2016	contacts	8ANC131	476	gp120	R	0.699	0.615	0.711		8ANC131 heavy chain contact; salt bridge contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	280	gp120, Loop D	N	0.117	0.090	0.170		8ANC134 heavy chain contact; light chain contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	281	gp120, Loop D	A	1.081	0.814	1.357		8ANC134 heavy chain contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	282	gp120, Loop D	K	0.260	0.337	0.297		8ANC134 heavy chain contact; salt bridge contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		8ANC134 salt bridge contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	426	gp120, beta20/beta21	M	0.598	0.866	0.274		8ANC134 heavy chain contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	431	gp120, beta20/beta21	G	0.072	0.036	0.039		8ANC134 heavy chain contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	456	gp120, beta23	R	0.196	0.079	0.323		8ANC134 heavy chain contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	474	gp120	D	0.719	0.681	0.752		8ANC134 heavy chain contact; salt bridge contact
95	8ANC134 contacts	CD4BS	Zhou2015	contacts	8ANC134	476	gp120	R	0.699	0.615	0.711		8ANC134 heavy chain contact; salt bridge contact
96	PG9 escape mutations	V2-apex	Andrabi2015	neutralization	PG9	169	gp120, V2	V	1.974	1.770	1.344		PG9: Escape in Donor 64 at K169T
96	PG9 escape mutations	V2-apex	Andrabi2015	neutralization	PG9	171	gp120, V2	K	1.239	0.957	1.413		PG9: Escape in Donor 64 at K171E
97	PGT145 escape mutations	V2-apex	Andrabi2015	neutralization	PGT145	169	gp120, V2	V	1.974	1.770	1.344		PGT145: Escape in Donor 584 at K169S
97	PGT145 escape mutations	V2-apex	Andrabi2015	neutralization	PGT145	170	gp120, V2	Q	1.458	1.423	1.428		PGT145: Escape in Donor 584 at Q170K
97	PGT145 escape mutations	V2-apex	Andrabi2015	neutralization	PGT145	171	gp120, V2	K	1.239	0.957	1.413		PGT145: Escape in Donor 584 at K171I
98	VRC26.09 escape mutations	V2-apex	Andrabi2015	neutralization	VRC26.09	169	gp120, V2	V	1.974	1.770	1.344		VRC26.09: Escape in donor CAP256 at K169E
98	VRC26.09 escape mutations	V2-apex	Andrabi2015	neutralization	VRC26.09	170	gp120, V2	Q	1.458	1.423	1.428		VRC26.09: Escape in donor CAP256 at Q170K
98	VRC26.09 escape mutations	V2-apex	Andrabi2015	neutralization	VRC26.09	171	gp120, V2	K	1.239	0.957	1.413		VRC26.09: Escape in donor CAP256 by deletion of K171
99	CAP256-VRC26 lineage escape mutations	V2-apex	Bhiman2015	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163		The glycan at 139 was deleted/shifted in 4 of 6 clones in donor CAP256 at week 34 post-infection.
99	CAP256-VRC26 lineage escape mutations	V2-apex	Bhiman2015	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	166	gp120, V2	R	1.127	1.398	0.772		K169E is mutually exclusive with R166S and abrogates neutralization by VRC26 mAbs, and all viruses contained one of these mutations by week 159 post-infection in donor CAP256.
99	CAP256-VRC26 lineage escape mutations	V2-apex	Bhiman2015	neutralization	VRC26.01, VRC26.02, VRC26.03, VRC26.04, VRC26.05, VRC26.06, VRC26.07, VRC26.08, VRC26.09, VRC26.10, VRC26.11, VRC26.12, VRC26.13, VRC26.14, VRC26.15, VRC26.16, VRC26.17, VRC26.18, VRC26.19, VRC26.20, VRC26.21, VRC26.22, VRC26.23, VRC26.24, VRC26.25, VRC26.26, VRC26.27, VRC26.28, VRC26.29, VRC26.30, VRC26.31, VRC26.32, VRC26.33	169	gp120, V2	V	1.974	1.770	1.344		K169E is mutually exclusive with R166S and abrogates neutralization by VRC26 mAbs, and all viruses contained one of these mutations by week 159 post-infection in donor CAP256. Mutants K169T and K169Q reduced/abolished neutralization.
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	163	gp120, V2	T	0.360	0.638	0.154	computational prediction	b12 signature site
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	b12 signature site; Y associated with sensitivity; H or S associated with resistance
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	182	gp120, V2	I	0.694	0.957	0.587	computational prediction	b12 signature site
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	computational prediction	b12 signature site; D, E, or N associated with sensitivity; S or T associated with resistance
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	268	gp120	E	1.220	0.886	1.275	computational prediction	b12 signature site; E or S associated with sensitivity; K or R associated with resistance
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	computational prediction	b12 signature site; P or S associated with sensitivity; H associated with resistance
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	computational prediction	b12 signature site; A or P associated with sensitivity; I, L, or Q associated with resistance
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	computational prediction	b12 signature site; E or P associated with sensitivity
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	651	gp41	N	1.168	0.818	1.387	computational prediction	b12 signature site; D, I, or S associated with resistance; this site may affect exposure of the b12 epitope in the quaternary structure
102	b12 signature sites	CD4BS	Gnanakaran2010	signature	b12	655	gp41	K	0.968	0.431	1.358	computational prediction	b12 signature site; this site may affect exposure of the b12 epitope in the quaternary structure
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	96	gp120	W	0.054	0.091	0.020		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	102	gp120	E	0.792	0.522	0.426		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	109	gp120	I	0.101	0.116	0.051		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	274	gp120	S	0.233	0.121	0.230		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	277	gp120, Loop D	F	1.193	0.669	0.582		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	279	gp120, Loop D	D	0.860	0.850	0.898		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	280	gp120, Loop D	N	0.117	0.090	0.170		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	427	gp120, beta20/beta21	W	0.052	0.061	0.038		critical for A16 binding
103	A16 contacts	CD4BS	Qiao2016	contacts	A16	476	gp120	R	0.699	0.615	0.711		critical for A16 binding
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	88	gp120	N	0.053	0.041	0.048	neutralization assay	N88Q (glycan deletion) greatly diminished nuetralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	A512W greatly diminished nuetralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	V513I, V513A and V513W diminished neutralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	insertion 514b_T completely abrogated neutralization, G514W greatly diminished nuetralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	I515M and I515A diminished neutralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	neutralization assay	G516A greatly diminished nuetralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	neutralization assay	A517W diminished nuetralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	V518M, V518L, and V518W, but not V518A, diminished neutralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	neutralization assay	F519I and F519L diminished neutralization
104	VRC34.01 mutations affect neutralization	gp41 fusion domain	Kong2016a	neutralization	VRC34.01	611	gp41	N	0.050	0.039	0.054	neutralization assay	N611Q and N611D enhanced neutralization
105	PGT121 family and N137 glycan	V3-glycan	Garces2015	binding	PGT121, PGT122, PGT123, PGT124	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875		affinity maturation was primarily focused on avoiding, accommodating, or binding the N137 glycan; removal of the glycan increased Ab binding
106	8ANC195 contacts	gp120/gp41 interface	Kong2015a	contacts	8ANC195	234	gp120	N	0.584	0.757	0.341		8ANC195 contact
106	8ANC195 contacts	gp120/gp41 interface	Kong2015a	contacts	8ANC195	276	gp120, Loop D	N	0.120	0.063	0.169		8ANC195 contact
106	8ANC195 contacts	gp120/gp41 interface	Kong2015a	contacts	8ANC195	637	gp41	N	0.223	0.168	0.186		8ANC195 contact
107	PGT128 contacts	V3-glycan	Kong2015a	contacts	PGT128	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875		PGT128 binding
107	PGT128 contacts	V3-glycan	Kong2015a	contacts	PGT128	156	gp120, V1	N	0.217	0.220	0.224		PGT128 binding
107	PGT128 contacts	V3-glycan	Kong2015a	contacts	PGT128	262	gp120	N	0.029	0.029	0.028		PGT128 indirect interaction
107	PGT128 contacts	V3-glycan	Kong2015a	contacts	PGT128	301	gp120, V3 loop	N	0.261	0.176	0.104		PGT128 binding
107	PGT128 contacts	V3-glycan	Kong2015a	contacts	PGT128	332	gp120	N	0.904	0.491	0.693		PGT128 binding
108	PGDM1400 lineage requires N160	V2-apex	Sok2014	binding	PGDM1400, PGDM1401, PGDM1402, PGDM1403, PGDM1404, PGDM1405, PGDM1406, PGDM1407, PGDM1408, PGDM1409, PGDM1410, PGDM1411, PGDM1412	160	gp120, V2	N	0.401	0.452	0.358		N160 is required for neutralization by PGDM1400 lineage mAbs
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	97	gp120	K	0.433	0.421	0.511		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	102	gp120	E	0.792	0.522	0.426		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	122	gp120	L	0.120	0.101	0.121		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	124	gp120	P	0.047	0.018	0.029		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	275	gp120, Loop D	V	1.034	1.420	0.535		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	276	gp120, Loop D	N	0.120	0.063	0.169		VRC-PG04 heavy chain interaction and light chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	278	gp120, Loop D	T	0.657	0.715	0.481		VRC-PG04 light chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	279	gp120, Loop D	D	0.860	0.850	0.898		VRC-PG04 heavy chain interaction and light chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	280	gp120, Loop D	N	0.117	0.090	0.170		VRC-PG04 heavy chain interaction and light chain interaction, both with hydrogen bonding; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	281	gp120, Loop D	A	1.081	0.814	1.357		VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	282	gp120, Loop D	K	0.260	0.337	0.297		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	283	gp120, Loop D	T	0.992	1.091	0.474		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		VRC-PG04 heavy chain interaction, hydrogen bonding and salt bridge; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	426	gp120, beta20/beta21	M	0.598	0.866	0.274		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	427	gp120, beta20/beta21	W	0.052	0.061	0.038		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	429	gp120, beta20/beta21	K	1.406	0.961	1.308		VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	431	gp120, beta20/beta21	G	0.072	0.036	0.039		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	455	gp120, beta23	T	0.670	0.426	0.972		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	456	gp120, beta23	R	0.196	0.079	0.323		VRC-PG04 heavy chain interaction, hydrogen bonding; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	457	gp120, beta23	D	0.059	0.054	0.043		VRC-PG04 heavy chain interaction, salt bridge; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	458	gp120, beta23	G	0.097	0.045	0.095		VRC-PG04 heavy chain interaction(hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		VRC-PG04 heavy chain interaction and light chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		VRC-PG04 light chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		VRC-PG04 light chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	472	gp120	G	0.034	0.012	0.043		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	473	gp120	G	0.031	0.033	0.029		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	474	gp120	D	0.719	0.681	0.752		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	476	gp120	R	0.699	0.615	0.711		VRC-PG04 heavy chain interaction; calculated on the EBI PISA server
109	VRC-PG04 contacts	CD4BS	Wu2011	contacts	VRC-PG04	776	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction	L	0.265	0.197	0.214		VRC-PG04 heavy chain interaction (hydrogen bonding) and light chain interaction; calculated on the EBI PISA server
110	Mutations coupling nAb resistance with ceniciviroc sensitivity	V3-glycan	Kuwata2016	neutralization	0.5γ	315	gp120, V3 loop	R	1.120	1.028	0.196	neutralization assay, other	R315K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
110	Mutations coupling nAb resistance with ceniciviroc sensitivity	V3-glycan	Kuwata2016	neutralization	0.5γ	324	gp120, V3 loop	G	0.088	0.056	0.092	neutralization assay, other	G324R causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
110	Mutations coupling nAb resistance with ceniciviroc sensitivity	V3-glycan	Kuwata2016	neutralization	0.5γ	381	gp120	E	0.044	0.045	0.028	neutralization assay, other	E381K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	90	gp120	T	0.073	0.063	0.051	neutralization assay	T90A in strain JRCSF decreases PGT151 neutralization 56-fold (vanGils2016)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	501	gp120	A	0.102	0.017	0.221	neutralization assay	A501C abrogates PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	502	gp120	K	0.553	0.512	0.348	neutralization assay	R502A reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	A512W in strain JRCSF decreases PGT151 neutralization >240-fold (vanGils2016). A512W abrogates neutralization of CAP45 (Wibmer2017, Kong2016a)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	G514W in strain JRCSF decreases PGT151 neutralization >240-fold (vanGils2016). G514W reduces neutralization of CAP45 (Wibmer2017, Kong2016a).
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	V518W reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	521	gp41, fusion peptide	G	0.033	0.028	0.008	neutralization assay	G521W in strain JRCSF decreases PGT151 neutralization 11-fold (vanGils2016)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	533	gp41	A	0.083	0.103	0.041	neutralization assay	A533W in strain JRCSF decreases PGT151 neutralization >240-fold (vanGils2016)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	536	gp41	T	0.331	0.396	0.366	neutralization assay	T536W in strain JRCSF decreases PGT151 neutralization 124-fold (vanGils2016)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	537	gp41	L	0.010	0.006	0.008	neutralization assay	L537W in strain JRCSF decreases PGT151 neutralization >240-fold (vanGils2016)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	538	gp41	T	0.030	0.022	0.045	neutralization assay	T538W in strain JRCSF decreases PGT151 neutralization 144-fold (vanGils2016)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	540	gp41, Leu/Ile zipper-like sequence	Q	0.065	0.029	0.072	neutralization assay	Q540W in strain JRCSF decreases PGT151 neutralization >240-fold (vanGils2016)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	611	gp41	N	0.050	0.039	0.054	neutralization assay	N611A (Falkowska2014), N611Q (Kong2016a) or N611D (Falkowska and Kong) decreases PGT151 neutralization
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	613	gp41	S	0.379	0.207	0.216	neutralization assay	S613A reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	637	gp41	N	0.223	0.168	0.186	neutralization assay	N637K decreases PGT151 neutralization (Falkowska2014). K was the most strongly selected mutation and it increased the IC50 by 3.7-fold (Dingens2017).
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	641	gp41	L	1.839	1.530	0.830	neutralization assay	T641A reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	647	gp41	E	0.542	0.372	0.224	neutralization assay	E647A or E647G decreases PGT151 neutralization (Falkowska2014). E647G was the most strongly selected mutation with IC50 fold-change of 5.3 (Dingens2017). E647A abrogates neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	648	gp41	E	1.390	1.332	1.379	neutralization assay	E648K and E648R showed substantially reduced PGT151 neutralization (IC50 fold-change of 7.7 and 3.7, respectively); mutations to other amino acids (D, A, and H) had less than 1.5-fold change in IC50 (Dingens2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	654	gp41	E	0.313	0.174	0.105	neutralization assay	E654A reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	657	gp41	E	0.023	0.040	0.023	neutralization assay	E657A reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	659	gp41	E	0.745	0.523	0.383	neutralization assay	D659A reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	661	gp41	L	0.041	0.050	0.008	neutralization assay	L661A reduces PGT151 neutralization of CAP45 (Wibmer2017)
111	Mutation affects PGT151 neutralization	gp41 fusion domain	Dingens2017, Falkowska2014, Kong2016a, vanGils2016, Wibmer2017	neutralization	PGT151	663	gp41	L	0.094	0.094	0.053	neutralization assay	L663A reduces PGT151 neutralization of CAP45 (Wibmer2017)
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	83	gp120	E	0.033	0.039	0.035	mutational analysis, neutralization assay	E83A in strain JRCSF decreases ACS202 neutralization 57-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	85	gp120	V	2.208	1.797	1.418	mutational analysis, neutralization assay	V85A in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	87	gp120	V	1.538	1.611	1.463	mutational analysis, neutralization assay	E87A in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	90	gp120	T	0.073	0.063	0.051	mutational analysis, neutralization assay	T90A (which disrupts glycosylation of N88) in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	229	gp120	N	0.780	0.742	0.290	mutational analysis, neutralization assay	N229A in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	512	gp41, fusion peptide	A	0.175	0.260	0.110	mutational analysis, neutralization assay	A512W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	513	gp41, fusion peptide	V	0.711	0.736	0.506	mutational analysis, neutralization assay	V513W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	515	gp41, fusion peptide	I	1.106	1.147	0.877	mutational analysis, neutralization assay	I515W in strain JRCSF decreases ACS202 neutralization 15-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	516	gp41, fusion peptide	G	0.091	0.038	0.048	mutational analysis, neutralization assay	G516W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	517	gp41, fusion peptide	A	0.147	0.109	0.058	mutational analysis, neutralization assay	A517W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	520	gp41, fusion peptide	L	0.604	0.253	0.390	mutational analysis, neutralization assay	L520W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	521	gp41, fusion peptide	G	0.033	0.028	0.008	mutational analysis, neutralization assay	G521W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	525	gp41, fusion peptide	A	0.366	0.263	0.387	mutational analysis, neutralization assay	A525W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	528	gp41	S	0.020	0.012	0.022	mutational analysis, neutralization assay	S528W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	533	gp41	A	0.083	0.103	0.041	mutational analysis, neutralization assay	A533W in strain JRCSF decreases ACS202 neutralization 35-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	536	gp41	T	0.331	0.396	0.366	mutational analysis, neutralization assay	T536W in strain JRCSF decreases ACS202 neutralization >61-fold
112	Mutation affects ACS202 neutralization	gp41 fusion domain	vanGils2016	neutralization	ACS202	537	gp41	L	0.010	0.006	0.008	mutational analysis, neutralization assay	L537W in strain JRCSF decreases ACS202 neutralization 53-fold
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	97	gp120	K	0.433	0.421	0.511		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	124	gp120	P	0.047	0.018	0.029		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	198	gp120	T	0.458	0.264	0.469		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	275	gp120, Loop D	V	1.034	1.420	0.535		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	276	gp120, Loop D	N	0.120	0.063	0.169		N6 light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	278	gp120, Loop D	T	0.657	0.715	0.481		N6 light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	279	gp120, Loop D	D	0.860	0.850	0.898		N6 contact: hydrogen bond to N6 heavy chain Ser100; also light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	280	gp120, Loop D	N	0.117	0.090	0.170		N6 contact: hydrogen bond to N6 heavy chain Trp50; also hydrogen bond to N6 light chain Gln96
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	281	gp120, Loop D	A	1.081	0.814	1.357		N6 contact: hydrogen bond to N6 heavy chain Lys52
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	282	gp120, Loop D	K	0.260	0.337	0.297		N6 contact: hydrogen bond and salt bridge to N6 heavy chain Asp100
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	283	gp120, Loop D	T	0.992	1.091	0.474		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	355	gp120	N	0.671	0.893	0.297		N6 light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		N6 contact: hydrogen bonds to N6 heavy chain Arg71 and Tyr54, and salt bridge to N6 heavy chain Arg71
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	370	gp120, CD4 binding loop	E	0.035	0.017	0.055		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	425	gp120, beta20/beta21	N	0.405	0.138	0.177		N6 contact: hydrogen bond to N6 heavy chain Tyr54
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	426	gp120, beta20/beta21	M	0.598	0.866	0.274		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	427	gp120, beta20/beta21	W	0.052	0.061	0.038		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	430	gp120, beta20/beta21	V	0.397	0.080	0.073		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	455	gp120, beta23	T	0.670	0.426	0.972		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	456	gp120, beta23	R	0.196	0.079	0.323		N6 contact: hydrogen bond to N6 heavy chain Asn58
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	457	gp120, beta23	D	0.059	0.054	0.043		N6 contact: hydrogen bond to N6 heavy chain Arg64 and salt bridge to N6 heavy chain Arg64
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	458	gp120, beta23	G	0.097	0.045	0.095		N6 contact: hydrogen bond to N6 heavy chain Asn58; also light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		N6 contact: hydrogen bond to N6 heavy chain Asn58; also light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		N6 heavy chain contact; N6 light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		N6 heavy chain contact; N6 light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		N6 light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		N6 light chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	471	gp120, beta24	G	0.879	0.888	0.866		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	472	gp120	G	0.034	0.012	0.043		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	473	gp120	G	0.031	0.033	0.029		N6 contact: hydrogen bond to N6 heavy chain Gln53
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	474	gp120	D	0.719	0.681	0.752		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	475	gp120	M	0.281	0.092	0.106		N6 heavy chain contact
114	N6 contacts	CD4BS	Huang2016a	contacts	N6	476	gp120	R	0.699	0.615	0.711		N6 heavy chain contact
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	279	gp120, Loop D	D	0.860	0.850	0.898	alanine scanning, binding assay	D279A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay	K282A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	283	gp120, Loop D	T	0.992	1.091	0.474	alanine scanning, binding assay	T283A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	alanine scanning, binding assay	S365A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay	G366A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay	G367A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay	D368A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay	E370A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay	D457A decreases N6 binding to JRCSF to <33% of wild type
115	N6 alanine scanning	CD4BS	Huang2016a	binding	N6	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay	D474A decreases N6 binding to JRCSF to <33% of wild type
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	120	gp120	V	0.073	0.046	0.046	alanine scanning, binding assay, mutational analysis	V120N moderately reduced binding [Dingens2019, BG505.T332N]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	197	gp120	N	0.111	0.082	0.109	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with T or S (very strong effect); glycosylation motif [Dingens2019, BG505.T332N]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	198	gp120	T	0.458	0.264	0.469	alanine scanning, binding assay, mutational analysis	T198A moderately reduced binding; glycosylation motif [Dingens2019, BG505.T332N]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	209	gp120	S	0.715	0.531	0.791	alanine scanning, binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay, mutational analysis	N262A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	279	gp120, Loop D	D	0.860	0.850	0.898	alanine scanning, binding assay, mutational analysis	D279A eliminates VRC01 binding to JRCSF [Huang2016a]; significant site of viral escape; greatest binding reductions with R/L (moderate effect) [Dingens2019, BG505.T332N]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay, mutational analysis	K282A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	326	gp120, V3 loop	M	0.188	0.143	0.116	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with R/L (moderate effect) [Dingens2019, BG505.T332N]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay, mutational analysis	G366A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay, mutational analysis	G367A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay, mutational analysis	D368A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with Y or G (moderate effect) [Dingens2019, BG505.T332N]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay, mutational analysis	E370A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay, mutational analysis	I371A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	alanine scanning, binding assay, mutational analysis	V372A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay, mutational analysis	D457A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
116	mutations affecting VRC01 binding	CD4BS	Dingens2019, Huang2016a	binding	VRC01	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay, mutational analysis	D474A decreases VRC01 binding to JRCSF to <33% of wild type [Huang2016a]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	119	gp120, Cys 119 linked to Cys 205	C	0.014	0.012	0.022	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with Q (moderate effect) [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	120	gp120	V	0.073	0.046	0.046	alanine scanning, binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	122	gp120	L	0.120	0.101	0.121	alanine scanning, binding assay, mutational analysis	L122V moderately reduced binding [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	182	gp120, V2	I	0.694	0.957	0.587	alanine scanning, binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	197	gp120	N	0.111	0.082	0.109	alanine scanning, binding assay, mutational analysis	L179P moderately reduced binding [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	204	gp120	A	0.127	0.127	0.131	alanine scanning, binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	206	gp120	P	0.038	0.035	0.022	alanine scanning, binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	207	gp120	K	0.043	0.029	0.029	alanine scanning, binding assay, mutational analysis	significant site of viral escape especially with S or T which very strongly reduced binding; glycosylation motif [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	209	gp120	S	0.715	0.531	0.791	alanine scanning, binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay, mutational analysis	N262A decreases 3BNC117 binding to JRCSF to <33% of wild type [Huang2016a]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	274	gp120	S	0.233	0.121	0.230	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with Y (moderate effect) [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	279	gp120, Loop D	D	0.860	0.850	0.898	alanine scanning, binding assay, mutational analysis	D279A eliminates 3BNC117 binding to JRCSF [Huang2016a]; significant site of viral escape, greatest binding reduction with R (moderate effect) [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay, mutational analysis	K282A decreases 3BNC117 binding to JRCSF to <33% of wild type [Huang2016a]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	304	gp120, V3 loop	R	0.287	0.390	0.141	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with S (moderate effect) [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	308	gp120, V3 loop	R	0.108	0.091	0.127	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with D (moderate effect) [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	318	gp120, V3 loop	V	0.574	0.691	0.507	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with E (moderate effect) [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay, mutational analysis	G366A decreases 3BNC117 binding to JRCSF to <33% of wild type [Huang2016a]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay, mutational analysis	G367A decreases 3BNC117 binding to JRCSF to <33% of wild type [Huang2016a]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay, mutational analysis	D368A decreases 3BNC117 binding to JRCSF to <33% of wild type [Huang2016a]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	alanine scanning, binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay, mutational analysis	E370A decreases 3BNC117 binding to JRCSF to <33% of wild type [Huang2016a]
117	mutations affecting 3BNC117 binding	CD4BS	Dingens2019, Huang2016a	binding	3BNC117	471	gp120, beta24	G	0.879	0.888	0.866	alanine scanning, binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with L (strong effect) or I (moderate effect) [Dingens2019, BG505.T332N]
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay	N262A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	280	gp120, Loop D	N	0.117	0.090	0.170	alanine scanning, binding assay	N280A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay	K282A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay	G366A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay	G367A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay	D368A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay	E370A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	alanine scanning, binding assay	V372A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay	D457A eliminates VRC-PG04 binding to JRCSF
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	alanine scanning, binding assay	R469A decreases VRC-PG04 binding to JRCSF to <33% of wild type
118	VRC-PG04 alanine scanning	CD4BS	Huang2016a	binding	VRC-PG04	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay	D474A eliminates VRC-PG04 binding to JRCSF
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay	K282A decreases 12A21 binding to JRCSF to <33% of wild type
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay	G366A decreases 12A21 binding to JRCSF to <33% of wild type
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay	G367A decreases 12A21 binding to JRCSF to <33% of wild type
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay	D368A decreases 12A21 binding to JRCSF to <33% of wild type
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay	E370A decreases 12A21 binding to JRCSF to <33% of wild type
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A decreases 12A21 binding to JRCSF to <33% of wild type
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay	D457A decreases 12A21 binding to JRCSF to <33% of wild type
119	12A21 alanine scanning	CD4BS	Huang2016a	binding	12A21	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay	D474A decreases 12A21 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	197	gp120	N	0.111	0.082	0.109	alanine scanning, binding assay	N197T decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay	N262A eliminates VRC27 binding to JRCSF
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	279	gp120, Loop D	D	0.860	0.850	0.898	alanine scanning, binding assay	D279A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	280	gp120, Loop D	N	0.117	0.090	0.170	alanine scanning, binding assay	N280A eliminates VRC27 binding to JRCSF
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	283	gp120, Loop D	T	0.992	1.091	0.474	alanine scanning, binding assay	T283A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay	G366A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay	G367A eliminates VRC27 binding to JRCSF
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay	D368A eliminates VRC27 binding to JRCSF
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay	E370A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A eliminates VRC27 binding to JRCSF
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	alanine scanning, binding assay	V372A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	373	gp120, CD4 binding loop	T	0.953	0.872	0.371	alanine scanning, binding assay	M373A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay	D457A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	alanine scanning, binding assay	I467A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	alanine scanning, binding assay	R469A eliminates VRC27 binding to JRCSF
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	472	gp120	G	0.034	0.012	0.043	alanine scanning, binding assay	G472A eliminates VRC27 binding to JRCSF
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	473	gp120	G	0.031	0.033	0.029	alanine scanning, binding assay	G473A decreases VRC27 binding to JRCSF to <33% of wild type
120	VRC27 alanine scanning	CD4BS	Huang2016a	binding	VRC27	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay	D474A eliminates VRC27 binding to JRCSF
121	Mutation affects 2G12 binding	glycan	Alam2017	binding	2G12	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	binding assay	2G12 binding is decreased by the N295A mutation of JRCSF, with a fold knockdown effect of >105.
121	Mutation affects 2G12 binding	glycan	Alam2017	binding	2G12	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	binding assay	2G12 binding is decreased by the T297A mutation of JRCSF, with a fold knockdown effect of >105.
121	Mutation affects 2G12 binding	glycan	Alam2017	binding	2G12	339	gp120	N	1.157	1.082	1.026	binding assay	2G12 binding is decreased by the N339A mutation of JRCSF, with a fold knockdown effect of 14.33.
121	Mutation affects 2G12 binding	glycan	Alam2017	binding	2G12	392	gp120, V4 loop	N	0.561	0.454	0.804	binding assay	2G12 binding is decreased by the N392A mutation of JRCSF, with a fold knockdown effect of >105.
122	Mutation affects neutralization of V3 mAbs	V3-glycan	Alam2017	neutralization	DH563, PGT121, PGT128, VRC41.01, VRC41.02	301	gp120, V3 loop	N	0.261	0.176	0.104	neutralization assay	N301A increased the resistance of the BG505 virus for neutralization by PGT121 and PGT128; N301A decreased the binding of JRCSF by VRC41.01 and PGT128
122	Mutation affects neutralization of V3 mAbs	V3-glycan	Alam2017	neutralization	DH563, PGT121, PGT128, VRC41.01, VRC41.02	303	gp120, V3 loop	T	0.297	0.190	0.202	neutralization assay	T303A increased the resistance of the RW020 virus for neutralization by PGT121, PGT128, VRC41.01, and VRC41.02
122	Mutation affects neutralization of V3 mAbs	V3-glycan	Alam2017	neutralization	DH563, PGT121, PGT128, VRC41.01, VRC41.02	332	gp120	N	0.904	0.491	0.693	neutralization assay	T332N decreased the resistance of the BG505 virus for neutralization by VRC41.01 and VRC41.02; N332A reduced binding by VRC41.01, VRC41.02, PGT128, and DH563
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	276	gp120, Loop D	N	0.120	0.063	0.169	binding assay	N276A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <2% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	278	gp120, Loop D	T	0.657	0.715	0.481	binding assay	T278A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH28, and HJ16 to <25% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	363	gp120	Q	1.839	1.587	1.352	binding assay	delta371I/P363 double mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98 and VRC01 to <2% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	binding assay	S365K mutation of subtype B strain YU2 decreases binding of mAb PGV04 to <25% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	binding assay	D368A mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98, CH13, and VRC01 to <25% of wt binding; D368R mutation of subtype B strain YU2 decreases binding of mAbs VRC01, PGV04, and B12 to <25% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	binding assay	delta371I/P363 double mutation of subtype CRF01_AE strain A244 decreases binding of mAbs CH98 and VRC01 to <2% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	419	gp120	R	0.516	0.341	0.500	binding assay	R419G mutation of subtype B strain YU2 decreases binding of mAb B12 to <25% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	455	gp120, beta23	T	0.670	0.426	0.972	binding assay	T455E mutation of subtype B strain YU2 decreases binding of mAb B12 to <25% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	binding assay	G459E mutation of subtype B strain YU2 decreases binding of mAb PGV04 to <25% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	473	gp120	G	0.031	0.033	0.029	binding assay	G473R mutation of subtype B strain YU2 decreases binding of mAbs VRC01 and PGV04 to <25% of wt binding
123	Mutation decreases binding to CD4BS mAbs	CD4BS	Easterhoff2017	binding	b12, b6, CH13, CH28, CH98, HJ16, VRC01, VRC-PG04	476	gp120	R	0.699	0.615	0.711	binding assay	R476V mutation of subtype B strain YU2 decreases binding of mAb B6 to <25% of wt binding
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	669	gp41	L	0.020	0.023	0.000		contacts VH3-15 region residues of DH511.2 and DH511.2_K3
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	670	gp41	W	0.026	0.028	0.035		contacts VH3-15 region residues of DH511.2 and DH511.2_K3
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	671	gp41	N	0.779	0.669	0.885		contacts VH3-15 region residues of DH511.2 and DH511.2_K3
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	672	gp41	W	0.017	0.023	0.014		contacts both VH3-15 region residues and HCDR3 residues of DH511.2 and DH511.2_K3; mutation W672A in strain COT6 caused increased resistance to neutralization by several DH511 lineage members
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	673	gp41	F	0.058	0.065	0.073		contacts VH3-15 region residues of DH511.2 and DH511.2_K3; mutation F673A in strain COT6 caused increased sensitivity to neutralization by several DH511 lineage members
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	674	gp41	N	1.182	1.029	1.344		contacts VH3-15 region residues of DH511.2 and DH511.2_K3; mutations D674A and D674S in strain COT6 caused increased sensitivity to neutralization by several DH511 lineage members
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	676	gp41	T	0.683	0.610	0.674		contacts HCDR3 residues of DH511.2 and DH511.2_K3
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.010	0.018	0.008		contacts HCDR3 residues of DH511.2 and DH511.2_K3
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008		contacts HCDR3 residues of DH511.2 and DH511.2_K3
124	DH511.2 and DH511.2_K3 contacts	MPER	Williams2017	contacts	DH511.2, DH511.2_K3	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569		contacts HCDR3 residues of DH511.2 and DH511.2_K3
125	Mutation affects CD4 binding		Finzi2010	Env feature		66	gp120	H	0.019	0.017	0.000	binding assay	H66A decreases CD4 binding
125	Mutation affects CD4 binding		Finzi2010	Env feature		69	gp120	W	0.008	0.000	0.008	binding assay	W69L decreases CD4 binding and CCR5 binding
125	Mutation affects CD4 binding		Finzi2010	Env feature		107	gp120	D	0.030	0.030	0.048	binding assay	D107A decreases CD4 binding and CCR5 binding
125	Mutation affects CD4 binding		Finzi2010	Env feature		111	gp120	L	0.122	0.048	0.221	binding assay	L111A decreases CD4 binding and CCR5 binding
125	Mutation affects CD4 binding		Finzi2010	Env feature		112	gp120	W	0.016	0.018	0.000	binding assay	W112A decreases CD4 binding (W112 does not contact CD4, but lines the Phe 43 cavity and, along with I109, interacts with W427, a cavity-lining residue that does contact CD4)
126	Mutation affects binding to 17b and 412d	CD4i	Finzi2010	binding	17b, 412d	69	gp120	W	0.008	0.000	0.008	binding assay	W69L decreases binding to 17b and 412d
126	Mutation affects binding to 17b and 412d	CD4i	Finzi2010	binding	17b, 412d	107	gp120	D	0.030	0.030	0.048	binding assay	D107A decreases binding to 17b and 412d
126	Mutation affects binding to 17b and 412d	CD4i	Finzi2010	binding	17b, 412d	111	gp120	L	0.122	0.048	0.221	binding assay	L111A decreases binding to 17b and 412d
127	W69 is important for ADCC	cluster A	Ding2015	other feature	A32	69	gp120	W	0.008	0.000	0.008		W69 is important for ADCC responses mediated by anti-cluster A antibodies
128	VRC38.01 contacts	V2-apex	Cale2017, Gorman2020	contacts	VRC38.01	132	gp120, V1-hypervariable, V1	T	1.450	0.849	1.573	cryo-EM, X-ray crystallography	HC contact [Gorman2020]
128	VRC38.01 contacts	V2-apex	Cale2017, Gorman2020	contacts	VRC38.01	133	gp120, V1-hypervariable, V1	D	1.456	1.052	1.360	cryo-EM, X-ray crystallography	side-chain hydrogen bond contact [Cale2017]; HC contact [Gorman2020]
128	VRC38.01 contacts	V2-apex	Cale2017, Gorman2020	contacts	VRC38.01	156	gp120, V1	N	0.217	0.220	0.224	cryo-EM, X-ray crystallography	side-chain hydrogen bond contact [Cale2017]; HC contact [Gorman2020]
128	VRC38.01 contacts	V2-apex	Cale2017, Gorman2020	contacts	VRC38.01	158	gp120, V2	S	0.297	0.185	0.291	cryo-EM, X-ray crystallography	side-chain hydrogen bond contact [Cale2017]; HC contact [Gorman2020]
128	VRC38.01 contacts	V2-apex	Cale2017, Gorman2020	contacts	VRC38.01	168	gp120, V2	K	0.547	0.666	0.396	cryo-EM, X-ray crystallography	side-chain hydrogen bond contact [Cale2017]; HC contact [Gorman2020]
128	VRC38.01 contacts	V2-apex	Cale2017, Gorman2020	contacts	VRC38.01	171	gp120, V2	K	1.239	0.957	1.413	cryo-EM, X-ray crystallography	side-chain hydrogen bond contact [Cale2017]; HC contact [Gorman2020]
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	127	gp120	V	0.093	0.112	0.093	neutralization assay	V127A made BG505 and JRCSF more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	129	gp120	L	0.048	0.056	0.029	neutralization assay	L129A made BG505 more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	155	gp120, V1	K	0.854	0.423	0.831	neutralization assay	K155A made JRCSF more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	156	gp120, V1	N	0.217	0.220	0.224	neutralization assay	N156A made BG505 and JRCSF more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	158	gp120, V2	S	0.297	0.185	0.291	neutralization assay	S158A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	159	gp120, V2	F	0.165	0.034	0.038	neutralization assay	F159A made BG505 and JRCSF more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	T162A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	168	gp120, V2	K	0.547	0.666	0.396	neutralization assay	K168A made BG505 more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	K169A/V169A made BG505/JRCSF more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	171	gp120, V2	K	1.239	0.957	1.413	neutralization assay	K171A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	173	gp120, V2	Y	1.165	0.808	1.158	neutralization assay	K173A made BG505, JRCSF, and WITO more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	175	gp120, V2	F	0.498	0.868	0.271	neutralization assay	L175A made BG505 more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	184	gp120, V2	I	1.060	0.599	0.530	neutralization assay	I184 made JRCSF more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	neutralization assay	D185 made JRCSF more resistant to neutralization by V1V2 NAbs
129	Mutation affects neutralization by V1V2 glycan mAbs	V2-apex	Cale2017	neutralization	CH01, PG9, PGT145, VRC38.01	189	gp120, V2-hypervariable, V2	T	1.811	1.348	1.638	neutralization assay	T189A made JRCSF more sensitive to neutralization by CH01
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848		light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581		light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875		light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	156	gp120, V1	N	0.217	0.220	0.224		non-primary glycan contact; four-fold greater neutralization when no glycan is present
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	301	gp120, V3 loop	N	0.261	0.176	0.104		non-primary glycan contact
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	321	gp120, V3 loop	G	1.031	0.842	1.108		light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	322	gp120, V3 loop	K	0.370	0.347	0.283		light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	323	gp120, V3 loop	I	0.575	0.531	0.263		light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	324	gp120, V3 loop	G	0.088	0.056	0.092		contact with GDIR motif; light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	325	gp120, V3 loop	N	0.653	0.622	0.622		contact with GDIR motif; heavy chain interaction; light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	326	gp120, V3 loop	M	0.188	0.143	0.116		contact with GDIR motif; heavy chain interaction; light chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	327	gp120, V3 loop	R	0.118	0.066	0.073		contact with GDIR motif; heavy chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	328	gp120, V3 loop	Q	1.001	0.816	0.882		heavy chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	329	gp120, V3 loop	A	0.044	0.034	0.022		heavy chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	330	gp120, V3 loop	H	0.743	0.559	0.655		heavy chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	332	gp120	N	0.904	0.491	0.693		primary glycan contact
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	415	gp120, V4 loop	T	0.846	0.760	0.656		heavy chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	416	gp120, V4 loop	L	0.416	0.174	0.580		heavy chain interaction
131	10-1074 contacts	V3-glycan	Barnes2018, Gristick2016	contacts	10-1074	417	gp120, V4 loop	P	0.836	0.736	0.922		heavy chain interaction
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	197	gp120	N	0.111	0.082	0.109	X-ray crystallography	glycan interaction
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	276	gp120, Loop D	N	0.120	0.063	0.169	X-ray crystallography	glycan interaction
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	279	gp120, Loop D	D	0.860	0.850	0.898	X-ray crystallography	primary contact; N279/N280 of BG505 interact with heavy chain D93
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	primary contact; N279/N280 of BG505 interact with heavy chain D93
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	363	gp120	Q	1.839	1.587	1.352	X-ray crystallography	minor interaction with N363 glycan of BG505
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	heavy chain interaction
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	R456 of BG505 interacts with heavy chain D93
132	IOMA contacts	CD4BS	Gristick2016	contacts	IOMA	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	X-ray crystallography	G459 of BG505 interacts with heavy chain D93
134	GPGQ motif affects neutralization and coreceptor usage		Coetzer2006, Gorny2006	Env feature		312	gp120, V3 loop	G	0.189	0.362	0.008		GPGQ vs GPGR at the V3 apex affects the ability of the virus to elicit neutralizing response, and also affects coreceptor usage.
134	GPGQ motif affects neutralization and coreceptor usage		Coetzer2006, Gorny2006	Env feature		313	gp120, V3 loop	P	0.307	0.424	0.078		GPGQ vs GPGR at the V3 apex affects the ability of the virus to elicit neutralizing response, and also affects coreceptor usage.
134	GPGQ motif affects neutralization and coreceptor usage		Coetzer2006, Gorny2006	Env feature		314	gp120, V3 loop	G	0.053	0.095	0.014		GPGQ vs GPGR at the V3 apex affects the ability of the virus to elicit neutralizing response, and also affects coreceptor usage.
134	GPGQ motif affects neutralization and coreceptor usage		Coetzer2006, Gorny2006	Env feature		315	gp120, V3 loop	R	1.120	1.028	0.196		GPGQ vs GPGR at the V3 apex affects the ability of the virus to elicit neutralizing response, and also affects coreceptor usage.
135	Mutation greatly reduces PGT121 neutralization	V3-glycan	Ferguson2013	neutralization	PGT121	332	gp120	N	0.904	0.491	0.693	neutralization assay	N332A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
135	Mutation greatly reduces PGT121 neutralization	V3-glycan	Ferguson2013	neutralization	PGT121	334	gp120	S	0.780	0.501	0.890	neutralization assay	S334A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
136	Mutation greatly reduces PGT123 neutralization	V3-glycan	Ferguson2013	neutralization	PGT123	325	gp120, V3 loop	N	0.653	0.622	0.622	neutralization assay	D325A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
136	Mutation greatly reduces PGT123 neutralization	V3-glycan	Ferguson2013	neutralization	PGT123	332	gp120	N	0.904	0.491	0.693	neutralization assay	N332A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
136	Mutation greatly reduces PGT123 neutralization	V3-glycan	Ferguson2013	neutralization	PGT123	334	gp120	S	0.780	0.501	0.890	neutralization assay	S334A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
137	Mutation greatly reduces PGT125 neutralization	V3-glycan	Ferguson2013	neutralization	PGT125	301	gp120, V3 loop	N	0.261	0.176	0.104	neutralization assay	N301A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
137	Mutation greatly reduces PGT125 neutralization	V3-glycan	Ferguson2013	neutralization	PGT125	303	gp120, V3 loop	T	0.297	0.190	0.202	neutralization assay	T303A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
138	Mutation greatly reduces PGT126 and PGT127 neutralization	V3-glycan	Ferguson2013	neutralization	PGT126, PGT127	301	gp120, V3 loop	N	0.261	0.176	0.104	neutralization assay	N301A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
138	Mutation greatly reduces PGT126 and PGT127 neutralization	V3-glycan	Ferguson2013	neutralization	PGT126, PGT127	303	gp120, V3 loop	T	0.297	0.190	0.202	neutralization assay	T303A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
138	Mutation greatly reduces PGT126 and PGT127 neutralization	V3-glycan	Ferguson2013	neutralization	PGT126, PGT127	332	gp120	N	0.904	0.491	0.693	neutralization assay	N332A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
138	Mutation greatly reduces PGT126 and PGT127 neutralization	V3-glycan	Ferguson2013	neutralization	PGT126, PGT127	334	gp120	S	0.780	0.501	0.890	neutralization assay	S334A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
139	Mutation greatly reduces PGT128 neutralization	V3-glycan	Ferguson2013	neutralization	PGT128	303	gp120, V3 loop	T	0.297	0.190	0.202	neutralization assay	T303A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
140	Mutation greatly reduces PGT130 neutralization	V3-glycan	Ferguson2013	neutralization	PGT130	301	gp120, V3 loop	N	0.261	0.176	0.104	neutralization assay	N301A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
140	Mutation greatly reduces PGT130 neutralization	V3-glycan	Ferguson2013	neutralization	PGT130	303	gp120, V3 loop	T	0.297	0.190	0.202	neutralization assay	T303A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
140	Mutation greatly reduces PGT130 neutralization	V3-glycan	Ferguson2013	neutralization	PGT130	307	gp120, V3 loop	I	0.067	0.030	0.111	neutralization assay	I307A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
140	Mutation greatly reduces PGT130 neutralization	V3-glycan	Ferguson2013	neutralization	PGT130	309	gp120, V3 loop	I	0.921	0.359	0.965	neutralization assay	I309A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
140	Mutation greatly reduces PGT130 neutralization	V3-glycan	Ferguson2013	neutralization	PGT130	324	gp120, V3 loop	G	0.088	0.056	0.092	neutralization assay	G324A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
140	Mutation greatly reduces PGT130 neutralization	V3-glycan	Ferguson2013	neutralization	PGT130	325	gp120, V3 loop	N	0.653	0.622	0.622	neutralization assay	D325A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
140	Mutation greatly reduces PGT130 neutralization	V3-glycan	Ferguson2013	neutralization	PGT130	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
141	Mutation greatly reduces PGT135 neutralization	V3-glycan	Ferguson2013	neutralization	PGT135	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	neutralization assay	T297A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
141	Mutation greatly reduces PGT135 neutralization	V3-glycan	Ferguson2013	neutralization	PGT135	330	gp120, V3 loop	H	0.743	0.559	0.655	neutralization assay	H330A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
141	Mutation greatly reduces PGT135 neutralization	V3-glycan	Ferguson2013	neutralization	PGT135	332	gp120	N	0.904	0.491	0.693	neutralization assay	N332A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
141	Mutation greatly reduces PGT135 neutralization	V3-glycan	Ferguson2013	neutralization	PGT135	334	gp120	S	0.780	0.501	0.890	neutralization assay	S334A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
141	Mutation greatly reduces PGT135 neutralization	V3-glycan	Ferguson2013	neutralization	PGT135	392	gp120, V4 loop	N	0.561	0.454	0.804	neutralization assay	N392A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
141	Mutation greatly reduces PGT135 neutralization	V3-glycan	Ferguson2013	neutralization	PGT135	394	gp120, V4 loop	T	1.078	0.715	1.439	neutralization assay	T394A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
142	Mutation greatly reduces PGT143 neutralization	V2-apex	Ferguson2013	neutralization	PGT143	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
142	Mutation greatly reduces PGT143 neutralization	V2-apex	Ferguson2013	neutralization	PGT143	166	gp120, V2	R	1.127	1.398	0.772	neutralization assay	R166A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
143	Mutation greatly reduces PGT145 neutralization	V2-apex	Ferguson2013	neutralization	PGT145	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A mutation in JR-CSF increased IC50 of neutralization >30-fold relative to wild type virus.
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	binding assay	Ala or Gly mutations reduce binding of VRC34.01
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP5.01
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	binding assay	Ala or Gly mutations reduce binding of VRC34.01
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP5.01
144	VRC34.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	VRC34.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP5.01
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	453	gp120, beta23	L	0.494	0.517	0.199	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	454	gp120, beta23	L	0.118	0.118	0.065	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	456	gp120, beta23	R	0.196	0.079	0.323	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	471	gp120, beta24	G	0.879	0.888	0.866	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	474	gp120	D	0.719	0.681	0.752	binding assay	mutation to alanine reduces binding
146	Mutation decreases binding of Y498	CD4BS	Sun2017	binding	Y498	476	gp120	R	0.699	0.615	0.711	binding assay	mutation to alanine reduces binding
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848		light chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581		light chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875		light chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504		light chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163		light chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	156	gp120, V1	N	0.217	0.220	0.224		glycan contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	325	gp120, V3 loop	N	0.653	0.622	0.622		heavy chain contact; light chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	326	gp120, V3 loop	M	0.188	0.143	0.116		heavy chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	327	gp120, V3 loop	R	0.118	0.066	0.073		heavy chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	328	gp120, V3 loop	Q	1.001	0.816	0.882		heavy chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	329	gp120, V3 loop	A	0.044	0.034	0.022		heavy chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	332	gp120	N	0.904	0.491	0.693		glycan contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392		glycan contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	392	gp120, V4 loop	N	0.561	0.454	0.804		glycan contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	415	gp120, V4 loop	T	0.846	0.760	0.656		heavy chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	416	gp120, V4 loop	L	0.416	0.174	0.580		heavy chain contact
147	BG18 contacts	V3-glycan	Barnes2018	contacts	BG18	417	gp120, V4 loop	P	0.836	0.736	0.922		heavy chain contact
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	501	gp120	A	0.102	0.017	0.221	neutralization assay	A501C abrogates neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	502	gp120	K	0.553	0.512	0.348	neutralization assay	R502A reduces neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	505	gp120	V	0.074	0.091	0.064	neutralization assay	V505A reduces neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	508	gp120, RxKR Cleaved by cellular protease similar to furin	R	0.117	0.055	0.153	neutralization assay	R508A abrogates neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	V513W abrogates neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	G514W reduces neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	652	gp41	Q	0.030	0.041	0.041	neutralization assay	Q652A reduces neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	656	gp41	N	0.025	0.034	0.033	neutralization assay	N656D abrogates neutralization of CAP45
149	Mutation affects neutralization by CAP248-2B	gp120/gp41 interface	Wibmer2017	neutralization	CAP248-2B	666	gp41	W	0.003	0.000	0.000	neutralization assay	W666A abrogates neutralization of CAP45
151	Mutation affects neutralization by VRC34	gp41 fusion domain	Wibmer2017	neutralization	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	A512W abrogates neutralization of CAP45
151	Mutation affects neutralization by VRC34	gp41 fusion domain	Wibmer2017	neutralization	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	V513W abrogates neutralization of CAP45
151	Mutation affects neutralization by VRC34	gp41 fusion domain	Wibmer2017	neutralization	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	G514W reduces neutralization of CAP45
151	Mutation affects neutralization by VRC34	gp41 fusion domain	Wibmer2017	neutralization	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	V515W abrogates neutralization of CAP45
151	Mutation affects neutralization by VRC34	gp41 fusion domain	Wibmer2017	neutralization	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	V518W abrogates neutralization of CAP45
151	Mutation affects neutralization by VRC34	gp41 fusion domain	Wibmer2017	neutralization	VRC34.01	613	gp41	S	0.379	0.207	0.216	neutralization assay	S613A increases neutralization of CAP45
152	Mutation affects neutralization by 35O22	gp120/gp41 interface	Wibmer2017	neutralization	35O22	501	gp120	A	0.102	0.017	0.221	neutralization assay	A501C abrogates neutralization of CAP45
152	Mutation affects neutralization by 35O22	gp120/gp41 interface	Wibmer2017	neutralization	35O22	510	gp120, RxKR Cleaved by cellular protease similar to furin	K	0.116	0.153	0.085	neutralization assay	K510A reduces neutralization of CAP45
152	Mutation affects neutralization by 35O22	gp120/gp41 interface	Wibmer2017	neutralization	35O22	667	gp41	A	1.332	0.545	1.537	neutralization assay	N667Q reduces neutralization of CAP45
153	Mutations affect neutralization by 10E8	MPER	Wibmer2017	neutralization	10E8	504	gp120	R	0.224	0.049	0.216	neutralization assay	R504A increases neutralization of CAP45
153	Mutations affect neutralization by 10E8	MPER	Wibmer2017	neutralization	10E8	506	gp120	V	0.020	0.006	0.038	neutralization assay	V506A increases neutralization of CAP45
153	Mutations affect neutralization by 10E8	MPER	Wibmer2017	neutralization	10E8	508	gp120, RxKR Cleaved by cellular protease similar to furin	R	0.117	0.055	0.153	neutralization assay	R508A increases neutralization of CAP45
153	Mutations affect neutralization by 10E8	MPER	Wibmer2017	neutralization	10E8	666	gp41	W	0.003	0.000	0.000	neutralization assay	W666A increases neutralization of CAP45
153	Mutations affect neutralization by 10E8	MPER	Wibmer2017	neutralization	10E8	672	gp41	W	0.017	0.023	0.014	neutralization assay	W672L/F673L abrogates neutralization of CAP45
153	Mutations affect neutralization by 10E8	MPER	Wibmer2017	neutralization	10E8	673	gp41	F	0.058	0.065	0.073	neutralization assay	W672L/F673L abrogates neutralization of CAP45
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	neutralization assay	D140E mediated a 1.6-fold decrease in neutralization potency [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	neutralization assay	R151K mediated a 1.6-fold decrease in neutralization potency [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	156	gp120, V1	N	0.217	0.220	0.224	neutralization assay	4-fold greater potency when glycan 156 is absent [Gristick2016]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	322	gp120, V3 loop	K	0.370	0.347	0.283	neutralization assay	D322E and D322G each mediated a 1.4-fold decrease in neutralization potency, D322A had no effect [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	323	gp120, V3 loop	I	0.575	0.531	0.263	neutralization assay	I323G mediated a 2.5-fold decrease in neutralization potency [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	325	gp120, V3 loop	N	0.653	0.622	0.622	neutralization assay	D325E and D325S mediated respective 27.2- and 3.0-fold decreases in neutralization potency while D325N had no effect; GDIR motif [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	327	gp120, V3 loop	R	0.118	0.066	0.073	neutralization assay	R327A mediated a 4.0-fold decrease in neutralization potency; GDIR motif [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	330	gp120, V3 loop	H	0.743	0.559	0.655	neutralization assay	H330R mediated a 35.1-fold decrease in neutralization potency [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	332	gp120	N	0.904	0.491	0.693	neutralization assay	YU2 mutations N332K, N332S, or N332Y decrease 10-1074 neutralization >9 fold [Schommers2020]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	334	gp120	S	0.780	0.501	0.890	neutralization assay	YU2 mutations S334D or S334N decrease 10-1074 neutralization >9 fold [Schommers2020]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	415	gp120, V4 loop	T	0.846	0.760	0.656	neutralization assay	T415R and T415Y mediated respective 4.8- and 2.7-fold decreases in neutralization potency [Dingens2019, BG505.T332N]
154	10-1074 neutralization	V3-glycan	Dingens2019, Gristick2016, Schommers2020	neutralization	10-1074	441	gp120	G	0.060	0.041	0.037	neutralization assay	G441P mediated a 2.2-fold decrease in neutralization potency [Dingens2019, BG505.T332N]
155	PGT122 glycan contacts	V3-glycan	Gristick2016	contacts	PGT122	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875		PGT122 glycan contact
155	PGT122 glycan contacts	V3-glycan	Gristick2016	contacts	PGT122	156	gp120, V1	N	0.217	0.220	0.224		PGT122 glycan contact
155	PGT122 glycan contacts	V3-glycan	Gristick2016	contacts	PGT122	301	gp120, V3 loop	N	0.261	0.176	0.104		PGT122 glycan contact
156	PGT122 neutralization	V3-glycan	Gristick2016	neutralization	PGT122	156	gp120, V1	N	0.217	0.220	0.224	neutralization assay	about 2-fold more potent when glycan is present
157	NIH45-46G54W mutations causing resistance	CD4BS	Diskin2013	neutralization	NIH45-46G54W	279	gp120, Loop D	D	0.860	0.850	0.898		Mutations at this site are found in strains resistant to NIH45-46G45W
157	NIH45-46G54W mutations causing resistance	CD4BS	Diskin2013	neutralization	NIH45-46G54W	280	gp120, Loop D	N	0.117	0.090	0.170		Mutations at this site are found in strains resistant to NIH45-46G45W
157	NIH45-46G54W mutations causing resistance	CD4BS	Diskin2013	neutralization	NIH45-46G54W	458	gp120, beta23	G	0.097	0.045	0.095		Mutations at either position found in strains resistant to NIH45-46G45W
157	NIH45-46G54W mutations causing resistance	CD4BS	Diskin2013	neutralization	NIH45-46G54W	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		Mutations at either position found in strains resistant to NIH45-46G45W
158	MPER membrane fusion mutations confer sensitivity	CD4i	Fu2018	neutralization	17b	670	gp41	W	0.026	0.028	0.035	neutralization assay	W670A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
158	MPER membrane fusion mutations confer sensitivity	CD4i	Fu2018	neutralization	17b	673	gp41	F	0.058	0.065	0.073	neutralization assay	F673A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
158	MPER membrane fusion mutations confer sensitivity	CD4i	Fu2018	neutralization	17b	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	neutralization assay	W680A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
167	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	CD4BS	McGuire2013, McGuire2016	binding	VRC01	276	gp120, Loop D	N	0.120	0.063	0.169		Elimination of the 276 NLGS from the 426c Env confers binding to germline-reverted NIH45-46 and VRC01. If NLGS at positions 460 and 463 are also eliminated, the binding is improved.
167	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	CD4BS	McGuire2013, McGuire2016	binding	VRC01	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		In combination with the elimination of the 276 NLGS, elimination of the 460 and 463 (V5) from the 426c Env confers and improves binding to germline-reverted NIH45-46 and VRC01.
167	Removal of glycosylation sites confers binding to germline-reverted NIH45-46 and VRC01	CD4BS	McGuire2013, McGuire2016	binding	VRC01	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		In combination with the elimination of the 276 NLGS, elimination of the 460 and 463 (V5) from the 426c Env confers and improves binding to germline-reverted NIH45-46 and VRC01.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acids D, Y, H are associated with resistance. Amino acid V is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	155	gp120, V1	K	0.854	0.423	0.831	computational prediction	Amino acid R, T are associated with resistance. Amino acid K is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) L is associated with resistance. Amino acid(s) I is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	240	gp120	T	1.789	1.338	1.717	computational prediction	Amino acid(s) K is associated with resistance.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	252	gp120	R	0.688	0.592	0.148	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) D is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	289	gp120	N	1.027	0.835	0.551	computational prediction	Amino acid(s) NxST is associated with resistance. Amino acid(s) K is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	293	gp120	E	2.081	1.967	1.722	computational prediction	Amino acid(s) E is associated with resistance.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) V, I, NxST is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) T is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) Y, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	304	gp120, V3 loop	R	0.287	0.390	0.141	computational prediction	Amino acid(s) R is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	311	gp120, V3 loop	R	0.768	1.050	0.114	computational prediction	Amino acid(s) I is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	323	gp120, V3 loop	I	0.575	0.531	0.263	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	325	gp120, V3 loop	N	0.653	0.622	0.622	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) D is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) E, V, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) D, N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) S, T is associated with resistance. Amino acid(s) A is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	344	gp120	Q	1.728	1.306	1.923	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) A is associated with resistance.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	413	gp120, V4 loop	T	1.440	1.451	1.561	computational prediction	Amino acid(s) NxST is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	415	gp120, V4 loop	T	0.846	0.760	0.656	computational prediction	Amino acid(s) T is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	448	gp120	N	0.648	0.448	0.927	computational prediction	Amino acid(s) NxST, N is associated with resistance.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	583	gp41, Leu/Ile zipper-like sequence	V	0.988	0.424	0.701	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S, A is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	640	gp41	S	2.068	1.971	1.834	computational prediction	Amino acid(s) D is associated with resistance.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) A is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid(s) NxST, N is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	688	gp41, gp41 transmembrane	I	0.192	0.201	0.176	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) V is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	746	gp41, gp41 cytoplasmic tail	I	1.629	1.911	0.739	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	750	gp41, gp41 cytoplasmic tail	N	1.528	1.692	0.891	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) N, D is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.849	0.667	0.984	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) Q is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.825	0.183	0.621	computational prediction	Amino acid(s) F is associated with resistance.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	1.141	0.355	0.328	computational prediction	Amino acid(s) V, L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
168	V3 Signature Summary	V3-glycan	Bricault2019	signature	PGT121	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.534	1.502	1.006	computational prediction	Amino acid(s) A is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acids D, H are associated with resistance. Amino acid V is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	155	gp120, V1	K	0.854	0.423	0.831	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) I is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	197	gp120	N	0.111	0.082	0.109	computational prediction	Amino acid(s) NxST, N is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	252	gp120	R	0.688	0.592	0.148	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) N is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) I is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) N is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	304	gp120, V3 loop	R	0.287	0.390	0.141	computational prediction	Amino acid(s) R is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction	Amino acid(s) T is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	325	gp120, V3 loop	N	0.653	0.622	0.622	computational prediction	Amino acid(s) N is associated with resistance. Amino acid(s) D is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) E, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	333	gp120	I	0.901	0.855	0.293	computational prediction	Amino acid(s) V is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S, T is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	344	gp120	Q	1.728	1.306	1.923	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) A is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	computational prediction	Amino acid(s) NxST, N is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	415	gp120, V4 loop	T	0.846	0.760	0.656	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) A is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	583	gp41, Leu/Ile zipper-like sequence	V	0.988	0.424	0.701	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) V, A is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) E is associated with resistance.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.031	0.756	1.040	computational prediction	Amino acid(s) G, N, NxST is associated with resistance. Amino acid(s) D is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	746	gp41, gp41 cytoplasmic tail	I	1.629	1.911	0.739	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	750	gp41, gp41 cytoplasmic tail	N	1.528	1.692	0.891	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) H is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	1.141	0.355	0.328	computational prediction	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
169	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.1	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.534	1.502	1.006	computational prediction	Amino acid(s) A is associated with resistance. Amino acid(s) I is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acids D, H are associated with resistance. Amino acid V is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	155	gp120, V1	K	0.854	0.423	0.831	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) L is associated with resistance. Amino acid(s) I is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid(s) D is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	240	gp120	T	1.789	1.338	1.717	computational prediction	Amino acid(s) K is associated with resistance.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	252	gp120	R	0.688	0.592	0.148	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) NxST, N is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	282	gp120, Loop D	K	0.260	0.337	0.297	computational prediction	Amino acid(s) K is associated with resistance.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	289	gp120	N	1.027	0.835	0.551	computational prediction	Amino acid(s) K is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) V, I, NxST is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) T is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) D, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) NxST is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	304	gp120, V3 loop	R	0.287	0.390	0.141	computational prediction	Amino acid(s) R is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction	Amino acid(s) V is associated with resistance.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) A, V is associated with resistance. Amino acid(s) T is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	323	gp120, V3 loop	I	0.575	0.531	0.263	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	325	gp120, V3 loop	N	0.653	0.622	0.622	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) D is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) K, N is associated with resistance. Amino acid(s) Q is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) E, D, V, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) A, E is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	344	gp120	Q	1.728	1.306	1.923	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) S is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	413	gp120, V4 loop	T	1.440	1.451	1.561	computational prediction	Amino acid(s) NxST is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	415	gp120, V4 loop	T	0.846	0.760	0.656	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) N, S is associated with resistance. Amino acid(s) A is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	442	gp120	Q	2.193	1.699	0.964	computational prediction	Amino acid(s) NxST, Q is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	448	gp120	N	0.648	0.448	0.927	computational prediction	Amino acid(s) NxST, N is associated with resistance.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	583	gp41, Leu/Ile zipper-like sequence	V	0.988	0.424	0.701	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) E is associated with resistance.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid(s) D is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	746	gp41, gp41 cytoplasmic tail	I	1.629	1.911	0.739	computational prediction	Amino acid(s) V, T is associated with resistance.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	750	gp41, gp41 cytoplasmic tail	N	1.528	1.692	0.891	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) H, N, D is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.849	0.667	0.984	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) Q is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.825	0.183	0.621	computational prediction	Amino acid(s) F is associated with resistance. Amino acid(s) L is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	1.141	0.355	0.328	computational prediction	Amino acid(s) V, L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
172	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.534	1.502	1.006	computational prediction	Amino acid(s) A is associated with resistance.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acid L is associated with resistance. Amino acid V is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	240	gp120	T	1.789	1.338	1.717	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) T is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	252	gp120	R	0.688	0.592	0.148	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) D is associated with resistance. Amino acid(s) N is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	293	gp120	E	2.081	1.967	1.722	computational prediction	Amino acid(s) NxST, N is associated with resistance.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) E, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) G is associated with resistance.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	304	gp120, V3 loop	R	0.287	0.390	0.141	computational prediction	Amino acid(s) R is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) T is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	323	gp120, V3 loop	I	0.575	0.531	0.263	computational prediction	Amino acid(s) I is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	325	gp120, V3 loop	N	0.653	0.622	0.622	computational prediction	Amino acid(s) D is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) Q is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) D, N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	344	gp120	Q	1.728	1.306	1.923	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) NxST is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	392	gp120, V4 loop	N	0.561	0.454	0.804	computational prediction	Amino acid(s) NxST is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	415	gp120, V4 loop	T	0.846	0.760	0.656	computational prediction	Amino acid(s) T, I is associated with resistance. Amino acid(s) T is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	442	gp120	Q	2.193	1.699	0.964	computational prediction	Amino acid(s) E, K is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	688	gp41, gp41 transmembrane	I	0.192	0.201	0.176	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) V is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.031	0.756	1.040	computational prediction	Amino acid(s) G, N is associated with resistance. Amino acid(s) D is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	746	gp41, gp41 cytoplasmic tail	I	1.629	1.911	0.739	computational prediction	Amino acid(s) V is associated with resistance.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.825	0.183	0.621	computational prediction	Amino acid(s) F is associated with resistance.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	1.141	0.355	0.328	computational prediction	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
173	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT128	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.534	1.502	1.006	computational prediction	Amino acid(s) T is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acids Y, H are associated with resistance. Amino acid V is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	155	gp120, V1	K	0.854	0.423	0.831	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) I is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	240	gp120	T	1.789	1.338	1.717	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) T is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	252	gp120	R	0.688	0.592	0.148	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) NxST, N is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	289	gp120	N	1.027	0.835	0.551	computational prediction	Amino acid(s) K is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	293	gp120	E	2.081	1.967	1.722	computational prediction	Amino acid(s) K is associated with resistance.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) V, I, NxST is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) Y, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	304	gp120, V3 loop	R	0.287	0.390	0.141	computational prediction	Amino acid(s) R is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction	Amino acid(s) T is associated with resistance.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	323	gp120, V3 loop	I	0.575	0.531	0.263	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	325	gp120, V3 loop	N	0.653	0.622	0.622	computational prediction	Amino acid(s) N, K is associated with resistance. Amino acid(s) D is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) E, V, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	333	gp120	I	0.901	0.855	0.293	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) L is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	344	gp120	Q	1.728	1.306	1.923	computational prediction	Amino acid(s) N, E, NxST is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) A is associated with resistance.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	computational prediction	Amino acid(s) NxST is associated with resistance.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	392	gp120, V4 loop	N	0.561	0.454	0.804	computational prediction	Amino acid(s) NxST is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	415	gp120, V4 loop	T	0.846	0.760	0.656	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) E, S is associated with resistance. Amino acid(s) A is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	448	gp120	N	0.648	0.448	0.927	computational prediction	Amino acid(s) NxST, N is associated with resistance.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	583	gp41, Leu/Ile zipper-like sequence	V	0.988	0.424	0.701	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) D, A is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) A is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.031	0.756	1.040	computational prediction	Amino acid(s) G is associated with resistance. Amino acid(s) D is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	746	gp41, gp41 cytoplasmic tail	I	1.629	1.911	0.739	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	750	gp41, gp41 cytoplasmic tail	N	1.528	1.692	0.891	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) H is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.849	0.667	0.984	computational prediction	Amino acid(s) Q is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	1.141	0.355	0.328	computational prediction	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	835	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	G	0.753	0.515	0.917	computational prediction	Amino acid(s) G is associated with resistance.
174	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.6	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.534	1.502	1.006	computational prediction	Amino acid(s) A is associated with resistance. Amino acid(s) T is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acid H is associated with resistance. Amino acid V is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	155	gp120, V1	K	0.854	0.423	0.831	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) I is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	240	gp120	T	1.789	1.338	1.717	computational prediction	Amino acid(s) K is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	252	gp120	R	0.688	0.592	0.148	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) R is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	289	gp120	N	1.027	0.835	0.551	computational prediction	Amino acid(s) K is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) Y, S is associated with resistance. Amino acid(s) N is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	304	gp120, V3 loop	R	0.287	0.390	0.141	computational prediction	Amino acid(s) R is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) K is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) T is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	323	gp120, V3 loop	I	0.575	0.531	0.263	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) I is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	325	gp120, V3 loop	N	0.653	0.622	0.622	computational prediction	Amino acid(s) N is associated with resistance. Amino acid(s) D is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) E, K, T is associated with resistance. Amino acid(s) N, NxST is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	333	gp120	I	0.901	0.855	0.293	computational prediction	Amino acid(s) V is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	344	gp120	Q	1.728	1.306	1.923	computational prediction	Amino acid(s) N is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) A is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	computational prediction	Amino acid(s) NxST is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	392	gp120, V4 loop	N	0.561	0.454	0.804	computational prediction	Amino acid(s) NxST is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	415	gp120, V4 loop	T	0.846	0.760	0.656	computational prediction	Amino acid(s) I is associated with resistance. Amino acid(s) T is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	448	gp120	N	0.648	0.448	0.927	computational prediction	Amino acid(s) NxST is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	583	gp41, Leu/Ile zipper-like sequence	V	0.988	0.424	0.701	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) D, A is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) A is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.031	0.756	1.040	computational prediction	Amino acid(s) G, N, NxST is associated with resistance. Amino acid(s) D is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	746	gp41, gp41 cytoplasmic tail	I	1.629	1.911	0.739	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) G is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	750	gp41, gp41 cytoplasmic tail	N	1.528	1.692	0.891	computational prediction	Amino acid(s) S is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.849	0.667	0.984	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) Q is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	801	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	1.141	0.355	0.328	computational prediction	Amino acid(s) L is associated with resistance. Amino acid(s) Q is associated with sensitivity.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	835	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	G	0.753	0.515	0.917	computational prediction	Amino acid(s) G is associated with resistance.
175	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	DH270.5	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.534	1.502	1.006	computational prediction	Amino acid(s) A is associated with resistance.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acid V is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	155	gp120, V1	K	0.854	0.423	0.831	computational prediction	Amino acid(s) R is associated with resistance. Amino acid(s) K is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) NxST is associated with resistance.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid(s) M is associated with resistance. Amino acid(s) I is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) NxST is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	289	gp120	N	1.027	0.835	0.551	computational prediction	Amino acid(s) K is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction	Amino acid(s) I is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) V is associated with resistance.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) K is associated with resistance.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) S is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) E is associated with resistance.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	746	gp41, gp41 cytoplasmic tail	I	1.629	1.911	0.739	computational prediction	Amino acid(s) V is associated with resistance.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	770	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction)	R	0.849	0.667	0.984	computational prediction	Amino acid(s) R is associated with resistance.
176	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT123	836	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	A	1.534	1.502	1.006	computational prediction	Amino acid(s) I is associated with resistance.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acid V is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid(s) M is associated with resistance.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid(s) NxST is associated with resistance.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) NxST is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) E is associated with resistance.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction	Amino acid(s) V is associated with resistance. Amino acid(s) I is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) V is associated with resistance.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	323	gp120, V3 loop	I	0.575	0.531	0.263	computational prediction	Amino acid I is associated withs sensitivity
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	328	gp120, V3 loop	Q	1.001	0.816	0.882	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) Q is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T is associated with resistance. Amino acid(s) A is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	344	gp120	Q	1.728	1.306	1.923	computational prediction	Amino acid(s) K is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) S is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid(s) Q is associated with resistance. Amino acid(s) NxST, N is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	415	gp120, V4 loop	T	0.846	0.760	0.656	computational prediction	Amino acid(s) T is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) A is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
177	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-996	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) E is associated with resistance.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acid V is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) I is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid(s) I is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid(s) NxST is associated with resistance.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	289	gp120	N	1.027	0.835	0.551	computational prediction	Amino acid(s) K is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) T is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction	Amino acid(s) I is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) A is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	442	gp120	Q	2.193	1.699	0.964	computational prediction	Amino acid(s) E is associated with resistance.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	612	gp41	A	1.453	1.525	1.055	computational prediction	Amino acid(s) S is associated with resistance. Amino acid(s) A is associated with sensitivity.
178	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT126	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.825	0.183	0.621	computational prediction	Amino acid(s) F is associated with resistance. Amino acid(s) L is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	85	gp120	V	2.208	1.797	1.418	computational prediction	Amino acid V is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) I is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid(s) NxST is associated with resistance.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) T is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid(s) Y is associated with resistance. Amino acid(s) H is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid(s) S is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	442	gp120	Q	2.193	1.699	0.964	computational prediction	Amino acid(s) E is associated with resistance. Amino acid(s) NxST is associated with sensitivity.
179	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT127	750	gp41, gp41 cytoplasmic tail	N	1.528	1.692	0.891	computational prediction	Amino acid(s) D is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid I is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid(s) NxST is associated with resistance.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	computational prediction	Amino acid(s) NxST is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid T is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid S is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid H is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) N, NxST is associated with resistance. Amino acid S is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	442	gp120	Q	2.193	1.699	0.964	computational prediction	Amino acid E is associated with resistance. Amino acid NxST is associated with sensitivity.
180	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT125	750	gp41, gp41 cytoplasmic tail	N	1.528	1.692	0.891	computational prediction	Amino acid D is associated with sensitivity.
181	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT130	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid I is associated with sensitivity.
181	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT130	184	gp120, V2	I	1.060	0.599	0.530	computational prediction	Amino acid L is associated with resistance.
181	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT130	230	gp120	N	0.954	0.896	0.544	computational prediction	Amino acid N is associated with resistance.
181	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT130	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid N is associated with resistance. Amino acid S is associated with sensitivity.
181	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT130	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid G is associated with resistance.
181	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT130	583	gp41, Leu/Ile zipper-like sequence	V	0.988	0.424	0.701	computational prediction	Amino acid V is associated with sensitivity.
182	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074V	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction	Amino acid K is associated with sensitivity.
182	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074V	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid Y is associated with resistance. Amino acid H is associated with sensitivity.
182	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074V	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acids D, K, T are associated with resistance. Amino acids N, NxST are associated with sensitivity.
182	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074V	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acids N, NxST are associated with resistance. Amino acid S  is associated with sensitivity.
182	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074V	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid T is associated with resistance.
182	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074V	413	gp120, V4 loop	T	1.440	1.451	1.561	computational prediction	Amino acids NxST are associated with sensitivity.
182	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	10-1074V	774	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	0.825	0.183	0.621	computational prediction	Amino acid F is associated with resistance. Amino acid L is associated with sensitivity.
183	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT135	330	gp120, V3 loop	H	0.743	0.559	0.655	computational prediction	Amino acid Y is associated with resistance. Amino acid H is associated with sensitivity.
183	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT135	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) N, NxST is associated with sensitivity.
183	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT135	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acids N, NxST are associated with resistance. Amino acid S is associated with sensitivity.
183	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT135	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid S is associated with sensitivity.
183	V3 Signature Analysis Summary	V3-glycan	Bricault2019	signature	PGT135	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	computational prediction	Amino acid(s) NxST is associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	31	gp120	T	2.195	1.529	2.035	computational prediction	Amino acid T is associated with resistance. Amino acids A, L are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	33	gp120	K	1.441	1.559	0.973	computational prediction	Amino acid(s) K are associated with resistance.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	49	gp120	T	1.652	0.958	0.335	computational prediction	Amino acid(s) T are associated with resistance.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) N are associated with resistance.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) K, D are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	161	gp120, V2	I	1.565	0.964	1.568	computational prediction	Amino acid(s) V are associated with resistance. Amino acid(s) M are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	162	gp120, V2	S	0.289	0.445	0.179	computational prediction	Amino acid(s) T are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	164	gp120, V2	S	1.660	1.925	0.453	computational prediction	Amino acid(s) G, S are associated with resistance. Amino acid(s) E are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) R are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) E, V are associated with resistance. Amino acid(s) K are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid(s) H, Y are associated with resistance. Amino acid(s) S, Y are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	177	gp120, V2	Y	0.349	0.638	0.144	computational prediction	Amino acid(s) N are associated with resistance. Amino acid(s) Y are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) T are associated with resistance.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) R are associated with resistance.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) NxST, N are associated with resistance.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	340	gp120	N	1.893	1.537	1.869	computational prediction	Amino acid(s) D, N are associated with resistance. Amino acid(s) E, K are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) M are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	644	gp41	S	2.131	1.538	1.732	computational prediction	Amino acid(s) T are associated with resistance. Amino acid(s) R are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	677	gp41	N	1.187	1.199	1.100	computational prediction	Amino acid(s) Q are associated with resistance. Amino acid(s) N are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	717	gp41, gp41 cytoplasmic tail	F	0.487	0.533	0.386	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	743	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	D	1.031	0.756	1.040	computational prediction	Amino acid(s) D are associated with resistance.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
184	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.974	0.214	0.405	computational prediction	Amino acid(s) Q are associated with resistance.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	33	gp120	K	1.441	1.559	0.973	computational prediction	Amino acid K is associated with resistance. Amino acid N  is associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	49	gp120	T	1.652	0.958	0.335	computational prediction	Amino acid(s) T are associated with resistance. Amino acid(s) E are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) NxST are associated with resistance.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) K, D, S are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	161	gp120, V2	I	1.565	0.964	1.568	computational prediction	Amino acid(s) V are associated with resistance.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	162	gp120, V2	S	0.289	0.445	0.179	computational prediction	Amino acid(s) T are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	164	gp120, V2	S	1.660	1.925	0.453	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) R are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) V are associated with resistance. Amino acid(s) K are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	171	gp120, V2	K	1.239	0.957	1.413	computational prediction	Amino acid(s) E, Q are associated with resistance. Amino acid(s) K are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	172	gp120, V2	E	1.506	1.172	1.484	computational prediction	Amino acid(s) V are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid(s) Y are associated with resistance.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	177	gp120, V2	Y	0.349	0.638	0.144	computational prediction	Amino acid(s) N are associated with resistance. Amino acid(s) Y are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) R are associated with resistance.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction	Amino acid(s) M are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S, N are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	644	gp41	S	2.131	1.538	1.732	computational prediction	Amino acid(s) S, T are associated with resistance. Amino acid(s) T, R are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	677	gp41	N	1.187	1.199	1.100	computational prediction	Amino acid(s) Q are associated with resistance. Amino acid(s) N are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) I are associated with sensitivity.
185	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG16	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.974	0.214	0.405	computational prediction	Amino acid(s) Q are associated with resistance. Amino acid(s) R are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	33	gp120	K	1.441	1.559	0.973	computational prediction	Amino acid K is associated with resistance. Amino acid N  is associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) NxST, N are associated with resistance. Amino acid(s) D are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) K, D, S are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	161	gp120, V2	I	1.565	0.964	1.568	computational prediction	Amino acid(s) V are associated with resistance.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	162	gp120, V2	S	0.289	0.445	0.179	computational prediction	Amino acid(s) T are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	164	gp120, V2	S	1.660	1.925	0.453	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) E are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) K are associated with resistance.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) T are associated with resistance.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) E, Q, V are associated with resistance. Amino acid(s) K are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction	Amino acid(s) K are associated with resistance.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	171	gp120, V2	K	1.239	0.957	1.413	computational prediction	Amino acid(s) K are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	223	gp120	F	0.692	0.166	0.328	computational prediction	Amino acid(s) F are associated with resistance. Amino acid(s) Y are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) R are associated with resistance.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction	Amino acid(s) I are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) NxST, N are associated with resistance.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	644	gp41	S	2.131	1.538	1.732	computational prediction	Amino acid(s) S, T are associated with resistance. Amino acid(s) T are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	677	gp41	N	1.187	1.199	1.100	computational prediction	Amino acid(s) Q are associated with resistance. Amino acid(s) N are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
186	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PG9	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.974	0.214	0.405	computational prediction	Amino acid(s) R are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	33	gp120	K	1.441	1.559	0.973	computational prediction	Amino acid K is associated with resistance. Amino acid N  is associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	49	gp120	T	1.652	0.958	0.335	computational prediction	Amino acid(s) T are associated with resistance. Amino acid(s) D are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) D are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) NxST , N  are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	161	gp120, V2	I	1.565	0.964	1.568	computational prediction	Amino acid(s) V are associated with resistance. Amino acid(s) M are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) S, K are associated with resistance. Amino acid(s) R are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) G, N, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) V are associated with resistance. Amino acid(s) K are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	172	gp120, V2	E	1.506	1.172	1.484	computational prediction	Amino acid(s) V are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid(s) Y are associated with resistance. Amino acid(s) S are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	297	gp120, Lectin DC-SIGN binding site (N295-T297)	T	0.814	0.654	0.977	computational prediction	Amino acid(s) T are associated with resistance.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) S are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction	Amino acid(s) L are associated with resistance.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	340	gp120	N	1.893	1.537	1.869	computational prediction	Amino acid(s) D are associated with resistance.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	644	gp41	S	2.131	1.538	1.732	computational prediction	Amino acid(s) T are associated with resistance.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	717	gp41, gp41 cytoplasmic tail	F	0.487	0.533	0.386	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) I are associated with sensitivity.
187	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.974	0.214	0.405	computational prediction	Amino acid(s) Q are associated with resistance. Amino acid(s) R are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	49	gp120	T	1.652	0.958	0.335	computational prediction	Amino acid(s) NxST, N, T are associated with resistance. Amino acid K is associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) NxST , N  are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	161	gp120, V2	I	1.565	0.964	1.568	computational prediction	Amino acid(s) A are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	164	gp120, V2	S	1.660	1.925	0.453	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) R are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) G, N, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) E, V, T are associated with resistance. Amino acid(s) K are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	172	gp120, V2	E	1.506	1.172	1.484	computational prediction	Amino acid(s) V are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid(s) Y are associated with resistance. Amino acid(s) S are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	211	gp120	E	0.840	0.366	0.364	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	223	gp120	F	0.692	0.166	0.328	computational prediction	Amino acid(s) F are associated with resistance. Amino acid(s) Y are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) R, G are associated with resistance. Amino acid(s) S are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction	Amino acid(s) L are associated with resistance.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) T are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) NxST are associated with resistance.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	335	gp120	R	1.840	1.758	1.937	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction	Amino acid(s) M are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	588	gp41, Leu/Ile zipper-like sequence	K	1.087	1.197	0.871	computational prediction	Amino acid(s) K are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	632	gp41	D	0.712	0.402	0.373	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	644	gp41	S	2.131	1.538	1.732	computational prediction	Amino acid(s) R are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
188	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.26	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.974	0.214	0.405	computational prediction	Amino acid(s) Q are associated with resistance.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	49	gp120	T	1.652	0.958	0.335	computational prediction	Amino acid T is associated with resistance. Amino acid K is associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) NxST , N  are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	162	gp120, V2	S	0.289	0.445	0.179	computational prediction	Amino acid(s) T are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	164	gp120, V2	S	1.660	1.925	0.453	computational prediction	Amino acid(s) N, S are associated with resistance. Amino acid(s) E are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) L are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) R are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) G, N are associated with resistance. Amino acid(s) D are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) E, M, Q, V, T are associated with resistance. Amino acid(s) K are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	172	gp120, V2	E	1.506	1.172	1.484	computational prediction	Amino acid(s) V are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid(s) S are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	211	gp120	E	0.840	0.366	0.364	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) S are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) V are associated with resistance. Amino acid(s) T are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction	Amino acid(s) M are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	632	gp41	D	0.712	0.402	0.373	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	644	gp41	S	2.131	1.538	1.732	computational prediction	Amino acid(s) R are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
189	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.08	805	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	Q	0.974	0.214	0.405	computational prediction	Amino acid(s) Q are associated with resistance.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	49	gp120	T	1.652	0.958	0.335	computational prediction	Amino acid T is associated with resistance.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) N are associated with resistance. Amino acid(s) H are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) K, D are associated with resistance. Amino acid(s) NxST , N  are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	161	gp120, V2	I	1.565	0.964	1.568	computational prediction	Amino acid(s) I, V are associated with resistance. Amino acid(s) A, M are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	162	gp120, V2	S	0.289	0.445	0.179	computational prediction	Amino acid(s) T are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	164	gp120, V2	S	1.660	1.925	0.453	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) I are associated with resistance. Amino acid(s) L are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) S, G are associated with resistance. Amino acid(s) R are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) E, Q, V are associated with resistance. Amino acid(s) K, R are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	172	gp120, V2	E	1.506	1.172	1.484	computational prediction	Amino acid(s) V are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid(s) S are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	211	gp120	E	0.840	0.366	0.364	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) S are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	318	gp120, V3 loop	V	0.574	0.691	0.507	computational prediction	Amino acid(s) Y are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) NxST are associated with resistance.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) M are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	588	gp41, Leu/Ile zipper-like sequence	K	1.087	1.197	0.871	computational prediction	Amino acid(s) K are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	644	gp41	S	2.131	1.538	1.732	computational prediction	Amino acid(s) R are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	677	gp41	N	1.187	1.199	1.100	computational prediction	Amino acid(s) N are associated with sensitivity.
190	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGDM1400	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) NxST  are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	164	gp120, V2	S	1.660	1.925	0.453	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) E are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	165	gp120, V2	I	1.321	1.292	1.011	computational prediction	Amino acid(s) I are associated with resistance.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid(s) S, T, K are associated with resistance. Amino acid(s) R are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid(s) G, T are associated with resistance. Amino acid(s) D are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	169	gp120, V2	V	1.974	1.770	1.344	computational prediction	Amino acid(s) E, V, T are associated with resistance. Amino acid(s) K are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	172	gp120, V2	E	1.506	1.172	1.484	computational prediction	Amino acid(s) V are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid(s) S are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	211	gp120	E	0.840	0.366	0.364	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) S are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid(s) T are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	332	gp120	N	0.904	0.491	0.693	computational prediction	Amino acid(s) NxST are associated with resistance.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction	Amino acid(s) M are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	632	gp41	D	0.712	0.402	0.373	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) D are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	636	gp41	N	1.371	1.127	1.081	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S are associated with sensitivity.
191	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	VRC26.25	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) I are associated with sensitivity.
192	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	CH01	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) NxST, N are associated with resistance. Amino acid H is associated with sensitivity.
192	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	CH01	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) NxST  are associated with sensitivity.
192	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	CH01	161	gp120, V2	I	1.565	0.964	1.568	computational prediction	Amino acid I is associated with resistance.
192	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	CH01	171	gp120, V2	K	1.239	0.957	1.413	computational prediction	Amino acid K is associated with sensitivity.
192	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	CH01	223	gp120	F	0.692	0.166	0.328	computational prediction	Amino acid F is associated with resistance. Amino acid Y is associated with sensitivity.
194	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT142	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) NxST , N  are associated with sensitivity.
195	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT143	160	gp120, V2	N	0.401	0.452	0.358	computational prediction	Amino acid(s) NxST , N  are associated with sensitivity.
195	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT143	162	gp120, V2	S	0.289	0.445	0.179	computational prediction	Amino acid T is associated with sensitivity.
195	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT143	166	gp120, V2	R	1.127	1.398	0.772	computational prediction	Amino acid K is associated with resistance. Amino acid R is associated with sensitivity.
195	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT143	167	gp120, V2	G	0.601	1.122	0.185	computational prediction	Amino acid D is associated with sensitivity.
195	V2 Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT143	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction	Amino acid H is associated with resistance.
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	132	gp120, V1-hypervariable, V1	T	1.450	0.849	1.573	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	133	gp120, V1-hypervariable, V1	D	1.456	1.052	1.360	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	141	gp120, V1-hypervariable, V1	N	2.221	2.077	2.148	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	143	gp120, V1-hypervariable, V1	S	2.014	1.990	1.810	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	144	gp120, V1-hypervariable, V1	S	2.255	2.072	2.207	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	145	gp120, V1-hypervariable, V1	G	2.331	2.228	2.255	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	146	gp120, V1-hypervariable, V1	R	2.697	2.583	2.629	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	147	gp120, V1-hypervariable, V1	M	2.618	2.513	2.375	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	148	gp120, V1-hypervariable, V1	I	2.707	2.671	2.548	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	149	gp120, V1-hypervariable, V1	M	2.457	2.375	2.256	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	150	gp120, V1-hypervariable, V1	E	2.374	2.019	2.328	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	computational prediction	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	186	gp120, V2-hypervariable, V2	N	1.871	1.592	1.819	computational prediction	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	187	gp120, V2-hypervariable, V2	D	1.817	1.813	1.638	computational prediction	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	188	gp120, V2-hypervariable, V2	T	1.874	1.618	1.850	computational prediction	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	189	gp120, V2-hypervariable, V2	T	1.811	1.348	1.638	computational prediction	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
196	hypervariable loop characteristic correlations with bNAb sensitivity	V3-glycan	Bricault2019	signature	10-1074, 10-1074V, DH270.6, PGT121, PGT128	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	computational prediction	V2 hypervariable loop: length (both V2 and V1+V2) and number of PNGs in this region are associated with resistance for V3 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	132	gp120, V1-hypervariable, V1	T	1.450	0.849	1.573	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	133	gp120, V1-hypervariable, V1	D	1.456	1.052	1.360	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	141	gp120, V1-hypervariable, V1	N	2.221	2.077	2.148	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	143	gp120, V1-hypervariable, V1	S	2.014	1.990	1.810	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	144	gp120, V1-hypervariable, V1	S	2.255	2.072	2.207	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	145	gp120, V1-hypervariable, V1	G	2.331	2.228	2.255	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	146	gp120, V1-hypervariable, V1	R	2.697	2.583	2.629	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	147	gp120, V1-hypervariable, V1	M	2.618	2.513	2.375	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	148	gp120, V1-hypervariable, V1	I	2.707	2.671	2.548	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	149	gp120, V1-hypervariable, V1	M	2.457	2.375	2.256	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	150	gp120, V1-hypervariable, V1	E	2.374	2.019	2.328	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	computational prediction	V1 hypervariable loop: length (both V1 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	computational prediction	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	186	gp120, V2-hypervariable, V2	N	1.871	1.592	1.819	computational prediction	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	187	gp120, V2-hypervariable, V2	D	1.817	1.813	1.638	computational prediction	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	188	gp120, V2-hypervariable, V2	T	1.874	1.618	1.850	computational prediction	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	189	gp120, V2-hypervariable, V2	T	1.811	1.348	1.638	computational prediction	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
197	hypervariable loop characteristic correlations with bNAb sensitivity	V2-apex	Bricault2019	signature	PG16, PG9, PGDM1400, PGT142, PGT145, VRC26.08, VRC26.25, VRC26.26	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	computational prediction	V2 hypervariable loop: high charge associated with sensitivity; length (both V2 and V1+V2) associated with resistance for V2 Abs
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	132	gp120, V1-hypervariable, V1	T	1.450	0.849	1.573	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	133	gp120, V1-hypervariable, V1	D	1.456	1.052	1.360	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	141	gp120, V1-hypervariable, V1	N	2.221	2.077	2.148	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	143	gp120, V1-hypervariable, V1	S	2.014	1.990	1.810	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	144	gp120, V1-hypervariable, V1	S	2.255	2.072	2.207	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	145	gp120, V1-hypervariable, V1	G	2.331	2.228	2.255	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	146	gp120, V1-hypervariable, V1	R	2.697	2.583	2.629	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	147	gp120, V1-hypervariable, V1	M	2.618	2.513	2.375	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	148	gp120, V1-hypervariable, V1	I	2.707	2.671	2.548	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	149	gp120, V1-hypervariable, V1	M	2.457	2.375	2.256	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	150	gp120, V1-hypervariable, V1	E	2.374	2.019	2.328	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	computational prediction	V1 hypervariable loop: V1 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	computational prediction	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	186	gp120, V2-hypervariable, V2	N	1.871	1.592	1.819	computational prediction	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	187	gp120, V2-hypervariable, V2	D	1.817	1.813	1.638	computational prediction	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	188	gp120, V2-hypervariable, V2	T	1.874	1.618	1.850	computational prediction	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	189	gp120, V2-hypervariable, V2	T	1.811	1.348	1.638	computational prediction	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	computational prediction	V2 hypervariable loop: V2 (and V1+V2) length associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	computational prediction	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	computational prediction	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	computational prediction	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	computational prediction	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	464	gp120, V5-hypervariable, V5 loop	E	2.371	2.269	2.299	computational prediction	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
200	hypervariable loop characteristic correlations with bNAb sensitivity	CD4BS	Bricault2019	signature	12A12, 3BNC117, 8ANC131, CH103, CH235.12, N6, NIH45-46, VRC01, VRC07, VRC07-523-LS	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517	computational prediction	V5 hypervariable loop: high V5 length and high number of PNGs in V5 associated with higher resistance
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	132	gp120, V1-hypervariable, V1	T	1.450	0.849	1.573	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	133	gp120, V1-hypervariable, V1	D	1.456	1.052	1.360	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	141	gp120, V1-hypervariable, V1	N	2.221	2.077	2.148	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	143	gp120, V1-hypervariable, V1	S	2.014	1.990	1.810	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	144	gp120, V1-hypervariable, V1	S	2.255	2.072	2.207	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	145	gp120, V1-hypervariable, V1	G	2.331	2.228	2.255	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	146	gp120, V1-hypervariable, V1	R	2.697	2.583	2.629	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	147	gp120, V1-hypervariable, V1	M	2.618	2.513	2.375	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	148	gp120, V1-hypervariable, V1	I	2.707	2.671	2.548	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	149	gp120, V1-hypervariable, V1	M	2.457	2.375	2.256	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	150	gp120, V1-hypervariable, V1	E	2.374	2.019	2.328	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
201	hypervariable loop characteristic correlations with bNAb sensitivity	MPER	Bricault2019	signature	10E8, 2F5, 4E10	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	computational prediction	V1 hypervariable loop: high number of PNGs in this region associated with sensitivity
202	Signature Analysis Summary	CD4BS	Bricault2019	signature	3BNC117	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acid L is associated with resistance. Amino acid E is associated with sensitivity.
203	Signature Analysis Summary	CD4BS	Bricault2019	signature	b12	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acid Q is associated with resistance. Amino acid R is associated with sensitivity.
204	Signature Analysis Summary	CD4i	Bricault2019	signature	3BC176	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Q associated with resistance
205	Signature Analysis Summary	CD4BS	Bricault2019	signature	CH103	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acids Q, M are associated with resistance. Amino acids K, G, R are associated with sensitivity.
206	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC03	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acid Q is associated with resistance. Amino acids K, R are associated with sensitivity.
207	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC06b	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acids Q, M are associated with resistance. Amino acid R is associated with sensitivity.
208	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC-CH31	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acid Q is associated with sensitivity.
209	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC01	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acid Q is associated with sensitivity.
210	Signature Analysis Summary	CD4BS	Bricault2019	signature	8ANC131	5	Signal peptide	E	0.643	0.746	0.316	computational prediction	Amino acid Q is associated with sensitivity.
211	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC07-523-LS	26	Signal peptide	M	0.857	0.183	0.949	computational prediction	Amino acid M is associated with resistance. Amino acid I is associated with sensitivity.
212	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46	26	Signal peptide	M	0.857	0.183	0.949	computational prediction	Amino acid M is associated with resistance. Amino acid I is associated with sensitivity.
213	Signature Analysis Summary	CD4BS	Bricault2019	signature	12A12	26	Signal peptide	M	0.857	0.183	0.949	computational prediction	Amino acid M is associated with resistance. Amino acid I is associated with sensitivity.
214	Signature Analysis Summary	CD4BS	Bricault2019	signature	CH235.12	26	Signal peptide	M	0.857	0.183	0.949	computational prediction	Amino acid(s) Y, M are associated with resistance.
216	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC-PG04	30	Signal peptide	A	1.193	0.487	1.122	computational prediction	Amino acid V is associated with sensitivity.
217	Signature Analysis Summary	CD4BS	Bricault2019	signature	N6	31	gp120	T	2.195	1.529	2.035	computational prediction	Amino acid N is associated with resistance.
218	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC07	60	gp120	A	0.530	0.461	0.396	computational prediction	Amino acid G is associated with resistance. Amino acid A is associated with sensitivity.
219	Signature Analysis Summary	CD4BS	Bricault2019	signature	HJ16	60	gp120	A	0.530	0.461	0.396	computational prediction	Amino acid S is associated with sensitivity.
219	Signature Analysis Summary	CD4BS	Bricault2019	signature	HJ16	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid(s) NxST are associated with sensitivity.
219	Signature Analysis Summary	CD4BS	Bricault2019	signature	HJ16	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) NxST are associated with sensitivity.
219	Signature Analysis Summary	CD4BS	Bricault2019	signature	HJ16	362	gp120	K	1.874	1.265	1.997	computational prediction	Amino acid T is associated with sensitivity.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	87	gp120	V	1.538	1.611	1.463	computational prediction	Amino acid K is associated with resistance.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	192	gp120, V2	K	0.847	0.835	0.851	computational prediction	Amino acid R is associated with sensitivity.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	291	gp120	S	1.139	1.292	0.739	computational prediction	Amino acid A is associated with resistance.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	395	gp120, V4 loop	W	1.843	0.454	2.171	computational prediction	Amino acid W is associated with sensitivity.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	425	gp120, beta20/beta21	N	0.405	0.138	0.177	computational prediction	Amino acid R is associated with resistance. Amino acid N is associated with sensitivity.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	442	gp120	Q	2.193	1.699	0.964	computational prediction	Amino acid(s) NxST, N are associated with resistance.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	471	gp120, beta24	G	0.879	0.888	0.866	computational prediction	Amino acid G is associated with sensitivity.
220	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC16	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.681	1.417	1.296	computational prediction	Amino acid I is associated with resistance.
221	Signature Analysis Summary	CD4i	Bricault2019	signature	3BC176	87	gp120	V	1.538	1.611	1.463	computational prediction	Amino acid K is associated with resistance.
221	Signature Analysis Summary	CD4i	Bricault2019	signature	3BC176	442	gp120	Q	2.193	1.699	0.964	computational prediction	Amino acid Q is associated with sensitivity.
221	Signature Analysis Summary	CD4i	Bricault2019	signature	3BC176	507	gp120	Q	1.089	0.082	0.603	computational prediction	Amino acid Q is associated with sensitivity.
223	Signature Analysis Summary	silent face	Bricault2019	signature	VRC-PG05	99	gp120	D	1.169	0.830	0.366	computational prediction	Amino acid K is associated with sensitivity.
223	Signature Analysis Summary	silent face	Bricault2019	signature	VRC-PG05	291	gp120	S	1.139	1.292	0.739	computational prediction	Amino acid S is associated with sensitivity.
223	Signature Analysis Summary	silent face	Bricault2019	signature	VRC-PG05	316	gp120, V3 loop	A	1.151	0.736	0.966	computational prediction	Amino acid V is associated with sensitivity.
223	Signature Analysis Summary	silent face	Bricault2019	signature	VRC-PG05	518	gp41, fusion peptide	L	1.201	1.110	0.718	computational prediction	Amino acid V is associated with resistance.
223	Signature Analysis Summary	silent face	Bricault2019	signature	VRC-PG05	654	gp41	E	0.313	0.174	0.105	computational prediction	Amino acid E is associated with resistance. Amino acid D is associated with sensitivity.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid S is associated with resistance.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	234	gp120	N	0.584	0.757	0.341	computational prediction	Amino acid(s) NxST are associated with resistance.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	268	gp120	E	1.220	0.886	1.275	computational prediction	Amino acid E is associated with resistance.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) N, NxST are associated with sensitivity.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	395	gp120, V4 loop	W	1.843	0.454	2.171	computational prediction	Amino acid(s) N, NxST are associated with sensitivity.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	456	gp120, beta23	R	0.196	0.079	0.323	computational prediction	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	458	gp120, beta23	G	0.097	0.045	0.095	computational prediction	Amino acid G is associated with sensitivity.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	Amino acid G is associated with sensitivity.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	616	gp41	N	0.226	0.238	0.269	computational prediction	Amino acid(s) NxST are associated with resistance.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	618	gp41	S	0.742	0.725	0.780	computational prediction	Amino acid(s) NxST are associated with resistance.
224	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WPY	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.681	1.417	1.296	computational prediction	Amino acid I is associated with resistance. Amino acid V is associated with sensitivity.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	130	gp120	K	1.274	0.883	1.495	computational prediction	Amino acid S is associated with resistance.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	268	gp120	E	1.220	0.886	1.275	computational prediction	Amino acid E is associated with resistance.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) N, NxST are associated with sensitivity.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	456	gp120, beta23	R	0.196	0.079	0.323	computational prediction	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	458	gp120, beta23	G	0.097	0.045	0.095	computational prediction	Amino acid G is associated with sensitivity.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	Amino acid G is associated with sensitivity.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	616	gp41	N	0.226	0.238	0.269	computational prediction	Amino acid(s) N, NxST are associated with sensitivity.
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	618	gp41	S	0.742	0.725	0.780	computational prediction	Amino acid NxST is associated with resistance
225	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46WY	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.681	1.417	1.296	computational prediction	Amino acid V is associated with sensitivity.
226	Signature Analysis Summary	CD4BS	Bricault2019	signature	1B2530	183	gp120, V2	P	1.179	1.107	0.787	computational prediction	Amino acid S is associated with resistance.
226	Signature Analysis Summary	CD4BS	Bricault2019	signature	1B2530	234	gp120	N	0.584	0.757	0.341	computational prediction	Amino acid N is associated with resistance.
226	Signature Analysis Summary	CD4BS	Bricault2019	signature	1B2530	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) NxST are associated with sensitivity.
226	Signature Analysis Summary	CD4BS	Bricault2019	signature	1B2530	456	gp120, beta23	R	0.196	0.079	0.323	computational prediction	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
226	Signature Analysis Summary	CD4BS	Bricault2019	signature	1B2530	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	Amino acid G is associated with sensitivity.
226	Signature Analysis Summary	CD4BS	Bricault2019	signature	1B2530	471	gp120, beta24	G	0.879	0.888	0.866	computational prediction	Amino acid G is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	192	gp120, V2	K	0.847	0.835	0.851	computational prediction	Amino acid I is associated with resistance. Amino acid R is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	275	gp120, Loop D	V	1.034	1.420	0.535	computational prediction	Amino acid K is associated with resistance.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	computational prediction	Amino acid H is associated with resistance. Amino acid S is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	computational prediction	Amino acid I is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	computational prediction	Amino acid(s) N, NxST are associated with resistance.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	395	gp120, V4 loop	W	1.843	0.454	2.171	computational prediction	Amino acid(s) S, NxST are associated with resistance. Amino acid Y is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	471	gp120, beta24	G	0.879	0.888	0.866	computational prediction	Amino acid E is associated with resistance. Amino acid G is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	474	gp120	D	0.719	0.681	0.752	computational prediction	Amino acid N is associated with resistance. Amino acid D is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	700	gp41, gp41 cytoplasmic tail	A	0.977	1.185	0.798	computational prediction	Amino acid A is associated with sensitivity.
227	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC13	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.681	1.417	1.296	computational prediction	Amino acid I is associated with resistance. Amino acid V is associated with sensitivity.
228	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46	229	gp120	N	0.780	0.742	0.290	computational prediction	Amino acid R is associated with resistance
228	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46	358	gp120	T	0.810	0.513	0.929	computational prediction	Amino acid T is associated with sensitivity
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	234	gp120	N	0.584	0.757	0.341	computational prediction	Amino acid(s) N, NxST are associated with resistance.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid N is associated with sensitivity.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	computational prediction	Amino acid I is associated with sensitivity.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	395	gp120, V4 loop	W	1.843	0.454	2.171	computational prediction	Amino acid(s) K, N, NxST are associated with resistance.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	456	gp120, beta23	R	0.196	0.079	0.323	computational prediction	Amino acid S is associated with resistance. Amino acid R is associated with sensitivity.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	458	gp120, beta23	G	0.097	0.045	0.095	computational prediction	Amino acid G is associated with sensitivity.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	Amino acid G is associated with sensitivity.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239	computational prediction	Amino acid E is associated with sensitivity.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	618	gp41	S	0.742	0.725	0.780	computational prediction	Amino acid(s) NxST, N are associated with resistance. Amino acid S is associated with sensitivity.
229	Signature Analysis Summary	CD4BS	Bricault2019	signature	NIH45-46G54W	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.681	1.417	1.296	computational prediction	Amino acid I is associated with resistance. Amino acid V is associated with sensitivity.
230	Signature Analysis Summary	gp120/gp41 interface	Bricault2019	signature	8ANC195	234	gp120	N	0.584	0.757	0.341	computational prediction	Amino acid S is associated with resistance. Amino acid(s) N, NxST are associated with sensitivity.
230	Signature Analysis Summary	gp120/gp41 interface	Bricault2019	signature	8ANC195	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid(s) NxST are associated with sensitivity.
231	Signature Analysis Summary	CD4BS	Bricault2019	signature	3BNC55	234	gp120	N	0.584	0.757	0.341	computational prediction	Amino acid(s) NxST are associated with resistance.
231	Signature Analysis Summary	CD4BS	Bricault2019	signature	3BNC55	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction	Amino acid N is associated with sensitivity.
231	Signature Analysis Summary	CD4BS	Bricault2019	signature	3BNC55	279	gp120, Loop D	D	0.860	0.850	0.898	computational prediction	Amino acid N is associated with resistance. Amino acid D is associated with sensitivity.
231	Signature Analysis Summary	CD4BS	Bricault2019	signature	3BNC55	456	gp120, beta23	R	0.196	0.079	0.323	computational prediction	Amino acid R is associated with sensitivity.
231	Signature Analysis Summary	CD4BS	Bricault2019	signature	3BNC55	833	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	V	1.681	1.417	1.296	computational prediction	Amino acid V is associated with sensitivity.
232	Signature Analysis Summary	CD4BS	Bricault2019	signature	3BNC176	271	gp120	V	1.230	0.623	0.635	computational prediction	Amino acid V is associated with sensitivity
233	Signature Analysis Summary	CD4BS	Bricault2019	signature	CH44	291	gp120	S	1.139	1.292	0.739	computational prediction	Amino acid P is associated with resistance
234	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC22	33	gp120	K	1.441	1.559	0.973	computational prediction	Amino acid K is associated with sensitivity.
234	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC22	432	gp120, beta20/beta21	K	1.137	0.339	0.564	computational prediction	Amino acid Q is associated with resistance. Amino acid K is associated with sensitivity.
234	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC22	507	gp120	Q	1.089	0.082	0.603	computational prediction	Amino acid Q is associated with sensitivity.
235	Signature Analysis Summary	CD4BS	Bricault2019	signature	VRC07-523-LS	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	computational prediction	Amino acid D is associated with resistance
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	65	gp120	V	1.035	1.023	0.310	computational prediction	Amino acid V is associated with resistance. Amino acid K is associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	158	gp120, V2	S	0.297	0.185	0.291	computational prediction	Amino acid(s) T are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	240	gp120	T	1.789	1.338	1.717	computational prediction	Amino acid(s) N, H are associated with resistance. Amino acid(s) K are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	268	gp120	E	1.220	0.886	1.275	computational prediction	Amino acid(s) G are associated with resistance.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	270	gp120	V	0.797	0.669	0.297	computational prediction	Amino acid(s) I are associated with resistance. Amino acid(s) V are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	277	gp120, Loop D	F	1.193	0.669	0.582	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) F, I are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	281	gp120, Loop D	A	1.081	0.814	1.357	computational prediction	Amino acid(s) V are associated with resistance. Amino acid(s) A are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) S are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) NxST, N are associated with resistance.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	308	gp120, V3 loop	R	0.108	0.091	0.127	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) H, T are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) NxST, N are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) E, D are associated with resistance. Amino acid(s) T, A are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	346	gp120	A	1.871	1.083	1.831	computational prediction	Amino acid(s) G, K, S are associated with resistance. Amino acid(s) A, V are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	354	gp120	G	2.149	1.918	1.123	computational prediction	Amino acid(s) NxST, P are associated with resistance. Amino acid(s) G are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	413	gp120, V4 loop	T	1.440	1.451	1.561	computational prediction	Amino acid(s) NxST are associated with resistance. Amino acid(s) T are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	432	gp120, beta20/beta21	K	1.137	0.339	0.564	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) Q, K are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) E, A are associated with resistance. Amino acid(s) S, P, Q are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	446	gp120	S	2.139	1.139	1.774	computational prediction	Amino acid(s) N, NxST, K are associated with resistance. Amino acid(s) S, E, V are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	471	gp120, beta24	G	0.879	0.888	0.866	computational prediction	Amino acid(s) E are associated with resistance.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	515	gp41, fusion peptide	I	1.106	1.147	0.877	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) M are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	618	gp41	S	0.742	0.725	0.780	computational prediction	Amino acid(s) S are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	619	gp41	L	1.866	1.312	1.871	computational prediction	Amino acid(s) Q are associated with resistance. Amino acid(s) L are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	620	gp41	E	2.000	1.701	2.182	computational prediction	Amino acid(s) T are associated with resistance. Amino acid(s) E are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) A, K are associated with resistance. Amino acid(s) E are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	664	gp41	D	0.197	0.156	0.346	computational prediction	Amino acid(s) D are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	665	gp41	K	0.986	0.656	0.879	computational prediction	Amino acid(s) Q, S are associated with resistance. Amino acid(s) K are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	667	gp41	A	1.332	0.545	1.537	computational prediction	Amino acid(s) D, E, K, N are associated with resistance. Amino acid(s) A are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	668	gp41	S	0.842	0.596	0.758	computational prediction	Amino acid(s) N are associated with resistance. Amino acid(s) S are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	671	gp41	N	0.779	0.669	0.885	computational prediction	Amino acid(s) S are associated with resistance.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) D are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	725	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	R	0.615	0.214	0.471	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) R are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	726	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.780	0.251	0.717	computational prediction	Amino acid(s) D are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	742	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	R	0.630	0.389	0.785	computational prediction	Amino acid(s) K are associated with resistance. Amino acid(s) R are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	788	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	R	0.810	0.131	0.670	computational prediction	Amino acid(s) K are associated with resistance. Amino acid(s) L are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	809	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	N	1.417	0.673	0.545	computational prediction	Amino acid(s) K, R are associated with resistance. Amino acid(s) N, I are associated with sensitivity.
236	Signature Analysis Summary	MPER	Bricault2019	signature	2F5	837	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	C	1.664	1.664	1.096	computational prediction	Amino acid(s) C are associated with resistance. Amino acid(s) W are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	65	gp120	V	1.035	1.023	0.310	computational prediction	Amino acid K is associated with resistance.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	80	gp120	N	0.634	0.695	0.562	computational prediction	Amino acid(s) N are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	268	gp120	E	1.220	0.886	1.275	computational prediction	Amino acid(s) K are associated with resistance.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	277	gp120, Loop D	F	1.193	0.669	0.582	computational prediction	Amino acid(s) I are associated with resistance.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) NxST are associated with resistance.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	446	gp120	S	2.139	1.139	1.774	computational prediction	Amino acid(s) E are associated with resistance.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	672	gp41	W	0.017	0.023	0.014	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	673	gp41	F	0.058	0.065	0.073	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) NxST are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	676	gp41	T	0.683	0.610	0.674	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) T are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
237	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2	809	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	N	1.417	0.673	0.545	computational prediction	Amino acid(s) K are associated with resistance.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	65	gp120	V	1.035	1.023	0.310	computational prediction	Amino acid K is associated with resistance.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	268	gp120	E	1.220	0.886	1.275	computational prediction	Amino acid(s) K are associated with resistance.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) NxST, N are associated with resistance.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) S are associated with sensitivity.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	620	gp41	E	2.000	1.701	2.182	computational prediction	Amino acid(s) Q are associated with resistance.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) A are associated with resistance.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	672	gp41	W	0.017	0.023	0.014	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	673	gp41	F	0.058	0.065	0.073	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid(s) S are associated with resistance.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	676	gp41	T	0.683	0.610	0.674	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) T are associated with sensitivity.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
238	Signature Analysis Summary	MPER	Bricault2019	signature	DH511.2_K3	809	gp41, gp41 cytoplasmic tail, LLP-3 Leucine zipper-like amphypathic helix, a-Catenin interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	N	1.417	0.673	0.545	computational prediction	Amino acid(s) K are associated with resistance.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	65	gp120	V	1.035	1.023	0.310	computational prediction	Amino acid K is associated with resistance.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	80	gp120	N	0.634	0.695	0.562	computational prediction	Amino acid(s) N are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	268	gp120	E	1.220	0.886	1.275	computational prediction	Amino acid(s) K are associated with resistance. Amino acid(s) E are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	270	gp120	V	0.797	0.669	0.297	computational prediction	Amino acid(s) I are associated with resistance. Amino acid(s) V are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	277	gp120, Loop D	F	1.193	0.669	0.582	computational prediction	Amino acid(s) I are associated with resistance. Amino acid(s) F are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) S, Y are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) NxST are associated with resistance.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	308	gp120, V3 loop	R	0.108	0.091	0.127	computational prediction	Amino acid(s) H are associated with resistance.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	334	gp120	S	0.780	0.501	0.890	computational prediction	Amino acid(s) NxST are associated with resistance.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T are associated with resistance.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	432	gp120, beta20/beta21	K	1.137	0.339	0.564	computational prediction	Amino acid(s) K are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) Q are associated with resistance. Amino acid(s) S are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	446	gp120	S	2.139	1.139	1.774	computational prediction	Amino acid(s) E are associated with resistance. Amino acid(s) S are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	620	gp41	E	2.000	1.701	2.182	computational prediction	Amino acid(s) Q, S are associated with resistance. Amino acid(s) E are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) A, T are associated with resistance. Amino acid(s) E are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	667	gp41	A	1.332	0.545	1.537	computational prediction	Amino acid(s) S are associated with resistance.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	671	gp41	N	0.779	0.669	0.885	computational prediction	Amino acid(s) T are associated with resistance. Amino acid(s) N are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	672	gp41	W	0.017	0.023	0.014	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	673	gp41	F	0.058	0.065	0.073	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) N, NxST are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	676	gp41	T	0.683	0.610	0.674	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) T are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	702	gp41, gp41 cytoplasmic tail	L	0.416	0.497	0.316	computational prediction	Amino acid(s) I are associated with resistance. Amino acid(s) L are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	725	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	R	0.615	0.214	0.471	computational prediction	Amino acid(s) R are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	726	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.780	0.251	0.717	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) G are associated with sensitivity.
240	Signature Analysis Summary	MPER	Bricault2019	signature	10E8	837	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	C	1.664	1.664	1.096	computational prediction	Amino acid(s) C are associated with resistance. Amino acid(s) W, Y are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	240	gp120	T	1.789	1.338	1.717	computational prediction	Amino acid T is associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	268	gp120	E	1.220	0.886	1.275	computational prediction	Amino acid(s) K are associated with resistance. Amino acid(s) E are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	277	gp120, Loop D	F	1.193	0.669	0.582	computational prediction	Amino acid(s) I are associated with resistance. Amino acid(s) L are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	281	gp120, Loop D	A	1.081	0.814	1.357	computational prediction	Amino acid(s) V are associated with resistance. Amino acid(s) A are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	300	gp120, V3 loop	N	1.159	0.738	1.054	computational prediction	Amino acid(s) D are associated with resistance. Amino acid(s) Y are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction	Amino acid(s) NxST, N are associated with resistance.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	336	gp120	A	2.124	1.826	2.418	computational prediction	Amino acid(s) T, S are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	440	gp120	S	1.932	1.712	1.017	computational prediction	Amino acid(s) S are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	446	gp120	S	2.139	1.139	1.774	computational prediction	Amino acid(s) E are associated with resistance.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	471	gp120, beta24	G	0.879	0.888	0.866	computational prediction	Amino acid(s) G, A are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	616	gp41	N	0.226	0.238	0.269	computational prediction	Amino acid(s) NxST are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	618	gp41	S	0.742	0.725	0.780	computational prediction	Amino acid(s) NxST, N are associated with resistance. Amino acid(s) S are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	619	gp41	L	1.866	1.312	1.871	computational prediction	Amino acid(s) I, Q are associated with resistance. Amino acid(s) K, Y are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	620	gp41	E	2.000	1.701	2.182	computational prediction	Amino acid(s) A are associated with resistance. Amino acid(s) E are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	662	gp41	E	1.024	0.874	0.369	computational prediction	Amino acid(s) T are associated with resistance.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	664	gp41	D	0.197	0.156	0.346	computational prediction	Amino acid(s) G are associated with resistance.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	667	gp41	A	1.332	0.545	1.537	computational prediction	Amino acid(s) E are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	671	gp41	N	0.779	0.669	0.885	computational prediction	Amino acid(s) S are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	672	gp41	W	0.017	0.023	0.014	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) W are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	673	gp41	F	0.058	0.065	0.073	computational prediction	Amino acid(s) L are associated with resistance. Amino acid(s) F are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid(s) S are associated with resistance. Amino acid(s) D, N, NxST are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	676	gp41	T	0.683	0.610	0.674	computational prediction	Amino acid(s) S, A are associated with resistance. Amino acid(s) T are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	computational prediction	Amino acid(s) G are associated with resistance. Amino acid(s) W are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	computational prediction	Amino acid(s) R are associated with resistance. Amino acid(s) K are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	702	gp41, gp41 cytoplasmic tail	L	0.416	0.497	0.316	computational prediction	Amino acid(s) L are associated with sensitivity.
241	Signature Analysis Summary	MPER	Bricault2019	signature	4E10	726	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.780	0.251	0.717	computational prediction	Amino acid(s) D are associated with resistance.
242	Signature Analysis Summary	MPER	Bricault2019	signature	Z13e1	674	gp41	N	1.182	1.029	1.344	computational prediction	Amino acid D is associated with sensitivity.
242	Signature Analysis Summary	MPER	Bricault2019	signature	Z13e1	788	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	R	0.810	0.131	0.670	computational prediction	Amino acid R is associated with resistance.
244	Mutations allowing binding of germline variants of mAbs 12A21, NIH45-46, VRC01, VRC-PG19, and VRC-PG	CD4BS	McGuire2016	other feature		278	gp120, Loop D	T	0.657	0.715	0.481	binding assay	On a background of N276D, N460D and N463D, introducing S278R alone, or with G471S, permits the binding of germline variants of VRC01, NIH45-46, VRC-PG19, VRC-PG20 and 12A21
244	Mutations allowing binding of germline variants of mAbs 12A21, NIH45-46, VRC01, VRC-PG19, and VRC-PG	CD4BS	McGuire2016	other feature		471	gp120, beta24	G	0.879	0.888	0.866	binding assay	On a background of N276D, N460D and N463D, introducing S278R alone, or with G471S, permits the binding of germline variants of VRC01, NIH45-46, VRC-PG19, VRC-PG20 and 12A21
246	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	CD4BS	LaBranche2018	neutralization	12A12, 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
246	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	CD4BS	LaBranche2018	neutralization	12A12, 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	neutralization assay	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
246	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	CD4BS	LaBranche2018	neutralization	12A12, 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	neutralization assay	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
246	Neutralization of Env 426c and its glycan-deleted mutant by CD4BS Abs	CD4BS	LaBranche2018	neutralization	12A12, 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20	471	gp120, beta24	G	0.879	0.888	0.866	neutralization assay	Glycan deletions of 426c env-pseudotyped viruses at sites 278, 471, 460 and 463 (S278R/G471S/N460D/N463D) increased neutralization sensitivity to 3BNC117, VRC01, VRC03, VRC07, VRC18b, VRC-PG20, and 12A12.
247	Altered glycosylation affects neutralization by CD4BS bnAbs	CD4BS	LaBranche2018	neutralization	3BNC117, VRC03, VRC-PG20	276	gp120, Loop D	N	0.120	0.063	0.169	neutralization assay	When viruses were produced in 293s GnT1- cells, N276D alone increased VRC03 and VRC-PG20 neutralization, while N460D and N463D increased 3BNC117, VRC03, and VRC-PG20 neutralization
247	Altered glycosylation affects neutralization by CD4BS bnAbs	CD4BS	LaBranche2018	neutralization	3BNC117, VRC03, VRC-PG20	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	neutralization assay	When viruses were produced in 293s GnT1- cells, N276D alone increased VRC03 and VRC-PG20 neutralization, while N460D and N463D increased 3BNC117, VRC03, and VRC-PG20 neutralization
247	Altered glycosylation affects neutralization by CD4BS bnAbs	CD4BS	LaBranche2018	neutralization	3BNC117, VRC03, VRC-PG20	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	neutralization assay	When viruses were produced in 293s GnT1- cells, N276D alone increased VRC03 and VRC-PG20 neutralization, while N460D and N463D increased 3BNC117, VRC03, and VRC-PG20 neutralization
248	Selects for breadth-driven Abs in CAP256 lineages	V2-apex	Sacks2019	neutralization	VRC26.20	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay, sequence analysis	~66% of C viruses present K169; however, the rarer form 169Q (~6.5% of C viruses) improves neutralization breadth of CAP26.20, suggesting it helped select bNAbs in the CAP256 lineage
249	SF12 interaction sites	silent face	Schoofs2019	contacts	SF12	262	gp120	N	0.029	0.029	0.028	X-ray crystallography	SF12 recognizes a mostly glycan-focused epitope on HIV-1 Env, interacting with glycans N448, N262, and N295.
249	SF12 interaction sites	silent face	Schoofs2019	contacts	SF12	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	X-ray crystallography	SF12 recognizes a mostly glycan-focused epitope on HIV-1 Env, interacting with glycans N448, N262, and N295.
249	SF12 interaction sites	silent face	Schoofs2019	contacts	SF12	448	gp120	N	0.648	0.448	0.927	X-ray crystallography	SF12 recognizes a mostly glycan-focused epitope on HIV-1 Env, interacting with glycans N448, N262, and N295.
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	276	gp120, Loop D	N	0.120	0.063	0.169	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	278	gp120, Loop D	T	0.657	0.715	0.481	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	279	gp120, Loop D	D	0.860	0.850	0.898	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	280	gp120, Loop D	N	0.117	0.090	0.170	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	281	gp120, Loop D	A	1.081	0.814	1.357	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	282	gp120, Loop D	K	0.260	0.337	0.297	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	357	gp120	K	1.086	0.868	0.941	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	455	gp120, beta23	T	0.670	0.426	0.972	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	456	gp120, beta23	R	0.196	0.079	0.323	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	457	gp120, beta23	D	0.059	0.054	0.043	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	458	gp120, beta23	G	0.097	0.045	0.095	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	cryo-EM, X-ray crystallography	DRVIA7 contact
250	DRVIA7 contacts	CD4BS	Kong2016	contacts	DRVIA7	473	gp120	G	0.031	0.033	0.029	cryo-EM, X-ray crystallography	DRVIA7 contact
251	PGT121 resistance after immunotherapy	V3-glycan	Stephenson2021	immunotherapy	PGT121	325	gp120, V3 loop	N	0.653	0.622	0.622	sequence analysis	mutations at 325, particularly mutations from D to N, E or K, were associated with resistance to PGT121 in multiple patients during PGT121 immunotherapy
251	PGT121 resistance after immunotherapy	V3-glycan	Stephenson2021	immunotherapy	PGT121	332	gp120	N	0.904	0.491	0.693	sequence analysis	loss of glycan N332, often together with certain mutations at 325, were associated with resistance to PGT121 in multiple patients during PGT121 immunotherapy
254	2F5 and 4E10 signature sites	MPER	Wang2011b	signature	2F5, 4E10	22	Signal peptide	L	0.758	0.187	0.227	computational prediction	L associated with sensitivity; 22L and 29S sites were always coincident
254	2F5 and 4E10 signature sites	MPER	Wang2011b	signature	2F5, 4E10	29	Signal peptide	S	1.134	0.660	1.376	computational prediction	S associated with sensitivity; 22L and 29S sites were always coincident
254	2F5 and 4E10 signature sites	MPER	Wang2011b	signature	2F5, 4E10	706	gp41, gp41 cytoplasmic tail	N	0.469	0.312	0.722	computational prediction	N associated with sensitivity
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	659	gp41	E	0.745	0.523	0.383	neutralization assay	E659D increased the IC50 up to 9-fold for 4E10 and 4-fold for 2F5 (Tang2023)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	660	gp41	L	0.010	0.006	0.000	neutralization assay	L660A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	661	gp41	L	0.041	0.050	0.008	neutralization assay	L661A increases sensitivity to 2F5 and 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	663	gp41	L	0.094	0.094	0.053	neutralization assay	L663A increases sensitivity to 2F5 and 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	664	gp41	D	0.197	0.156	0.346	neutralization assay	D664A increases resistance to 2F5, but not 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	665	gp41	K	0.986	0.656	0.879	neutralization assay	K665A increases resistance to 2F5, but not 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	666	gp41	W	0.003	0.000	0.000	neutralization assay	W666A increases resistance to 2F5, increases sensitivity to 4E10, and greatly decreases viral infectivity (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	669	gp41	L	0.020	0.023	0.000	neutralization assay	L669A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	670	gp41	W	0.026	0.028	0.035	neutralization assay	W670A increases sensitivity to 2F5 and 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	671	gp41	N	0.779	0.669	0.885	neutralization assay	N671A increases sensitivity to 2F5 and 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	672	gp41	W	0.017	0.023	0.014	neutralization assay	W672A increases sensitivity to 2F5, increases resistance to 4E10, and decreases viral infectivity; W672F or W672Y increases sensitivity to both 2F5 and 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	673	gp41	F	0.058	0.065	0.073	neutralization assay	F673A increases sensitivity to 2F5, but increases resistance to 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	675	gp41	I	0.050	0.059	0.069	neutralization assay	I675A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	677	gp41	N	1.187	1.199	1.100	neutralization assay	K677R increased the IC50 2-fold for 4E10 and 2F5 (Tang2023)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.010	0.018	0.008	neutralization assay	W678A increases sensitivity to 2F5 and 4E10 (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008	neutralization assay	L679A increases sensitivity to 2F5 and 4E10 and decreases viral infectivity (Zwick2005)
256	Mutation affects neutralization by 2F5 and 4E10	MPER	Tang2023, Zwick2005	neutralization	2F5, 4E10	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	neutralization assay	W680A increases sensitivity to 2F5, but increases resistance to 4E10 (Zwick2005)
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	662	gp41	E	1.024	0.874	0.369	neutralization assay	A662G increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	663	gp41	L	0.094	0.094	0.053	neutralization assay	L663A increased sensitivity 10-fold or more for H4K3
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	666	gp41	W	0.003	0.000	0.000	neutralization assay	W666A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	669	gp41	L	0.020	0.023	0.000	neutralization assay	L669A increased sensitivity 10-fold or more for H4K3
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	671	gp41	N	0.779	0.669	0.885	neutralization assay	S671A increased resistance 10-fold or more for H4K3
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	672	gp41	W	0.017	0.023	0.014	neutralization assay	W672A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	673	gp41	F	0.058	0.065	0.073	neutralization assay	F673A increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	674	gp41	N	1.182	1.029	1.344	neutralization assay	D674A, D674E or D674T increased resistance 10-fold or more for PGXZL1, H4K3, 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	675	gp41	I	0.050	0.059	0.069	neutralization assay	I675A increased sensitivity 10-fold or more for 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	677	gp41	N	1.187	1.199	1.100	neutralization assay	K677A increased sensitivity 10-fold or more for H4K3, 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.010	0.018	0.008	neutralization assay	W678A increased sensitivity 10-fold or more for PGXZL1, H4K3, 4E10
257	Mutation affects neutralization by PGZL1, H4K3, or 4E10	MPER	Zhang2019a	neutralization	4E10, H4K3, PGZL1	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	neutralization assay	W680A increased resistance 10-fold or more for PGXZL1, H4K3
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	672	gp41	W	0.017	0.023	0.014		PGZL1 contact
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	673	gp41	F	0.058	0.065	0.073		PGZL1 contact
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	674	gp41	N	1.182	1.029	1.344		MPER polymorphisms D674S, D674T, and D674E are predicted to contact PGZL1
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	675	gp41	I	0.050	0.059	0.069		PGZL1 contact
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	676	gp41	T	0.683	0.610	0.674		PGZL1 contact
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	677	gp41	N	1.187	1.199	1.100		PGZL1 contact
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008		PGZL1 contact
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081		PGZL1 contact
258	PGZL1 contacts	MPER	Zhang2019a	contacts	PGZL1	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036		PGZL1 contact
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	671	gp41	N	0.779	0.669	0.885		contact with LN01 heavy chain residue Tyr 58
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	673	gp41	F	0.058	0.065	0.073		contact with LN01 heavy chain residues Thr 50 and Trp 100h; contact with light chain residue Trp 96
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	674	gp41	N	1.182	1.029	1.344		contact with LN01 light chain residues Ser 93 and Thr 94
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	676	gp41	T	0.683	0.610	0.674		contact with LN01 heavy chain residues Ser 100f and Trp 100h
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	677	gp41	N	1.187	1.199	1.100		contact with LN01 light chain residues Tyr 32 and His 92
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081		contact with LN01 heavy chain residues Phe 100e and Ser 100f
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569		contact with LN01 heavy chain residues Phe 100, Trp 100a, and Ser 100b
259	LN01 contacts	MPER	Pinto2019	contacts	LN01	687	gp41, gp41 transmembrane	M	0.343	0.263	0.330		contact with LN01 heavy chain residue Trp 100a
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	123	gp120	T	0.033	0.028	0.038		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	276	gp120, Loop D	N	0.120	0.063	0.169		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	278	gp120, Loop D	T	0.657	0.715	0.481		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	279	gp120, Loop D	D	0.860	0.850	0.898		N60P23 contact (based on 93TH057 strain with 279N)
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	280	gp120, Loop D	N	0.117	0.090	0.170		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	281	gp120, Loop D	A	1.081	0.814	1.357		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	282	gp120, Loop D	K	0.260	0.337	0.297		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	430	gp120, beta20/beta21	V	0.397	0.080	0.073		N60P23 contact (based on 93TH057 strain with 430T)
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	431	gp120, beta20/beta21	G	0.072	0.036	0.039		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	432	gp120, beta20/beta21	K	1.137	0.339	0.564		N60P23 contact (based on 93TH057 strain with 432Q)
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	455	gp120, beta23	T	0.670	0.426	0.972		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	456	gp120, beta23	R	0.196	0.079	0.323		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	457	gp120, beta23	D	0.059	0.054	0.043		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	458	gp120, beta23	G	0.097	0.045	0.095		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		N60P23 contact (based on 93TH057 strain with 460A)
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		N60P23 contact (based on 93TH057 strain with 461N)
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	472	gp120	G	0.034	0.012	0.043		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	473	gp120	G	0.031	0.033	0.029		N60P23 contact
260	N60P23 contacts	CD4BS	Sajadi2018	contacts	N60P23	474	gp120	D	0.719	0.681	0.752		N60P23 contact (based on 93TH057 strain with 474N)
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	97	gp120	K	0.433	0.421	0.511		N49P7 contact, hydrogen bond with CDR H3
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	275	gp120, Loop D	V	1.034	1.420	0.535		N49P7 contact, based on 93TH057 strain with 275E
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	276	gp120, Loop D	N	0.120	0.063	0.169		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	278	gp120, Loop D	T	0.657	0.715	0.481		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	279	gp120, Loop D	D	0.860	0.850	0.898		N49P7 contact, based on 93TH057 strain with 279N
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	280	gp120, Loop D	N	0.117	0.090	0.170		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	281	gp120, Loop D	A	1.081	0.814	1.357		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	282	gp120, Loop D	K	0.260	0.337	0.297		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	428	gp120, beta20/beta21	Q	0.052	0.053	0.054		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	429	gp120, beta20/beta21	K	1.406	0.961	1.308		N49P7 contact, based on 93TH057 strain with 429G
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	455	gp120, beta23	T	0.670	0.426	0.972		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	456	gp120, beta23	R	0.196	0.079	0.323		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	457	gp120, beta23	D	0.059	0.054	0.043		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	458	gp120, beta23	G	0.097	0.045	0.095		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	471	gp120, beta24	G	0.879	0.888	0.866		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	473	gp120	G	0.031	0.033	0.029		N49P7 contact
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	474	gp120	D	0.719	0.681	0.752		N49P7 contact, hydrogen bond with CDR H2, based on 93TH057 strain with 474N
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	476	gp120	R	0.699	0.615	0.711		N49P7 contact, based on 93TH057 strain with 476K
261	N49P7 contacts	CD4BS	Sajadi2018	contacts	N49P7	477	gp120	D	0.167	0.112	0.249		N49P7 contact, salt bridge with CDR H3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	61	gp120	Y	0.465	0.299	0.148		N49P6 contact: hydrogen bond with CDR H3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	64	gp120	E	0.019	0.022	0.008		N49P6 contacts: hydrogen bonds with CDR H1 & CDR H3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	65	gp120	V	1.035	1.023	0.310		N49P6 contact: hydrogen bond & van der Waals with HC FWR1 (based on BG505 SOSIP.664 strain 65K)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	66	gp120	H	0.019	0.017	0.000		N49P6 contact: hydrogen bond with HC FWR1
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	96	gp120	W	0.054	0.091	0.020		N49P6 contact
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	102	gp120	E	0.792	0.522	0.426		N49P6 contacts: CDR H2 & CDR H3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	275	gp120, Loop D	V	1.034	1.420	0.535		N49P6 contact: CDR H3 (based on 93TH057 strain with 275E)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	276	gp120, Loop D	N	0.120	0.063	0.169		N49P6 contacts: CDR H3, CDR L1, CDR L3; CDR L3 also contacts 276-linked carbohydrate
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	278	gp120, Loop D	T	0.657	0.715	0.481		N49P6 contact: van der Waals with CDR L3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	279	gp120, Loop D	D	0.860	0.850	0.898		N49P6 contacts: hydrogen bond with CDR H3, & van der Waals with CDR L3 (based on BG505 SOSIP.664 & 93TH057 strains with 279N)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	280	gp120, Loop D	N	0.117	0.090	0.170		N49P6 contacts: hydrogen bonds with CDR H2 & CDR L3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	281	gp120, Loop D	A	1.081	0.814	1.357		N49P6 contact: CDR H3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	282	gp120, Loop D	K	0.260	0.337	0.297		N49P6 contact: CDR H3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	365	gp120, CD4 binding loop	S	0.574	0.489	0.619		N49P6 contact: CDR H2 antiparallel beta-sheet
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	366	gp120, CD4 binding loop	G	0.034	0.012	0.028		N49P6 contacts: CDR H2 antiparallel beta-sheet, weak hydrogen bond with CDR H2
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	367	gp120, CD4 binding loop	G	0.016	0.034	0.008		N49P6 contact: CDR H2 antiparallel beta-sheet
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	368	gp120, CD4 binding loop	D	0.024	0.023	0.029		N49P6 contacts: CDR H2 antiparallel beta-sheet; salt bridge with HC FWR3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	371	gp120, CD4 binding loop	I	0.451	0.389	0.507		N49P6 contact (based on BG505 SOSIP.664 strain with 371V & 93TH057 strain with 371I)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	428	gp120, beta20/beta21	Q	0.052	0.053	0.054		N49P6 contact
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	430	gp120, beta20/beta21	V	0.397	0.080	0.073		N49P6 contact (based on BG505 SOSIP.664 strain with 430I & 93TH057 strain with 430V)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	455	gp120, beta23	T	0.670	0.426	0.972		N49P6 contact: CDR H2
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	456	gp120, beta23	R	0.196	0.079	0.323		N49P6 contact: CDR H2
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	457	gp120, beta23	D	0.059	0.054	0.043		N49P6 contact: CDR H2
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	458	gp120, beta23	G	0.097	0.045	0.095		N49P6 contacts: CDR H2 & CDR L3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268		N49P6 contacts: CDR H2; hydrogen bond with CDR L3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		N49P6 contact (based on BG505 SOSIP.664 strain with 460S)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		N49P6 contact (based on BG505 SOSIP.664 strain with 465T)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239		N49P6 contact
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870		N49P6 contact (based on BG505 SOSIP.664 strain with 467T)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051		N49P6 contact
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	472	gp120	G	0.034	0.012	0.043		N49P6 contact
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	473	gp120	G	0.031	0.033	0.029		N49P6 contact: CDR H2 & CDR H3
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	474	gp120	D	0.719	0.681	0.752		N49P6 contact: CDR H2 & CDR H3 (based on BG505 SOSIP.664 strain with 474D & 93TH057 strain with 474N)
262	N49P6 contacts	CD4BS	Tolbert2021	contacts	N49P6	476	gp120	R	0.699	0.615	0.711		N49P6 contact: CDR H2 & CDR H3 (based on BG505 SOSIP.664 strain with 476R & 93TH057 strain with 476K)
263	VRC-PG05 contacts	silent face	Zhou2018	contacts	VRC-PG05	262	gp120	N	0.029	0.029	0.028		VRC-PG05 contact
263	VRC-PG05 contacts	silent face	Zhou2018	contacts	VRC-PG05	293	gp120	E	2.081	1.967	1.722		VRC-PG05 contact
263	VRC-PG05 contacts	silent face	Zhou2018	contacts	VRC-PG05	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557		VRC-PG05 contact
263	VRC-PG05 contacts	silent face	Zhou2018	contacts	VRC-PG05	446	gp120	S	2.139	1.139	1.774		VRC-PG05 contact
263	VRC-PG05 contacts	silent face	Zhou2018	contacts	VRC-PG05	447	gp120	S	0.038	0.024	0.023		VRC-PG05 contact
263	VRC-PG05 contacts	silent face	Zhou2018	contacts	VRC-PG05	448	gp120	N	0.648	0.448	0.927		VRC-PG05 contact
264	VRC-PG05 sensitivity and escape	silent face	Zhou2018	neutralization	VRC-PG05	291	gp120	S	1.139	1.292	0.739	neutralization assay	S291 required for sensitivity to VRC-PG05, based on neutralization panel data
264	VRC-PG05 sensitivity and escape	silent face	Zhou2018	neutralization	VRC-PG05	293	gp120	E	2.081	1.967	1.722	neutralization assay	E293 required for sensitivity to VRC-PG05, based on neutralization panel data; mutation of N448 or E293 were dominant means of escape from VRC-PG05
264	VRC-PG05 sensitivity and escape	silent face	Zhou2018	neutralization	VRC-PG05	362	gp120	K	1.874	1.265	1.997	neutralization assay	362 associated with sensitivity to VRC-PG05, based on neutralization panel data
264	VRC-PG05 sensitivity and escape	silent face	Zhou2018	neutralization	VRC-PG05	375	gp120	S	0.790	0.753	0.372	neutralization assay	375 associated with sensitivity to VRC-PG05, based on neutralization panel data
264	VRC-PG05 sensitivity and escape	silent face	Zhou2018	neutralization	VRC-PG05	448	gp120	N	0.648	0.448	0.927	neutralization assay	mutation of N448 or E293 were dominant means of escape from VRC-PG05
265	Q563R affects neutralization of MPER mAbs	MPER	Joshi2020	neutralization	10E8, 2F5, 4E10, 7H6, Z13e1	563	gp41, Leu/Ile zipper-like sequence	Q	0.066	0.086	0.050	neutralization assay	Q563R allows for better binding and increased sensitivity to neutralization by MPER mAbs; Q563R dramatically decreases viral infectivity by disrupting membrane fusion and 6-helix bundle formation
267	m36 contacts	CD4i	Wan2013	contacts	m36	123	gp120	T	0.033	0.028	0.038	computational prediction, molecular modeling, mutational analysis	m36 contact
267	m36 contacts	CD4i	Wan2013	contacts	m36	124	gp120	P	0.047	0.018	0.029	computational prediction, molecular modeling, mutational analysis	m36 contact
267	m36 contacts	CD4i	Wan2013	contacts	m36	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	computational prediction, molecular modeling, mutational analysis	m36 contact
267	m36 contacts	CD4i	Wan2013	contacts	m36	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	computational prediction, molecular modeling, mutational analysis	m36 contact
267	m36 contacts	CD4i	Wan2013	contacts	m36	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction, molecular modeling, mutational analysis	m36 contact
267	m36 contacts	CD4i	Wan2013	contacts	m36	427	gp120, beta20/beta21	W	0.052	0.061	0.038	computational prediction, molecular modeling, mutational analysis	m36 contact
268	CAP257-RH1 contacts	CD4BS	Wibmer2016	contacts	CAP257-RH1	276	gp120, Loop D	N	0.120	0.063	0.169		RH1 contact
268	CAP257-RH1 contacts	CD4BS	Wibmer2016	contacts	CAP257-RH1	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373		RH1 contact
268	CAP257-RH1 contacts	CD4BS	Wibmer2016	contacts	CAP257-RH1	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218		RH1 contact
268	CAP257-RH1 contacts	CD4BS	Wibmer2016	contacts	CAP257-RH1	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969		RH1 contact
268	CAP257-RH1 contacts	CD4BS	Wibmer2016	contacts	CAP257-RH1	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042		RH1 contact
268	CAP257-RH1 contacts	CD4BS	Wibmer2016	contacts	CAP257-RH1	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517		RH1 contact
269	Mutation affects CAP257-RH1 neutralization	CD4BS	Wibmer2016	neutralization	CAP257-RH1	276	gp120, Loop D	N	0.120	0.063	0.169	neutralization assay	N276Q abrogates neutralization of strain RHPA
269	Mutation affects CAP257-RH1 neutralization	CD4BS	Wibmer2016	neutralization	CAP257-RH1	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	T278A abrogates neutralization of strain RHPA
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	121	gp120	K	0.385	0.360	0.187	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	123	gp120	T	0.033	0.028	0.038	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	124	gp120	P	0.047	0.018	0.029	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	127	gp120	V	0.093	0.112	0.093	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	160	gp120, V2	N	0.401	0.452	0.358	X-ray crystallography	PGT145 glycan contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	161	gp120, V2	I	1.565	0.964	1.568	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	162	gp120, V2	S	0.289	0.445	0.179	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	166	gp120, V2	R	1.127	1.398	0.772	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	167	gp120, V2	G	0.601	1.122	0.185	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	168	gp120, V2	K	0.547	0.666	0.396	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	169	gp120, V2	V	1.974	1.770	1.344	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	309	gp120, V3 loop	I	0.921	0.359	0.965	X-ray crystallography	PGT145 contact
270	PGT145 contacts	V2-apex	Chuang2019	contacts	PGT145	315	gp120, V3 loop	R	1.120	1.028	0.196	X-ray crystallography	PGT145 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	157	gp120, Cys 131 linked to Cys 157 forms V1 loop	C	0.015	0.017	0.031	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	158	gp120, V2	S	0.297	0.185	0.291	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	160	gp120, V2	N	0.401	0.452	0.358	X-ray crystallography	PG9 glycan contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	162	gp120, V2	S	0.289	0.445	0.179	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	163	gp120, V2	T	0.360	0.638	0.154	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	166	gp120, V2	R	1.127	1.398	0.772	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	167	gp120, V2	G	0.601	1.122	0.185	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	168	gp120, V2	K	0.547	0.666	0.396	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	169	gp120, V2	V	1.974	1.770	1.344	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	170	gp120, V2	Q	1.458	1.423	1.428	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	171	gp120, V2	K	1.239	0.957	1.413	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	172	gp120, V2	E	1.506	1.172	1.484	X-ray crystallography	PG9 contact
271	PG9 contacts	V2-apex	Chuang2019	contacts	PG9	173	gp120, V2	Y	1.165	0.808	1.158	X-ray crystallography	PG9 glycan contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	156	gp120, V1	N	0.217	0.220	0.224	X-ray crystallography	PGT121 glycan contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	301	gp120, V3 loop	N	0.261	0.176	0.104	X-ray crystallography	PGT121 glycan contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	321	gp120, V3 loop	G	1.031	0.842	1.108	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	322	gp120, V3 loop	K	0.370	0.347	0.283	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	323	gp120, V3 loop	I	0.575	0.531	0.263	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	324	gp120, V3 loop	G	0.088	0.056	0.092	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	325	gp120, V3 loop	N	0.653	0.622	0.622	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	326	gp120, V3 loop	M	0.188	0.143	0.116	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	327	gp120, V3 loop	R	0.118	0.066	0.073	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	328	gp120, V3 loop	Q	1.001	0.816	0.882	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	330	gp120, V3 loop	H	0.743	0.559	0.655	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	332	gp120	N	0.904	0.491	0.693	X-ray crystallography	PGT121 glycan contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	415	gp120, V4 loop	T	0.846	0.760	0.656	X-ray crystallography	PGT121 contact
272	PGT121 contacts	V3-glycan	Chuang2019	contacts	PGT121	417	gp120, V4 loop	P	0.836	0.736	0.922	X-ray crystallography	PGT121 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	105	gp120	H	0.479	0.429	0.187	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	122	gp120	L	0.120	0.101	0.121	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	123	gp120	T	0.033	0.028	0.038	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	124	gp120	P	0.047	0.018	0.029	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	198	gp120	T	0.458	0.264	0.469	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	199	gp120	S	0.086	0.108	0.068	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	257	gp120	T	0.024	0.024	0.015	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	275	gp120, Loop D	V	1.034	1.420	0.535	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	375	gp120	S	0.790	0.753	0.372	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	425	gp120, beta20/beta21	N	0.405	0.138	0.177	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	426	gp120, beta20/beta21	M	0.598	0.866	0.274	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	427	gp120, beta20/beta21	W	0.052	0.061	0.038	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	429	gp120, beta20/beta21	K	1.406	0.961	1.308	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	431	gp120, beta20/beta21	G	0.072	0.036	0.039	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	432	gp120, beta20/beta21	K	1.137	0.339	0.564	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	457	gp120, beta23	D	0.059	0.054	0.043	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	458	gp120, beta23	G	0.097	0.045	0.095	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	470	gp120, beta24	P	0.043	0.039	0.037	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	472	gp120	G	0.034	0.012	0.043	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	473	gp120	G	0.031	0.033	0.029	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	474	gp120	D	0.719	0.681	0.752	X-ray crystallography	VRC16 contact
273	VRC16 contacts	CD4BS	Chuang2019	contacts	VRC16	477	gp120	D	0.167	0.112	0.249	X-ray crystallography	VRC16 contact
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	80	gp120	N	0.634	0.695	0.562	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	82	gp120	Q	0.287	0.200	0.268	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	83	gp120	E	0.033	0.039	0.035	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	84	gp120	V	1.321	0.916	1.327	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	85	gp120	V	2.208	1.797	1.418	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	87	gp120	V	1.538	1.611	1.463	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	88	gp120	N	0.053	0.041	0.048	X-ray crystallography	VRC34.01 glycan contact (Chuang2019); glycan forms H-bonds and favorable interactions (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	229	gp120	N	0.780	0.742	0.290	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	230	gp120	N	0.954	0.896	0.544	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	231	gp120	K	0.797	0.578	0.780	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	241	gp120	N	0.169	0.183	0.134	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	X-ray crystallography	VRC34.01 contact (Chuang2019), interacts with hydrophobic pocket (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	X-ray crystallography	VRC34.01 contact (Chuang2019), interacts with hydrophobic pocket (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	X-ray crystallography	VRC34.01 contact (Chuang2019), interacts with hydrophobic pocket (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	X-ray crystallography	VRC34.01 contact (Chuang2019), interacts with hydrophobic pocket (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	X-ray crystallography	VRC34.01 contact (Chuang2019), interacts with hydrophobic pocket (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	X-ray crystallography	VRC34.01 contact (Chuang2019), interacts with hydrophobic pocket (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	X-ray crystallography	VRC34.01 contact (Chuang2019), stacks side chains with CDRH2  (Kong2016a)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	520	gp41, fusion peptide	L	0.604	0.253	0.390	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	521	gp41, fusion peptide	G	0.033	0.028	0.008	X-ray crystallography	VRC34.01 contact (Chuang2019)
274	VRC34.01 contacts	gp41 fusion domain	Chuang2019, Kong2016a	contacts	VRC34.01	648	gp41	E	1.390	1.332	1.379	X-ray crystallography	VRC34.01 contact (Chuang2019)
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay	N262A reduces NC-Cow1 binding to JRCSF
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay	K282A reduces NC-Cow1 binding to BG505
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay	G367A reduces NC-Cow1 binding to BG505
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	alanine scanning, binding assay	L369A reduces NC-Cow1 binding to BG505
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	V371A reduces NC-Cow1 binding to BG505
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	alanine scanning, binding assay	T372A reduces NC-Cow1 binding to JRCSF
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	472	gp120	G	0.034	0.012	0.043	alanine scanning, binding assay	G472A reduces NC-Cow1 binding to BG505 and JRCSF
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	473	gp120	G	0.031	0.033	0.029	alanine scanning, binding assay	G473A reduces NC-Cow1 binding to JRCSF
275	Mutation affects NC-Cow1 binding	CD4BS	Sok2017	binding	NC-Cow1	476	gp120	R	0.699	0.615	0.711	alanine scanning, binding assay	R476A reduces NC-Cow1 binding to JRCSF
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay	N262A decreases binding
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay	G366A decreases binding
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A decreases binding and significantly affects neutralization
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	455	gp120, beta23	T	0.670	0.426	0.972	alanine scanning, binding assay	T455A decreases binding
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay	D457A decreases binding
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	471	gp120, beta24	G	0.879	0.888	0.866	alanine scanning, binding assay	G471A decreases binding and significantly affects neutralization
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	472	gp120	G	0.034	0.012	0.043	alanine scanning, binding assay	G472A decreases binding
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	473	gp120	G	0.031	0.033	0.029	alanine scanning, binding assay	G473A decreases binding
276	Mutation affects binding of MEL-1872	CD4BS	Heydarchi2022	binding	MEL-1872	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay	D474A decreases binding
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	262	gp120	N	0.029	0.029	0.028	cryo-EM	glycan contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	cryo-EM	glycan contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	332	gp120	N	0.904	0.491	0.693	cryo-EM	glycan contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	334	gp120	S	0.780	0.501	0.890	cryo-EM	Van der Waals contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	411	gp120, V4 loop	S	1.596	1.682	1.577	cryo-EM	Van der Waals contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	412	gp120, V4 loop	D	2.190	2.094	2.182	cryo-EM	Van der Waals contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	413	gp120, V4 loop	T	1.440	1.451	1.561	cryo-EM	Van der Waals contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	444	gp120	R	1.754	1.507	0.494	cryo-EM	Van der Waals contact
277	7-269 contacts	glycan	Lorin2022	contacts	7-269	446	gp120	S	2.139	1.139	1.774	cryo-EM	Van der Waals contact
278	VRC01.23LS primary contacts	CD4BS	Kwon2021	contacts	VRC01.23LS	276	gp120, Loop D	N	0.120	0.063	0.169	cryo-EM	hydrogen bonding networks between glycan at 276 of gp120 and Arg66 of VRC01.23 light chain
278	VRC01.23LS primary contacts	CD4BS	Kwon2021	contacts	VRC01.23LS	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	cryo-EM	distance of 9.5A between Thr461 of gp120 and Leu4 of VRC01.23
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	117	gp120	K	0.199	0.084	0.120	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	121	gp120	K	0.385	0.360	0.187	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	156	gp120, V1	N	0.217	0.220	0.224	X-ray crystallography	N156 interaction with PGT145 paratope residue Y173 stabilizes V1/V2 and restricts glycan conformations
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	160	gp120, V2	N	0.401	0.452	0.358	X-ray crystallography	N160 interaction with PGT145 paratope residue K171 stabilizes V1/V2 and restricts glycan conformations
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	161	gp120, V2	I	1.565	0.964	1.568	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	162	gp120, V2	S	0.289	0.445	0.179	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	164	gp120, V2	S	1.660	1.925	0.453	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	165	gp120, V2	I	1.321	1.292	1.011	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	166	gp120, V2	R	1.127	1.398	0.772	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	167	gp120, V2	G	0.601	1.122	0.185	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	168	gp120, V2	K	0.547	0.666	0.396	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	169	gp120, V2	V	1.974	1.770	1.344	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	170	gp120, V2	Q	1.458	1.423	1.428	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	171	gp120, V2	K	1.239	0.957	1.413	X-ray crystallography	PGT145 contact
279	PGT145 epitope	V2-apex	Lee2017	contacts	PGT145	315	gp120, V3 loop	R	1.120	1.028	0.196	X-ray crystallography	PGT145 contact
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	127	gp120	V	0.093	0.112	0.093	alanine scanning, neutralization assay	BG505 V127A mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	156	gp120, V1	N	0.217	0.220	0.224	alanine scanning, neutralization assay	BG505 N156K mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	160	gp120, V2	N	0.401	0.452	0.358	alanine scanning, neutralization assay	BG505 N160K or N160A mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	161	gp120, V2	I	1.565	0.964	1.568	alanine scanning, neutralization assay	BG505 M161A mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	162	gp120, V2	S	0.289	0.445	0.179	alanine scanning, neutralization assay	BG505 T162A mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	166	gp120, V2	R	1.127	1.398	0.772	alanine scanning, neutralization assay	BG505 R166A mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	167	gp120, V2	G	0.601	1.122	0.185	alanine scanning, neutralization assay	BG505 D167A mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	168	gp120, V2	K	0.547	0.666	0.396	alanine scanning, neutralization assay	BG505 K168A mutation associated with resistance to neutralization
280	Mutation causes resistance to V2 bnAbs	V2-apex	Lee2017	neutralization	PGDM1400, PGT143, PGT145	169	gp120, V2	V	1.974	1.770	1.344	alanine scanning, neutralization assay	BG505 K169A mutation associated with resistance to neutralization
281	Mutation affects 3BNC117 neutralization	CD4BS	Schommers2020	neutralization	3BNC117	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	YU2 double mutation N278I/A281T decreases 3BNC117 neutralization >80 fold
281	Mutation affects 3BNC117 neutralization	CD4BS	Schommers2020	neutralization	3BNC117	279	gp120, Loop D	D	0.860	0.850	0.898	neutralization assay	YU2 mutation N279K decreases 3BNC117 neutralization >80 fold
281	Mutation affects 3BNC117 neutralization	CD4BS	Schommers2020	neutralization	3BNC117	280	gp120, Loop D	N	0.117	0.090	0.170	neutralization assay	YU2 mutation N280Y decreases 3BNC117 neutralization >9 fold
281	Mutation affects 3BNC117 neutralization	CD4BS	Schommers2020	neutralization	3BNC117	281	gp120, Loop D	A	1.081	0.814	1.357	neutralization assay	YU2 mutation A281T, or double mutation N278I/A281T, decreases 3BNC117 neutralization >80 fold
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	113	gp120	D	0.135	0.092	0.134	neutralization assay	D113N mediated a 4.1-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	119	gp120, Cys 119 linked to Cys 205	C	0.014	0.012	0.022	neutralization assay	C119R mediated a 1.6-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	neutralization assay	D140E mediated a 1.8-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	neutralization assay	R151K mediated a 1.7-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	197	gp120	N	0.111	0.082	0.109	neutralization assay	N197D enchances nuetralization (Kong2016a);  N197E and N197S mediated respective ~50-fold increase and 26-fold decrease in neutralization potency; glycosylation motif (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	198	gp120	T	0.458	0.264	0.469	neutralization assay	T198A mediated a 3.6-fold decrease in neutralization potency; glycosylation motif (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	YU2 double mutation T278I/A281T decreases VRC01 neutralization >20 fold (Schommers2020)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	279	gp120, Loop D	D	0.860	0.850	0.898	neutralization assay	YU2 mutation N279K decreases VRC01 neutralization >20 fold (Schommers2020);  N279K mediated a >175-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	280	gp120, Loop D	N	0.117	0.090	0.170	neutralization assay	YU2 mutation N280Y decreases VRC01 neutralization >20 fold (Schommers2020)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	281	gp120, Loop D	A	1.081	0.814	1.357	neutralization assay	YU2 mutation A281T, or double mutation T278I/A281T, decreases VRC01 neutralization >20 fold (Schommers2020)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	326	gp120, V3 loop	M	0.188	0.143	0.116	neutralization assay	I326Y mediated a 2.9-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	327	gp120, V3 loop	R	0.118	0.066	0.073	neutralization assay	R327A mediated a 1.3-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	neutralization assay	L369K mediated a 4.01-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
282	Mutation affects VRC01 neutralization	CD4BS	Dingens2019, Kong2016a, Schommers2020	neutralization	VRC01	441	gp120	G	0.060	0.041	0.037	neutralization assay	G441P mediated a 1.4-fold decrease in neutralization potency (Dingens2019, BG505.T332N)
283	Mutation affects N6 neutralization	CD4BS	Schommers2020	neutralization	N6	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	YU2 mutation A281T decreases N6 neutralization 15 fold; double mutation T278I/A281T decreases N6 neutralization >50 fold
283	Mutation affects N6 neutralization	CD4BS	Schommers2020	neutralization	N6	281	gp120, Loop D	A	1.081	0.814	1.357	neutralization assay	YU2 double mutation T278I/A281T decreases N6 neutralization >50 fold
284	Mutation affects 8ANC131 neutralization	CD4BS	Schommers2020	neutralization	8ANC131	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	YU2 double mutation T278I/A281T decreases 8ANC195 neutralization >9 fold
284	Mutation affects 8ANC131 neutralization	CD4BS	Schommers2020	neutralization	8ANC131	279	gp120, Loop D	D	0.860	0.850	0.898	neutralization assay	YU2 N279K decreases 8ANC131 neutralization >9 fold
284	Mutation affects 8ANC131 neutralization	CD4BS	Schommers2020	neutralization	8ANC131	280	gp120, Loop D	N	0.117	0.090	0.170	neutralization assay	YU2 N280Y decreases 8ANC131 neutralization >9 fold
284	Mutation affects 8ANC131 neutralization	CD4BS	Schommers2020	neutralization	8ANC131	281	gp120, Loop D	A	1.081	0.814	1.357	neutralization assay	YU2 A281T decreases 8ANC131 neutralization >9 fold; double mutation T278I/A281T decreases 8ANC195 neutralization >9 fold
284	Mutation affects 8ANC131 neutralization	CD4BS	Schommers2020	neutralization	8ANC131	458	gp120, beta23	G	0.097	0.045	0.095	neutralization assay	YU2 G458D decreases 8ANC131 neutralization 5 fold
284	Mutation affects 8ANC131 neutralization	CD4BS	Schommers2020	neutralization	8ANC131	471	gp120, beta24	G	0.879	0.888	0.866	neutralization assay	YU2 G471R decreases 8ANC131 neutralization >9 fold
285	Mutation affects 8ANC195 neutralization	gp120/gp41 interface	Kong2016a, Schommers2020	neutralization	8ANC195	234	gp120	N	0.584	0.757	0.341	neutralization assay	N234A greatly decreases neutralization (Kong2016a)
285	Mutation affects 8ANC195 neutralization	gp120/gp41 interface	Kong2016a, Schommers2020	neutralization	8ANC195	276	gp120, Loop D	N	0.120	0.063	0.169	neutralization assay	YU2 N276D decreases 8ANC195 neutralization >5 fold (Schommers2020)
285	Mutation affects 8ANC195 neutralization	gp120/gp41 interface	Kong2016a, Schommers2020	neutralization	8ANC195	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	YU2 T278K, T278A, or T278I decreases 8ANC195 neutralization >5 fold; double mutation T278I/A281T decreases 8ANC195 neutralization >5 fold (Schommers2020); T278A greatly decreases neutralization (Kong2016a)
285	Mutation affects 8ANC195 neutralization	gp120/gp41 interface	Kong2016a, Schommers2020	neutralization	8ANC195	281	gp120, Loop D	A	1.081	0.814	1.357	neutralization assay	YU2 double mutation T278I/A281T decreases 8ANC195 neutralization >5 fold (Schommers2020)
286	Mutation affects neutralization of PGDM1400 and PG16	V2-apex	Schommers2020	neutralization	PG16, PGDM1400	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	YU2 mutations N160K or N160T decrease neutralization >6 fold
286	Mutation affects neutralization of PGDM1400 and PG16	V2-apex	Schommers2020	neutralization	PG16, PGDM1400	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	YU2 mutations T162I or T162N decrease neutralization >6 fold
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	197	gp120	N	0.111	0.082	0.109	cryo-EM	CDRH1 contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	198	gp120	T	0.458	0.264	0.469	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	207	gp120	K	0.043	0.029	0.029	cryo-EM	CDRH1 contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	276	gp120, Loop D	N	0.120	0.063	0.169	cryo-EM	light chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	279	gp120, Loop D	D	0.860	0.850	0.898	cryo-EM	light chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	280	gp120, Loop D	N	0.117	0.090	0.170	cryo-EM	light chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	281	gp120, Loop D	A	1.081	0.814	1.357	cryo-EM	light and heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	282	gp120, Loop D	K	0.260	0.337	0.297	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	283	gp120, Loop D	T	0.992	1.091	0.474	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	304	gp120, V3 loop	R	0.287	0.390	0.141	cryo-EM	CDRH1 contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	306	gp120, V3 loop	R	0.732	0.860	0.338	cryo-EM	CDRH1 contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	308	gp120, V3 loop	R	0.108	0.091	0.127	cryo-EM	CDRH1 contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	316	gp120, V3 loop	A	1.151	0.736	0.966	cryo-EM	CDRH1 contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	318	gp120, V3 loop	V	0.574	0.691	0.507	cryo-EM	CDRH1 contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	457	gp120, beta23	D	0.059	0.054	0.043	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	458	gp120, beta23	G	0.097	0.045	0.095	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	cryo-EM	heavy chain contact
287	561_01_18 contacts	CD4BS	Schommers2020	contacts	561_01_18	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	cryo-EM	light chain contact
288	561_01_18 escape mutations	CD4BS	Schommers2020	neutralization	561_01_18	119	gp120, Cys 119 linked to Cys 205	C	0.014	0.012	0.022	mutational analysis	escape mutations in BG505; mutations at C119 may reduce accessibility to the highly conserved K207 by disordering the V1/V2 loop structure
288	561_01_18 escape mutations	CD4BS	Schommers2020	neutralization	561_01_18	207	gp120	K	0.043	0.029	0.029	mutational analysis	escape mutations in BG505 through disruption of interaction with CDRH1
288	561_01_18 escape mutations	CD4BS	Schommers2020	neutralization	561_01_18	304	gp120, V3 loop	R	0.287	0.390	0.141	mutational analysis	escape mutations in BG505 through disruption of interaction with CDRH1
288	561_01_18 escape mutations	CD4BS	Schommers2020	neutralization	561_01_18	318	gp120, V3 loop	V	0.574	0.691	0.507	mutational analysis	escape mutations in BG505 through disruption of interaction with CDRH1
289	Mutation decreases binding of m66 and m66.6	CD4BS	Zhu2011	binding	m66, m66.6	660	gp41	L	0.010	0.006	0.000	alanine scanning, surface plasmon resonance	L660A abrogates binding to MPER peptide (Env residues 657-670)
289	Mutation decreases binding of m66 and m66.6	CD4BS	Zhu2011	binding	m66, m66.6	663	gp41	L	0.094	0.094	0.053	alanine scanning, surface plasmon resonance	L663A abrogates binding to MPER peptide (Env residues 657-670)
289	Mutation decreases binding of m66 and m66.6	CD4BS	Zhu2011	binding	m66, m66.6	664	gp41	D	0.197	0.156	0.346	alanine scanning, surface plasmon resonance	D664A abrogates binding to MPER peptide (Env residues 657-670)
289	Mutation decreases binding of m66 and m66.6	CD4BS	Zhu2011	binding	m66, m66.6	665	gp41	K	0.986	0.656	0.879	alanine scanning, surface plasmon resonance	K665A abrogates binding to MPER peptide (Env residues 657-670)
289	Mutation decreases binding of m66 and m66.6	CD4BS	Zhu2011	binding	m66, m66.6	666	gp41	W	0.003	0.000	0.000	alanine scanning, surface plasmon resonance	W666A abrogates binding to MPER peptide (Env residues 657-670)
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	168	gp120, V2	K	0.547	0.666	0.396	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	169	gp120, V2	V	1.974	1.770	1.344	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	171	gp120, V2	K	1.239	0.957	1.413	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	172	gp120, V2	E	1.506	1.172	1.484	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	176	gp120, V2	F	0.166	0.303	0.042	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	178	gp120, V2	K	1.232	1.386	0.988	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	180	gp120, V2	D	0.031	0.033	0.029	alanine scanning, binding assay, X-ray crystallography	CH58 contact
290	CH58 contacts	V2-apex	Liao2013b	contacts	CH58	183	gp120, V2	P	1.179	1.107	0.787	alanine scanning, binding assay, X-ray crystallography	CH58 contact
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	168	gp120, V2	K	0.547	0.666	0.396	X-ray crystallography	key hydrophobic amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	169	gp120, V2	V	1.974	1.770	1.344	X-ray crystallography	key hydrophobic amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	171	gp120, V2	K	1.239	0.957	1.413	X-ray crystallography	key hydrophobic amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	172	gp120, V2	E	1.506	1.172	1.484	X-ray crystallography	key amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	173	gp120, V2	Y	1.165	0.808	1.158	X-ray crystallography	key hydrophobic amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	175	gp120, V2	F	0.498	0.868	0.271	X-ray crystallography	key amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	176	gp120, V2	F	0.166	0.303	0.042	X-ray crystallography	key amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	178	gp120, V2	K	1.232	1.386	0.988	X-ray crystallography	key hydrophobic amino acid contact of IGHV5-51 V2-apex antibodies
291	Contacts of IGHV5-51 V2 antibodies	V2-apex	vanEeden2018, Wibmer2018	contacts	CAP228-16H, CAP228-3D, CH58	180	gp120, V2	D	0.031	0.033	0.029	X-ray crystallography	key hydrophobic amino acid contact of IGHV5-51 V2-apex antibodies
292	438-B11 contacts	V3-glycan	Kumar2020	contacts	438-B11	156	gp120, V1	N	0.217	0.220	0.224	X-ray crystallography	438-B11 contact
292	438-B11 contacts	V3-glycan	Kumar2020	contacts	438-B11	301	gp120, V3 loop	N	0.261	0.176	0.104	X-ray crystallography	438-B11 contact
292	438-B11 contacts	V3-glycan	Kumar2020	contacts	438-B11	332	gp120	N	0.904	0.491	0.693	X-ray crystallography	438-B11 contact
292	438-B11 contacts	V3-glycan	Kumar2020	contacts	438-B11	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	X-ray crystallography	438-B11 contact
292	438-B11 contacts	V3-glycan	Kumar2020	contacts	438-B11	392	gp120, V4 loop	N	0.561	0.454	0.804	X-ray crystallography	438-B11 contact
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	63	gp120	T	1.295	0.663	1.217	cryo-EM, X-ray crystallography	potential H bond
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	64	gp120	E	0.019	0.022	0.008	cryo-EM, X-ray crystallography	potential H bond
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	197	gp120	N	0.111	0.082	0.109	cryo-EM, X-ray crystallography	glycan contact
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	276	gp120, Loop D	N	0.120	0.063	0.169	cryo-EM, X-ray crystallography	glycan contact
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	280	gp120, Loop D	N	0.117	0.090	0.170	cryo-EM, X-ray crystallography	potential H bond
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	301	gp120, V3 loop	N	0.261	0.176	0.104	cryo-EM, X-ray crystallography	glycan contact
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	363	gp120	Q	1.839	1.587	1.352	cryo-EM, X-ray crystallography	glycan contact
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	cryo-EM, X-ray crystallography	potential H bond
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	456	gp120, beta23	R	0.196	0.079	0.323	cryo-EM, X-ray crystallography	potential H bond
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	458	gp120, beta23	G	0.097	0.045	0.095	cryo-EM, X-ray crystallography	potential H bond
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	cryo-EM, X-ray crystallography	potential H bond
293	BG24 contacts	CD4BS	Barnes2022	contacts	BG24	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	cryo-EM, X-ray crystallography	potential H bond
294	Mutations associated with immunotherapy with BG24 or VRC01	CD4BS	Barnes2022	immunotherapy	BG24, VRC01	276	gp120, Loop D	N	0.120	0.063	0.169	sequence analysis	YU2-infected mice injected with BG24 developed N276D mutation at high frequency
294	Mutations associated with immunotherapy with BG24 or VRC01	CD4BS	Barnes2022	immunotherapy	BG24, VRC01	279	gp120, Loop D	D	0.860	0.850	0.898	sequence analysis	YU2-infected mice injected with BG24 or VRC01 developed N279K mutation at high frequency
294	Mutations associated with immunotherapy with BG24 or VRC01	CD4BS	Barnes2022	immunotherapy	BG24, VRC01	280	gp120, Loop D	N	0.117	0.090	0.170	sequence analysis	YU2-infected mice injected with BG24 or VRC01 developed N280D mutation at high frequency
294	Mutations associated with immunotherapy with BG24 or VRC01	CD4BS	Barnes2022	immunotherapy	BG24, VRC01	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	sequence analysis	YU2-infected mice injected with BG24 developed G366R mutation at high frequency
294	Mutations associated with immunotherapy with BG24 or VRC01	CD4BS	Barnes2022	immunotherapy	BG24, VRC01	375	gp120	S	0.790	0.753	0.372	sequence analysis	YU2-infected mice injected with VRC01 developed S375R mutation at high frequency
294	Mutations associated with immunotherapy with BG24 or VRC01	CD4BS	Barnes2022	immunotherapy	BG24, VRC01	458	gp120, beta23	G	0.097	0.045	0.095	sequence analysis	YU2-infected mice injected with BG24 or VRC01 developed G459 mutations at high frequency
295	Mutation abrogates BG24 OR VRC01 neutralization	CD4BS	Barnes2022	neutralization	BG24, VRC01	278	gp120, Loop D	T	0.657	0.715	0.481	neutralization assay	T278I/A281T double mutant in YU2 abrogates BG24 and VRC01 neutralization
295	Mutation abrogates BG24 OR VRC01 neutralization	CD4BS	Barnes2022	neutralization	BG24, VRC01	279	gp120, Loop D	D	0.860	0.850	0.898	neutralization assay	N279K in YU2 abrogates BG24 neutralization; N279H in YU2 abrogates BG24 neutralization, but not VRC01
295	Mutation abrogates BG24 OR VRC01 neutralization	CD4BS	Barnes2022	neutralization	BG24, VRC01	280	gp120, Loop D	N	0.117	0.090	0.170	neutralization assay	N280Y in YU2 abrogates BG24 and VRC01 neutralization
295	Mutation abrogates BG24 OR VRC01 neutralization	CD4BS	Barnes2022	neutralization	BG24, VRC01	281	gp120, Loop D	A	1.081	0.814	1.357	neutralization assay	A281T or T278I/A281T double mutant in YU2 abrogates or greatly reduces BG24 and VRC01 neutralization
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	mutational analysis, sequence analysis, X-ray crystallography	Env with Y or W associated with low apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	mutational analysis, sequence analysis, X-ray crystallography	glycosylation associated with low apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		189	gp120, V2-hypervariable, V2	T	1.811	1.348	1.638	mutational analysis, sequence analysis, X-ray crystallography	T189 only found in Envs with low apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		328	gp120, V3 loop	Q	1.001	0.816	0.882	mutational analysis, sequence analysis, X-ray crystallography	positively-charged amino acids associated with high apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		330	gp120, V3 loop	H	0.743	0.559	0.655	mutational analysis, sequence analysis, X-ray crystallography	T330 (instead of H330) associated with high apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		332	gp120	N	0.904	0.491	0.693	mutational analysis, sequence analysis, X-ray crystallography	glycosylation associated with low apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		334	gp120	S	0.780	0.501	0.890	mutational analysis, sequence analysis, X-ray crystallography	glycosylation associated with high apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		362	gp120	K	1.874	1.265	1.997	mutational analysis, sequence analysis, X-ray crystallography	glycosylation associated with high apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		363	gp120	Q	1.839	1.587	1.352	mutational analysis, sequence analysis, X-ray crystallography	prolinated amino acids associated with low apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		425	gp120, beta20/beta21	N	0.405	0.138	0.177	mutational analysis, sequence analysis, X-ray crystallography	N425 (not a glyco site) associated with high apoptosis induction; N425R and R476K were the two mutations most strongly associated with loss of apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	mutational analysis, sequence analysis, X-ray crystallography	glycosylation associated with high apoptosis induction
296	Predicted association with Env-mediated apoptosis		Joshi2014	other feature		476	gp120	R	0.699	0.615	0.711	mutational analysis, sequence analysis, X-ray crystallography	R476 (instead of K476) associated with high apoptosis induction; N425R and R476K were the two mutations most strongly associated with loss of apoptosis induction
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	other, X-ray crystallography	secondary interaction, hydrogen bond
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	other, X-ray crystallography	secondary interaction, hydrogen bonds
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	156	gp120, V1	N	0.217	0.220	0.224	other, X-ray crystallography	secondary interaction with glycan, deglycosylation mutation ablates neutralization
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	323	gp120, V3 loop	I	0.575	0.531	0.263	other, X-ray crystallography	hydrogen bond
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	324	gp120, V3 loop	G	0.088	0.056	0.092	other, X-ray crystallography	primary interaction, hydrogen bonds
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	325	gp120, V3 loop	N	0.653	0.622	0.622	other, X-ray crystallography	primary interaction, hydrogen bonds
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	327	gp120, V3 loop	R	0.118	0.066	0.073	other, X-ray crystallography	cation-pi stacking, hydrogen bond
297	Ab1485 contacts	V3-glycan	Wang2020	contacts	Ab1485	332	gp120	N	0.904	0.491	0.693	other, X-ray crystallography	primary interaction with glycan, deglycosylation mutation ablates neutralization
298	Mutations affecting neutralization by 19.3H-L3	other	Murphy2013	neutralization	19.3H-L3	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	mutational analysis, sequence analysis, X-ray crystallography	I295R/N and I295T independently mediated full & partial nAb escape respectively.
298	Mutations affecting neutralization by 19.3H-L3	other	Murphy2013	neutralization	19.3H-L3	334	gp120	S	0.780	0.501	0.890	mutational analysis, sequence analysis, X-ray crystallography	S335N and S335Q independently mediated full and slight neutralization escape. Note: Paper assigns this as residue 335, but it aligns with HXB2 residue 334.
298	Mutations affecting neutralization by 19.3H-L3	other	Murphy2013	neutralization	19.3H-L3	337	gp120	K	2.008	1.862	2.151	mutational analysis, sequence analysis, X-ray crystallography	E338K and K338/G/I/Q/R all independently mediated increased neutralization resistance. Residue 338 may form a salt bridge with antigen-binding site. Note: Paper assigns this as residue 338, but it aligns with HXB2 residue 337.
298	Mutations affecting neutralization by 19.3H-L3	other	Murphy2013	neutralization	19.3H-L3	340	gp120	N	1.893	1.537	1.869	mutational analysis, sequence analysis, X-ray crystallography	D341N independently increased neutralization sensitivity. Note: Paper assigns this as residue 341, but it aligns with HXB2 residue 340.
299	Mutations affecting binding of VRC34.01 to fusion peptide epitope	gp41 fusion domain	Shen2020	binding	VRC34.01	88	gp120	N	0.053	0.041	0.048	alanine scanning, X-ray crystallography	glycan deletion reduced binding
299	Mutations affecting binding of VRC34.01 to fusion peptide epitope	gp41 fusion domain	Shen2020	binding	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	alanine scanning, X-ray crystallography	alanine or glycine ablated binding
299	Mutations affecting binding of VRC34.01 to fusion peptide epitope	gp41 fusion domain	Shen2020	binding	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	alanine scanning, X-ray crystallography	hydrogen bond and hydrophobic contacts; alanine or glycine ablated binding
299	Mutations affecting binding of VRC34.01 to fusion peptide epitope	gp41 fusion domain	Shen2020	binding	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	alanine scanning, X-ray crystallography	hydrogen bonds; alanine, but not glycine, ablated binding
301	VRC34.05 contacts	gp41 fusion domain	Shen2020	contacts	VRC34.05	88	gp120	N	0.053	0.041	0.048	surface plasmon resonance, X-ray crystallography	deglycosylation reduced binding to BG505 DS-SOSIP Env trimer
301	VRC34.05 contacts	gp41 fusion domain	Shen2020	contacts	VRC34.05	515	gp41, fusion peptide	I	1.106	1.147	0.877	surface plasmon resonance, X-ray crystallography	hydrogen bonds
301	VRC34.05 contacts	gp41 fusion domain	Shen2020	contacts	VRC34.05	516	gp41, fusion peptide	G	0.091	0.038	0.048	surface plasmon resonance, X-ray crystallography	hydrogen bonds
302	VRC26.25 contacts	V2-apex	Gorman2020, Yin2021	contacts	VRC26.25	130	gp120	K	1.274	0.883	1.495	cryo-EM	N130 and N160 have direct contacts with CDR H1 [Gorman2020]
302	VRC26.25 contacts	V2-apex	Gorman2020, Yin2021	contacts	VRC26.25	156	gp120, V1	N	0.217	0.220	0.224	cryo-EM	the density of glycan N156 was evident close to the surface of Env, and extended to contact the CDR L2 [Gorman2020]
302	VRC26.25 contacts	V2-apex	Gorman2020, Yin2021	contacts	VRC26.25	160	gp120, V2	N	0.401	0.452	0.358	cryo-EM	N130 and N160 have direct contacts with CDR H1 [Gorman2020]; HC Q100n contacts a critical glycan at SOSIP N160 [Yin2021]
302	VRC26.25 contacts	V2-apex	Gorman2020, Yin2021	contacts	VRC26.25	166	gp120, V2	R	1.127	1.398	0.772	cryo-EM	direct Ab contact; escape mutations often removed direct electrostatic interactions from Env positions 166 and 169 [Gorman2020]
302	VRC26.25 contacts	V2-apex	Gorman2020, Yin2021	contacts	VRC26.25	168	gp120, V2	K	0.547	0.666	0.396	cryo-EM	K168 interacts with heavy chain [Gorman2020]
302	VRC26.25 contacts	V2-apex	Gorman2020, Yin2021	contacts	VRC26.25	169	gp120, V2	V	1.974	1.770	1.344	cryo-EM	direct Ab contact; escape mutations often removed direct electrostatic interactions from Env positions 166 and 169 [Gorman2020]
302	VRC26.25 contacts	V2-apex	Gorman2020, Yin2021	contacts	VRC26.25	170	gp120, V2	Q	1.458	1.423	1.428	cryo-EM	R170 interacts with heavy chain [Gorman2020]; HC E100b interacts with a network basic of residues including SOSIP R170 [Yin2021]
303	L184F escapes V2-targeting bnAbs	V2-apex	Mishra2020	neutralization	CH01, PG16, PG9, PGDM1400, PGT145, VRC26.25	184	gp120, V2	I	1.060	0.599	0.530	neutralization assay, X-ray crystallography	L184 is critical in modulating interprotomer interactions at the trimer apex; L184F allows escape from neutralization by V2-targeting bnAbs PG9, PG16, PGT145, PGDM1400, CAP256.25, and CH01.
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has N137 while HXB2 has D137
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	301	gp120, V3 loop	N	0.261	0.176	0.104	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have N137
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	321	gp120, V3 loop	G	1.031	0.842	1.108	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has D321 while HXB2 has G321
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	322	gp120, V3 loop	K	0.370	0.347	0.283	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has I322 while HXB2 has K322
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	323	gp120, V3 loop	I	0.575	0.531	0.263	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have I323
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	324	gp120, V3 loop	G	0.088	0.056	0.092	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have G324
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	325	gp120, V3 loop	N	0.653	0.622	0.622	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has D325 while HXB2 has N325
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	326	gp120, V3 loop	M	0.188	0.143	0.116	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has I326 while HXB2 has M326
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	327	gp120, V3 loop	R	0.118	0.066	0.073	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have R327
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	442	gp120	Q	2.193	1.699	0.964	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has V442 while HXB2 has Q442
304	PGT128 contacts with BG505 SOSIP.664 Env trimer (PDB 5ACO)	V3-glycan	Nogal2020	contacts	PGT128	444	gp120	R	1.754	1.507	0.494	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have R444
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has N137 but HXB2 has D137
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has I138 but HXB2 has T138
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has T139 but HXB2 has N139
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have N295
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	325	gp120, V3 loop	N	0.653	0.622	0.622	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has D325 but HXB2 has N325
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	326	gp120, V3 loop	M	0.188	0.143	0.116	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has I326 but HXB2 has M326
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	327	gp120, V3 loop	R	0.118	0.066	0.073	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have R327
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	328	gp120, V3 loop	Q	1.001	0.816	0.882	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have Q328
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	330	gp120, V3 loop	H	0.743	0.559	0.655	cryo-EM	Ab side chain contact, BG505 SOSIP.664 and HXB2 both have H330
305	BG18 contacts with BG505 SOSIP.664 Env trimer (PDB 6CH7)	V3-glycan	Nogal2020	contacts	BG18	332	gp120	N	0.904	0.491	0.693	cryo-EM	Ab side chain contact, BG505 SOSIP.664 has HXB2 both have N332
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	88	gp120	N	0.053	0.041	0.048	alanine scanning, neutralization assay	Ala scanning, N88A mutation makes JRFL and LAI neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	89	gp120	V	0.111	0.081	0.117	alanine scanning, neutralization assay	V89A mutation makes JRFL and LAI neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	90	gp120	T	0.073	0.063	0.051	alanine scanning, neutralization assay	T90A mutation makes JRFL neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	227	gp120	K	0.218	0.288	0.161	alanine scanning, neutralization assay	K227A mutation makes JRFL neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	230	gp120	N	0.954	0.896	0.544	alanine scanning, neutralization assay	N230A mutation makes JRFL neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	232	gp120	T	1.649	1.451	0.426	alanine scanning, neutralization assay	T232A mutation makes JRFL and LAI neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	241	gp120	N	0.169	0.183	0.134	alanine scanning, neutralization assay	N241A mutation makes JRFL and LAI neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	243	gp120	S	0.058	0.058	0.051	alanine scanning, neutralization assay	S243A mutation makes JRFL neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	244	gp120	T	0.455	0.157	0.178	alanine scanning, neutralization assay	T244V mutation makes LAI neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	489	gp120	V	0.120	0.132	0.133	alanine scanning, neutralization assay	V489A mutation makes LAI neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	624	gp41	N	1.565	1.592	1.486	alanine scanning, neutralization assay	N624Q mutation makes LAI neutralization resistant.
306	35O22 mutations affecting neutralization	gp120/gp41 interface	Huang2014	neutralization	35O22	625	gp41	H	0.220	0.185	0.214	alanine scanning, neutralization assay	N625A mutation makes JRFL neutralization resistant, but T627A did not, suggesting that N625 may be binding directly, and not glycosylated; N625Q in JRCSF also dramatically reduced binding.
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	305	gp120, V3 loop	K	1.097	0.713	0.943	X-ray crystallography	main chain contact
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	307	gp120, V3 loop	I	0.067	0.030	0.111	X-ray crystallography	main chain contact
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	308	gp120, V3 loop	R	0.108	0.091	0.127	X-ray crystallography	H bond
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	309	gp120, V3 loop	I	0.921	0.359	0.965	X-ray crystallography	main chain contact
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	312	gp120, V3 loop	G	0.189	0.362	0.008	X-ray crystallography	linear epitope position
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	313	gp120, V3 loop	P	0.307	0.424	0.078	X-ray crystallography	linear epitope position
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	314	gp120, V3 loop	G	0.053	0.095	0.014	X-ray crystallography	linear epitope position
307	447-52D contacts	V3-glycan	Dhillon2008	contacts	447-52D	315	gp120, V3 loop	R	1.120	1.028	0.196	X-ray crystallography	linear epitope position; salt bridge and cation interactions
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	564	gp41, Leu/Ile zipper-like sequence	H	0.264	0.262	0.108	X-ray crystallography	HK20 contact, H bonding with heavy chain
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	567	gp41, Leu/Ile zipper-like sequence	Q	0.564	0.139	0.056	X-ray crystallography	HK20 contact
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	568	gp41, Leu/Ile zipper-like sequence	L	0.022	0.018	0.029	X-ray crystallography	HK20 contact
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	571	gp41, Leu/Ile zipper-like sequence	W	0.015	0.006	0.015	X-ray crystallography	HK20 contact, H bonding with heavy chain
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	573	gp41, Leu/Ile zipper-like sequence	I	0.081	0.079	0.050	X-ray crystallography	HK20 contact
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	574	gp41, Leu/Ile zipper-like sequence	K	0.032	0.036	0.022	X-ray crystallography	HK20 contact
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	575	gp41, Leu/Ile zipper-like sequence	Q	0.012	0.012	0.008	X-ray crystallography	HK20 contact, H bonding with heavy chain
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	577	gp41, Leu/Ile zipper-like sequence	Q	0.110	0.121	0.104	X-ray crystallography	HK20 contact
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	579	gp41, Leu/Ile zipper-like sequence	R	0.031	0.030	0.028	X-ray crystallography	HK20 contact
308	HK20 contacts	gp41 fusion domain	Sabin2010	contacts	HK20	636	gp41	N	1.371	1.127	1.081	X-ray crystallography	HK20 contact
310	QA255.105 epitope	V3-glycan	Williams2015	binding	QA255.105	313	gp120, V3 loop	P	0.307	0.424	0.078	binding assay	QA255.105 linear epitope PGQAF
310	QA255.105 epitope	V3-glycan	Williams2015	binding	QA255.105	314	gp120, V3 loop	G	0.053	0.095	0.014	binding assay	QA255.105 linear epitope PGQAF
310	QA255.105 epitope	V3-glycan	Williams2015	binding	QA255.105	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay	QA255.105 linear epitope PGQAF
310	QA255.105 epitope	V3-glycan	Williams2015	binding	QA255.105	316	gp120, V3 loop	A	1.151	0.736	0.966	binding assay	QA255.105 linear epitope PGQAF
310	QA255.105 epitope	V3-glycan	Williams2015	binding	QA255.105	317	gp120, V3 loop	F	0.758	1.090	0.223	binding assay	QA255.105 linear epitope PGQAF
312	10A3 epitope	V3-glycan	Qin2015	binding	10A3	304	gp120, V3 loop	R	0.287	0.390	0.141	binding assay	10A3 linear epitope RKSIRIG
312	10A3 epitope	V3-glycan	Qin2015	binding	10A3	305	gp120, V3 loop	K	1.097	0.713	0.943	binding assay	10A3 linear epitope RKSIRIG
312	10A3 epitope	V3-glycan	Qin2015	binding	10A3	306	gp120, V3 loop	R	0.732	0.860	0.338	binding assay	10A3 linear epitope RKSIRIG
312	10A3 epitope	V3-glycan	Qin2015	binding	10A3	307	gp120, V3 loop	I	0.067	0.030	0.111	binding assay	10A3 linear epitope RKSIRIG
312	10A3 epitope	V3-glycan	Qin2015	binding	10A3	308	gp120, V3 loop	R	0.108	0.091	0.127	binding assay	10A3 linear epitope RKSIRIG
312	10A3 epitope	V3-glycan	Qin2015	binding	10A3	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	10A3 linear epitope RKSIRIG
312	10A3 epitope	V3-glycan	Qin2015	binding	10A3	310	gp120, V3 loop	Q	1.564	1.479	0.283	binding assay	10A3 linear epitope RKSIRIG
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	314	gp120, V3 loop	G	0.053	0.095	0.014	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	316	gp120, V3 loop	A	1.151	0.736	0.966	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	317	gp120, V3 loop	F	0.758	1.090	0.223	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	318	gp120, V3 loop	V	0.574	0.691	0.507	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	319	gp120, V3 loop	T	0.995	0.913	0.339	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	320	gp120, V3 loop	I	0.720	0.564	0.782	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	321	gp120, V3 loop	G	1.031	0.842	1.108	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	322	gp120, V3 loop	K	0.370	0.347	0.283	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	323	gp120, V3 loop	I	0.575	0.531	0.263	binding assay	10A37 linear epitope GQAFYATGDII
313	10A37 epitope	V3-glycan	Qin2015	binding	10A37	324	gp120, V3 loop	G	0.088	0.056	0.092	binding assay	10A37 linear epitope GQAFYATGDII
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	308	gp120, V3 loop	R	0.108	0.091	0.127	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	310	gp120, V3 loop	Q	1.564	1.479	0.283	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	311	gp120, V3 loop	R	0.768	1.050	0.114	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	312	gp120, V3 loop	G	0.189	0.362	0.008	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	313	gp120, V3 loop	P	0.307	0.424	0.078	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	314	gp120, V3 loop	G	0.053	0.095	0.014	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	316	gp120, V3 loop	A	1.151	0.736	0.966	binding assay	0.5γ epitope SIHIGPGRAF
314	0.5γ epitope	V3-glycan	RamirezValdez2015	binding	0.5γ	317	gp120, V3 loop	F	0.758	1.090	0.223	binding assay	0.5γ epitope SIHIGPGRAF
315	KD-247 epitope	V3-glycan	Eda2006a	binding	KD-247	311	gp120, V3 loop	R	0.768	1.050	0.114	binding assay	KD-247 epitope IGPGR
315	KD-247 epitope	V3-glycan	Eda2006a	binding	KD-247	312	gp120, V3 loop	G	0.189	0.362	0.008	binding assay	KD-247 epitope IGPGR
315	KD-247 epitope	V3-glycan	Eda2006a	binding	KD-247	313	gp120, V3 loop	P	0.307	0.424	0.078	binding assay	KD-247 epitope IGPGR
315	KD-247 epitope	V3-glycan	Eda2006a	binding	KD-247	314	gp120, V3 loop	G	0.053	0.095	0.014	binding assay	KD-247 epitope IGPGR
315	KD-247 epitope	V3-glycan	Eda2006a	binding	KD-247	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay	KD-247 epitope IGPGR
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	306	gp120, V3 loop	R	0.732	0.860	0.338	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	307	gp120, V3 loop	I	0.067	0.030	0.111	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	308	gp120, V3 loop	R	0.108	0.091	0.127	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	310	gp120, V3 loop	Q	1.564	1.479	0.283	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	311	gp120, V3 loop	R	0.768	1.050	0.114	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	312	gp120, V3 loop	G	0.189	0.362	0.008	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	313	gp120, V3 loop	P	0.307	0.424	0.078	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	314	gp120, V3 loop	G	0.053	0.095	0.014	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	316	gp120, V3 loop	A	1.151	0.736	0.966	binding assay	HGN194 epitope RRSVRIGPGQTF
316	HGN194 epitope	V3-glycan	Corti2010	binding	HGN194	317	gp120, V3 loop	F	0.758	1.090	0.223	binding assay	HGN194 epitope RRSVRIGPGQTF
317	Residues that affect neutralization by VRC42.01	MPER	Krebs2019	neutralization	VRC42.01	662	gp41	E	1.024	0.874	0.369	alanine scanning, neutralization assay	Ala mediates a 0.54 fold decrease (founder) and 2.9 fold decrease (BG1168) in neutralization sensitivity
317	Residues that affect neutralization by VRC42.01	MPER	Krebs2019	neutralization	VRC42.01	672	gp41	W	0.017	0.023	0.014	alanine scanning, neutralization assay	Ala mediates a 105 fold decrease (founder) and 15 fold decrease (BG1168) in neutralization sensitivity
317	Residues that affect neutralization by VRC42.01	MPER	Krebs2019	neutralization	VRC42.01	674	gp41	N	1.182	1.029	1.344	alanine scanning, neutralization assay	Ala mediates a 2.1 fold decrease (founder) and 2.9 fold decrease (BG1168) in neutralization sensitivity
317	Residues that affect neutralization by VRC42.01	MPER	Krebs2019	neutralization	VRC42.01	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	alanine scanning, neutralization assay	Ala mediates a 47 fold decrease (founder) and 2.7 fold decrease (BG1168) in neutralization sensitivity
320	ACS101 contacts	CD4BS	vanSchooten2022a	contacts	ACS101	279	gp120, Loop D	D	0.860	0.850	0.898	cryo-EM	heavy chain and light chain interaction
320	ACS101 contacts	CD4BS	vanSchooten2022a	contacts	ACS101	280	gp120, Loop D	N	0.117	0.090	0.170	cryo-EM	heavy chain and light chain interaction
320	ACS101 contacts	CD4BS	vanSchooten2022a	contacts	ACS101	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	cryo-EM	heavy chain interaction
320	ACS101 contacts	CD4BS	vanSchooten2022a	contacts	ACS101	456	gp120, beta23	R	0.196	0.079	0.323	cryo-EM	heavy chain and light chain interaction
320	ACS101 contacts	CD4BS	vanSchooten2022a	contacts	ACS101	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	cryo-EM	light chain interaction
320	ACS101 contacts	CD4BS	vanSchooten2022a	contacts	ACS101	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	cryo-EM	heavy chain interaction
320	ACS101 contacts	CD4BS	vanSchooten2022a	contacts	ACS101	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	cryo-EM	heavy chain interaction
321	ACS114 contacts	silent face	vanSchooten2022	contacts	ACS114	262	gp120	N	0.029	0.029	0.028	cryo-EM, X-ray crystallography	contact
321	ACS114 contacts	silent face	vanSchooten2022	contacts	ACS114	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	cryo-EM, X-ray crystallography	contact
321	ACS114 contacts	silent face	vanSchooten2022	contacts	ACS114	301	gp120, V3 loop	N	0.261	0.176	0.104	cryo-EM, X-ray crystallography	contact
321	ACS114 contacts	silent face	vanSchooten2022	contacts	ACS114	332	gp120	N	0.904	0.491	0.693	cryo-EM, X-ray crystallography	contact
321	ACS114 contacts	silent face	vanSchooten2022	contacts	ACS114	339	gp120	N	1.157	1.082	1.026	cryo-EM, X-ray crystallography	contact
321	ACS114 contacts	silent face	vanSchooten2022	contacts	ACS114	448	gp120	N	0.648	0.448	0.927	cryo-EM, X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	88	gp120	N	0.053	0.041	0.048	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	528	gp41	S	0.020	0.012	0.022	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	531	gp41	G	0.005	0.006	0.000	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	532	gp41	A	0.065	0.055	0.058	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	536	gp41	T	0.331	0.396	0.366	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	623	gp41	W	0.068	0.066	0.043	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	624	gp41	N	1.565	1.592	1.486	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	625	gp41	H	0.220	0.185	0.214	X-ray crystallography	contact
322	ACS122 contacts	gp120/gp41 interface	vanSchooten2022	contacts	ACS122	628	gp41	W	0.008	0.000	0.008	X-ray crystallography	contact
323	Mutation affects ACS114 neutralization	silent face	vanSchooten2022	neutralization	ACS114	262	gp120	N	0.029	0.029	0.028	alanine scanning, neutralization assay	N262A in JRCSF enhanced neutralization of ACS114
323	Mutation affects ACS114 neutralization	silent face	vanSchooten2022	neutralization	ACS114	283	gp120, Loop D	T	0.992	1.091	0.474	alanine scanning, neutralization assay	T283A in JRCSF enhanced neutralization of ACS114
323	Mutation affects ACS114 neutralization	silent face	vanSchooten2022	neutralization	ACS114	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	alanine scanning, neutralization assay	N295A in JRCSF completely abrogated neutralization of ACS114
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	198	gp120	T	0.458	0.264	0.469	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	276	gp120, Loop D	N	0.120	0.063	0.169	cryo-EM, X-ray crystallography	VRC-PG19 contact with amino acid and glycan
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	278	gp120, Loop D	T	0.657	0.715	0.481	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	279	gp120, Loop D	D	0.860	0.850	0.898	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	280	gp120, Loop D	N	0.117	0.090	0.170	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	281	gp120, Loop D	A	1.081	0.814	1.357	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	283	gp120, Loop D	T	0.992	1.091	0.474	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	352	gp120	Q	1.680	0.842	1.079	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	353	gp120	F	0.759	0.735	0.488	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	430	gp120, beta20/beta21	V	0.397	0.080	0.073	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	456	gp120, beta23	R	0.196	0.079	0.323	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	457	gp120, beta23	D	0.059	0.054	0.043	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	458	gp120, beta23	G	0.097	0.045	0.095	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	cryo-EM, X-ray crystallography	VRC-PG19 contact
324	VRC-PG19 contacts	CD4BS	Dubrovskaya2019	contacts	VRC-PG19	473	gp120	G	0.031	0.033	0.029	cryo-EM, X-ray crystallography	VRC-PG19 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	234	gp120	N	0.584	0.757	0.341	cryo-EM, X-ray crystallography	E70 glycan contact; deletion of the N-glycan at N234 rendered viruses resistant to E70
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	278	gp120, Loop D	T	0.657	0.715	0.481	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	279	gp120, Loop D	D	0.860	0.850	0.898	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	280	gp120, Loop D	N	0.117	0.090	0.170	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	353	gp120	F	0.759	0.735	0.488	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	354	gp120	G	2.149	1.918	1.123	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	356	gp120	N	1.011	0.741	0.894	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	357	gp120	K	1.086	0.868	0.941	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	455	gp120, beta23	T	0.670	0.426	0.972	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	456	gp120, beta23	R	0.196	0.079	0.323	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	457	gp120, beta23	D	0.059	0.054	0.043	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	464	gp120, V5-hypervariable, V5 loop	E	2.371	2.269	2.299	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239	cryo-EM, X-ray crystallography	E70 contact
325	E70 contacts	CD4BS	Dubrovskaya2019	contacts	E70	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	cryo-EM, X-ray crystallography	E70 contact
326	1C2 contacts	gp120/gp41 interface	Dubrovskaya2019	contacts	1C2	31	gp120	T	2.195	1.529	2.035	cryo-EM	HCDR3 of 1C2 is near the tryptophan clasp of gp41, marked by residue W31 (Fig 6A)
326	1C2 contacts	gp120/gp41 interface	Dubrovskaya2019	contacts	1C2	88	gp120	N	0.053	0.041	0.048	cryo-EM	1C2 HC framework regions interact with glycan N88 and stabilize in a position close to glycan N625; removal of N-glycans N88 and N625 improved 1C2 cell-surface binding, consistent with glycan impediment
326	1C2 contacts	gp120/gp41 interface	Dubrovskaya2019	contacts	1C2	623	gp41	W	0.068	0.066	0.043	cryo-EM	1C2 is shown in proximity with W623 (Fig 6B)
326	1C2 contacts	gp120/gp41 interface	Dubrovskaya2019	contacts	1C2	625	gp41	H	0.220	0.185	0.214	cryo-EM	removal of N-glycans N88 and N625 improved 1C2 cell-surface binding, consistent with glycan impediment
327	2E7 contacts	MPER	Strokappe2019	contacts	2E7	588	gp41, Leu/Ile zipper-like sequence	K	1.087	1.197	0.871	X-ray crystallography	llama VHH 2E7 contact
327	2E7 contacts	MPER	Strokappe2019	contacts	2E7	589	gp41, Leu/Ile zipper-like sequence	D	0.041	0.035	0.029	X-ray crystallography	llama VHH 2E7 contact
327	2E7 contacts	MPER	Strokappe2019	contacts	2E7	596	gp41	W	0.026	0.028	0.000	X-ray crystallography	llama VHH 2E7 contact
328	Mutation affects M4008_N1 neutralization	V3-glycan	Chan2021	neutralization	M4008_N1	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	mutational analysis, neutralization assay	N137A mutation in BG505 improves neutralization potency
328	Mutation affects M4008_N1 neutralization	V3-glycan	Chan2021	neutralization	M4008_N1	156	gp120, V1	N	0.217	0.220	0.224	mutational analysis, neutralization assay	N156Q mutation in BG505 improves neutralization potency; N156Q in JR-FL decreases neutralization potency
328	Mutation affects M4008_N1 neutralization	V3-glycan	Chan2021	neutralization	M4008_N1	197	gp120	N	0.111	0.082	0.109	mutational analysis, neutralization assay	N197Q mutation in BG505 improves neutralization potency; D197N in JR-FL decreases neutralization potency
328	Mutation affects M4008_N1 neutralization	V3-glycan	Chan2021	neutralization	M4008_N1	303	gp120, V3 loop	T	0.297	0.190	0.202	mutational analysis, neutralization assay	T303A mutation in BG505 or JR-FL decreases neutralization potency
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	65	gp120	V	1.035	1.023	0.310	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	163	gp120, V2	T	0.360	0.638	0.154	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	164	gp120, V2	S	1.660	1.925	0.453	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	170	gp120, V2	Q	1.458	1.423	1.428	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	172	gp120, V2	E	1.506	1.172	1.484	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	197	gp120	N	0.111	0.082	0.109	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	198	gp120	T	0.458	0.264	0.469	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	206	gp120	P	0.038	0.035	0.022	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	207	gp120	K	0.043	0.029	0.029	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	303	gp120, V3 loop	T	0.297	0.190	0.202	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	304	gp120, V3 loop	R	0.287	0.390	0.141	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	305	gp120, V3 loop	K	1.097	0.713	0.943	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	306	gp120, V3 loop	R	0.732	0.860	0.338	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	308	gp120, V3 loop	R	0.108	0.091	0.127	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	314	gp120, V3 loop	G	0.053	0.095	0.014	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	316	gp120, V3 loop	A	1.151	0.736	0.966	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	318	gp120, V3 loop	V	0.574	0.691	0.507	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	321	gp120, V3 loop	G	1.031	0.842	1.108	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	323	gp120, V3 loop	I	0.575	0.531	0.263	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	324	gp120, V3 loop	G	0.088	0.056	0.092	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	430	gp120, beta20/beta21	V	0.397	0.080	0.073	cryo-EM	key contact
329	M4000_N1 contacts	V3-glycan	Chan2021	contacts	M4008_N1	440	gp120	S	1.932	1.712	1.017	cryo-EM	key contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	183	gp120, V2	P	1.179	1.107	0.787	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	194	gp120, V2	T	0.503	0.906	0.161	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	195	gp120, V2	S	0.897	1.019	0.466	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	280	gp120, Loop D	N	0.117	0.090	0.170	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	384	gp120	Y	0.075	0.124	0.023	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	421	gp120, beta20/beta21	K	0.312	0.374	0.203	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	424	gp120, beta20/beta21	I	0.579	0.566	0.347	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	425	gp120, beta20/beta21	N	0.405	0.138	0.177	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	457	gp120, beta23	D	0.059	0.054	0.043	cryo-EM	contact
330	M1214_N1 contacts	other	Jia2020	contacts	M1214_N1	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	cryo-EM	contact
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	323	gp120, V3 loop	I	0.575	0.531	0.263	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reduction with G (moderate effect)
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	325	gp120, V3 loop	N	0.653	0.622	0.622	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with K (strong effect) and R/L/W (moderate effects); GDIR motif
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	326	gp120, V3 loop	M	0.188	0.143	0.116	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reduction with K (moderate effect); GDIR motif
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	327	gp120, V3 loop	R	0.118	0.066	0.073	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with H/S/V/A/I/E/T (moderate effects); GDIR motif
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	330	gp120, V3 loop	H	0.743	0.559	0.655	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with E/T/N/A/K/Q (moderate effects)
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	332	gp120	N	0.904	0.491	0.693	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with D/K/T/R/Y (moderate effects)
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	334	gp120	S	0.780	0.501	0.890	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with H/Q/L/V/R/P/G/N (moderate effects); glycosylation motif
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	346	gp120	A	1.871	1.083	1.831	binding assay, mutational analysis	BG505.T332N: V346Q moderately reduced binding
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	380	gp120	G	0.030	0.029	0.008	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reduction with K (moderate effect)
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	406	gp120, V4-hypervariable, V4 loop	N	1.900	2.211	1.307	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	408	gp120, V4-hypervariable, V4 loop	T	0.981	1.334	0.554	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reduction with K (moderate effect)
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	415	gp120, V4 loop	T	0.846	0.760	0.656	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with R/E (strong effects) and F/Y (moderate effects)
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	419	gp120	R	0.516	0.341	0.500	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	443	gp120	I	0.151	0.119	0.131	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
331	mutations affecting PGT121 binding	V3-glycan	Dingens2019	binding	PGT121	471	gp120, beta24	G	0.879	0.888	0.866	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	119	gp120, Cys 119 linked to Cys 205	C	0.014	0.012	0.022	mutational analysis, neutralization assay	BG505: C119R mediated a 1.2-fold decrease in neutralization potency
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	mutational analysis, neutralization assay	BG505: D140E mediated a 1.6-fold decrease in neutralization potency
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	mutational analysis, neutralization assay	BG505: R151K mediated a 1.3-fold decrease in neutralization potency
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	322	gp120, V3 loop	K	0.370	0.347	0.283	mutational analysis, neutralization assay	BG505: D322E and D322G each mediated a 1.4-fold decrease in neutralization potency
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	323	gp120, V3 loop	I	0.575	0.531	0.263	mutational analysis, neutralization assay	BG505: I323G mediated a 1.9-fold decrease in neutralization potency
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	325	gp120, V3 loop	N	0.653	0.622	0.622	mutational analysis, neutralization assay	BG505: D325E and D325S mediated respective 1.7- and 1.2-fold decreases in neutralization potency while D325N had no effect; GDIR motif
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	326	gp120, V3 loop	M	0.188	0.143	0.116	mutational analysis, neutralization assay	BG505: I326Y mediated a 1.3-fold decrease in neutralization potency; GDIR motif
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	327	gp120, V3 loop	R	0.118	0.066	0.073	mutational analysis, neutralization assay	BG505: R327A mediated a 3.4-fold decrease in neutralization potency; GDIR motif
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	330	gp120, V3 loop	H	0.743	0.559	0.655	mutational analysis, neutralization assay	BG505: H330R mediated a 1.6-fold decrease in IC50 neutralization potency
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	415	gp120, V4 loop	T	0.846	0.760	0.656	mutational analysis, neutralization assay	BG505: T415R and T415Y mediated respective 3.8- and 2.4-fold decreases in neutralization potency
332	mutations affecting neutralization by PGT121	V3-glycan	Dingens2019	neutralization	PGT121	441	gp120	G	0.060	0.041	0.037	mutational analysis, neutralization assay	BG505: G441P mediated a 2.6-fold decrease in neutralization potency
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	molecular modeling	PGT121 contact with BG505
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	molecular modeling	PGT121 contact with BG505
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	molecular modeling	PGT121 contact with BG505
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	156	gp120, V1	N	0.217	0.220	0.224	molecular modeling	PGT121 contact with BG505
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	322	gp120, V3 loop	K	0.370	0.347	0.283	molecular modeling	PGT121 contact with BG505
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	324	gp120, V3 loop	G	0.088	0.056	0.092	molecular modeling	PGT121 contact with BG505, GDIR motif
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	325	gp120, V3 loop	N	0.653	0.622	0.622	molecular modeling	PGT121 contact with BG505, GDIR motif
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	326	gp120, V3 loop	M	0.188	0.143	0.116	molecular modeling	PGT121 contact with BG505, GDIR motif
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	327	gp120, V3 loop	R	0.118	0.066	0.073	molecular modeling	PGT121 contact with BG505, GDIR motif
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	328	gp120, V3 loop	Q	1.001	0.816	0.882	molecular modeling	PGT121 contact with BG505
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	330	gp120, V3 loop	H	0.743	0.559	0.655	molecular modeling	PGT121 contact with BG505
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	332	gp120	N	0.904	0.491	0.693	molecular modeling	PGT121 contact with BG505; glycosylation motif
333	PGT121 contacts	V3-glycan	Dingens2019	contacts	PGT121	417	gp120, V4 loop	P	0.836	0.736	0.922	molecular modeling	PGT121 contact with BG505
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	137	gp120, V1-hypervariable, V1	D	1.936	1.887	1.875	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	156	gp120, V1	N	0.217	0.220	0.224	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	301	gp120, V3 loop	N	0.261	0.176	0.104	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	322	gp120, V3 loop	K	0.370	0.347	0.283	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	324	gp120, V3 loop	G	0.088	0.056	0.092	molecular modeling	10-1074 contact with BG505.T332N, GDIR motif
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	325	gp120, V3 loop	N	0.653	0.622	0.622	molecular modeling	10-1074 contact with BG505.T332N, GDIR motif
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	326	gp120, V3 loop	M	0.188	0.143	0.116	molecular modeling	10-1074 contact with BG505.T332N, GDIR motif
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	327	gp120, V3 loop	R	0.118	0.066	0.073	molecular modeling	10-1074 contact with BG505.T332N, GDIR motif
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	328	gp120, V3 loop	Q	1.001	0.816	0.882	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	330	gp120, V3 loop	H	0.743	0.559	0.655	molecular modeling	10-1074 contact with BG505.T332N
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	332	gp120	N	0.904	0.491	0.693	molecular modeling	10-1074 contact with BG505.T332N; glycosylation motif
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	334	gp120	S	0.780	0.501	0.890	molecular modeling	10-1074 contact with BG505.T332N; glycosylation motif
334	10-1074 contacts	V3-glycan	Dingens2019	contacts	10-1074	417	gp120, V4 loop	P	0.836	0.736	0.922	molecular modeling	10-1074 contact with BG505.T332N
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	67	gp120	N	0.017	0.012	0.022	binding assay, mutational analysis	BG505.T332N: N67A moderately reduced binding
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	204	gp120	A	0.127	0.127	0.131	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	323	gp120, V3 loop	I	0.575	0.531	0.263	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	325	gp120, V3 loop	N	0.653	0.622	0.622	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with R/Q/W/L/I/G/Y (strong effects) and K/C/F/V/E/M/T (moderate effects); GDIR motif
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	327	gp120, V3 loop	R	0.118	0.066	0.073	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reduction with S (moderate effect); GDIR motif
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	328	gp120, V3 loop	Q	1.001	0.816	0.882	binding assay, mutational analysis	BG505.T332N: Q328P moderately reduced binding
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	330	gp120, V3 loop	H	0.743	0.559	0.655	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	332	gp120	N	0.904	0.491	0.693	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with I (strong effect) and Q/D/R/F/V/K/H/E/T/A/Y/S (moderate effects); glycosylation motif
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	334	gp120	S	0.780	0.501	0.890	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reductions with L/R/F/Q/A/V/N (strong effects) and G/H/Y/K/D/I/E (moderate effects); glycosylation motif
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	415	gp120, V4 loop	T	0.846	0.760	0.656	binding assay, mutational analysis	BG505.T332N: significant site of viral escape; greatest binding reduction with R (moderate effect)
335	mutations affecting 10-1074 binding	V3-glycan	Dingens2019	binding	10-1074	441	gp120	G	0.060	0.041	0.037	binding assay, mutational analysis	BG505.T332N: significant site of viral escape
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	105	gp120	H	0.479	0.429	0.187	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	198	gp120	T	0.458	0.264	0.469	molecular modeling	contact with strain JR-FL, glycosylation motif
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	199	gp120	S	0.086	0.108	0.068	molecular modeling	contact with strain JR-FL, glycosylation motif
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	276	gp120, Loop D	N	0.120	0.063	0.169	molecular modeling	contact with strain JR-FL, glycosylation motif
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	278	gp120, Loop D	T	0.657	0.715	0.481	molecular modeling	contact with strain JR-FL, glycosylation motif
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	279	gp120, Loop D	D	0.860	0.850	0.898	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	280	gp120, Loop D	N	0.117	0.090	0.170	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	281	gp120, Loop D	A	1.081	0.814	1.357	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	362	gp120	K	1.874	1.265	1.997	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	427	gp120, beta20/beta21	W	0.052	0.061	0.038	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	455	gp120, beta23	T	0.670	0.426	0.972	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	456	gp120, beta23	R	0.196	0.079	0.323	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	457	gp120, beta23	D	0.059	0.054	0.043	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	458	gp120, beta23	G	0.097	0.045	0.095	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	molecular modeling	contact with strain JR-FL
336	VRC01 contacts	CD4BS	Dingens2019	contacts	VRC01	473	gp120	G	0.031	0.033	0.029	molecular modeling	contact with strain JR-FL
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	197	gp120	N	0.111	0.082	0.109	molecular modeling	contact with BG505.T332N; glycosylation motif
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	207	gp120	K	0.043	0.029	0.029	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	276	gp120, Loop D	N	0.120	0.063	0.169	molecular modeling	contact with BG505.T332N; glycosylation motif
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	278	gp120, Loop D	T	0.657	0.715	0.481	molecular modeling	contact with BG505.T332N; glycosylation motif
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	279	gp120, Loop D	D	0.860	0.850	0.898	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	280	gp120, Loop D	N	0.117	0.090	0.170	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	281	gp120, Loop D	A	1.081	0.814	1.357	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	282	gp120, Loop D	K	0.260	0.337	0.297	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	306	gp120, V3 loop	R	0.732	0.860	0.338	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	308	gp120, V3 loop	R	0.108	0.091	0.127	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	316	gp120, V3 loop	A	1.151	0.736	0.966	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	392	gp120, V4 loop	N	0.561	0.454	0.804	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	430	gp120, beta20/beta21	V	0.397	0.080	0.073	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	456	gp120, beta23	R	0.196	0.079	0.323	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	457	gp120, beta23	D	0.059	0.054	0.043	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	458	gp120, beta23	G	0.097	0.045	0.095	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	464	gp120, V5-hypervariable, V5 loop	E	2.371	2.269	2.299	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	molecular modeling	contact with BG505.T332N
337	3BNC117 contacts	CD4BS	Dingens2019	contacts	3BNC117	471	gp120, beta24	G	0.879	0.888	0.866	molecular modeling	contact with BG505.T332N
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	50	gp120	T	0.264	0.133	0.502	binding assay, mutational analysis	T50H moderately reduced binding [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	160	gp120, V2	N	0.401	0.452	0.358	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with I/L/R (strong effects) and D/P/H/K/V/Y/T (moderate effects), glycosylation motif [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	162	gp120, V2	S	0.289	0.445	0.179	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with N/P (moderate effects), glycosylation motif [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	166	gp120, V2	R	1.127	1.398	0.772	binding assay, mutational analysis	R166E moderately reduced binding [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	169	gp120, V2	V	1.974	1.770	1.344	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with D/N/E (moderate effects) [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	171	gp120, V2	K	1.239	0.957	1.413	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with E (strong effect) and T/F/S/V (moderate effects) [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	231	gp120	K	0.797	0.578	0.780	binding assay, mutational analysis	D moderately reduced binding [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay, mutational analysis	R moderately reduced binding [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	327	gp120, V3 loop	R	0.118	0.066	0.073	binding assay, mutational analysis	Q moderately reduced binding [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	335	gp120	R	1.840	1.758	1.937	binding assay, mutational analysis	Y moderately reduced binding [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	binding assay, mutational analysis	Y moderately reduced binding [Dingens2019, BG505.T332N]
338	mutations affecting PG9 binding	V2-apex	Dingens2019	binding	PG9	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	I moderately reduced binding [Dingens2019, BG505.T332N]
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	156	gp120, V1	N	0.217	0.220	0.224	molecular modeling	contact with CAP45 strain, glycosylation motif
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	158	gp120, V2	S	0.297	0.185	0.291	molecular modeling	contact with CAP45 strain, glycosylation motif
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	160	gp120, V2	N	0.401	0.452	0.358	molecular modeling	contact with CAP45 strain, glycosylation motif
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	162	gp120, V2	S	0.289	0.445	0.179	molecular modeling	contact with CAP45 strain, glycosylation motif
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	164	gp120, V2	S	1.660	1.925	0.453	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	165	gp120, V2	I	1.321	1.292	1.011	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	166	gp120, V2	R	1.127	1.398	0.772	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	167	gp120, V2	G	0.601	1.122	0.185	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	168	gp120, V2	K	0.547	0.666	0.396	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	169	gp120, V2	V	1.974	1.770	1.344	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	170	gp120, V2	Q	1.458	1.423	1.428	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	171	gp120, V2	K	1.239	0.957	1.413	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	172	gp120, V2	E	1.506	1.172	1.484	molecular modeling	contact with CAP45 strain
339	PG9 contacts	V2-apex	Dingens2019	contacts	PG9	173	gp120, V2	Y	1.165	0.808	1.158	molecular modeling	contact with CAP45 strain
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	121	gp120	K	0.385	0.360	0.187	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with E/L/Q/C (moderate effects) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	123	gp120	T	0.033	0.028	0.038	binding assay, mutational analysis	significant site of viral escape, greatest binding reduction with R (moderate effect) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	124	gp120	P	0.047	0.018	0.029	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with D (strong effect) or R (moderate effect) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	127	gp120	V	0.093	0.112	0.093	binding assay, mutational analysis	significant site of viral escape, greatest binding reduction with R (moderate effect) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	160	gp120, V2	N	0.401	0.452	0.358	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with D (strong effect) or L/I/T/C/W/M/E/P/Q (moderate effects), glycosylation motif [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	162	gp120, V2	S	0.289	0.445	0.179	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with R/P (moderate effects), glyscosylation motif [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	166	gp120, V2	R	1.127	1.398	0.772	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with M/T/V (strong effects) or L/A/S/N/Y/I/F/G/Q (moderate effects) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	169	gp120, V2	V	1.974	1.770	1.344	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with E (strong effect) or F/N/Y (moderate effects) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	197	gp120	N	0.111	0.082	0.109	binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	202	gp120	T	0.639	0.291	0.547	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with R/K (moderate effects) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	203	gp120	Q	0.073	0.090	0.048	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with R (moderate effect) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	312	gp120, V3 loop	G	0.189	0.362	0.008	binding assay, mutational analysis	significant site of viral escape, greatest binding reductions with R (moderate effect) [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	313	gp120, V3 loop	P	0.307	0.424	0.078	binding assay, mutational analysis	P313R moderately reduced binding [Dingens2019, BG505.T332N]
340	mutations affecting PGT145 binding	V2-apex	Dingens2019	binding	PGT145	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay, mutational analysis	significant site of viral escape [Dingens2019, BG505.T332N]
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	121	gp120	K	0.385	0.360	0.187	molecular modeling	contact with BG505.T332N
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	124	gp120	P	0.047	0.018	0.029	molecular modeling	contact with BG505.T332N
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	127	gp120	V	0.093	0.112	0.093	molecular modeling	contact with BG505.T332N
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	160	gp120, V2	N	0.401	0.452	0.358	molecular modeling	contact with BG505.T332N, glycosylation motif
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	161	gp120, V2	I	1.565	0.964	1.568	molecular modeling	contact with BG505.T332N, glycosylation motif
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	162	gp120, V2	S	0.289	0.445	0.179	molecular modeling	contact with BG505.T332N, glycosylation motif
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	166	gp120, V2	R	1.127	1.398	0.772	molecular modeling	contact with BG505.T332N
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	167	gp120, V2	G	0.601	1.122	0.185	molecular modeling	contact with BG505.T332N
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	168	gp120, V2	K	0.547	0.666	0.396	molecular modeling	contact with BG505.T332N
341	PGT145 contacts	V2-apex	Dingens2019	contacts	PGT145	169	gp120, V2	V	1.974	1.770	1.344	molecular modeling	contact with BG505.T332N
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	44	gp120	V	0.058	0.023	0.039	binding assay, mutational analysis	V44L strongly reduced binding [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	85	gp120	V	2.208	1.797	1.418	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with Q/V (strong effects) or S/N/D (moderate effects) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	88	gp120	N	0.053	0.041	0.048	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with T/G (strong effects) or S/H/R/W/L/A/F/Q/M/E (moderate effects); glycosylation motif [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	90	gp120	T	0.073	0.063	0.051	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with R/G/N/V/A/H/I/K/E/L (moderate effects); glycosylation motif [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	229	gp120	N	0.780	0.742	0.290	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with M/R/L/S (moderate effects) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	243	gp120	S	0.058	0.058	0.051	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with Q/D/R (moderate effects) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	287	gp120	Q	0.713	0.363	0.618	binding assay, mutational analysis	Q287H moderately reduced binding [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	343	gp120	K	2.024	1.978	1.742	binding assay, mutational analysis	G343M moderately reduced binding [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	491	gp120	I	0.383	0.358	0.441	binding assay, mutational analysis	I491Y moderately reduced binding [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with L/E/M/G/I/T (moderate effects) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with P (strong effect) and L/G/F/N/S/M (moderate effect) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with V/I/M [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with P/S (strong effects) or T/Y/M/F (moderate effects) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with A/L/V/E/Y (moderate effects) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with W (moderate effect) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	524	gp41, fusion peptide	G	0.127	0.129	0.125	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with A/S/V/I/Q/H/E/T (moderate effects) [BG505.T332N]
342	mutations affecting VRC34.01 binding	gp41 fusion domain	Dingens2019	binding	VRC34.01	629	gp41	M	0.943	0.350	0.132	binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with A (moderate effect) [BG505.T332N]
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	80	gp120	N	0.634	0.695	0.562	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	84	gp120	V	1.321	0.916	1.327	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	85	gp120	V	2.208	1.797	1.418	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	87	gp120	V	1.538	1.611	1.463	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	88	gp120	N	0.053	0.041	0.048	molecular modeling	contact with BG505.T332N, glycosylation motif
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	229	gp120	N	0.780	0.742	0.290	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	230	gp120	N	0.954	0.896	0.544	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	231	gp120	K	0.797	0.578	0.780	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	241	gp120	N	0.169	0.183	0.134	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling	contact with BG505.T332N
343	VRC34.01 contacts	gp41 fusion domain	Dingens2019	contacts	VRC34.01	520	gp41, fusion peptide	L	0.604	0.253	0.390	molecular modeling	contact with BG505.T332N
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	122	gp120	L	0.120	0.101	0.121	binding assay, mutational analysis	L122V moderately reduced binding [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972	binding assay, mutational analysis	significant site of viral escape [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	224	gp120	A	0.117	0.115	0.034	binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with K (moderate effect) [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	318	gp120, V3 loop	V	0.574	0.691	0.507	binding assay, mutational analysis	significant site of viral escape [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	327	gp120, V3 loop	R	0.118	0.066	0.073	binding assay, mutational analysis	significant site of viral escape [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	448	gp120	N	0.648	0.448	0.927	binding assay, mutational analysis	G409H moderately reduced binding [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	512	gp41, fusion peptide	A	0.175	0.260	0.110	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with L/E (strong effects) and Y/Q (moderate effects) [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	514	gp41, fusion peptide	G	0.544	0.691	0.502	binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with Y (moderate effect) [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	611	gp41	N	0.050	0.039	0.054	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with S/R (strong effects) and K/M/A/Y/I/H/Q/E/L/C/V (moderate effects); glycosylation motif [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	612	gp41	A	1.453	1.525	1.055	binding assay, mutational analysis	S612P strongly reduced binding; glycosylation motif [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	613	gp41	S	0.379	0.207	0.216	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with Y/D/L/V/K/I/Q (strong effects) and M/C/A/R/N/G/E/H/F (moderate effects); glycosylation motif [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	629	gp41	M	0.943	0.350	0.132	binding assay, mutational analysis	significant site of viral escape [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	637	gp41	N	0.223	0.168	0.186	binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with R/Q (moderate effect); glycosylation motif [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	639	gp41	T	0.207	0.049	0.189	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with A/KR (moderate effects); glycosylation motif [BG505.T3332N]
344	mutations affecting PGT151 binding	gp41 fusion domain	Dingens2019	binding	PGT151	647	gp41	E	0.542	0.372	0.224	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with F (moderate effect) [BG505.T3332N]
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	58	gp120	A	0.024	0.036	0.029	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	82	gp120	Q	0.287	0.200	0.268	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	83	gp120	E	0.033	0.039	0.035	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	84	gp120	V	1.321	0.916	1.327	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	245	gp120	V	0.094	0.077	0.079	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	246	gp120	Q	0.091	0.072	0.098	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	262	gp120	N	0.029	0.029	0.028	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	448	gp120	N	0.648	0.448	0.927	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	512	gp41, fusion peptide	A	0.175	0.260	0.110	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	514	gp41, fusion peptide	G	0.544	0.691	0.502	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	521	gp41, fusion peptide	G	0.033	0.028	0.008	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	522	gp41, fusion peptide	F	0.086	0.061	0.165	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	542	gp41, Leu/Ile zipper-like sequence	R	0.054	0.052	0.062	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	543	gp41, Leu/Ile zipper-like sequence	Q	0.529	0.768	0.202	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	549	gp41, Leu/Ile zipper-like sequence	V	0.023	0.017	0.022	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	550	gp41, Leu/Ile zipper-like sequence	Q	0.055	0.023	0.031	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	554	gp41, Leu/Ile zipper-like sequence	N	0.048	0.050	0.057	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	592	gp41	L	0.309	0.093	0.126	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	611	gp41	N	0.050	0.039	0.054	molecular modeling	contact with strain JR-FL; glycosylation motif
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	637	gp41	N	0.223	0.168	0.186	molecular modeling	contact with strain JR-FL; glycosylation motif
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	638	gp41	Y	0.091	0.096	0.110	molecular modeling	contact with strain JR-FL; glycosylation motif
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	640	gp41	S	2.068	1.971	1.834	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	641	gp41	L	1.839	1.530	0.830	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	643	gp41	H	0.066	0.065	0.084	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	644	gp41	S	2.131	1.538	1.732	molecular modeling	contact with strain JR-FL
345	PGT151 contacts	gp41 fusion domain	Dingens2019	contacts	PGT151	647	gp41	E	0.542	0.372	0.224	molecular modeling	contact with strain JR-FL
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	609	gp41	P	0.193	0.053	0.403	binding assay, mutational analysis	significant site of viral escape [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	643	gp41	H	0.066	0.065	0.084	binding assay, mutational analysis	significant site of viral escape [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	671	gp41	N	0.779	0.669	0.885	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with T/L (strong effects) and A/Y/R/V (moderate effects) [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	672	gp41	W	0.017	0.023	0.014	binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with V (moderate effect) [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	673	gp41	F	0.058	0.065	0.073	binding assay, mutational analysis	significant site of viral escape; greatest binding reductions with R/L/V/A (moderate effects) [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	676	gp41	T	0.683	0.610	0.674	binding assay, mutational analysis	significant site of viral escape [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	binding assay, mutational analysis	significant site of viral escape [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	682	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	I	0.033	0.042	0.041	binding assay, mutational analysis	significant site of viral escape [BG505.T332N]
346	mutations affecting 10E8 binding	MPER	Dingens2019	binding	10E8	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	binding assay, mutational analysis	significant site of viral escape; greatest binding reduction with Y (strong effect) [BG505.T332N]
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	665	gp41	K	0.986	0.656	0.879	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	668	gp41	S	0.842	0.596	0.758	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	669	gp41	L	0.020	0.023	0.000	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	670	gp41	W	0.026	0.028	0.035	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	671	gp41	N	0.779	0.669	0.885	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	672	gp41	W	0.017	0.023	0.014	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	673	gp41	F	0.058	0.065	0.073	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	676	gp41	T	0.683	0.610	0.674	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	677	gp41	N	1.187	1.199	1.100	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	molecular modeling	10E8 contact
347	10E8 contacts	MPER	Dingens2019	contacts	10E8	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	molecular modeling	10E8 contact
348	VRC03 signature predictions	CD4BS	Liu2019	signature	VRC03	65	gp120	V	1.035	1.023	0.310	computational prediction, neutralization assay	K65 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
348	VRC03 signature predictions	CD4BS	Liu2019	signature	VRC03	304	gp120, V3 loop	R	0.287	0.390	0.141	computational prediction, neutralization assay	R304 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
348	VRC03 signature predictions	CD4BS	Liu2019	signature	VRC03	318	gp120, V3 loop	V	0.574	0.691	0.507	computational prediction, neutralization assay	Y318 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
348	VRC03 signature predictions	CD4BS	Liu2019	signature	VRC03	440	gp120	S	1.932	1.712	1.017	computational prediction, neutralization assay	Q440 was associated with 1.5 fold or greater increased or decreased neutralization by VRC03
349	Mutation affects neutralization by VRC01_FR3-03	CD4BS	Liu2019	neutralization	VRC01_FR3-03	207	gp120	K	0.043	0.029	0.029	mutational analysis, neutralization assay	BG505 mutation K207A decreases VRC01_FR3-03 neutralization 1.5 fold or more
349	Mutation affects neutralization by VRC01_FR3-03	CD4BS	Liu2019	neutralization	VRC01_FR3-03	304	gp120, V3 loop	R	0.287	0.390	0.141	mutational analysis, neutralization assay	BG505 mutation R304A, R304E or R304A/R308A decreases VRC01_FR3-03 neutralization 1.5 fold or more
349	Mutation affects neutralization by VRC01_FR3-03	CD4BS	Liu2019	neutralization	VRC01_FR3-03	308	gp120, V3 loop	R	0.108	0.091	0.127	mutational analysis, neutralization assay	BG505 mutation R308A, R308E or R304A/R308A decreases VRC01_FR3-03 neutralization 1.5 fold or more
349	Mutation affects neutralization by VRC01_FR3-03	CD4BS	Liu2019	neutralization	VRC01_FR3-03	318	gp120, V3 loop	V	0.574	0.691	0.507	mutational analysis, neutralization assay	BG505 mutation Y318F or Y318E decreases VRC01_FR3-03 neutralization 1.5 fold or more
350	Mutation affects neutralization by VRC07_FR3-03	CD4BS	Liu2019	neutralization	VRC07_FR3-03	304	gp120, V3 loop	R	0.287	0.390	0.141	mutational analysis, neutralization assay	BG505 mutation R304E decreases VRC07_FR3-03 neutralization 1.5 fold or more
350	Mutation affects neutralization by VRC07_FR3-03	CD4BS	Liu2019	neutralization	VRC07_FR3-03	308	gp120, V3 loop	R	0.108	0.091	0.127	mutational analysis, neutralization assay	BG505 mutation R308E decreases VRC07_FR3-03 neutralization 1.5 fold or more
350	Mutation affects neutralization by VRC07_FR3-03	CD4BS	Liu2019	neutralization	VRC07_FR3-03	318	gp120, V3 loop	V	0.574	0.691	0.507	mutational analysis, neutralization assay	BG505 mutation Y318E decreases VRC07_FR3-03 neutralization 1.5 fold or more
351	Mutation affects neutralization by VRC07-523-LS_FR3-03	CD4BS	Liu2019	neutralization	VRC07-523-LS_FR3-03	207	gp120	K	0.043	0.029	0.029	mutational analysis, neutralization assay	BG505 mutation K207A decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
351	Mutation affects neutralization by VRC07-523-LS_FR3-03	CD4BS	Liu2019	neutralization	VRC07-523-LS_FR3-03	304	gp120, V3 loop	R	0.287	0.390	0.141	mutational analysis, neutralization assay	BG505 mutation R304A, R304E or R304A/R308A decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
351	Mutation affects neutralization by VRC07-523-LS_FR3-03	CD4BS	Liu2019	neutralization	VRC07-523-LS_FR3-03	308	gp120, V3 loop	R	0.108	0.091	0.127	mutational analysis, neutralization assay	BG505 mutation R308E or R304A/R308A decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
351	Mutation affects neutralization by VRC07-523-LS_FR3-03	CD4BS	Liu2019	neutralization	VRC07-523-LS_FR3-03	318	gp120, V3 loop	V	0.574	0.691	0.507	mutational analysis, neutralization assay	BG505 mutation Y318E decreases VRC07-523-LS_FR3-0 neutralization 1.5 fold or more
352	Mutation affects neutralization by N6_FR3-03	CD4BS	Liu2019	neutralization	N6-FR3_03	207	gp120	K	0.043	0.029	0.029	mutational analysis, neutralization assay	BG505 mutation K207A decreases N6_FR3-03 neutralization 1.5 fold or more
352	Mutation affects neutralization by N6_FR3-03	CD4BS	Liu2019	neutralization	N6-FR3_03	304	gp120, V3 loop	R	0.287	0.390	0.141	mutational analysis, neutralization assay	BG505 mutation R304A, R304E or R304A/R308A decreases N6_FR3-0 neutralization 2 fold or more
352	Mutation affects neutralization by N6_FR3-03	CD4BS	Liu2019	neutralization	N6-FR3_03	308	gp120, V3 loop	R	0.108	0.091	0.127	mutational analysis, neutralization assay	BG505 mutation R308A, R308E or R304A/R308A decreases N6_FR3-0 neutralization 2 fold or more
352	Mutation affects neutralization by N6_FR3-03	CD4BS	Liu2019	neutralization	N6-FR3_03	318	gp120, V3 loop	V	0.574	0.691	0.507	mutational analysis, neutralization assay	BG505 mutation Y318A, Y318F or Y318E decreases N6_FR3-0 neutralization 2 fold or more
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	671	gp41	N	0.779	0.669	0.885	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	673	gp41	F	0.058	0.065	0.073	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	674	gp41	N	1.182	1.029	1.344	X-ray crystallography	VRC42.01 contact (D674 for founder MPER in structure)
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	675	gp41	I	0.050	0.059	0.069	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	676	gp41	T	0.683	0.610	0.674	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	677	gp41	N	1.187	1.199	1.100	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036	X-ray crystallography	VRC42.01 contact
353	VRC42.01 contacts	MPER	Krebs2019	contacts	VRC42.01	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	X-ray crystallography	VRC42.01 contact
354	Residues that affect neutralization by VRC42.04	MPER	Krebs2019	neutralization	VRC42.04	672	gp41	W	0.017	0.023	0.014	alanine scanning, neutralization assay	W672A results in 25.6-fold decrease (founder) and 3.03-fold decrease (BG1168) in neutralization sensitivity
354	Residues that affect neutralization by VRC42.04	MPER	Krebs2019	neutralization	VRC42.04	673	gp41	F	0.058	0.065	0.073	alanine scanning, neutralization assay	F673A results in 25.6-fold decrease (founder) and 2.78-fold decrease (BG1168) in neutralization sensitivity
354	Residues that affect neutralization by VRC42.04	MPER	Krebs2019	neutralization	VRC42.04	674	gp41	N	1.182	1.029	1.344	alanine scanning, neutralization assay	D674A results in 2.1-fold decrease (founder) and 2.59-fold decrease (BG1168) in neutralization sensitivity
354	Residues that affect neutralization by VRC42.04	MPER	Krebs2019	neutralization	VRC42.04	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	alanine scanning, neutralization assay	W680A results in 20-fold decrease (founder) and 3.03-fold decrease (BG1168) in neutralization sensitivity
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	671	gp41	N	0.779	0.669	0.885	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	672	gp41	W	0.017	0.023	0.014	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	674	gp41	N	1.182	1.029	1.344	X-ray crystallography	contact residue (D674 in MPER in structure)
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	675	gp41	I	0.050	0.059	0.069	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	676	gp41	T	0.683	0.610	0.674	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	677	gp41	N	1.187	1.199	1.100	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036	X-ray crystallography	contact residue
355	VRC42.04 contacts	MPER	Krebs2019	contacts	VRC42.04	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	X-ray crystallography	contact residue
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	671	gp41	N	0.779	0.669	0.885	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	672	gp41	W	0.017	0.023	0.014	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	673	gp41	F	0.058	0.065	0.073	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	674	gp41	N	1.182	1.029	1.344	X-ray crystallography	VRC42.N1 contact (D674 in founder MPER in structure)
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	675	gp41	I	0.050	0.059	0.069	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	676	gp41	T	0.683	0.610	0.674	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	677	gp41	N	1.187	1.199	1.100	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	X-ray crystallography	VRC42.N1 contact
356	VRC42.N1 contacts	MPER	Krebs2019	contacts	VRC42.N1	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	X-ray crystallography	VRC42.N1 contact
357	Residues that affect neutralization by VRC43.01	MPER	Krebs2019	neutralization	VRC43.01	662	gp41	E	1.024	0.874	0.369	alanine scanning, computational prediction, neutralization assay	E662A results in 0.46-fold decrease (founder) and 6.4-fold decrease (BG1168) in neutralization sensitivity.
357	Residues that affect neutralization by VRC43.01	MPER	Krebs2019	neutralization	VRC43.01	667	gp41	A	1.332	0.545	1.537	alanine scanning, computational prediction, neutralization assay	G was found only in neutralization resistant strains while Q and D were preferentially found in neutralization-resistant strains.
357	Residues that affect neutralization by VRC43.01	MPER	Krebs2019	neutralization	VRC43.01	671	gp41	N	0.779	0.669	0.885	alanine scanning, computational prediction, neutralization assay	N671A results in 2.5-fold decrease (founder) and 15-fold decrease (BG1168) n neutralization sensitivity. T and S were preferentially found in neutralization-resistant strains
357	Residues that affect neutralization by VRC43.01	MPER	Krebs2019	neutralization	VRC43.01	674	gp41	N	1.182	1.029	1.344	alanine scanning, computational prediction, neutralization assay	D674A results in 39-fold decrease (founder) and 93-fold decrease (BG1168) in neutralization sensitivity. G and S were preferentially found in neutralization-resistant strains
357	Residues that affect neutralization by VRC43.01	MPER	Krebs2019	neutralization	VRC43.01	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	alanine scanning, computational prediction, neutralization assay	W680A results in 3.9-old decrease (founder) and 30-fold decrease (BG1168) in neutralization sensitivity
357	Residues that affect neutralization by VRC43.01	MPER	Krebs2019	neutralization	VRC43.01	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	alanine scanning, computational prediction, neutralization assay	R683A results in 6.1-fold decrease in BG1168 neutralization sensitivity; Founder Env with K683A was non-functional
358	Residues that affect neutralization by VRC46.01	MPER	Krebs2019	neutralization	VRC46.01	662	gp41	E	1.024	0.874	0.369	alanine scanning, neutralization assay	E662A results in 0.32 fold-decrease (founder) and 5.7-fold decrease (BG1168) in neutralization sensitivity
358	Residues that affect neutralization by VRC46.01	MPER	Krebs2019	neutralization	VRC46.01	664	gp41	D	0.197	0.156	0.346	alanine scanning, neutralization assay	D664A results in 3-fold decrease in neutralization sensitivity vs. both founder and BG1168 WT
358	Residues that affect neutralization by VRC46.01	MPER	Krebs2019	neutralization	VRC46.01	673	gp41	F	0.058	0.065	0.073	alanine scanning, neutralization assay	F673A results in 50.4-fold decrease (founder) and 7.39-fold decrease (BG1168) in neutralization sensitivity
358	Residues that affect neutralization by VRC46.01	MPER	Krebs2019	neutralization	VRC46.01	674	gp41	N	1.182	1.029	1.344	alanine scanning, neutralization assay	D674A results in 50.4-fold decrease (founder) and 6.39-fold decrease (BG1168) in neutralization sensitivity
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	665	gp41	K	0.986	0.656	0.879	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	666	gp41	W	0.003	0.000	0.000	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	667	gp41	A	1.332	0.545	1.537	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	668	gp41	S	0.842	0.596	0.758	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	669	gp41	L	0.020	0.023	0.000	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	670	gp41	W	0.026	0.028	0.035	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	671	gp41	N	0.779	0.669	0.885	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	673	gp41	F	0.058	0.065	0.073	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	674	gp41	N	1.182	1.029	1.344	X-ray crystallography	VRC46.01 contact (D674 in founder MPER in structure)
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	675	gp41	I	0.050	0.059	0.069	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	676	gp41	T	0.683	0.610	0.674	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	677	gp41	N	1.187	1.199	1.100	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	678	gp41, gp41 transmembrane, residue impacts MPER bNAb binding	W	0.010	0.018	0.008	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	X-ray crystallography	VRC46.01 contact
359	VRC46.01 contacts	MPER	Krebs2019	contacts	VRC46.01	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	X-ray crystallography	VRC46.01 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	671	gp41	N	0.779	0.669	0.885	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	672	gp41	W	0.017	0.023	0.014	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	673	gp41	F	0.058	0.065	0.073	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	674	gp41	N	1.182	1.029	1.344	molecular modeling	4E10 contact (D672 in MPER peptide in structure)
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	675	gp41	I	0.050	0.059	0.069	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	676	gp41	T	0.683	0.610	0.674	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	677	gp41	N	1.187	1.199	1.100	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	679	gp41, gp41 transmembrane	L	0.022	0.034	0.008	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036	molecular modeling	4E10 contact
360	4E10 contacts	MPER	Krebs2019	contacts	4E10	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	molecular modeling	4E10 contact
361	Residues that affect neutralization by 4E10	MPER	Krebs2019	neutralization	4E10	662	gp41	E	1.024	0.874	0.369	alanine scanning, binding assay, neutralization assay	E662A results in 0.35-fold decrease (founder) and 2.88-fold decrease (BG1168) in neutralization sensitivity
361	Residues that affect neutralization by 4E10	MPER	Krebs2019	neutralization	4E10	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay, neutralization assay	F673A results in 0.29-fold decrease (founder) and 4.30-fold decrease (BG1168) in neutralization sensitivity
362	Residues that affect 10E8 binding	MPER	Krebs2019	binding	10E8	671	gp41	N	0.779	0.669	0.885	alanine scanning, binding assay	N671A results in ~4 fold reduction in MPER peptide binding
362	Residues that affect 10E8 binding	MPER	Krebs2019	binding	10E8	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay	W672A results in ~100 fold reduction in MPER peptide binding
362	Residues that affect 10E8 binding	MPER	Krebs2019	binding	10E8	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay	F673A results in ~700 fold reduction in MPER peptide binding
362	Residues that affect 10E8 binding	MPER	Krebs2019	binding	10E8	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	alanine scanning, binding assay	R683A results in ~40 fold reduction in MPER peptide binding
363	Residues that affect neutralization by VRC42.02	MPER	Krebs2019	neutralization	VRC42.02	662	gp41	E	1.024	0.874	0.369	alanine scanning, binding assay, neutralization assay	Ala mediates a 0.28-fold decrease (founder) and 5.90-fold decrease (BG1168) in neutralization sensitivity.
363	Residues that affect neutralization by VRC42.02	MPER	Krebs2019	neutralization	VRC42.02	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay, neutralization assay	Ala mediates a 0.46-fold decrease (founder) and 4.42-fold decrease (BG1168) in neutralization sensitivity
363	Residues that affect neutralization by VRC42.02	MPER	Krebs2019	neutralization	VRC42.02	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay, neutralization assay	Ala mediates a 2.06-fold decrease (founder) and 8.90-fold decrease (BG1168) in neutralization sensitivity
363	Residues that affect neutralization by VRC42.02	MPER	Krebs2019	neutralization	VRC42.02	674	gp41	N	1.182	1.029	1.344	alanine scanning, binding assay, neutralization assay	D674A mediates a 2.85 fold decrease (founder) and 3.27 fold decrease (BG1168) in neutralization sensitivity
364	Residues that affect neutralization by VRC42.03	MPER	Krebs2019	neutralization	VRC42.03	662	gp41	E	1.024	0.874	0.369	alanine scanning, binding assay, neutralization assay	Ala mediates a 0.26-fold decrease (founder) and 2.69-fold decrease (BG1168) in neutralization sensitivity
364	Residues that affect neutralization by VRC42.03	MPER	Krebs2019	neutralization	VRC42.03	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay, neutralization assay	Ala mediates a 66.3-fold decrease (founder) and 6.17-fold decrease (BG1168) in neutralization sensitivity
364	Residues that affect neutralization by VRC42.03	MPER	Krebs2019	neutralization	VRC42.03	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay, neutralization assay	Ala mediates a 2.28-fold decrease (founder) and 4.00-fold decrease (BG1168) in neutralization sensitivity
364	Residues that affect neutralization by VRC42.03	MPER	Krebs2019	neutralization	VRC42.03	674	gp41	N	1.182	1.029	1.344	alanine scanning, binding assay, neutralization assay	D674A mediates a 2.72-fold decrease (founder) and 3.64-fold decrease (BG1168) in neutralization sensitivity
365	Residues important for neutralization by VRC43.02	MPER	Krebs2019	neutralization	VRC43.02	662	gp41	E	1.024	0.874	0.369	alanine scanning, neutralization assay	Ala mediates a 0.48 fold decrease (founder) and 9.06 fold decrease (BG1168) in neutralization sensitivity
365	Residues important for neutralization by VRC43.02	MPER	Krebs2019	neutralization	VRC43.02	674	gp41	N	1.182	1.029	1.344	alanine scanning, neutralization assay	D674A mediates a 12.4 fold decrease (founder) and 41.3 fold decrease (BG1168) in neutralization sensitivity
365	Residues important for neutralization by VRC43.02	MPER	Krebs2019	neutralization	VRC43.02	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	alanine scanning, neutralization assay	W680A mediates a 2.70 fold decrease (founder) and 2.06 fold decrease (BG1168) in neutralization sensitivity
366	Residues important for neutralization by VRC43.03	MPER	Krebs2019	neutralization	VRC43.03	662	gp41	E	1.024	0.874	0.369	alanine scanning, neutralization assay	Ala mediates a 0.44 fold decrease (founder) and 8.94 fold decrease (BG1168) in neutralization sensitivity
366	Residues important for neutralization by VRC43.03	MPER	Krebs2019	neutralization	VRC43.03	671	gp41	N	0.779	0.669	0.885	alanine scanning, neutralization assay	N671A mediates a 2.14 fold decrease (founder) and 9.71 fold decrease (BG1168) in neutralization sensitivity
366	Residues important for neutralization by VRC43.03	MPER	Krebs2019	neutralization	VRC43.03	674	gp41	N	1.182	1.029	1.344	alanine scanning, neutralization assay	D674A mediates a 21.0 fold decrease (founder) and 48.1 fold decrease (BG1168) in neutralization sensitivity
366	Residues important for neutralization by VRC43.03	MPER	Krebs2019	neutralization	VRC43.03	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	alanine scanning, neutralization assay	W680A mediates a 12.3 fold decrease (founder) and 18.3 fold decrease (BG1168) in neutralization sensitivity
367	RHA1.V2.01 contacts	V2-apex	Roark2021	contacts	RHA1.V2.01	121	gp120	K	0.385	0.360	0.187	cryo-EM, mutational analysis, neutralization assay	Heavy chain contact
367	RHA1.V2.01 contacts	V2-apex	Roark2021	contacts	RHA1.V2.01	166	gp120, V2	R	1.127	1.398	0.772	cryo-EM, mutational analysis, neutralization assay	Heavy chain contact; R166G, R166S, R169T, or R166K+R169K associated with resistance to neutralization
367	RHA1.V2.01 contacts	V2-apex	Roark2021	contacts	RHA1.V2.01	169	gp120, V2	V	1.974	1.770	1.344	cryo-EM, mutational analysis, neutralization assay	Heavy chain contact; R166G, R166S, R169T, or R166K+R169K associated with resistance to neutralization
368	RHA1.V2.01 signatures	V2-apex	Roark2021	signature	RHA1.V2.01	130	gp120	K	1.274	0.883	1.495	computational prediction, neutralization assay	glycan or N associated with resistance
368	RHA1.V2.01 signatures	V2-apex	Roark2021	signature	RHA1.V2.01	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
368	RHA1.V2.01 signatures	V2-apex	Roark2021	signature	RHA1.V2.01	166	gp120, V2	R	1.127	1.398	0.772	computational prediction, neutralization assay	R associated with sensitivity; K associated with resistance
368	RHA1.V2.01 signatures	V2-apex	Roark2021	signature	RHA1.V2.01	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	D associated with sensitivity
368	RHA1.V2.01 signatures	V2-apex	Roark2021	signature	RHA1.V2.01	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	R associated with sensitivity; V associated with resistance
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	130	gp120	K	1.274	0.883	1.495	computational prediction, neutralization assay	N or glycan associated with resistance
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	161	gp120, V2	I	1.565	0.964	1.568	computational prediction, neutralization assay	I associated with resistance; M associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	162	gp120, V2	S	0.289	0.445	0.179	computational prediction, neutralization assay	T associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	164	gp120, V2	S	1.660	1.925	0.453	computational prediction, neutralization assay	S or N associated with resistance; E associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	165	gp120, V2	I	1.321	1.292	1.011	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	166	gp120, V2	R	1.127	1.398	0.772	computational prediction, neutralization assay	R associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	D associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	V, M or Q associated with resistance; K or R associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction, neutralization assay	Q associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	172	gp120, V2	E	1.506	1.172	1.484	computational prediction, neutralization assay	E associated with resistance; V associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction, neutralization assay	Y associated with resistance
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	184	gp120, V2	I	1.060	0.599	0.530	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	200	gp120	V	1.296	0.683	0.916	computational prediction, neutralization assay	V associated with resistance; A associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	211	gp120	E	0.840	0.366	0.364	computational prediction, neutralization assay	E associated with resistance; D associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	281	gp120, Loop D	A	1.081	0.814	1.357	computational prediction, neutralization assay	A associated with resistance; V associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction, neutralization assay	I associated with resistance; V associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	308	gp120, V3 loop	R	0.108	0.091	0.127	computational prediction, neutralization assay	H associated with resistance; R associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction, neutralization assay	M or L associated with resistance; I associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	315	gp120, V3 loop	R	1.120	1.028	0.196	computational prediction, neutralization assay	R associated with resistance; Q associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	362	gp120	K	1.874	1.265	1.997	computational prediction, neutralization assay	glycan associated with resistance; Q, A or E associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	419	gp120	R	0.516	0.341	0.500	computational prediction, neutralization assay	R associated with resistance; K associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction, neutralization assay	R or L associated with resistance; M associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	518	gp41, fusion peptide	L	1.201	1.110	0.718	computational prediction, neutralization assay	L associated with resistance; V associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	588	gp41, Leu/Ile zipper-like sequence	K	1.087	1.197	0.871	computational prediction, neutralization assay	Q associated with resistance; K associated with sensitivity
369	PCT64-35M signature sites	V2-apex	Roark2021	signature	PCT64-35M	788	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction, Perilipin-3 interaction; intracellular trafficking	R	0.810	0.131	0.670	computational prediction, neutralization assay	R associated with resistance; L associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	128	gp120	S	0.188	0.339	0.088	computational prediction, neutralization assay	T associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	161	gp120, V2	I	1.565	0.964	1.568	computational prediction, neutralization assay	V associated with resistance; M associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	162	gp120, V2	S	0.289	0.445	0.179	computational prediction, neutralization assay	T associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	164	gp120, V2	S	1.660	1.925	0.453	computational prediction, neutralization assay	S associated with resistance; E associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	165	gp120, V2	I	1.321	1.292	1.011	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	166	gp120, V2	R	1.127	1.398	0.772	computational prediction, neutralization assay	G associated with resistance; R associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	N associated with resistance; D associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	V associated with resistance; K associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction, neutralization assay	Q associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	172	gp120, V2	E	1.506	1.172	1.484	computational prediction, neutralization assay	E or D associated with resistance; V associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	182	gp120, V2	I	0.694	0.957	0.587	computational prediction, neutralization assay	V associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	200	gp120	V	1.296	0.683	0.916	computational prediction, neutralization assay	V associated with resistance
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	232	gp120	T	1.649	1.451	0.426	computational prediction, neutralization assay	T associated with resistance
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	275	gp120, Loop D	V	1.034	1.420	0.535	computational prediction, neutralization assay	K associated with resistance; E associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction, neutralization assay	R associated with resistance
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	308	gp120, V3 loop	R	0.108	0.091	0.127	computational prediction, neutralization assay	T associated with resistance
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction, neutralization assay	L associated with resistance
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	313	gp120, V3 loop	P	0.307	0.424	0.078	computational prediction, neutralization assay	P associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	315	gp120, V3 loop	R	1.120	1.028	0.196	computational prediction, neutralization assay	R associated with resistance; Q associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	332	gp120	N	0.904	0.491	0.693	computational prediction, neutralization assay	glycan associated with resistance
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	362	gp120	K	1.874	1.265	1.997	computational prediction, neutralization assay	glycan associated with resistance
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction, neutralization assay	R associated with resistance; M associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	636	gp41	N	1.371	1.127	1.081	computational prediction, neutralization assay	D associated with resistance; S associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	654	gp41	E	0.313	0.174	0.105	computational prediction, neutralization assay	D associated with resistance; E associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	784	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, CaM interaction, p115-RhoGEF interaction	L	0.607	0.534	0.440	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
370	PGDM signature sites	V2-apex	Roark2021	signature	PGDM1400	835	gp41, gp41 cytoplasmic tail, LLP-1 amphipathic helix, CaM interaction, Gag matrix interaction; Env incorporation, p115-RhoGEF interaction	G	0.753	0.515	0.917	computational prediction, neutralization assay	R associated with resistance; G associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	161	gp120, V2	I	1.565	0.964	1.568	computational prediction, neutralization assay	V associated with resistance; M associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	162	gp120, V2	S	0.289	0.445	0.179	computational prediction, neutralization assay	T associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	164	gp120, V2	S	1.660	1.925	0.453	computational prediction, neutralization assay	S associated with resistance
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	D associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	V associated with resistance; K associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction, neutralization assay	K associated with resistance; Q associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	171	gp120, V2	K	1.239	0.957	1.413	computational prediction, neutralization assay	K associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction, neutralization assay	Q associated with resistance
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction, neutralization assay	R associated with resistance
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	313	gp120, V3 loop	P	0.307	0.424	0.078	computational prediction, neutralization assay	P associated with sensitivity
371	PG9 signature sites	V2-apex	Roark2021	signature	PG9	315	gp120, V3 loop	R	1.120	1.028	0.196	computational prediction, neutralization assay	R associated with resistance; Q associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	130	gp120	K	1.274	0.883	1.495	computational prediction, neutralization assay	N or glycan associated with resistance;  D associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	159	gp120, V2	F	0.165	0.034	0.038	computational prediction, neutralization assay	Y associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	161	gp120, V2	I	1.565	0.964	1.568	computational prediction, neutralization assay	I associated with resistance; M associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	165	gp120, V2	I	1.321	1.292	1.011	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	D associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	V associated with resistance
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction, neutralization assay	associated with resistance
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	171	gp120, V2	K	1.239	0.957	1.413	computational prediction, neutralization assay	Q associated with resistance; K associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	172	gp120, V2	E	1.506	1.172	1.484	computational prediction, neutralization assay	D associated with resistance
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	174	gp120, V2	A	0.419	0.155	0.145	computational prediction, neutralization assay	A associated with resistance; S associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	305	gp120, V3 loop	K	1.097	0.713	0.943	computational prediction, neutralization assay	Q associated with resistance
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction, neutralization assay	R associated with resistance
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction, neutralization assay	L associated with resistance; I associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	315	gp120, V3 loop	R	1.120	1.028	0.196	computational prediction, neutralization assay	R associated with resistance; Q associated with sensitivity
372	CH01 signature sites	V2-apex	Roark2021	signature	CH01	337	gp120	K	2.008	1.862	2.151	computational prediction, neutralization assay	N or glycan associated with resistance
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	128	gp120	S	0.188	0.339	0.088	computational prediction, neutralization assay	T associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	161	gp120, V2	I	1.565	0.964	1.568	computational prediction, neutralization assay	V associated with resistance; M associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	162	gp120, V2	S	0.289	0.445	0.179	computational prediction, neutralization assay	T associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	166	gp120, V2	R	1.127	1.398	0.772	computational prediction, neutralization assay	Q associated with resistance; R associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	D associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	V associated with resistance; K associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction, neutralization assay	associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	172	gp120, V2	E	1.506	1.172	1.484	computational prediction, neutralization assay	V associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	177	gp120, V2	Y	0.349	0.638	0.144	computational prediction, neutralization assay	N associated with resistance; Y associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	202	gp120	T	0.639	0.291	0.547	computational prediction, neutralization assay	A associated with resistance; T associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction, neutralization assay	R associated with resistance
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	313	gp120, V3 loop	P	0.307	0.424	0.078	computational prediction, neutralization assay	P associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	315	gp120, V3 loop	R	1.120	1.028	0.196	computational prediction, neutralization assay	R associated with resistance; Q associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	320	gp120, V3 loop	I	0.720	0.564	0.782	computational prediction, neutralization assay	T associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	332	gp120	N	0.904	0.491	0.693	computational prediction, neutralization assay	N or glycan associated with resistance
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	334	gp120	S	0.780	0.501	0.890	computational prediction, neutralization assay	S associated with resistance; N or glycan associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction, neutralization assay	R associated with resistance; M associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	446	gp120	S	2.139	1.139	1.774	computational prediction, neutralization assay	S or I associated with resistance; V associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	computational prediction, neutralization assay	R associated with resistance; K associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	717	gp41, gp41 cytoplasmic tail	F	0.487	0.533	0.386	computational prediction, neutralization assay	L associated with resistance; F associated with sensitivity
373	PGT145 signature sites	V2-apex	Roark2021	signature	PGT145	775	gp41, gp41 cytoplasmic tail, LLP-2 amphipathic helix, NF-kappaB activation (TAK1 interaction), CaM interaction, p115-RhoGEF interaction	L	1.101	0.166	0.579	computational prediction, neutralization assay	L associated with resistance; I associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	164	gp120, V2	S	1.660	1.925	0.453	computational prediction, neutralization assay	S or N associated with resistance; E associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	165	gp120, V2	I	1.321	1.292	1.011	computational prediction, neutralization assay	L associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	166	gp120, V2	R	1.127	1.398	0.772	computational prediction, neutralization assay	K associated with resistance; R associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	N associated with resistance; D associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	M, Q, or V associated with resistance; K associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction, neutralization assay	associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	172	gp120, V2	E	1.506	1.172	1.484	computational prediction, neutralization assay	D associated with resistance; V associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	173	gp120, V2	Y	1.165	0.808	1.158	computational prediction, neutralization assay	Y associated with resistance
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	181	gp120, V2	I	0.968	0.929	0.855	computational prediction, neutralization assay	V associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	184	gp120, V2	I	1.060	0.599	0.530	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	192	gp120, V2	K	0.847	0.835	0.851	computational prediction, neutralization assay	T associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	200	gp120	V	1.296	0.683	0.916	computational prediction, neutralization assay	V associated with resistance; T or A associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	306	gp120, V3 loop	R	0.732	0.860	0.338	computational prediction, neutralization assay	R associated with resistance; S associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	308	gp120, V3 loop	R	0.108	0.091	0.127	computational prediction, neutralization assay	H or N associated with resistance; R associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction, neutralization assay	L associated with resistance; I associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	315	gp120, V3 loop	R	1.120	1.028	0.196	computational prediction, neutralization assay	R associated with resistance; Q associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	362	gp120	K	1.874	1.265	1.997	computational prediction, neutralization assay	N or glycan associated with resistance; E associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	387	gp120, V4 loop	S	0.365	0.647	0.045	computational prediction, neutralization assay	S associated with resistance; T associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	393	gp120, V4 loop	S	1.559	0.650	2.132	computational prediction, neutralization assay	S associated with resistance; G or N associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	426	gp120, beta20/beta21	M	0.598	0.866	0.274	computational prediction, neutralization assay	L associated with resistance; M associated with sensitivity
374	VRC26.08 signature sites	V2-apex	Roark2021	signature	VRC26.08	732	gp41, gp41 cytoplasmic tail, Kennedy epitope (highly immunogenic)	G	0.890	0.262	0.816	computational prediction, neutralization assay	G associated with resistance; R associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	121	gp120	K	0.385	0.360	0.187	computational prediction, neutralization assay	associated with resistance
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	160	gp120, V2	N	0.401	0.452	0.358	computational prediction, neutralization assay	glycan associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	162	gp120, V2	S	0.289	0.445	0.179	computational prediction, neutralization assay	T associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	164	gp120, V2	S	1.660	1.925	0.453	computational prediction, neutralization assay	S or G associated with resistance; E associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	165	gp120, V2	I	1.321	1.292	1.011	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	166	gp120, V2	R	1.127	1.398	0.772	computational prediction, neutralization assay	I associated with resistance; R associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	167	gp120, V2	G	0.601	1.122	0.185	computational prediction, neutralization assay	I associated with resistance; D associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	168	gp120, V2	K	0.547	0.666	0.396	computational prediction, neutralization assay	K associated with resistance; R associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	169	gp120, V2	V	1.974	1.770	1.344	computational prediction, neutralization assay	V associated with resistance; K associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	170	gp120, V2	Q	1.458	1.423	1.428	computational prediction, neutralization assay	associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	172	gp120, V2	E	1.506	1.172	1.484	computational prediction, neutralization assay	D associated with resistance; V associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	184	gp120, V2	I	1.060	0.599	0.530	computational prediction, neutralization assay	I associated with resistance; L associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	200	gp120	V	1.296	0.683	0.916	computational prediction, neutralization assay	V associated with resistance; T or A associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	307	gp120, V3 loop	I	0.067	0.030	0.111	computational prediction, neutralization assay	I associated with resistance; V associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	308	gp120, V3 loop	R	0.108	0.091	0.127	computational prediction, neutralization assay	N associated with resistance; R associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	309	gp120, V3 loop	I	0.921	0.359	0.965	computational prediction, neutralization assay	L associated with resistance; I associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	315	gp120, V3 loop	R	1.120	1.028	0.196	computational prediction, neutralization assay	R or K associated with resistance; Q associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	352	gp120	Q	1.680	0.842	1.079	computational prediction, neutralization assay	Q associated with resistance; H associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	362	gp120	K	1.874	1.265	1.997	computational prediction, neutralization assay	glycan associated with resistance; E associated with sensitivity
375	VRC26.25 signature sites	V2-apex	Roark2021	signature	VRC26.25	518	gp41, fusion peptide	L	1.201	1.110	0.718	computational prediction, neutralization assay	L or M associated with resistance; V associated with sensitivity
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	80	gp120	N	0.634	0.695	0.562	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	84	gp120	V	1.321	0.916	1.327	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	neutralization assay	differential neutralization selection >10%
376	DF1W-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DF1W-a.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	85	gp120	V	2.208	1.797	1.418	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	neutralization assay	differential neutralization selection >10%
377	0PV-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-a.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	differential neutralization selection >10%
378	0PV-b.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	0PV-b.01	524	gp41, fusion peptide	G	0.127	0.129	0.125	neutralization assay	differential neutralization selection >10%
379	DFPH-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	differential neutralization selection >10%
379	DFPH-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	differential neutralization selection >10%
379	DFPH-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	differential neutralization selection >10%
379	DFPH-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	differential neutralization selection >10%
379	DFPH-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	neutralization assay	differential neutralization selection >10%
379	DFPH-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	differential neutralization selection >10%
380	DFPH-a.15 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.15	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	differential neutralization selection >10%
380	DFPH-a.15 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.15	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	differential neutralization selection >10%
380	DFPH-a.15 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.15	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	differential neutralization selection >10%
380	DFPH-a.15 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.15	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	differential neutralization selection >10%
380	DFPH-a.15 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.15	516	gp41, fusion peptide	G	0.091	0.038	0.048	neutralization assay	differential neutralization selection >10%
380	DFPH-a.15 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.15	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	differential neutralization selection >10%
380	DFPH-a.15 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	DFPH-a.15	519	gp41, fusion peptide	F	0.695	0.243	0.837	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	84	gp120	V	1.321	0.916	1.327	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	85	gp120	V	2.208	1.797	1.418	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	91	gp120	E	0.029	0.033	0.023	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	521	gp41, fusion peptide	G	0.033	0.028	0.008	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	524	gp41, fusion peptide	G	0.127	0.129	0.125	neutralization assay	differential neutralization selection >10%
381	A12V163-a.01 neutralization-associated sites	gp41 fusion domain	Kong2019	neutralization	A12V163-a.01	629	gp41	M	0.943	0.350	0.132	neutralization assay	differential neutralization selection >10%
382	0PV-c.01 contacts	gp41 fusion domain	Kong2019	contacts	0PV-a.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	cryo-EM, X-ray crystallography	0PV-c.01 contact
382	0PV-c.01 contacts	gp41 fusion domain	Kong2019	contacts	0PV-a.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	cryo-EM, X-ray crystallography	0PV-c.01 contact
382	0PV-c.01 contacts	gp41 fusion domain	Kong2019	contacts	0PV-a.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	cryo-EM, X-ray crystallography	0PV-c.01 contact
382	0PV-c.01 contacts	gp41 fusion domain	Kong2019	contacts	0PV-a.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	cryo-EM, X-ray crystallography	0PV-c.01 contact
382	0PV-c.01 contacts	gp41 fusion domain	Kong2019	contacts	0PV-a.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	cryo-EM, X-ray crystallography	0PV-c.01 contact
383	DFPH-a.15 contacts	gp41 fusion domain	Kong2019	contacts	DFPH-a.15	512	gp41, fusion peptide	A	0.175	0.260	0.110	cryo-EM, X-ray crystallography	DFPH-a.15 contact
383	DFPH-a.15 contacts	gp41 fusion domain	Kong2019	contacts	DFPH-a.15	513	gp41, fusion peptide	V	0.711	0.736	0.506	cryo-EM, X-ray crystallography	DFPH-a.15 contact
383	DFPH-a.15 contacts	gp41 fusion domain	Kong2019	contacts	DFPH-a.15	515	gp41, fusion peptide	I	1.106	1.147	0.877	cryo-EM, X-ray crystallography	DFPH-a.15 contact
383	DFPH-a.15 contacts	gp41 fusion domain	Kong2019	contacts	DFPH-a.15	517	gp41, fusion peptide	A	0.147	0.109	0.058	cryo-EM, X-ray crystallography	DFPH-a.15 contact
383	DFPH-a.15 contacts	gp41 fusion domain	Kong2019	contacts	DFPH-a.15	519	gp41, fusion peptide	F	0.695	0.243	0.837	cryo-EM, X-ray crystallography	DFPH-a.15 contact
384	mutations affecting PGT121 binding	V3-glycan	Kwon2015	binding	PGT121	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191W reduced binding
384	mutations affecting PGT121 binding	V3-glycan	Kwon2015	binding	PGT121	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P enhanced binding
384	mutations affecting PGT121 binding	V3-glycan	Kwon2015	binding	PGT121	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	BG505 SOSIP.664: A433P enhanced binding
386	mutations affecting PGT128 binding	V3-glycan	Kwon2015	binding	PGT128	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191W reduced binding
386	mutations affecting PGT128 binding	V3-glycan	Kwon2015	binding	PGT128	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P reduced binding
386	mutations affecting PGT128 binding	V3-glycan	Kwon2015	binding	PGT128	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	BG505 SOSIP.664: A433P enhanced binding
388	mutations affecting 2G12 binding	glycan	Kwon2015	binding	2G12	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191W reduced binding
388	mutations affecting 2G12 binding	glycan	Kwon2015	binding	2G12	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P enhanced binding
388	mutations affecting 2G12 binding	glycan	Kwon2015	binding	2G12	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	BG505 SOSIP.664: A433P enhanced binding
390	mutations affecting PGT151 binding	gp41 fusion domain	Kwon2015	binding	PGT151	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191W reduced binding
390	mutations affecting PGT151 binding	gp41 fusion domain	Kwon2015	binding	PGT151	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P enhanced binding
390	mutations affecting PGT151 binding	gp41 fusion domain	Kwon2015	binding	PGT151	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	BG505 SOSIP.664: A433P enhanced binding
391	mutations affecting 35O22 binding	gp120/gp41 interface	Kwon2015	binding	35O22	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191W reduced binding
391	mutations affecting 35O22 binding	gp120/gp41 interface	Kwon2015	binding	35O22	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P enhanced binding
391	mutations affecting 35O22 binding	gp120/gp41 interface	Kwon2015	binding	35O22	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	BG505 SOSIP.664: A433P enhanced binding
392	mutation affecting 8ANC195 binding	gp120/gp41 interface	Kwon2015	binding	8ANC195	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P enhanced binding
394	mutations affecting 447-52D binding	V3-glycan	Kwon2015	binding	447-52D	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664 with sCD4: Y191W reduced binding
394	mutations affecting 447-52D binding	V3-glycan	Kwon2015	binding	447-52D	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664 with sCD4: Q432P reduced binding
394	mutations affecting 447-52D binding	V3-glycan	Kwon2015	binding	447-52D	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	BG505 SOSIP.664 with sCD4: A433P abrogated binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	125	gp120	L	0.107	0.153	0.058	binding assay, mutational analysis	BG505 SOSIP.664: L125W reduced binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	129	gp120	L	0.048	0.056	0.029	binding assay, mutational analysis	BG505 SOSIP.664: V129F strongly reduced binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	177	gp120, V2	Y	0.349	0.638	0.144	binding assay, mutational analysis	BG505 SOSIP.664: Y177W/F reduced binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	180	gp120, V2	D	0.031	0.033	0.029	binding assay, mutational analysis	BG505 SOSIP.664: D180F/W strongly reduced binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	181	gp120, V2	I	0.968	0.929	0.855	binding assay, mutational analysis	BG505 SOSIP.664: V181F/W reduced binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191W reduced binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	194	gp120, V2	T	0.503	0.906	0.161	binding assay, mutational analysis	BG505 SOSIP.664: I194F, but not I194W, reduced binding
396	mutations affecting VRC01 binding	CD4BS	Kwon2015	binding	VRC01	421	gp120, beta20/beta21	K	0.312	0.374	0.203	binding assay, mutational analysis	BG505 SOSIP.664: K421W, but not K421F, reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	112	gp120	W	0.016	0.018	0.000	binding assay, mutational analysis	BG505 SOSIP.664: W112A/S strongly reduced and W112R abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	121	gp120	K	0.385	0.360	0.187	binding assay, mutational analysis	BG505 SOSIP.664: K121W/F strongly reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	125	gp120	L	0.107	0.153	0.058	binding assay, mutational analysis	BG505 SOSIP.664: L125W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	127	gp120	V	0.093	0.112	0.093	binding assay, mutational analysis	BG505 SOSIP.664: V127F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	129	gp120	L	0.048	0.056	0.029	binding assay, mutational analysis	BG505 SOSIP.664: V129F abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	BG505 SOSIP.664: E153F, but not E153W, reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	162	gp120, V2	S	0.289	0.445	0.179	binding assay, mutational analysis	BG505 SOSIP.664: T162F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	163	gp120, V2	T	0.360	0.638	0.154	binding assay, mutational analysis	BG505 SOSIP.664: T163F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	165	gp120, V2	I	1.321	1.292	1.011	binding assay, mutational analysis	BG505 SOSIP.664: L165F/W/Y abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	166	gp120, V2	R	1.127	1.398	0.772	binding assay, mutational analysis	BG505 SOSIP.664: R166Y/F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	167	gp120, V2	G	0.601	1.122	0.185	binding assay, mutational analysis	BG505 SOSIP.664: D167F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	175	gp120, V2	F	0.498	0.868	0.271	binding assay, mutational analysis	BG505 SOSIP.664: L175F/W reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	177	gp120, V2	Y	0.349	0.638	0.144	binding assay, mutational analysis	BG505 SOSIP.664: Y177F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	179	gp120, V2	L	0.963	0.857	1.159	binding assay, mutational analysis	BG505 SOSIP.664: L179F, but not L179W, reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	180	gp120, V2	D	0.031	0.033	0.029	binding assay, mutational analysis	BG505 SOSIP.664: D180F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	181	gp120, V2	I	0.968	0.929	0.855	binding assay, mutational analysis	BG505 SOSIP.664: V181F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	182	gp120, V2	I	0.694	0.957	0.587	binding assay, mutational analysis	BG505 SOSIP.664: V182F abrogated and V182W strongly reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191F/W reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	193	gp120, V2	L	0.140	0.202	0.055	binding assay, mutational analysis	BG505 SOSIP.664: L193W, but not L193F, reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	194	gp120, V2	T	0.503	0.906	0.161	binding assay, mutational analysis	BG505 SOSIP.664: I194F abrogated and I194W strongly reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	210	gp120	F	0.191	0.056	0.107	binding assay, mutational analysis	BG505 SOSIP.664: F210A/S/R reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	421	gp120, beta20/beta21	K	0.312	0.374	0.203	binding assay, mutational analysis	BG505 SOSIP.664: K421F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	422	gp120, beta20/beta21	Q	0.054	0.046	0.031	binding assay, mutational analysis	BG505 SOSIP.664: Q422F/W abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	423	gp120, beta20/beta21	I	0.383	0.383	0.411	binding assay, mutational analysis	BG505 SOSIP.664: I423W, but not I423F, abrogated binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P, but not Q432F/W, reduced binding
398	mutations affecting VRC26.09 binding	V2-apex	Kwon2015	binding	VRC26.09	530	gp41	M	0.017	0.024	0.000	binding assay, mutational analysis	BG505 SOSIP.664: M530W reduced binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	112	gp120	W	0.016	0.018	0.000	binding assay, mutational analysis	BG505 SOSIP.664: W112R, but not W112A/S, strongly reduced binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	121	gp120	K	0.385	0.360	0.187	binding assay, mutational analysis	BG505 SOSIP.664: K121W/F reduced binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	125	gp120	L	0.107	0.153	0.058	binding assay, mutational analysis	BG505 SOSIP.664: L125W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	127	gp120	V	0.093	0.112	0.093	binding assay, mutational analysis	BG505 SOSIP.664: V127F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	129	gp120	L	0.048	0.056	0.029	binding assay, mutational analysis	BG505 SOSIP.664: V129F abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	162	gp120, V2	S	0.289	0.445	0.179	binding assay, mutational analysis	BG505 SOSIP.664: T162F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	163	gp120, V2	T	0.360	0.638	0.154	binding assay, mutational analysis	BG505 SOSIP.664: T163F/W reduced binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	165	gp120, V2	I	1.321	1.292	1.011	binding assay, mutational analysis	BG505 SOSIP.664: L165F/W/Y reduced binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	166	gp120, V2	R	1.127	1.398	0.772	binding assay, mutational analysis	BG505 SOSIP.664: R166Y abrogated and R166F/W reduced binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	167	gp120, V2	G	0.601	1.122	0.185	binding assay, mutational analysis	BG505 SOSIP.664: D167F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	177	gp120, V2	Y	0.349	0.638	0.144	binding assay, mutational analysis	BG505 SOSIP.664: Y177F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	180	gp120, V2	D	0.031	0.033	0.029	binding assay, mutational analysis	BG505 SOSIP.664: D180F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	181	gp120, V2	I	0.968	0.929	0.855	binding assay, mutational analysis	BG505 SOSIP.664: V181F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	194	gp120, V2	T	0.503	0.906	0.161	binding assay, mutational analysis	BG505 SOSIP.664: I194F, but not I194W, reduced binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	421	gp120, beta20/beta21	K	0.312	0.374	0.203	binding assay, mutational analysis	BG505 SOSIP.664: K421F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	422	gp120, beta20/beta21	Q	0.054	0.046	0.031	binding assay, mutational analysis	BG505 SOSIP.664: Q422F/W abrogated binding
399	mutations affecting PGT145 binding	V2-apex	Kwon2015	binding	PGT145	423	gp120, beta20/beta21	I	0.383	0.383	0.411	binding assay, mutational analysis	BG505 SOSIP.664: I423W, but not I423F, abrogated binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	112	gp120	W	0.016	0.018	0.000	binding assay, mutational analysis	BG505 SOSIP.664: W112R/A/S reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	121	gp120	K	0.385	0.360	0.187	binding assay, mutational analysis	BG505 SOSIP.664: K121W, but not K121F, reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	125	gp120	L	0.107	0.153	0.058	binding assay, mutational analysis	BG505 SOSIP.664: L125W reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	127	gp120	V	0.093	0.112	0.093	binding assay, mutational analysis	BG505 SOSIP.664: V127F/W reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	129	gp120	L	0.048	0.056	0.029	binding assay, mutational analysis	BG505 SOSIP.664: V129F strongly reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	163	gp120, V2	T	0.360	0.638	0.154	binding assay, mutational analysis	BG505 SOSIP.664: T163F/W reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	165	gp120, V2	I	1.321	1.292	1.011	binding assay, mutational analysis	BG505 SOSIP.664: L165F/Y, but not L165W, reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	167	gp120, V2	G	0.601	1.122	0.185	binding assay, mutational analysis	BG505 SOSIP.664: D167F, but not D167W, abrogated binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	177	gp120, V2	Y	0.349	0.638	0.144	binding assay, mutational analysis	BG505 SOSIP.664: Y177F/W reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	180	gp120, V2	D	0.031	0.033	0.029	binding assay, mutational analysis	BG505 SOSIP.664: D180F/W strongly reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	181	gp120, V2	I	0.968	0.929	0.855	binding assay, mutational analysis	BG505 SOSIP.664: V181F/W reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	194	gp120, V2	T	0.503	0.906	0.161	binding assay, mutational analysis	BG505 SOSIP.664: I194F, but not I194W, reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	421	gp120, beta20/beta21	K	0.312	0.374	0.203	binding assay, mutational analysis	BG505 SOSIP.664: K421F/W strongly reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	422	gp120, beta20/beta21	Q	0.054	0.046	0.031	binding assay, mutational analysis	BG505 SOSIP.664: Q422F/W strongly reduced binding
400	mutations affecting PGT122 binding	V3-glycan	Kwon2015	binding	PGT122	423	gp120, beta20/beta21	I	0.383	0.383	0.411	binding assay, mutational analysis	BG505 SOSIP.664: I423W, but not I423F, reduced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	121	gp120	K	0.385	0.360	0.187	binding assay, mutational analysis	BG505 SOSIP.664: K121W, but not K121F, enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	125	gp120	L	0.107	0.153	0.058	binding assay, mutational analysis	BG505 SOSIP.664: L125W enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	127	gp120	V	0.093	0.112	0.093	binding assay, mutational analysis	BG505 SOSIP.664: V127F/W enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	129	gp120	L	0.048	0.056	0.029	binding assay, mutational analysis	BG505 SOSIP.664: V129F enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	BG505 SOSIP.664: E153F, but not E153W, enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	172	gp120, V2	E	1.506	1.172	1.484	binding assay, mutational analysis	BG505 SOSIP.664: V172W, but not V172F, enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	180	gp120, V2	D	0.031	0.033	0.029	binding assay, mutational analysis	BG505 SOSIP.664: D180F/W enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	181	gp120, V2	I	0.968	0.929	0.855	binding assay, mutational analysis	BG505 SOSIP.664: V181F/W enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	182	gp120, V2	I	0.694	0.957	0.587	binding assay, mutational analysis	BG505 SOSIP.664: V182F abrogated and V182W strongly reduced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	423	gp120, beta20/beta21	I	0.383	0.383	0.411	binding assay, mutational analysis	BG505 SOSIP.664: I423W, but not I423F,  enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	430	gp120, beta20/beta21	V	0.397	0.080	0.073	binding assay, mutational analysis	BG505 SOSIP.664: I430W, but not I430F, enhanced binding
401	mutations affecting F105 binding	CD4BS	Kwon2015	binding	F105	530	gp41	M	0.017	0.024	0.000	binding assay, mutational analysis	BG505 SOSIP.664: M530W enhanced binding
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	125	gp120	L	0.107	0.153	0.058	binding assay, mutational analysis	BG505 SOSIP.664: L125W enhanced binding w/out sCD4, and reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	127	gp120	V	0.093	0.112	0.093	binding assay, mutational analysis	BG505 SOSIP.664: V127F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	129	gp120	L	0.048	0.056	0.029	binding assay, mutational analysis	BG505 SOSIP.664: V129F enhanced binding w/out sCD4, and reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	BG505 SOSIP.664: E153F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	154	gp120, V1	I	1.204	1.013	1.150	binding assay, mutational analysis	BG505 SOSIP.664: L154F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	163	gp120, V2	T	0.360	0.638	0.154	binding assay, mutational analysis	BG505 SOSIP.664: T163F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	164	gp120, V2	S	1.660	1.925	0.453	binding assay, mutational analysis	BG505 SOSIP.664: E164F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	165	gp120, V2	I	1.321	1.292	1.011	binding assay, mutational analysis	BG505 SOSIP.664: L165F/W/Y enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	166	gp120, V2	R	1.127	1.398	0.772	binding assay, mutational analysis	BG505 SOSIP.664: R166Y, but not R166F/W, strongly reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	167	gp120, V2	G	0.601	1.122	0.185	binding assay, mutational analysis	BG505 SOSIP.664: D167F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	172	gp120, V2	E	1.506	1.172	1.484	binding assay, mutational analysis	BG505 SOSIP.664: V172F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	175	gp120, V2	F	0.498	0.868	0.271	binding assay, mutational analysis	BG505 SOSIP.664: L175F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	177	gp120, V2	Y	0.349	0.638	0.144	binding assay, mutational analysis	BG505 SOSIP.664: Y177W strongly reduced and Y177F abrogated binding, both w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	179	gp120, V2	L	0.963	0.857	1.159	binding assay, mutational analysis	BG505 SOSIP.664: L179W, but not L179F, enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	180	gp120, V2	D	0.031	0.033	0.029	binding assay, mutational analysis	BG505 SOSIP.664: D180F/W abrogated binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	181	gp120, V2	I	0.968	0.929	0.855	binding assay, mutational analysis	BG505 SOSIP.664: V181F/W reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	182	gp120, V2	I	0.694	0.957	0.587	binding assay, mutational analysis	BG505 SOSIP.664: V182F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	191	gp120, V2	Y	0.161	0.187	0.106	binding assay, mutational analysis	BG505 SOSIP.664: Y191F/W reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	194	gp120, V2	T	0.503	0.906	0.161	binding assay, mutational analysis	BG505 SOSIP.664: I194F, but not I194W, strongly reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	198	gp120	T	0.458	0.264	0.469	binding assay, mutational analysis	BG505 SOSIP.664: T198F/W enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	307	gp120, V3 loop	I	0.067	0.030	0.111	binding assay, mutational analysis	BG505 SOSIP.664: I307F, but not I307W, enhanced binding w/out sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	421	gp120, beta20/beta21	K	0.312	0.374	0.203	binding assay, mutational analysis	BG505 SOSIP.664: K421F/W reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	422	gp120, beta20/beta21	Q	0.054	0.046	0.031	binding assay, mutational analysis	BG505 SOSIP.664: Q422F/W reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	432	gp120, beta20/beta21	K	1.137	0.339	0.564	binding assay, mutational analysis	BG505 SOSIP.664: Q432P, but not Q432F/W, reduced binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	433	gp120, beta20/beta21	A	0.050	0.023	0.037	binding assay, mutational analysis	BG505 SOSIP.664: A433P abrogated binding w/ sCD4
402	mutations affecting 17b binding	CD4i	Kwon2015	binding	17b	530	gp41	M	0.017	0.024	0.000	binding assay, mutational analysis	BG505 SOSIP.664: M530W enhanced binding w/out sCD4
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	69	gp120	W	0.008	0.000	0.008	binding assay, mutational analysis	BG505 SOSIP.664: W69P reduced binding
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	110	gp120	S	0.187	0.214	0.196	binding assay, mutational analysis	BG505 SOSIP.664: S110W reduced binding
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	117	gp120	K	0.199	0.084	0.120	binding assay, mutational analysis	BG505 SOSIP.664: K117W reduced binding
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	118	gp120	P	0.018	0.006	0.022	binding assay, mutational analysis	BG505 SOSIP.664: P118W reduced binding
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	223	gp120	F	0.692	0.166	0.328	binding assay, mutational analysis	BG505 SOSIP.664: F223W reduced binding
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	316	gp120, V3 loop	A	1.151	0.736	0.966	binding assay, mutational analysis	BG505 SOSIP.664: 316W reduced binding
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	427	gp120, beta20/beta21	W	0.052	0.061	0.038	binding assay, mutational analysis	BG505 SOSIP.664: W427I, but not W427M, reduced binding
403	mutations affecting VRC26.09 binding	V2-apex	Chuang2017	binding	VRC26.09	429	gp120, beta20/beta21	K	1.406	0.961	1.308	binding assay, mutational analysis	BG505 SOSIP.664: R429L, but not R429N, reduced binding
404	mutations affecting PGT145 binding	V2-apex	Chuang2017	binding	PGT145	110	gp120	S	0.187	0.214	0.196	binding assay, mutational analysis	BG505 SOSIP.664: S110W reduced binding
404	mutations affecting PGT145 binding	V2-apex	Chuang2017	binding	PGT145	117	gp120	K	0.199	0.084	0.120	binding assay, mutational analysis	BG505 SOSIP.664: K117W reduced binding
405	mutations affecting PGT122 binding	V3-glycan	Chuang2017	binding	PGT122	110	gp120	S	0.187	0.214	0.196	binding assay, mutational analysis	BG505 SOSIP.664: S110W reduced binding
405	mutations affecting PGT122 binding	V3-glycan	Chuang2017	binding	PGT122	208	gp120	V	0.595	0.750	0.262	binding assay, mutational analysis	BG505 SOSIP.664: V208F, but not V208W, reduced binding
406	mutation affecting PGT151 binding	gp41 fusion domain	Chuang2017	binding	PGT151	69	gp120	W	0.008	0.000	0.008	binding assay, mutational analysis	BG505 SOSIP.664: W69P reduced binding
407	mutations affecting F105 binding	CD4BS	Chuang2017	binding	F105	115	gp120	S	0.128	0.058	0.167	binding assay, mutational analysis	BG505 SOSIP.664: S115W enhanced binding
407	mutations affecting F105 binding	CD4BS	Chuang2017	binding	F105	202	gp120	T	0.639	0.291	0.547	binding assay, mutational analysis	BG505 SOSIP.664: T202P enhanced binding
407	mutations affecting F105 binding	CD4BS	Chuang2017	binding	F105	208	gp120	V	0.595	0.750	0.262	binding assay, mutational analysis	BG505 SOSIP.664: V208F, but not V208W, enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	70	gp120	A	0.025	0.017	0.023	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, A70Y/F enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	75	gp120	V	0.013	0.006	0.008	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, V75W/F/M enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	110	gp120	S	0.187	0.214	0.196	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, S110W enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	111	gp120	L	0.122	0.048	0.221	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, L111F (but not F111Y) enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	115	gp120	S	0.128	0.058	0.167	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, S115W enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	118	gp120	P	0.018	0.006	0.022	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, P118W enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	120	gp120	V	0.073	0.046	0.046	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, V120W/T strongly enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	159	gp120, V2	F	0.165	0.034	0.038	binding assay, mutational analysis	BG505 SOSIP.664: with sCD4, F159Y reduced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	202	gp120	T	0.639	0.291	0.547	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, T202P very strongly enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	208	gp120	V	0.595	0.750	0.262	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, V208W/F enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	223	gp120	F	0.692	0.166	0.328	binding assay, mutational analysis	BG505 SOSIP.664: with sCD4, F223W strongly reduced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, I309W strongly enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	316	gp120, V3 loop	A	1.151	0.736	0.966	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, 316W enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	323	gp120, V3 loop	I	0.575	0.531	0.263	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, I323Y enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	427	gp120, beta20/beta21	W	0.052	0.061	0.038	binding assay, mutational analysis	BG505 SOSIP.664: with sCD4, W427I (but not W427M) strongly reduced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	429	gp120, beta20/beta21	K	1.406	0.961	1.308	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, R429N (but not R429L) enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	573	gp41, Leu/Ile zipper-like sequence	I	0.081	0.079	0.050	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, I573T strongly enhanced binding
408	mutations affecting 17b binding	CD4i	Chuang2017	binding	17b	594	gp41	G	0.056	0.042	0.073	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, G594N enhanced binding
409	mutations affecting 447-52D binding	V3-glycan	Chuang2017	binding	447-52D	159	gp120, V2	F	0.165	0.034	0.038	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, F159Y reduced binding
409	mutations affecting 447-52D binding	V3-glycan	Chuang2017	binding	447-52D	223	gp120	F	0.692	0.166	0.328	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, F223W reduced binding
409	mutations affecting 447-52D binding	V3-glycan	Chuang2017	binding	447-52D	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay, mutational analysis	BG505 SOSIP.664: I309W reduced binding with or without sCD4
409	mutations affecting 447-52D binding	V3-glycan	Chuang2017	binding	447-52D	427	gp120, beta20/beta21	W	0.052	0.061	0.038	binding assay, mutational analysis	BG505 SOSIP.664: with sCD4, W427I (but not W427M) reduced binding
409	mutations affecting 447-52D binding	V3-glycan	Chuang2017	binding	447-52D	544	gp41, Leu/Ile zipper-like sequence	L	0.181	0.069	0.311	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, L544Y reduced binding
409	mutations affecting 447-52D binding	V3-glycan	Chuang2017	binding	447-52D	580	gp41, Leu/Ile zipper-like sequence	I	0.362	0.440	0.134	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, V580L reduced binding
409	mutations affecting 447-52D binding	V3-glycan	Chuang2017	binding	447-52D	583	gp41, Leu/Ile zipper-like sequence	V	0.988	0.424	0.701	binding assay, mutational analysis	BG505 SOSIP.664: without sCD4, V583L strongly reduced binding
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	62	gp120	D	1.442	1.302	0.706	computational prediction, X-ray crystallography	BG505 SOSIP contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	65	gp120	V	1.035	1.023	0.310	computational prediction, X-ray crystallography	BG505 SOSIP contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	197	gp120	N	0.111	0.082	0.109	computational prediction, X-ray crystallography	BG505 SOSIP glycan contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	234	gp120	N	0.584	0.757	0.341	computational prediction, X-ray crystallography	BG505 SOSIP glycan contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	276	gp120, Loop D	N	0.120	0.063	0.169	computational prediction, X-ray crystallography	BG505 SOSIP glycan contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	301	gp120, V3 loop	N	0.261	0.176	0.104	computational prediction, X-ray crystallography	BG505 SOSIP glycan contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	362	gp120	K	1.874	1.265	1.997	computational prediction, X-ray crystallography	BG505 SOSIP glycan contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	computational prediction, X-ray crystallography	BG505 SOSIP contact
410	12A21 contacts	CD4BS	Umotoy2019	contacts	12A21	488	gp120	V	0.121	0.098	0.061	computational prediction, X-ray crystallography	BG505 SOSIP glycan contact
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	88	gp120	N	0.053	0.041	0.048	cryo-EM, X-ray crystallography	N88 and N241 are glycan contacts between ACS202 and SOSIP trimer
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	241	gp120	N	0.169	0.183	0.134	cryo-EM, X-ray crystallography	N88 and N241 are glycan contacts between ACS202 and SOSIP trimer
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	512	gp41, fusion peptide	A	0.175	0.260	0.110	cryo-EM, X-ray crystallography	the side chain of A512 is buried in a hydrophobic pocket formed by CDRL3-Y91, L94, F96, and CDRH3-Y100K
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	513	gp41, fusion peptide	V	0.711	0.736	0.506	cryo-EM, X-ray crystallography	hydrophobic interaction with CDRH3
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	515	gp41, fusion peptide	I	1.106	1.147	0.877	cryo-EM, X-ray crystallography	hydrophobic interaction with CDRH3
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	516	gp41, fusion peptide	G	0.091	0.038	0.048	cryo-EM, X-ray crystallography	G516-A517 of the FP is stabilized by ACS202
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	517	gp41, fusion peptide	A	0.147	0.109	0.058	cryo-EM, X-ray crystallography	G516-A517 of the FP is stabilized by ACS202
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	518	gp41, fusion peptide	L	1.201	1.110	0.718	cryo-EM, X-ray crystallography	G516-A517 of the FP is stabilized by ACS202
411	ACS202 contacts	gp41 fusion domain	Yuan2019	contacts	ACS202	519	gp41, fusion peptide	F	0.695	0.243	0.837	cryo-EM, X-ray crystallography	hydrophobic interaction with CDRH3
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	97	gp120	K	0.433	0.421	0.511	X-ray crystallography	HC hydrogen bond and salt bridge
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	275	gp120, Loop D	V	1.034	1.420	0.535	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	276	gp120, Loop D	N	0.120	0.063	0.169	X-ray crystallography	LC glycan contact
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	278	gp120, Loop D	T	0.657	0.715	0.481	X-ray crystallography	LC hydrogen bond
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	279	gp120, Loop D	D	0.860	0.850	0.898	X-ray crystallography	HC and LC interactions
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	HC and LC interactions
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	HC hydrogen bond
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	HC hydrogen bond and salt bridge
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	HC hydrogen bond and salt bridge
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	426	gp120, beta20/beta21	M	0.598	0.866	0.274	X-ray crystallography	HC hydrogen bond
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	427	gp120, beta20/beta21	W	0.052	0.061	0.038	X-ray crystallography	HC hydrogen bond
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	429	gp120, beta20/beta21	K	1.406	0.961	1.308	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	430	gp120, beta20/beta21	V	0.397	0.080	0.073	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	HC hydrogen bond
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	458	gp120, beta23	G	0.097	0.045	0.095	X-ray crystallography	HC and LC interactions
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	X-ray crystallography	HC and LC interactions
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	X-ray crystallography	HC and LC interactions
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	X-ray crystallography	HC and LC interactions
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	X-ray crystallography	HC and LC interactions
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	468	gp120, V5 loop, beta24	F	0.104	0.050	0.084	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	470	gp120, beta24	P	0.043	0.039	0.037	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	472	gp120	G	0.034	0.012	0.043	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	473	gp120	G	0.031	0.033	0.029	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	474	gp120	D	0.719	0.681	0.752	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	475	gp120	M	0.281	0.092	0.106	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	476	gp120	R	0.699	0.615	0.711	X-ray crystallography	HC interaction
412	2411a contacts	CD4BS	Chen2021	contacts	2411a	477	gp120	D	0.167	0.112	0.249	X-ray crystallography	HC interaction
413	PC39-55D binding	V3-glycan	Joyce2023	binding	PC39-55D	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
413	PC39-55D binding	V3-glycan	Joyce2023	binding	PC39-55D	301	gp120, V3 loop	N	0.261	0.176	0.104	alanine scanning, binding assay	N301A affects binding >50 fold
413	PC39-55D binding	V3-glycan	Joyce2023	binding	PC39-55D	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
413	PC39-55D binding	V3-glycan	Joyce2023	binding	PC39-55D	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
413	PC39-55D binding	V3-glycan	Joyce2023	binding	PC39-55D	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
413	PC39-55D binding	V3-glycan	Joyce2023	binding	PC39-55D	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	158	gp120, V2	S	0.297	0.185	0.291	alanine scanning, binding assay	S158A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	324	gp120, V3 loop	G	0.088	0.056	0.092	alanine scanning, binding assay	G324A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	326	gp120, V3 loop	M	0.188	0.143	0.116	alanine scanning, binding assay	I326A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
414	PC39-23D binding	V3-glycan	Joyce2023	binding	PC39-23D	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	158	gp120, V2	S	0.297	0.185	0.291	alanine scanning, binding assay	S158A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	301	gp120, V3 loop	N	0.261	0.176	0.104	alanine scanning, binding assay	N301A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	309	gp120, V3 loop	I	0.921	0.359	0.965	alanine scanning, binding assay	I309A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	318	gp120, V3 loop	V	0.574	0.691	0.507	alanine scanning, binding assay	Y318A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	324	gp120, V3 loop	G	0.088	0.056	0.092	alanine scanning, binding assay	G324A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	326	gp120, V3 loop	M	0.188	0.143	0.116	alanine scanning, binding assay	I326A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	330	gp120, V3 loop	H	0.743	0.559	0.655	alanine scanning, binding assay	H330A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
415	PC39-50I binding	V3-glycan	Joyce2023	binding	PC39-50I	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	324	gp120, V3 loop	G	0.088	0.056	0.092	alanine scanning, binding assay	G324A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
416	PC39-28D binding	V3-glycan	Joyce2023	binding	PC39-28D	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	301	gp120, V3 loop	N	0.261	0.176	0.104	alanine scanning, binding assay	N301A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	324	gp120, V3 loop	G	0.088	0.056	0.092	alanine scanning, binding assay	G324A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
417	PC39-50K binding	V3-glycan	Joyce2023	binding	PC39-50K	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	158	gp120, V2	S	0.297	0.185	0.291	alanine scanning, binding assay	S158A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	324	gp120, V3 loop	G	0.088	0.056	0.092	alanine scanning, binding assay	G324A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
418	PC39-23C binding	V3-glycan	Joyce2023	binding	PC39-23C	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
419	PC39-50E binding	V3-glycan	Joyce2023	binding	PC39-50E	158	gp120, V2	S	0.297	0.185	0.291	alanine scanning, binding assay	S158A affects binding >50 fold
419	PC39-50E binding	V3-glycan	Joyce2023	binding	PC39-50E	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
419	PC39-50E binding	V3-glycan	Joyce2023	binding	PC39-50E	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
419	PC39-50E binding	V3-glycan	Joyce2023	binding	PC39-50E	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
419	PC39-50E binding	V3-glycan	Joyce2023	binding	PC39-50E	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
419	PC39-50E binding	V3-glycan	Joyce2023	binding	PC39-50E	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
419	PC39-50E binding	V3-glycan	Joyce2023	binding	PC39-50E	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	158	gp120, V2	S	0.297	0.185	0.291	alanine scanning, binding assay	S158A affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	301	gp120, V3 loop	N	0.261	0.176	0.104	alanine scanning, binding assay	N301A affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
420	PC39-55C binding	V3-glycan	Joyce2023	binding	PC39-55C	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	159	gp120, V2	F	0.165	0.034	0.038	alanine scanning, binding assay	F159A affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
421	PC39-39B binding	V3-glycan	Joyce2023	binding	PC39-39B	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
422	PC39-50H binding	V3-glycan	Joyce2023	binding	PC39-50H	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
422	PC39-50H binding	V3-glycan	Joyce2023	binding	PC39-50H	325	gp120, V3 loop	N	0.653	0.622	0.622	alanine scanning, binding assay	D325A affects binding >50 fold
422	PC39-50H binding	V3-glycan	Joyce2023	binding	PC39-50H	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
422	PC39-50H binding	V3-glycan	Joyce2023	binding	PC39-50H	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
422	PC39-50H binding	V3-glycan	Joyce2023	binding	PC39-50H	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	158	gp120, V2	S	0.297	0.185	0.291	alanine scanning, binding assay	S158A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	298	gp120, V3 loop	R	0.020	0.018	0.022	alanine scanning, binding assay	R298A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	301	gp120, V3 loop	N	0.261	0.176	0.104	alanine scanning, binding assay	N301A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	307	gp120, V3 loop	I	0.067	0.030	0.111	alanine scanning, binding assay	I307A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	324	gp120, V3 loop	G	0.088	0.056	0.092	alanine scanning, binding assay	G324A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	327	gp120, V3 loop	R	0.118	0.066	0.073	alanine scanning, binding assay	R327A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	329	gp120, V3 loop	A	0.044	0.034	0.022	alanine scanning, binding assay	A329K affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	332	gp120	N	0.904	0.491	0.693	alanine scanning, binding assay	N332A affects binding >50 fold
423	PC39-50L binding	V3-glycan	Joyce2023	binding	PC39-50L	334	gp120	S	0.780	0.501	0.890	alanine scanning, binding assay	S334A affects binding >50 fold
424	1605A1, 1605A2, 1605A3, 1607A1 binding	other	vanHaaren2021	binding	1605A1, 1605A2, 1605A3, 1607A1	88	gp120	N	0.053	0.041	0.048	binding assay, negative stain EM	N88Q significantly decreases binding of 1605A2
424	1605A1, 1605A2, 1605A3, 1607A1 binding	other	vanHaaren2021	binding	1605A1, 1605A2, 1605A3, 1607A1	620	gp41	E	2.000	1.701	2.182	binding assay, negative stain EM	D620N, N624D, and E662A define the epitope
424	1605A1, 1605A2, 1605A3, 1607A1 binding	other	vanHaaren2021	binding	1605A1, 1605A2, 1605A3, 1607A1	624	gp41	N	1.565	1.592	1.486	binding assay, negative stain EM	D620N, N624D, and E662A define the epitope
424	1605A1, 1605A2, 1605A3, 1607A1 binding	other	vanHaaren2021	binding	1605A1, 1605A2, 1605A3, 1607A1	662	gp41	E	1.024	0.874	0.369	binding assay, negative stain EM	D620N, N624D, and E662A define the epitope
425	Mutation affects Env trimer stability		Leaman2013	other feature		139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	other	combination of N139del + I140del + N142S increases the thermal and chemical stability of ADA and JRFL
425	Mutation affects Env trimer stability		Leaman2013	other feature		140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	other	combination of N139del + I140del + N142S increases the thermal and chemical stability of ADA and JRFL
425	Mutation affects Env trimer stability		Leaman2013	other feature		142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972	other	combination of N139del + I140del + N142S increases the thermal and chemical stability of ADA and JRFL
425	Mutation affects Env trimer stability		Leaman2013	other feature		535	gp41	M	1.200	1.414	0.742	other	M535I increases the thermal and chemical stability of ADA and JRFL
425	Mutation affects Env trimer stability		Leaman2013	other feature		543	gp41, Leu/Ile zipper-like sequence	Q	0.529	0.768	0.202	other	L543Q increases the thermal and chemical stability of ADA and JRFL
425	Mutation affects Env trimer stability		Leaman2013	other feature		574	gp41, Leu/Ile zipper-like sequence	K	0.032	0.036	0.022	other	K574A decreases the thermostability of ADA; K574R increases the thermal and chemical stability of ADA and 3 other tested strains of subtypes A, B, and C
425	Mutation affects Env trimer stability		Leaman2013	other feature		625	gp41	H	0.220	0.185	0.214	other	combination of H625N + T626M increases the thermal and chemical stability of ADA and JRFL
425	Mutation affects Env trimer stability		Leaman2013	other feature		626	gp41	T	0.226	0.201	0.303	other	combination of H625N + T626M increases the thermal and chemical stability of ADA and JRFL
425	Mutation affects Env trimer stability		Leaman2013	other feature		649	gp41	S	0.216	0.274	0.075	other	S649A increases the thermal and chemical stability of ADA and 3 other tested strains of subtypes A, B, and C
426	Mutation increases neutralization sensitivity	CD4BS	Leaman2013	neutralization	b12, b6	574	gp41, Leu/Ile zipper-like sequence	K	0.032	0.036	0.022	neutralization assay, other	K574A decreases b6 neutralization IC50 250-fold for ADA and 49 fold for JRFL; K574A decreases b12 neutralization IC50 24-fold for ADA and 2.7 fold for JRFL
427	Mutation increases neutralization sensitivity	MPER	Leaman2013	neutralization	2F5, 4E10	574	gp41, Leu/Ile zipper-like sequence	K	0.032	0.036	0.022	neutralization assay, other	K574A decreases 2F5 neutralization IC50 91-fold for ADA and 7.2 fold for JRFL; K574A decreases 4E10 neutralization IC50 48-fold for ADA and 8.8 fold for JRFL
428	Mutation increases neutralization sensitivity	glycan	Leaman2013	neutralization	2G12	574	gp41, Leu/Ile zipper-like sequence	K	0.032	0.036	0.022	neutralization assay, other	K574A decreases 2G12 neutralization IC50 4 fold for ADA and 2 fold for JRFL
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	304	gp120, V3 loop	R	0.287	0.390	0.141	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	305	gp120, V3 loop	K	1.097	0.713	0.943	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	306	gp120, V3 loop	R	0.732	0.860	0.338	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	307	gp120, V3 loop	I	0.067	0.030	0.111	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	308	gp120, V3 loop	R	0.108	0.091	0.127	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	310	gp120, V3 loop	Q	1.564	1.479	0.283	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	311	gp120, V3 loop	R	0.768	1.050	0.114	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	312	gp120, V3 loop	G	0.189	0.362	0.008	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	313	gp120, V3 loop	P	0.307	0.424	0.078	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	314	gp120, V3 loop	G	0.053	0.095	0.014	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	316	gp120, V3 loop	A	1.151	0.736	0.966	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	317	gp120, V3 loop	F	0.758	1.090	0.223	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	318	gp120, V3 loop	V	0.574	0.691	0.507	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	319	gp120, V3 loop	T	0.995	0.913	0.339	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	320	gp120, V3 loop	I	0.720	0.564	0.782	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	321	gp120, V3 loop	G	1.031	0.842	1.108	binding assay	linear epitope binding region
431	BG505 infant V3 mAbs linear epitope	V3-glycan	Simonich2021	binding	BG505.13, BG505.34, BG505.48, BG505.49, BG505.50, BG505.56, BG505.57, BG505.61, BG505.63, BG505.68, BG505.69	322	gp120, V3 loop	K	0.370	0.347	0.283	binding assay	linear epitope binding region
432	Residue that affects binding by VRC42.01	MPER	Krebs2019	binding	VRC42.01	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay	Ala mediates an 8-fold reduction in MPER peptide binding
433	Residues that affect binding by VRC42.04	MPER	Krebs2019	binding	VRC42.04	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay	W672A mediates an ~30-fold reduction in MPER peptide binding
433	Residues that affect binding by VRC42.04	MPER	Krebs2019	binding	VRC42.04	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay	F673A mediates an ~60 fold reduction in MPER peptide binding
434	Residues that affect binding by 4E10	MPER	Krebs2019	binding	4E10	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay	W672A mediates an ~2-fold reduction in MPER peptide binding
434	Residues that affect binding by 4E10	MPER	Krebs2019	binding	4E10	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay	F673A mediates an ~2 fold reduction in MPER peptide binding
435	Residues that affect binding by VRC42.02	MPER	Krebs2019	binding	VRC42.02	671	gp41	N	0.779	0.669	0.885	alanine scanning, binding assay	N671A mediates an ~20-fold reduction in binding to MPER peptide
435	Residues that affect binding by VRC42.02	MPER	Krebs2019	binding	VRC42.02	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay	Ala mediates an ~30-fold reduction in binding to MPER peptide
435	Residues that affect binding by VRC42.02	MPER	Krebs2019	binding	VRC42.02	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay	Ala mediates an ~30-fold reduction in binding to MPER peptide
435	Residues that affect binding by VRC42.02	MPER	Krebs2019	binding	VRC42.02	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	alanine scanning, binding assay	W680A mediates an ~4-fold reduction in binding to MPER peptide
435	Residues that affect binding by VRC42.02	MPER	Krebs2019	binding	VRC42.02	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	alanine scanning, binding assay	R683A mediates an ~3-fold reduction in binding to MPER peptide
436	Mutation affects neutralization of MEL-1872	CD4BS	Heydarchi2022	neutralization	MEL-1872	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, neutralization assay	I371A decreases binding and significantly affects neutralization
436	Mutation affects neutralization of MEL-1872	CD4BS	Heydarchi2022	neutralization	MEL-1872	471	gp120, beta24	G	0.879	0.888	0.866	alanine scanning, neutralization assay	G471A decreases binding and significantly affects neutralization
437	Residues that affect binding by VRC42.03	MPER	Krebs2019	binding	VRC42.03	671	gp41	N	0.779	0.669	0.885	alanine scanning, binding assay	N671A mediates an ~20-fold reduction in binding to MPER peptide
437	Residues that affect binding by VRC42.03	MPER	Krebs2019	binding	VRC42.03	672	gp41	W	0.017	0.023	0.014	alanine scanning, binding assay	Ala mediates an ~50-fold reduction in MPER peptide binding
437	Residues that affect binding by VRC42.03	MPER	Krebs2019	binding	VRC42.03	673	gp41	F	0.058	0.065	0.073	alanine scanning, binding assay	Ala mediates an ~50 fold reduction in MPER peptide binding
437	Residues that affect binding by VRC42.03	MPER	Krebs2019	binding	VRC42.03	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	alanine scanning, binding assay	W680A mediates an ~2.5 fold reduction in binding to MPER peptide
437	Residues that affect binding by VRC42.03	MPER	Krebs2019	binding	VRC42.03	683	gp41, gp41 transmembrane	K	0.577	0.499	0.569	alanine scanning, binding assay	R683A mediates an ~2.5 fold reduction in binding to MPER peptide
438	Q563R affects binding of MPER mAbs	MPER	Joshi2020	binding	10E8, 2F5, 4E10, 7H6, Z13e1	563	gp41, Leu/Ile zipper-like sequence	Q	0.066	0.086	0.050	binding assay	Q563R allows for better binding and increased sensitivity to neutralization by MPER mAbs; Q563R dramatically decreases viral infectivity by disrupting membrane fusion and 6-helix bundle formation
439	Mutation affects NC-Cow1 neutralization	CD4BS	Sok2017	neutralization	NC-Cow1	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, neutralization assay	K282A reduces NC-Cow1 neutralization of JRCSF
439	Mutation affects NC-Cow1 neutralization	CD4BS	Sok2017	neutralization	NC-Cow1	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	alanine scanning, neutralization assay	V372A reduces NC-Cow1 neutralization of JRCSF
439	Mutation affects NC-Cow1 neutralization	CD4BS	Sok2017	neutralization	NC-Cow1	471	gp120, beta24	G	0.879	0.888	0.866	alanine scanning, neutralization assay	G471 reduces NC-Cow1 neutralization of JRCSF
439	Mutation affects NC-Cow1 neutralization	CD4BS	Sok2017	neutralization	NC-Cow1	472	gp120	G	0.034	0.012	0.043	alanine scanning, neutralization assay	V372A reduces NC-Cow1 neutralization of JRCSF
439	Mutation affects NC-Cow1 neutralization	CD4BS	Sok2017	neutralization	NC-Cow1	476	gp120	R	0.699	0.615	0.711	alanine scanning, neutralization assay	R476A reduces NC-Cow1 neutralization of JRCSF
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	83	gp120	E	0.033	0.039	0.035	binding assay, mutational analysis	E83A mutation partially affects ACS202 binding to trimer
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	87	gp120	V	1.538	1.611	1.463	binding assay, mutational analysis	E87A mutation almost completely abrogates ACS202 binding to trimer
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	88	gp120	N	0.053	0.041	0.048	binding assay, mutational analysis	N88Q mutation almost completely abrogates ACS202 binding to trimer
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	229	gp120	N	0.780	0.742	0.290	binding assay, mutational analysis	N229K mutation partially affects ACS202 binding to trimer
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	512	gp41, fusion peptide	A	0.175	0.260	0.110	binding assay, mutational analysis	A512W mutation reduces ACS202 binding to trimer substantially
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	515	gp41, fusion peptide	I	1.106	1.147	0.877	binding assay, mutational analysis	I515W mutation reduces ACS202 binding to trimer substantially
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	516	gp41, fusion peptide	G	0.091	0.038	0.048	binding assay, mutational analysis	G516W mutation reduces ACS202 binding to trimer substantially
440	Mutation affects ACS202 binding	gp41 fusion domain	vanGils2016	binding	ACS202	528	gp41	S	0.020	0.012	0.022	binding assay, mutational analysis	S528W mutation reduces ACS202 binding to trimer substantially
442	Key position for V3 mAb neutralization	V3-glycan	Mouquet2012a	neutralization	10-1074, 10-996, PGT121	332	gp120	N	0.904	0.491	0.693	neutralization assay	Position N332 is key for the binding and neutralization of PGT121, 10-1074, and 10-996, with PGT121 recognizing complex and high-mannose carbohydrates; some PGT121-sensitive strains carry mutations in the N332 gp120-associated PNGS
443	Key position for V3 mAb binding	V3-glycan	Mouquet2012a	binding	10-1074, 10-996, PGT121	332	gp120	N	0.904	0.491	0.693	binding assay	Position N332 is key for the binding and neutralization of PGT121, 10-1074, and 10-996, with PGT121 recognizing complex and high-mannose carbohydrates
444	Loss of glycan at 332 confers resistance to PGT121 and 10-1074	V3-glycan	Wang2018a	neutralization	10-1074, PGT121	332	gp120	N	0.904	0.491	0.693	neutralization assay	Loss of glycan at 332 confers resistance to PGT121 and 10-1074
445	CH59 contacts	V2-apex	Liao2013b	contacts	CH59	169	gp120, V2	V	1.974	1.770	1.344	alanine scanning, binding assay, X-ray crystallography	CH59 contact
445	CH59 contacts	V2-apex	Liao2013b	contacts	CH59	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, binding assay, X-ray crystallography	CH59 contact
445	CH59 contacts	V2-apex	Liao2013b	contacts	CH59	176	gp120, V2	F	0.166	0.303	0.042	alanine scanning, binding assay, X-ray crystallography	CH59 contact
445	CH59 contacts	V2-apex	Liao2013b	contacts	CH59	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, binding assay, X-ray crystallography	CH59 contact
446	3BC176 neutralization	CD4i	Klein2012	neutralization	3BC176	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	neutralization assay	3BC176 and 3BC315: loss of the N295 glycosylation site modestly reduces neutralization sensitivity
446	3BC176 neutralization	CD4i	Klein2012	neutralization	3BC176	406	gp120, V4-hypervariable, V4 loop	N	1.900	2.211	1.307	neutralization assay	3BC176 and 3BC315: loss of the N406 glycosylation site modestly reduces neutralization sensitivity
446	3BC176 neutralization	CD4i	Klein2012	neutralization	3BC176	448	gp120	N	0.648	0.448	0.927	neutralization assay	3BC176 and 3BC315: loss of the N448 glycosylation site modestly reduces neutralization sensitivity
446	3BC176 neutralization	CD4i	Klein2012	neutralization	3BC176	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	neutralization assay	3BC176 and 3BC315: loss of the N463 glycosylation site modestly reduces neutralization sensitivity
447	3BC315 neutralization	CD4i	Klein2012	neutralization	3BC315	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	neutralization assay	3BC176 and 3BC315: loss of the N295 glycosylation site modestly reduces neutralization sensitivity
447	3BC315 neutralization	CD4i	Klein2012	neutralization	3BC315	406	gp120, V4-hypervariable, V4 loop	N	1.900	2.211	1.307	neutralization assay	3BC176 and 3BC315: loss of the N406 glycosylation site modestly reduces neutralization sensitivity
447	3BC315 neutralization	CD4i	Klein2012	neutralization	3BC315	448	gp120	N	0.648	0.448	0.927	neutralization assay	3BC176 and 3BC315: loss of the N448 glycosylation site modestly reduces neutralization sensitivity
447	3BC315 neutralization	CD4i	Klein2012	neutralization	3BC315	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	neutralization assay	3BC176 and 3BC315: loss of the N463 glycosylation site modestly reduces neutralization sensitivity
448	3BC315 binding	CD4i	Klein2012	binding	3BC315	160	gp120, V2	N	0.401	0.452	0.358	binding assay	3BC176 and 3BC315: N160K reduces binding
448	3BC315 binding	CD4i	Klein2012	binding	3BC315	420	gp120	I	0.068	0.049	0.078	binding assay	3BC176 and 3BC315: I420R slightly enhances binding
449	3BC176 binding	CD4i	Lee2015	binding	3BC176	88	gp120	N	0.053	0.041	0.048	binding assay	3BC176 and 3BC315: N88 glycan plays a role in binding kinetics
450	3BC315 binding	CD4i	Lee2015	binding	3BC315	88	gp120	N	0.053	0.041	0.048	binding assay	3BC176 and 3BC315: N88 glycan plays a role in binding kinetics
450	3BC315 binding	CD4i	Lee2015	binding	3BC315	623	gp41	W	0.068	0.066	0.043	binding assay	3BC315: W623A abrogates binding
451	3BC315 neutralization	CD4i	Lee2015	neutralization	3BC315	619	gp41	L	1.866	1.312	1.871	neutralization assay	3BC315: L619Y reduces neutralization sensitivity
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	84	gp120	V	1.321	0.916	1.327	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	85	gp120	V	2.208	1.797	1.418	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	227	gp120	K	0.218	0.288	0.161	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	229	gp120	N	0.780	0.742	0.290	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	241	gp120	N	0.169	0.183	0.134	neutralization assay	S241N confers escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	243	gp120	S	0.058	0.058	0.051	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	Mutations confer escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	neutralization assay	V518W, V518M, and V518L confer drastic escape from VRC34.01
453	VRC34.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	VRC34.01	524	gp41, fusion peptide	G	0.127	0.129	0.125	neutralization assay	Mutations confer escape from VRC34.01
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	88	gp120	N	0.053	0.041	0.048	neutralization assay	Disrupting N88 glycan improved neutralization potency by vFP16.02
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	241	gp120	N	0.169	0.183	0.134	neutralization assay	S241N confers escape from vFP16.02
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	Mutations confer escape from vFP16.02
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	Mutations confer escape from vFP16.02
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	Mutations confer escape from vFP16.02
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	Mutations confer escape from vFP16.02
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	524	gp41, fusion peptide	G	0.127	0.129	0.125	neutralization assay	Mutations confer escape from vFP16.02
454	vFP16.02 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP16.02	611	gp41	N	0.050	0.039	0.054	neutralization assay	Disrupting N611 glycan improved neutralization potency by vFP16.02
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	88	gp120	N	0.053	0.041	0.048	neutralization assay	Disrupting N88 glycan improved neutralization potency by vFP20.01
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	241	gp120	N	0.169	0.183	0.134	neutralization assay	S241N confers escape from vFP20.01
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	neutralization assay	Mutations confer escape from vFP20.01
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	neutralization assay	Mutations confer escape from vFP20.01
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	neutralization assay	Mutations confer escape from vFP20.01
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	neutralization assay	Mutations confer escape from vFP20.01
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	524	gp41, fusion peptide	G	0.127	0.129	0.125	neutralization assay	Mutations confer escape from vFP20.01
455	vFP20.01 neutralization	gp41 fusion domain	Dingens2018, Xu2018	neutralization	vFP20.01	611	gp41	N	0.050	0.039	0.054	neutralization assay	Disrupting N611 glycan improved neutralization potency by vFP20.01
456	vFP16.02 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	vFP16.02	513	gp41, fusion peptide	V	0.711	0.736	0.506	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
456	vFP16.02 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	vFP16.02	514	gp41, fusion peptide	G	0.544	0.691	0.502	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
456	vFP16.02 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	vFP16.02	515	gp41, fusion peptide	I	1.106	1.147	0.877	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
457	vFP20.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	vFP20.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
457	vFP20.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	vFP20.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
457	vFP20.01 binding	gp41 fusion domain	Dingens2018, Xu2018	binding	vFP20.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	binding assay	Ala or Gly mutations reduce binding of VRC34.01, vFP1.01, vFP5.01, vFP7.04, vFP7.05, vFP16.02, vFP20.01
458	Mutations coupling nAb resistance with ceniciviroc sensitivity	CD4i	Kuwata2016	neutralization	4E9C	315	gp120, V3 loop	R	1.120	1.028	0.196	neutralization assay, other	R315K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
458	Mutations coupling nAb resistance with ceniciviroc sensitivity	CD4i	Kuwata2016	neutralization	4E9C	324	gp120, V3 loop	G	0.088	0.056	0.092	neutralization assay, other	G324R causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
458	Mutations coupling nAb resistance with ceniciviroc sensitivity	CD4i	Kuwata2016	neutralization	4E9C	381	gp120	E	0.044	0.045	0.028	neutralization assay, other	E381K causes resistance to NAbs 0.5γ and 4E9C, coupled with reversion to ceniciviroc-sensitivity
462	Signature Analysis Summary	V2-apex	Bricault2019	signature	PGT145	291	gp120	S	1.139	1.292	0.739	computational prediction	Amino acid P is associated with resistance
463	MPER membrane fusion mutations confer sensitivity	V3-glycan	Fu2018	neutralization	3791	670	gp41	W	0.026	0.028	0.035	neutralization assay	W670A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
463	MPER membrane fusion mutations confer sensitivity	V3-glycan	Fu2018	neutralization	3791	673	gp41	F	0.058	0.065	0.073	neutralization assay	F673A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
463	MPER membrane fusion mutations confer sensitivity	V3-glycan	Fu2018	neutralization	3791	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	neutralization assay	W680A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
464	MPER membrane fusion mutations confer sensitivity	CD4BS	Fu2018	neutralization	b6	670	gp41	W	0.026	0.028	0.035	neutralization assay	W670A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
464	MPER membrane fusion mutations confer sensitivity	CD4BS	Fu2018	neutralization	b6	673	gp41	F	0.058	0.065	0.073	neutralization assay	F673A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
464	MPER membrane fusion mutations confer sensitivity	CD4BS	Fu2018	neutralization	b6	680	gp41, gp41 transmembrane	W	0.069	0.083	0.081	neutralization assay	W680A mutants become more resistant to trimer-specific bnAbs and gain sensitivity to b6, 3791, and 17b
465	Mutation affects neutralization of 4E10	MPER	ORourke2009	neutralization	4E10	653	gp41	Q	0.018	0.028	0.008	neutralization assay	Q653R mutation gave >30-fold increase in neutralization sensitivity; this affects the assembly of the 6-helix bundle required for virus fusion, and alters the conformational equilibria favoring the prehairpin intermediate conformation required for the binding of the membrane proximal external region-specific neutralizing antibodies 2F5 and 4E10.
466	Mutation affects neutralization of 2F5	MPER	ORourke2009	neutralization	2F5	653	gp41	Q	0.018	0.028	0.008	neutralization assay	Q653R mutation gave >30-fold increase in neutralization sensitivity; this affects the assembly of the 6-helix bundle required for virus fusion, and alters the conformational equilibria favoring the prehairpin intermediate conformation required for the binding of the membrane proximal external region-specific neutralizing antibodies 2F5 and 4E10.
467	Mutation affects neutralization of 4E10	MPER	ORourke2010	neutralization	4E10	180	gp120, V2	D	0.031	0.033	0.029	neutralization assay	D180 is located within the LDI/V recognition motif of the alpha-4-beta-7 receptor binding site; the D180N mutation may induce a conformational change that exposes epitopes in both the gp120 and the gp41 portions of the envelope protein, such as the CD4 binding site and the MPER, that are normally concealed by conformational masking.
468	Mutation affects neutralization of 17b	CD4i	ORourke2010	neutralization	17b	180	gp120, V2	D	0.031	0.033	0.029	neutralization assay	D180 is located within the LDI/V recognition motif of the alpha-4-beta-7 receptor binding site; the D180N mutation may induce a conformational change that exposes epitopes in both the gp120 and the gp41 portions of the envelope protein, such as the CD4 binding site and the MPER, that are normally concealed by conformational masking.
469	Mutation affects neutralization of 2F5	MPER	ORourke2010	neutralization	2F5	180	gp120, V2	D	0.031	0.033	0.029	neutralization assay	D180 is located within the LDI/V recognition motif of the alpha-4-beta-7 receptor binding site; the D180N mutation may induce a conformational change that exposes epitopes in both the gp120 and the gp41 portions of the envelope protein, such as the CD4 binding site and the MPER, that are normally concealed by conformational masking.
470	Mutation affects neutralization of 4E10	MPER	ORourke2012	neutralization	4E10	197	gp120	N	0.111	0.082	0.109	neutralization assay	N197H confers generalized sensitivity to b12, sCD4, 4E10, but resistance to PG9, which depends on glycans.
470	Mutation affects neutralization of 4E10	MPER	ORourke2012	neutralization	4E10	384	gp120	Y	0.075	0.124	0.023	neutralization assay	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
470	Mutation affects neutralization of 4E10	MPER	ORourke2012	neutralization	4E10	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
470	Mutation affects neutralization of 4E10	MPER	ORourke2012	neutralization	4E10	589	gp41, Leu/Ile zipper-like sequence	D	0.041	0.035	0.029	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
470	Mutation affects neutralization of 4E10	MPER	ORourke2012	neutralization	4E10	668	gp41	S	0.842	0.596	0.758	neutralization assay	S668G/I675V in combination increased sensitivity to 4E10 and CD4 IgG, but not to PG16 or 17b, or VRC01
470	Mutation affects neutralization of 4E10	MPER	ORourke2012	neutralization	4E10	675	gp41	I	0.050	0.059	0.069	neutralization assay	S668G/I675V in combination increased sensitivity to 4E10 and CD4 igG, but not to PG16 or 17b, or VRC01
470	Mutation affects neutralization of 4E10	MPER	ORourke2012	neutralization	4E10	702	gp41, gp41 cytoplasmic tail	L	0.416	0.497	0.316	neutralization assay	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
471	Mutation affects neutralization of 17b	CD4i	ORourke2012	neutralization	17b	167	gp120, V2	G	0.601	1.122	0.185	neutralization assay	D167G did not change neutralization by PG9, PG16, b12, 4E10 or VRC01, but increased CD4 Ig and 17b sensitivity.
471	Mutation affects neutralization of 17b	CD4i	ORourke2012	neutralization	17b	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
471	Mutation affects neutralization of 17b	CD4i	ORourke2012	neutralization	17b	589	gp41, Leu/Ile zipper-like sequence	D	0.041	0.035	0.029	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
472	Mutation affects neutralization of b12	CD4BS	ORourke2012	neutralization	b12	197	gp120	N	0.111	0.082	0.109	neutralization assay	N197H confers generalized sensitivity to b12, sCD4, 4E10, but resistance to PG9, which depends on glycans.
472	Mutation affects neutralization of b12	CD4BS	ORourke2012	neutralization	b12	384	gp120	Y	0.075	0.124	0.023	neutralization assay	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
472	Mutation affects neutralization of b12	CD4BS	ORourke2012	neutralization	b12	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
472	Mutation affects neutralization of b12	CD4BS	ORourke2012	neutralization	b12	589	gp41, Leu/Ile zipper-like sequence	D	0.041	0.035	0.029	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
472	Mutation affects neutralization of b12	CD4BS	ORourke2012	neutralization	b12	702	gp41, gp41 cytoplasmic tail	L	0.416	0.497	0.316	neutralization assay	Y384H/L702P alone and in combination can confer sensitivity to 4E10, CD4 IgG and b12, but not to PG9/PG16 or VRC01
473	Mutation affects neutralization of PG16	V2-apex	ORourke2012	neutralization	PG16	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
473	Mutation affects neutralization of PG16	V2-apex	ORourke2012	neutralization	PG16	589	gp41, Leu/Ile zipper-like sequence	D	0.041	0.035	0.029	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
474	Mutation affects neutralization of PG9	V2-apex	ORourke2012	neutralization	PG9	197	gp120	N	0.111	0.082	0.109	neutralization assay	N197H confers generalized sensitivity to b12, sCD4, 4E10, but resistance to PG9, which depends on glycans.
474	Mutation affects neutralization of PG9	V2-apex	ORourke2012	neutralization	PG9	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
474	Mutation affects neutralization of PG9	V2-apex	ORourke2012	neutralization	PG9	589	gp41, Leu/Ile zipper-like sequence	D	0.041	0.035	0.029	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
475	Mutation affects neutralization of VRC01	CD4BS	ORourke2012	neutralization	VRC01	423	gp120, beta20/beta21	I	0.383	0.383	0.411	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, and 4E10, but simultaneously confers resistance to PG9, PG16, and VRC01
475	Mutation affects neutralization of VRC01	CD4BS	ORourke2012	neutralization	VRC01	589	gp41, Leu/Ile zipper-like sequence	D	0.041	0.035	0.029	neutralization assay	I423T/G589D combination confers enhanced sensitivity to CD4 IgG, b12, 17b, 4E10, but resistance to PG9, PG16, VRC01
476	Disulfide bond introduced in V1V2 affects binding of 2G12	glycan	deTaeye2019	binding	2G12	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
476	Disulfide bond introduced in V1V2 affects binding of 2G12	glycan	deTaeye2019	binding	2G12	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
476	Disulfide bond introduced in V1V2 affects binding of 2G12	glycan	deTaeye2019	binding	2G12	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
477	Disulfide bond introduced in V1V2 affects binding of CH01	V2-apex	deTaeye2019	binding	CH01	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
477	Disulfide bond introduced in V1V2 affects binding of CH01	V2-apex	deTaeye2019	binding	CH01	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
477	Disulfide bond introduced in V1V2 affects binding of CH01	V2-apex	deTaeye2019	binding	CH01	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
477	Disulfide bond introduced in V1V2 affects binding of CH01	V2-apex	deTaeye2019	binding	CH01	184	gp120, V2	I	1.060	0.599	0.530	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
477	Disulfide bond introduced in V1V2 affects binding of CH01	V2-apex	deTaeye2019	binding	CH01	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
478	Disulfide bond introduced in V1V2 affects neutralization of CH01	V2-apex	deTaeye2019	neutralization	CH01	184	gp120, V2	I	1.060	0.599	0.530	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
478	Disulfide bond introduced in V1V2 affects neutralization of CH01	V2-apex	deTaeye2019	neutralization	CH01	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
479	Disulfide bond introduced in V1V2 affects binding of CH103	CD4BS	deTaeye2019	binding	CH103	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
479	Disulfide bond introduced in V1V2 affects binding of CH103	CD4BS	deTaeye2019	binding	CH103	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
479	Disulfide bond introduced in V1V2 affects binding of CH103	CD4BS	deTaeye2019	binding	CH103	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
479	Disulfide bond introduced in V1V2 affects binding of CH103	CD4BS	deTaeye2019	binding	CH103	184	gp120, V2	I	1.060	0.599	0.530	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
479	Disulfide bond introduced in V1V2 affects binding of CH103	CD4BS	deTaeye2019	binding	CH103	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
480	Disulfide bond introduced in V1V2 affects neutralization of CH103	CD4BS	deTaeye2019	neutralization	CH103	184	gp120, V2	I	1.060	0.599	0.530	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
480	Disulfide bond introduced in V1V2 affects neutralization of CH103	CD4BS	deTaeye2019	neutralization	CH103	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
481	Disulfide bond introduced in V1V2 affects binding of PG16	V2-apex	deTaeye2019	binding	PG16	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
481	Disulfide bond introduced in V1V2 affects binding of PG16	V2-apex	deTaeye2019	binding	PG16	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
481	Disulfide bond introduced in V1V2 affects binding of PG16	V2-apex	deTaeye2019	binding	PG16	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
481	Disulfide bond introduced in V1V2 affects binding of PG16	V2-apex	deTaeye2019	binding	PG16	184	gp120, V2	I	1.060	0.599	0.530	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
481	Disulfide bond introduced in V1V2 affects binding of PG16	V2-apex	deTaeye2019	binding	PG16	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
482	Disulfide bond introduced in V1V2 affects neutralization of PG16	V2-apex	deTaeye2019	neutralization	PG16	184	gp120, V2	I	1.060	0.599	0.530	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
482	Disulfide bond introduced in V1V2 affects neutralization of PG16	V2-apex	deTaeye2019	neutralization	PG16	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
483	Disulfide bond introduced in V1V2 affects binding of PG9	V2-apex	deTaeye2019	binding	PG9	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
483	Disulfide bond introduced in V1V2 affects binding of PG9	V2-apex	deTaeye2019	binding	PG9	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
483	Disulfide bond introduced in V1V2 affects binding of PG9	V2-apex	deTaeye2019	binding	PG9	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
483	Disulfide bond introduced in V1V2 affects binding of PG9	V2-apex	deTaeye2019	binding	PG9	184	gp120, V2	I	1.060	0.599	0.530	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
483	Disulfide bond introduced in V1V2 affects binding of PG9	V2-apex	deTaeye2019	binding	PG9	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
484	Disulfide bond introduced in V1V2 affects neutralization of PG9	V2-apex	deTaeye2019	neutralization	PG9	184	gp120, V2	I	1.060	0.599	0.530	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
484	Disulfide bond introduced in V1V2 affects neutralization of PG9	V2-apex	deTaeye2019	neutralization	PG9	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
485	Disulfide bond introduced in V1V2 affects neutralization of PGDM1400	V2-apex	deTaeye2019	neutralization	PGDM1400	184	gp120, V2	I	1.060	0.599	0.530	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
485	Disulfide bond introduced in V1V2 affects neutralization of PGDM1400	V2-apex	deTaeye2019	neutralization	PGDM1400	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	mutational analysis, neutralization assay	Double mutant I184C/E190C increased sensitivity to neutralization by V2 bNAbs (5-fold for PG9, 3-fold for PG16, 6-fold for CH01, 3-fold for PGDM1400, 10-fold for CH103); mutants introduce a stabilizing disulfide bond
486	Disulfide bond introduced in V1V2 affects binding of PGT121	V3-glycan	deTaeye2019	binding	PGT121	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
486	Disulfide bond introduced in V1V2 affects binding of PGT121	V3-glycan	deTaeye2019	binding	PGT121	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
486	Disulfide bond introduced in V1V2 affects binding of PGT121	V3-glycan	deTaeye2019	binding	PGT121	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
487	Disulfide bond introduced in V1V2 affects binding of PGT145	V2-apex	deTaeye2019	binding	PGT145	184	gp120, V2	I	1.060	0.599	0.530	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
487	Disulfide bond introduced in V1V2 affects binding of PGT145	V2-apex	deTaeye2019	binding	PGT145	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
488	Disulfide bond introduced in V1V2 affects binding of PGT151	gp41 fusion domain	deTaeye2019	binding	PGT151	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
488	Disulfide bond introduced in V1V2 affects binding of PGT151	gp41 fusion domain	deTaeye2019	binding	PGT151	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
488	Disulfide bond introduced in V1V2 affects binding of PGT151	gp41 fusion domain	deTaeye2019	binding	PGT151	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
489	Disulfide bond introduced in V1V2 affects binding of VRC01	CD4BS	deTaeye2019	binding	VRC01	152	gp120, V1-hypervariable, V1	G	1.857	1.271	1.966	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
489	Disulfide bond introduced in V1V2 affects binding of VRC01	CD4BS	deTaeye2019	binding	VRC01	153	gp120, V1	E	0.978	0.592	1.034	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
489	Disulfide bond introduced in V1V2 affects binding of VRC01	CD4BS	deTaeye2019	binding	VRC01	178	gp120, V2	K	1.232	1.386	0.988	binding assay, mutational analysis	PGT121, PG9, PG16, CH01, and CH103 bound better to the E153C/R178C/G152E triple mutant, which includes a stabilizing disulfide bond
490	Disulfide bond introduced in V1V2 affects binding of VRC26.09	V2-apex	deTaeye2019	binding	VRC26.09	184	gp120, V2	I	1.060	0.599	0.530	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
490	Disulfide bond introduced in V1V2 affects binding of VRC26.09	V2-apex	deTaeye2019	binding	VRC26.09	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	binding assay, mutational analysis	Double mutant I184C/E190C increased binding by V2 bNAbs (PG9, PG16, PGT145, VRC26.09, CH01) and by CH103; these mutations introduce a stablizing disulfide bond
491	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	2158	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
491	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	2158	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
492	Mutations at the trimer apex affect sensitivity	MPER	Guzzo2018	neutralization	4E10	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
492	Mutations at the trimer apex affect sensitivity	MPER	Guzzo2018	neutralization	4E10	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
493	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	17b	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
493	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	17b	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
494	Mutations at the trimer apex affect sensitivity	MPER	Guzzo2018	neutralization	2F5	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
494	Mutations at the trimer apex affect sensitivity	MPER	Guzzo2018	neutralization	2F5	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
495	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	412d	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
495	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	412d	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
495	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	412d	300	gp120, V3 loop	N	1.159	0.738	1.054	alanine scanning, neutralization assay	N300A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
495	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	412d	305	gp120, V3 loop	K	1.097	0.713	0.943	alanine scanning, neutralization assay	K305A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
496	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	447-52D	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
496	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	447-52D	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
496	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	447-52D	300	gp120, V3 loop	N	1.159	0.738	1.054	alanine scanning, neutralization assay	N300A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
496	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	447-52D	305	gp120, V3 loop	K	1.097	0.713	0.943	alanine scanning, neutralization assay	K305A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
497	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	48d	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
497	Mutations at the trimer apex affect sensitivity	CD4i	Guzzo2018	neutralization	48d	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
498	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	654-D	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
498	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	654-D	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y177A increased neutralization sensitivity; Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
499	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	b13	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
499	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	b13	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
500	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	CH103	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
500	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	CH103	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
501	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	F105	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
501	Mutations at the trimer apex affect sensitivity	CD4BS	Guzzo2018	neutralization	F105	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
502	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	F425 B4e8	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
502	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	F425 B4e8	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
503	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	PG16	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
503	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	PG16	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
504	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	PG9	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
504	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	PG9	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
504	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	PG9	300	gp120, V3 loop	N	1.159	0.738	1.054	alanine scanning, neutralization assay	N300A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
504	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	PG9	305	gp120, V3 loop	K	1.097	0.713	0.943	alanine scanning, neutralization assay	K305A increased viral sensitivity for 412d and 447-52D, but decreased sensitivity for PG9
505	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT121	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
505	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT121	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
506	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT122	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
506	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT122	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
507	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT123	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
507	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT123	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
508	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT125	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
508	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT125	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
509	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT126	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
509	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT126	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
510	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT128	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
510	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT128	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
511	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT130	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
511	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT130	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
512	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT135	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
512	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	PGT135	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
513	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	VRC24	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
513	Mutations at the trimer apex affect sensitivity	V3-glycan	Guzzo2018	neutralization	VRC24	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
514	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	VRC26.08	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
514	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	VRC26.08	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
515	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	VRC38.01	173	gp120, V2	Y	1.165	0.808	1.158	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
515	Mutations at the trimer apex affect sensitivity	V2-apex	Guzzo2018	neutralization	VRC38.01	177	gp120, V2	Y	0.349	0.638	0.144	alanine scanning, neutralization assay	Y173A/Y177A double mutation increased viral sensitivity to weak and non-neutralizing mAbs (447-52D, b13, F105, 412D, 654-30D, 48d, F425 B4e8, 2158, 17b) and 2 strongly-neutralizing mAbs (4E10 and 2F5). Conversely, this double mutation decreased viral sensitivity to many strongly-neutralizing mAbs (PG9, PG16, VRC26.08, VRC38, PGT121, PGT122, PGT123, PGT125, PGT126, PGT128, PGT130, PGT135, VRC24, CH103).
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		32	gp120	E	1.683	1.314	0.968	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		33	gp120	K	1.441	1.559	0.973	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		85	gp120	V	2.208	1.797	1.418	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		87	gp120	V	1.538	1.611	1.463	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		97	gp120	K	0.433	0.421	0.511	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		130	gp120	K	1.274	0.883	1.495	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		134	gp120, V1-hypervariable, V1	L	2.183	2.322	1.627	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		135	gp120, V1-hypervariable, V1	K	2.174	2.373	1.848	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		136	gp120, V1-hypervariable, V1	N	2.544	2.300	2.581	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		138	gp120, V1-hypervariable, V1	T	2.336	2.112	2.504	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		139	gp120, V1-hypervariable, V1	N	2.188	1.946	2.163	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		140	gp120, V1-hypervariable, V1	T	2.271	2.104	2.340	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		141	gp120, V1-hypervariable, V1	N	2.221	2.077	2.148	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		142	gp120, V1-hypervariable, V1	S	2.041	1.992	1.972	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		145	gp120, V1-hypervariable, V1	G	2.331	2.228	2.255	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		146	gp120, V1-hypervariable, V1	R	2.697	2.583	2.629	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		151	gp120, V1-hypervariable, V1	K	2.576	2.285	2.605	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		268	gp120	E	1.220	0.886	1.275	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		271	gp120	V	1.230	0.623	0.635	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		275	gp120, Loop D	V	1.034	1.420	0.535	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		322	gp120, V3 loop	K	0.370	0.347	0.283	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		332	gp120	N	0.904	0.491	0.693	computational prediction	N332 glycosylation is associated with lower probability of the development of neutralizing antibody responses; the motif NLS is more often associated with development of neutralizing antibody responses, as compared with NIS.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		333	gp120	I	0.901	0.855	0.293	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		336	gp120	A	2.124	1.826	2.418	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		337	gp120	K	2.008	1.862	2.151	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		343	gp120	K	2.024	1.978	1.742	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		346	gp120	A	1.871	1.083	1.831	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		347	gp120	S	2.083	2.161	1.508	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		396	gp120, V4-hypervariable, V4 loop	F	2.411	2.159	2.350	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		399	gp120, V4-hypervariable, V4 loop	T	2.436	2.243	2.452	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		403	gp120, V4-hypervariable, V4 loop	E	2.442	2.430	2.183	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		404	gp120, V4-hypervariable, V4 loop	G	2.186	2.199	1.740	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		405	gp120, V4-hypervariable, V4 loop	S	2.165	2.388	1.715	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		406	gp120, V4-hypervariable, V4 loop	N	1.900	2.211	1.307	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		407	gp120, V4-hypervariable, V4 loop	N	1.624	1.992	1.038	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		412	gp120, V4 loop	D	2.190	2.094	2.182	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		440	gp120	S	1.932	1.712	1.017	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		464	gp120, V5-hypervariable, V5 loop	E	2.371	2.269	2.299	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
516	Env sites associated with development of nAb responses		vandenKerkhof2013	Env feature		621	gp41	Q	1.713	2.097	1.208	computational prediction	Specific amino acid motifs at this position are statistically associated with the development of cross-reactive neutralizing antibody responses.
517	mutation increases sensitivity to 4E10	MPER	Blish2008	neutralization	4E10	569	gp41, Leu/Ile zipper-like sequence	T	0.028	0.017	0.022	neutralization assay	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
517	mutation increases sensitivity to 4E10	MPER	Blish2008	neutralization	4E10	675	gp41	I	0.050	0.059	0.069	neutralization assay	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
518	mutation increases sensitivity to b12	CD4BS	Blish2008	neutralization	b12	569	gp41, Leu/Ile zipper-like sequence	T	0.028	0.017	0.022	neutralization assay	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
518	mutation increases sensitivity to b12	CD4BS	Blish2008	neutralization	b12	675	gp41	I	0.050	0.059	0.069	neutralization assay	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
519	mutation increases sensitivity to 2F5	MPER	Blish2008	neutralization	2F5	569	gp41, Leu/Ile zipper-like sequence	T	0.028	0.017	0.022	neutralization assay	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
519	mutation increases sensitivity to 2F5	MPER	Blish2008	neutralization	2F5	675	gp41	I	0.050	0.059	0.069	neutralization assay	T569A, I675V, and their double mutation increase the neutralization sensitivity of nAbs 4E10, 2F5, and b12 
520	mutation increases sensitivity to 4E10	MPER	Ringe2012a	neutralization	4E10	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036	neutralization assay	Y681H increases neutralization sensitivity of nAbs 4E10, 2F5, and b12 
521	mutation increases sensitivity to b12	CD4BS	Ringe2012a	neutralization	b12	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036	neutralization assay	Y681H increases neutralization sensitivity of nAbs 4E10, 2F5, and b12 
522	mutation increases sensitivity to 2F5	MPER	Ringe2012a	neutralization	2F5	681	gp41, gp41 transmembrane	Y	0.021	0.012	0.036	neutralization assay	Y681H increases neutralization sensitivity of nAbs 4E10, 2F5, and b12 
523	mutation increases sensitivity to 4E10	MPER	Shen2010	neutralization	4E10	669	gp41	L	0.020	0.023	0.000	neutralization assay	L669S increases neutralization sensitivity of nAbs 4E10 and 2F5
524	mutation increases sensitivity to 2F5	MPER	Shen2010	neutralization	2F5	669	gp41	L	0.020	0.023	0.000	neutralization assay	L669S increases neutralization sensitivity of nAbs 4E10 and 2F5
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	275	gp120, Loop D	V	1.034	1.420	0.535	X-ray crystallography	NC-Cow1 contact; buried surface area 1.3 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	279	gp120, Loop D	D	0.860	0.850	0.898	X-ray crystallography	NC-Cow1 contact; buried surface area 9.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	NC-Cow1 contact; buried surface area 16.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	NC-Cow1 contact; buried surface area 50.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	NC-Cow1 contact; buried surface area 28.1 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	NC-Cow1 contact; buried surface area 33.4 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	X-ray crystallography	NC-Cow1 contact; buried surface area 32.7 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	NC-Cow1 contact; buried surface area 22.4 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	NC-Cow1 contact; buried surface area 35 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	NC-Cow1 contact; buried surface area 26 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	NC-Cow1 contact; buried surface area 54.3 Angstroms on BG505 SOSIP.664; salt bridge contact (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	X-ray crystallography	NC-Cow1 contact; buried surface area 2.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	NC-Cow1 contact; buried surface area 34.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	X-ray crystallography	NC-Cow1 contact; buried surface area 59.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	X-ray crystallography	NC-Cow1 contact; buried surface area 4.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	375	gp120	S	0.790	0.753	0.372	X-ray crystallography	NC-Cow1 contact; buried surface area 2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	425	gp120, beta20/beta21	N	0.405	0.138	0.177	X-ray crystallography	NC-Cow1 contact; buried surface area 5.3 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	426	gp120, beta20/beta21	M	0.598	0.866	0.274	X-ray crystallography	NC-Cow1 contact; buried surface area 22.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	X-ray crystallography	NC-Cow1 contact; buried surface area 0.6 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	429	gp120, beta20/beta21	K	1.406	0.961	1.308	X-ray crystallography	NC-Cow1 contact; buried surface area 11.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	NC-Cow1 contact; buried surface area 37.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	NC-Cow1 contact; buried surface area 12.9 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	457	gp120, beta23	D	0.059	0.054	0.043	X-ray crystallography	NC-Cow1 contact; buried surface area 18.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	X-ray crystallography	NC-Cow1 contact; buried surface area 46.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	470	gp120, beta24	P	0.043	0.039	0.037	X-ray crystallography	NC-Cow1 contact; buried surface area 5.5 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	NC-Cow1 contact; buried surface area 21.1 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	472	gp120	G	0.034	0.012	0.043	X-ray crystallography	NC-Cow1 contact; buried surface area 4.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	473	gp120	G	0.031	0.033	0.029	X-ray crystallography	NC-Cow1 contact; buried surface area 45.8 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	474	gp120	D	0.719	0.681	0.752	X-ray crystallography	NC-Cow1 contact; buried surface area 28.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	475	gp120	M	0.281	0.092	0.106	X-ray crystallography	NC-Cow1 contact; buried surface area 15.4 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	476	gp120	R	0.699	0.615	0.711	X-ray crystallography	NC-Cow1 contact; buried surface area 4.3 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
525	NC-Cow1 contacts	CD4BS	Stanfield2020	contacts	NC-Cow1	477	gp120	D	0.167	0.112	0.249	X-ray crystallography	NC-Cow1 contact; buried surface area 6.2 Angstroms on BG505 SOSIP.664 (PDB 6OPA)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	49	gp120	T	1.652	0.958	0.335	X-ray crystallography	NIH45-46 scFv contact; buried surface area 17.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	96	gp120	W	0.054	0.091	0.020	X-ray crystallography	NIH45-46 scFv contact; buried surface area 12.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	97	gp120	K	0.433	0.421	0.511	X-ray crystallography	NIH45-46 scFv contact; buried surface area 29.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	98	gp120	N	0.034	0.045	0.022	X-ray crystallography	NIH45-46 scFv contact; buried surface area 5.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	99	gp120	D	1.169	0.830	0.366	X-ray crystallography	NIH45-46 scFv contact; buried surface area 16.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	102	gp120	E	0.792	0.522	0.426	X-ray crystallography	NIH45-46 scFv contact; buried surface area 31.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	105	gp120	H	0.479	0.429	0.187	X-ray crystallography	NIH45-46 scFv contact; buried surface area 12.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	109	gp120	I	0.101	0.116	0.051	X-ray crystallography	NIH45-46 scFv contact; buried surface area 3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	197	gp120	N	0.111	0.082	0.109	X-ray crystallography	NIH45-46 scFv contact; buried surface area 8.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	198	gp120	T	0.458	0.264	0.469	X-ray crystallography	NIH45-46 scFv contact; buried surface area 33.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	199	gp120	S	0.086	0.108	0.068	X-ray crystallography	NIH45-46 scFv contact; buried surface area 12.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	275	gp120, Loop D	V	1.034	1.420	0.535	X-ray crystallography	NIH45-46 scFv contact; buried surface area 27.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	276	gp120, Loop D	N	0.120	0.063	0.169	X-ray crystallography	NIH45-46 scFv contact; buried surface area 19.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	278	gp120, Loop D	T	0.657	0.715	0.481	X-ray crystallography	NIH45-46 scFv contact; buried surface area 42.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	279	gp120, Loop D	D	0.860	0.850	0.898	X-ray crystallography	NIH45-46 scFv contact; buried surface area 42.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	NIH45-46 scFv contact; buried surface area 47.7 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	NIH45-46 scFv contact; buried surface area 55.7 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	NIH45-46 scFv contact; buried surface area 30.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	NIH45-46 scFv contact; buried surface area 29.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	X-ray crystallography	NIH45-46 scFv contact; buried surface area 5.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	NIH45-46 scFv contact; buried surface area 47.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	NIH45-46 scFv contact; buried surface area 20.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	NIH45-46 scFv contact; buried surface area 18.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	NIH45-46 scFv contact; buried surface area 35.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	NIH45-46 scFv contact; buried surface area 2.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	X-ray crystallography	NIH45-46 scFv contact; buried surface area 35.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	425	gp120, beta20/beta21	N	0.405	0.138	0.177	X-ray crystallography	NIH45-46 scFv contact; buried surface area 11.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	427	gp120, beta20/beta21	W	0.052	0.061	0.038	X-ray crystallography	NIH45-46 scFv contact; buried surface area 21.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	428	gp120, beta20/beta21	Q	0.052	0.053	0.054	X-ray crystallography	NIH45-46 scFv contact; buried surface area 66 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	430	gp120, beta20/beta21	V	0.397	0.080	0.073	X-ray crystallography	NIH45-46 scFv contact; buried surface area 41.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	NIH45-46 scFv contact; buried surface area 38.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	NIH45-46 scFv contact; buried surface area 19.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	457	gp120, beta23	D	0.059	0.054	0.043	X-ray crystallography	NIH45-46 scFv contact; buried surface area 54.3 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	458	gp120, beta23	G	0.097	0.045	0.095	X-ray crystallography	NIH45-46 scFv contact; buried surface area 40.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	X-ray crystallography	NIH45-46 scFv contact; buried surface area 38.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	X-ray crystallography	NIH45-46 scFv contact; buried surface area 36.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	X-ray crystallography	NIH45-46 scFv contact; buried surface area 48.7 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	X-ray crystallography	NIH45-46 scFv contact; buried surface area 1.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	X-ray crystallography	NIH45-46 scFv contact; buried surface area 10.4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	465	gp120, V5-hypervariable, V5 loop, beta24	S	1.613	1.466	1.517	X-ray crystallography	NIH45-46 scFv contact; buried surface area 18.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	466	gp120, V5 loop, beta24	E	0.177	0.091	0.239	X-ray crystallography	NIH45-46 scFv contact; buried surface area 4 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	X-ray crystallography	NIH45-46 scFv contact; buried surface area 27.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	X-ray crystallography	NIH45-46 scFv contact; buried surface area 34.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	470	gp120, beta24	P	0.043	0.039	0.037	X-ray crystallography	NIH45-46 scFv contact; buried surface area 3.1 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	NIH45-46 scFv contact; buried surface area 7.2 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	472	gp120	G	0.034	0.012	0.043	X-ray crystallography	NIH45-46 scFv contact; buried surface area 1.5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	473	gp120	G	0.031	0.033	0.029	X-ray crystallography	NIH45-46 scFv contact; buried surface area 30.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	474	gp120	D	0.719	0.681	0.752	X-ray crystallography	NIH45-46 scFv contact; buried surface area 39 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	475	gp120	M	0.281	0.092	0.106	X-ray crystallography	NIH45-46 scFv contact; buried surface area 9.9 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	476	gp120	R	0.699	0.615	0.711	X-ray crystallography	NIH45-46 scFv contact; buried surface area 34.8 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	477	gp120	D	0.167	0.112	0.249	X-ray crystallography	NIH45-46 scFv contact; buried surface area 5 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
526	NIH45-46 scFv contacts	CD4BS	Stanfield2020	contacts	NIH45-46	480	gp120	R	0.050	0.047	0.049	X-ray crystallography	NIH45-46 scFv contact; buried surface area 14.6 Angstroms on BG505 SOSIP.664 (PDB 5D9Q)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	96	gp120	W	0.054	0.091	0.020	X-ray crystallography	VRC13 contact; buried surface area 21.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	97	gp120	K	0.433	0.421	0.511	X-ray crystallography	VRC13 contact; buried surface area 10.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	275	gp120, Loop D	V	1.034	1.420	0.535	X-ray crystallography	VRC13 contact; buried surface area 17.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	279	gp120, Loop D	D	0.860	0.850	0.898	X-ray crystallography	VRC13 contact; buried surface area 4.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	VRC13 contact; buried surface area 10.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	VRC13 contact; buried surface area 52.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	VRC13 contact; buried surface area 35.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	VRC13 contact; buried surface area 23.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	327	gp120, V3 loop	R	0.118	0.066	0.073	X-ray crystallography	VRC13 contact; buried surface area 11.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	364	gp120, CD4 binding loop	S	0.982	0.588	1.191	X-ray crystallography	VRC13 contact; buried surface area 15.8 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	VRC13 contact; buried surface area 44.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	VRC13 contact; buried surface area 45.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	VRC13 contact; buried surface area 44.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	VRC13 contact; buried surface area 48.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	369	gp120, CD4 binding loop	P	1.021	0.591	0.470	X-ray crystallography	VRC13 contact; buried surface area 57.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	VRC13 contact; buried surface area 1.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	X-ray crystallography	VRC13 contact; buried surface area 44.7 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	372	gp120, CD4 binding loop	V	1.011	0.776	0.391	X-ray crystallography	VRC13 contact; buried surface area 23.8 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	373	gp120, CD4 binding loop	T	0.953	0.872	0.371	X-ray crystallography	VRC13 contact; buried surface area 14.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	375	gp120	S	0.790	0.753	0.372	X-ray crystallography	VRC13 contact; buried surface area 21.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	384	gp120	Y	0.075	0.124	0.023	X-ray crystallography	VRC13 contact; buried surface area 18.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	419	gp120	R	0.516	0.341	0.500	X-ray crystallography	VRC13 contact; buried surface area 29.3 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	420	gp120	I	0.068	0.049	0.078	X-ray crystallography	VRC13 contact; buried surface area 6.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	421	gp120, beta20/beta21	K	0.312	0.374	0.203	X-ray crystallography	VRC13 contact; buried surface area 56.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	423	gp120, beta20/beta21	I	0.383	0.383	0.411	X-ray crystallography	VRC13 contact; buried surface area 26.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	VRC13 contact; buried surface area 43 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	457	gp120, beta23	D	0.059	0.054	0.043	X-ray crystallography	VRC13 contact; buried surface area 2.1 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	458	gp120, beta23	G	0.097	0.045	0.095	X-ray crystallography	VRC13 contact; buried surface area 4.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	X-ray crystallography	VRC13 contact; buried surface area 7.3 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	X-ray crystallography	VRC13 contact; buried surface area 20.2 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	470	gp120, beta24	P	0.043	0.039	0.037	X-ray crystallography	VRC13 contact; buried surface area 5.7 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	VRC13 contact; buried surface area 3.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	472	gp120	G	0.034	0.012	0.043	X-ray crystallography	VRC13 contact; buried surface area 6.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	473	gp120	G	0.031	0.033	0.029	X-ray crystallography	VRC13 contact; buried surface area 31.5 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	474	gp120	D	0.719	0.681	0.752	X-ray crystallography	VRC13 contact; buried surface area 23.4 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	476	gp120	R	0.699	0.615	0.711	X-ray crystallography	VRC13 contact; buried surface area 1.9 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	477	gp120	D	0.167	0.112	0.249	X-ray crystallography	VRC13 contact; buried surface area 8.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
527	VRC13 contacts	CD4BS	Stanfield2020	contacts	VRC13	480	gp120	R	0.050	0.047	0.049	X-ray crystallography	VRC13 contact; buried surface area 11.6 Angstroms on BG505 SOSIP.664 (PDB 4YDJ)
528	CD4 contacts		Stanfield2020	Env feature		124	gp120	P	0.047	0.018	0.029	X-ray crystallography	CD4 contact; buried surface area 32.5 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		125	gp120	L	0.107	0.153	0.058	X-ray crystallography	CD4 contact; buried surface area 8.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		126	gp120, Cys 126 linked to Cys 196	C	0.018	0.028	0.008	X-ray crystallography	CD4 contact; buried surface area 41.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		127	gp120	V	0.093	0.112	0.093	X-ray crystallography	CD4 contact; buried surface area 0.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		128	gp120	S	0.188	0.339	0.088	X-ray crystallography	CD4 contact; buried surface area 20.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		192	gp120, V2	K	0.847	0.835	0.851	X-ray crystallography	CD4 contact; buried surface area 23.5 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		194	gp120, V2	T	0.503	0.906	0.161	X-ray crystallography	CD4 contact; buried surface area 34.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		196	gp120, Cys 126 linked to Cys 196, V2 loop end	C	0.043	0.034	0.038	X-ray crystallography	CD4 contact; buried surface area 19 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		198	gp120	T	0.458	0.264	0.469	X-ray crystallography	CD4 contact; buried surface area 6.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		257	gp120	T	0.024	0.024	0.015	X-ray crystallography	CD4 contact; buried surface area 9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		278	gp120, Loop D	T	0.657	0.715	0.481	X-ray crystallography	CD4 contact; buried surface area 3.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		279	gp120, Loop D	D	0.860	0.850	0.898	X-ray crystallography	CD4 contact; buried surface area 34.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		280	gp120, Loop D	N	0.117	0.090	0.170	X-ray crystallography	CD4 contact; buried surface area 34.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		281	gp120, Loop D	A	1.081	0.814	1.357	X-ray crystallography	CD4 contact; buried surface area 52.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		282	gp120, Loop D	K	0.260	0.337	0.297	X-ray crystallography	CD4 contact; buried surface area 23.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		283	gp120, Loop D	T	0.992	1.091	0.474	X-ray crystallography	CD4 contact; buried surface area 26.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		365	gp120, CD4 binding loop	S	0.574	0.489	0.619	X-ray crystallography	CD4 contact; buried surface area 45.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		366	gp120, CD4 binding loop	G	0.034	0.012	0.028	X-ray crystallography	CD4 contact; buried surface area 16.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		367	gp120, CD4 binding loop	G	0.016	0.034	0.008	X-ray crystallography	CD4 contact; buried surface area 25.2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		368	gp120, CD4 binding loop	D	0.024	0.023	0.029	X-ray crystallography	CD4 contact; buried surface area 42 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		370	gp120, CD4 binding loop	E	0.035	0.017	0.055	X-ray crystallography	CD4 contact; buried surface area 16.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		371	gp120, CD4 binding loop	I	0.451	0.389	0.507	X-ray crystallography	CD4 contact; buried surface area 39.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		375	gp120	S	0.790	0.753	0.372	X-ray crystallography	CD4 contact; buried surface area 1.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		425	gp120, beta20/beta21	N	0.405	0.138	0.177	X-ray crystallography	CD4 contact; buried surface area 34.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		426	gp120, beta20/beta21	M	0.598	0.866	0.274	X-ray crystallography	CD4 contact; buried surface area 13.7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		427	gp120, beta20/beta21	W	0.052	0.061	0.038	X-ray crystallography	CD4 contact; buried surface area 29.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		428	gp120, beta20/beta21	Q	0.052	0.053	0.054	X-ray crystallography	CD4 contact; buried surface area 1.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		429	gp120, beta20/beta21	K	1.406	0.961	1.308	X-ray crystallography	CD4 contact; buried surface area 20.7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		430	gp120, beta20/beta21	V	0.397	0.080	0.073	X-ray crystallography	CD4 contact; buried surface area 90.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		431	gp120, beta20/beta21	G	0.072	0.036	0.039	X-ray crystallography	CD4 contact; buried surface area 13.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		432	gp120, beta20/beta21	K	1.137	0.339	0.564	X-ray crystallography	CD4 contact; buried surface area 5.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		455	gp120, beta23	T	0.670	0.426	0.972	X-ray crystallography	CD4 contact; buried surface area 25.4 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		456	gp120, beta23	R	0.196	0.079	0.323	X-ray crystallography	CD4 contact; buried surface area 14.7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		457	gp120, beta23	D	0.059	0.054	0.043	X-ray crystallography	CD4 contact; buried surface area 26.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		458	gp120, beta23	G	0.097	0.045	0.095	X-ray crystallography	CD4 contact; buried surface area 33.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		459	gp120, V5-hypervariable, V5 loop	G	0.292	0.205	0.268	X-ray crystallography	CD4 contact; buried surface area 10.1 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		460	gp120, V5-hypervariable, V5 loop	N	2.271	2.056	2.373	X-ray crystallography	CD4 contact; buried surface area 9.3 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	X-ray crystallography	CD4 contact; buried surface area 20.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		471	gp120, beta24	G	0.879	0.888	0.866	X-ray crystallography	CD4 contact; buried surface area 6.6 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		472	gp120	G	0.034	0.012	0.043	X-ray crystallography	CD4 contact; buried surface area 17.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		473	gp120	G	0.031	0.033	0.029	X-ray crystallography	CD4 contact; buried surface area 23.9 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		474	gp120	D	0.719	0.681	0.752	X-ray crystallography	CD4 contact; buried surface area 32.8 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		475	gp120	M	0.281	0.092	0.106	X-ray crystallography	CD4 contact; buried surface area 7 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		476	gp120	R	0.699	0.615	0.711	X-ray crystallography	CD4 contact; buried surface area 16.5 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
528	CD4 contacts		Stanfield2020	Env feature		477	gp120	D	0.167	0.112	0.249	X-ray crystallography	CD4 contact; buried surface area 2 Angstroms on BG505 SOSIP.664 (PDB 6CM3)
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	295	gp120, Lectin DC-SIGN binding site (N295-T297)	N	1.349	0.739	1.557	alanine scanning, neutralization assay	N295A increases neutralization resistance in some strains; N295A increases neutralization resistance of JRCSF 26-fold
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	330	gp120, V3 loop	H	0.743	0.559	0.655	alanine scanning, neutralization assay	N330A increases neutralization resistance in all strains tested; H330A in JRCSF confers neutralization resistance >950-fold
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	332	gp120	N	0.904	0.491	0.693	alanine scanning, neutralization assay	N332A confers neutralization resistance in all strains tested; N332A in JRCSF confers neutralization resistance >950-fold
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	339	gp120	N	1.157	1.082	1.026	alanine scanning, neutralization assay	The impact of a N339A mutation is strain specific, and can enhance PGT135 sensitivity
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	alanine scanning, neutralization assay	N386A has strain-specific effect on neutralization; N386A increases neutralization resistance of JRCSF 4.1-fold
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	392	gp120, V4 loop	N	0.561	0.454	0.804	alanine scanning, neutralization assay	N392A confers neutralization resistance in all strains tested; N392A in JRCSF confers neutralization resistance >950-fold
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	415	gp120, V4 loop	T	0.846	0.760	0.656	alanine scanning, neutralization assay	T415A increases neutralization resistance of JRCSF 5-fold
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	417	gp120, V4 loop	P	0.836	0.736	0.922	alanine scanning, neutralization assay	P417A increases neutralization resistance of JRCSF 5-fold
530	Mutation affects PGT135 neutralization	V3-glycan	Kong2013	neutralization	PGT135	419	gp120	R	0.516	0.341	0.500	alanine scanning, neutralization assay	R419A increases neutralization resistance of JRCSF 3.9-fold
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	87	gp120	V	1.538	1.611	1.463	alanine scanning, binding assay	E87A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	95	gp120	M	0.234	0.338	0.093	alanine scanning, binding assay	M95A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	125	gp120	L	0.107	0.153	0.058	alanine scanning, binding assay	L125A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	127	gp120	V	0.093	0.112	0.093	alanine scanning, binding assay	V127A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	165	gp120, V2	I	1.321	1.292	1.011	alanine scanning, binding assay	I165A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	166	gp120, V2	R	1.127	1.398	0.772	alanine scanning, binding assay	R166A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	172	gp120, V2	E	1.506	1.172	1.484	alanine scanning, binding assay	E172A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	176	gp120, V2	F	0.166	0.303	0.042	alanine scanning, binding assay	F176A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	180	gp120, V2	D	0.031	0.033	0.029	alanine scanning, binding assay	D180A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	184	gp120, V2	I	1.060	0.599	0.530	alanine scanning, binding assay	I184A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	alanine scanning, binding assay	D185A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	alanine scanning, binding assay	T190A increases b3 binding to >200% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	197	gp120	N	0.111	0.082	0.109	alanine scanning, binding assay	N197A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	199	gp120	S	0.086	0.108	0.068	alanine scanning, binding assay	S199A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	207	gp120	K	0.043	0.029	0.029	alanine scanning, binding assay	K207A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	210	gp120	F	0.191	0.056	0.107	alanine scanning, binding assay	F210A increases b3 binding to >200% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	213	gp120	I	0.060	0.048	0.065	alanine scanning, binding assay	I213A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	252	gp120	R	0.688	0.592	0.148	alanine scanning, binding assay	R252A increases b3 binding to >200% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	257	gp120	T	0.024	0.024	0.015	alanine scanning, binding assay	T257A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	276	gp120, Loop D	N	0.120	0.063	0.169	alanine scanning, binding assay	N276A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	279	gp120, Loop D	D	0.860	0.850	0.898	alanine scanning, binding assay	D279A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	350	gp120	R	1.744	1.273	1.912	alanine scanning, binding assay	R350A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	alanine scanning, binding assay	S365A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay	D368A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay	E370A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	384	gp120	Y	0.075	0.124	0.023	alanine scanning, binding assay	Y384A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	alanine scanning, binding assay	N386A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	395	gp120, V4 loop	W	1.843	0.454	2.171	alanine scanning, binding assay	W395A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	425	gp120, beta20/beta21	N	0.405	0.138	0.177	alanine scanning, binding assay	N425A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	426	gp120, beta20/beta21	M	0.598	0.866	0.274	alanine scanning, binding assay	M426A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	427	gp120, beta20/beta21	W	0.052	0.061	0.038	alanine scanning, binding assay	W427A increases b3 binding to >200% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	439	gp120	I	0.185	0.096	0.174	alanine scanning, binding assay	I439A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	450	gp120	T	0.023	0.018	0.022	alanine scanning, binding assay	T450A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	455	gp120, beta23	T	0.670	0.426	0.972	alanine scanning, binding assay	T455A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	alanine scanning, binding assay	E462A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	463	gp120, V5-hypervariable, V5 loop	N	2.057	1.967	2.042	alanine scanning, binding assay	S463A increases b3 binding to >200% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	alanine scanning, binding assay	I467A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	470	gp120, beta24	P	0.043	0.039	0.037	alanine scanning, binding assay	P470A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	472	gp120	G	0.034	0.012	0.043	alanine scanning, binding assay	G472A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	473	gp120	G	0.031	0.033	0.029	alanine scanning, binding assay	G473A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay	D474A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	475	gp120	M	0.281	0.092	0.106	alanine scanning, binding assay	M475A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	476	gp120	R	0.699	0.615	0.711	alanine scanning, binding assay	R476A decreases b3 binding to <50% of WT in strain JRCSF
531	b3 binding alanine scanning	CD4BS	Pantophlet2003	binding	b3	479	gp120	W	0.031	0.035	0.023	alanine scanning, binding assay	W479A decreases b3 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	87	gp120	V	1.538	1.611	1.463	alanine scanning, binding assay	E87A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	112	gp120	W	0.016	0.018	0.000	alanine scanning, binding assay	W112A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	113	gp120	D	0.135	0.092	0.134	alanine scanning, binding assay	D113A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	121	gp120	K	0.385	0.360	0.187	alanine scanning, binding assay	K121A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	122	gp120	L	0.120	0.101	0.121	alanine scanning, binding assay	L122A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	125	gp120	L	0.107	0.153	0.058	alanine scanning, binding assay	L125A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	127	gp120	V	0.093	0.112	0.093	alanine scanning, binding assay	V127A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	165	gp120, V2	I	1.321	1.292	1.011	alanine scanning, binding assay	I165A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	166	gp120, V2	R	1.127	1.398	0.772	alanine scanning, binding assay	R166A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	176	gp120, V2	F	0.166	0.303	0.042	alanine scanning, binding assay	F176A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	180	gp120, V2	D	0.031	0.033	0.029	alanine scanning, binding assay	D180A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	184	gp120, V2	I	1.060	0.599	0.530	alanine scanning, binding assay	I184A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	alanine scanning, binding assay	T190A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	198	gp120	T	0.458	0.264	0.469	alanine scanning, binding assay	T198A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	202	gp120	T	0.639	0.291	0.547	alanine scanning, binding assay	T202A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	207	gp120	K	0.043	0.029	0.029	alanine scanning, binding assay	K207A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	210	gp120	F	0.191	0.056	0.107	alanine scanning, binding assay	F210A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	213	gp120	I	0.060	0.048	0.065	alanine scanning, binding assay	I213A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	252	gp120	R	0.688	0.592	0.148	alanine scanning, binding assay	R252A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	256	gp120	S	0.095	0.070	0.078	alanine scanning, binding assay	S256A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	257	gp120	T	0.024	0.024	0.015	alanine scanning, binding assay	T257A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay	N262A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	273	gp120	R	0.246	0.162	0.341	alanine scanning, binding assay	R273A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	276	gp120, Loop D	N	0.120	0.063	0.169	alanine scanning, binding assay	N276A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay	K282A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	283	gp120, Loop D	T	0.992	1.091	0.474	alanine scanning, binding assay	T283A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	337	gp120	K	2.008	1.862	2.151	alanine scanning, binding assay	Q337A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	350	gp120	R	1.744	1.273	1.912	alanine scanning, binding assay	R350A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	alanine scanning, binding assay	S365A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay	G366A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay	G367A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay	E370A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	373	gp120, CD4 binding loop	T	0.953	0.872	0.371	alanine scanning, binding assay	M373A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	384	gp120	Y	0.075	0.124	0.023	alanine scanning, binding assay	Y384A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	alanine scanning, binding assay	N386A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	388	gp120, V4 loop	T	0.864	0.778	0.701	alanine scanning, binding assay	T388A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	395	gp120, V4 loop	W	1.843	0.454	2.171	alanine scanning, binding assay	W395A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	421	gp120, beta20/beta21	K	0.312	0.374	0.203	alanine scanning, binding assay	K421A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	426	gp120, beta20/beta21	M	0.598	0.866	0.274	alanine scanning, binding assay	M426A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	430	gp120, beta20/beta21	V	0.397	0.080	0.073	alanine scanning, binding assay	V430A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	432	gp120, beta20/beta21	K	1.137	0.339	0.564	alanine scanning, binding assay	K432A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	439	gp120	I	0.185	0.096	0.174	alanine scanning, binding assay	I439A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	450	gp120	T	0.023	0.018	0.022	alanine scanning, binding assay	T450A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	455	gp120, beta23	T	0.670	0.426	0.972	alanine scanning, binding assay	T455A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	456	gp120, beta23	R	0.196	0.079	0.323	alanine scanning, binding assay	R456A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay	D457A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	458	gp120, beta23	G	0.097	0.045	0.095	alanine scanning, binding assay	G458A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	alanine scanning, binding assay	N461A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	467	gp120, V5 loop, beta24	I	0.857	0.955	0.870	alanine scanning, binding assay	I467A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	alanine scanning, binding assay	R469A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	470	gp120, beta24	P	0.043	0.039	0.037	alanine scanning, binding assay	P470A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	471	gp120, beta24	G	0.879	0.888	0.866	alanine scanning, binding assay	G471A increases b6 binding to >200% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	472	gp120	G	0.034	0.012	0.043	alanine scanning, binding assay	G472A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	474	gp120	D	0.719	0.681	0.752	alanine scanning, binding assay	D474A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	475	gp120	M	0.281	0.092	0.106	alanine scanning, binding assay	M475A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	476	gp120	R	0.699	0.615	0.711	alanine scanning, binding assay	R476A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	477	gp120	D	0.167	0.112	0.249	alanine scanning, binding assay	D477A decreases b6 binding to <50% of WT in strain JRCSF
532	b6 binding alanine scanning	CD4BS	Pantophlet2003	binding	b6	479	gp120	W	0.031	0.035	0.023	alanine scanning, binding assay	W479A decreases b6 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	87	gp120	V	1.538	1.611	1.463	alanine scanning, binding assay	E87A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	112	gp120	W	0.016	0.018	0.000	alanine scanning, binding assay	W112A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	113	gp120	D	0.135	0.092	0.134	alanine scanning, binding assay	D113A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	121	gp120	K	0.385	0.360	0.187	alanine scanning, binding assay	K121A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	122	gp120	L	0.120	0.101	0.121	alanine scanning, binding assay	L122A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	123	gp120	T	0.033	0.028	0.038	alanine scanning, binding assay	T123A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	125	gp120	L	0.107	0.153	0.058	alanine scanning, binding assay	L125A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	165	gp120, V2	I	1.321	1.292	1.011	alanine scanning, binding assay	I165A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	176	gp120, V2	F	0.166	0.303	0.042	alanine scanning, binding assay	F176A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	180	gp120, V2	D	0.031	0.033	0.029	alanine scanning, binding assay	D180A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	184	gp120, V2	I	1.060	0.599	0.530	alanine scanning, binding assay	I184A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	alanine scanning, binding assay	D185A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	190	gp120, V2-hypervariable, V2	S	1.982	1.204	1.698	alanine scanning, binding assay	T190A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	197	gp120	N	0.111	0.082	0.109	alanine scanning, binding assay	N197A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	198	gp120	T	0.458	0.264	0.469	alanine scanning, binding assay	T198A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	202	gp120	T	0.639	0.291	0.547	alanine scanning, binding assay	T202A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	207	gp120	K	0.043	0.029	0.029	alanine scanning, binding assay	K207A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	213	gp120	I	0.060	0.048	0.065	alanine scanning, binding assay	I213A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	252	gp120	R	0.688	0.592	0.148	alanine scanning, binding assay	R252A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	256	gp120	S	0.095	0.070	0.078	alanine scanning, binding assay	S256A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	257	gp120	T	0.024	0.024	0.015	alanine scanning, binding assay	T257A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	262	gp120	N	0.029	0.029	0.028	alanine scanning, binding assay	N262A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	272	gp120	I	0.234	0.341	0.107	alanine scanning, binding assay	V272A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	273	gp120	R	0.246	0.162	0.341	alanine scanning, binding assay	R273A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	276	gp120, Loop D	N	0.120	0.063	0.169	alanine scanning, binding assay	N276A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	279	gp120, Loop D	D	0.860	0.850	0.898	alanine scanning, binding assay	D279A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	282	gp120, Loop D	K	0.260	0.337	0.297	alanine scanning, binding assay	K282A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	343	gp120	K	2.024	1.978	1.742	alanine scanning, binding assay	K343A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	350	gp120	R	1.744	1.273	1.912	alanine scanning, binding assay	R350A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	alanine scanning, binding assay	S365A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	366	gp120, CD4 binding loop	G	0.034	0.012	0.028	alanine scanning, binding assay	G366A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	367	gp120, CD4 binding loop	G	0.016	0.034	0.008	alanine scanning, binding assay	G367A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	368	gp120, CD4 binding loop	D	0.024	0.023	0.029	alanine scanning, binding assay	D368A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	370	gp120, CD4 binding loop	E	0.035	0.017	0.055	alanine scanning, binding assay	E370A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	371	gp120, CD4 binding loop	I	0.451	0.389	0.507	alanine scanning, binding assay	I371A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	373	gp120, CD4 binding loop	T	0.953	0.872	0.371	alanine scanning, binding assay	M373A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	384	gp120	Y	0.075	0.124	0.023	alanine scanning, binding assay	Y384A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	alanine scanning, binding assay	N386A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	388	gp120, V4 loop	T	0.864	0.778	0.701	alanine scanning, binding assay	T388A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	395	gp120, V4 loop	W	1.843	0.454	2.171	alanine scanning, binding assay	W395A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	421	gp120, beta20/beta21	K	0.312	0.374	0.203	alanine scanning, binding assay	K421A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	426	gp120, beta20/beta21	M	0.598	0.866	0.274	alanine scanning, binding assay	M426A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	427	gp120, beta20/beta21	W	0.052	0.061	0.038	alanine scanning, binding assay	W427A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	430	gp120, beta20/beta21	V	0.397	0.080	0.073	alanine scanning, binding assay	V430A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	432	gp120, beta20/beta21	K	1.137	0.339	0.564	alanine scanning, binding assay	K432A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	439	gp120	I	0.185	0.096	0.174	alanine scanning, binding assay	I439A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	450	gp120	T	0.023	0.018	0.022	alanine scanning, binding assay	T450A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	455	gp120, beta23	T	0.670	0.426	0.972	alanine scanning, binding assay	T455A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	456	gp120, beta23	R	0.196	0.079	0.323	alanine scanning, binding assay	R456A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	457	gp120, beta23	D	0.059	0.054	0.043	alanine scanning, binding assay	D457A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	458	gp120, beta23	G	0.097	0.045	0.095	alanine scanning, binding assay	G458A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	461	gp120, V5-hypervariable, V5 loop	S	2.017	1.979	2.218	alanine scanning, binding assay	N461A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	462	gp120, V5-hypervariable, V5 loop	N	1.910	1.948	1.969	alanine scanning, binding assay	E462A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	469	gp120, V5 loop, beta24	R	0.055	0.051	0.051	alanine scanning, binding assay	R469A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	470	gp120, beta24	P	0.043	0.039	0.037	alanine scanning, binding assay	P470A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	471	gp120, beta24	G	0.879	0.888	0.866	alanine scanning, binding assay	G471A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	472	gp120	G	0.034	0.012	0.043	alanine scanning, binding assay	G472A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	473	gp120	G	0.031	0.033	0.029	alanine scanning, binding assay	G473A increases b12 binding to >200% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	476	gp120	R	0.699	0.615	0.711	alanine scanning, binding assay	R476A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	477	gp120	D	0.167	0.112	0.249	alanine scanning, binding assay	D477A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	479	gp120	W	0.031	0.035	0.023	alanine scanning, binding assay	W479A decreases b12 binding to <50% of WT in strain JRCSF
533	b12 binding alanine scanning	CD4BS	Pantophlet2003	binding	b12	480	gp120	R	0.050	0.047	0.049	alanine scanning, binding assay	R480A decreases b12 binding to <50% of WT in strain JRCSF
534	2G12 binding alanine scanning	glycan	Pantophlet2003	binding	2G12	176	gp120, V2	F	0.166	0.303	0.042	alanine scanning, binding assay	F176A increases 2G12 binding to >200% of WT in strain JRCSF
534	2G12 binding alanine scanning	glycan	Pantophlet2003	binding	2G12	197	gp120	N	0.111	0.082	0.109	alanine scanning, binding assay	N197A increases 2G12 binding to >200% of WT in strain JRCSF
534	2G12 binding alanine scanning	glycan	Pantophlet2003	binding	2G12	365	gp120, CD4 binding loop	S	0.574	0.489	0.619	alanine scanning, binding assay	S365A increases 2G12 binding to >200% of WT in strain JRCSF
534	2G12 binding alanine scanning	glycan	Pantophlet2003	binding	2G12	386	gp120, V4 loop, Lectin DC-SIGN binding site (N386-T388)	N	0.447	0.494	0.392	alanine scanning, binding assay	N386A decreases 2G12 binding to <50% of WT in strain JRCSF
534	2G12 binding alanine scanning	glycan	Pantophlet2003	binding	2G12	395	gp120, V4 loop	W	1.843	0.454	2.171	alanine scanning, binding assay	W395A decreases 2G12 binding to <50% of WT in strain JRCSF
534	2G12 binding alanine scanning	glycan	Pantophlet2003	binding	2G12	479	gp120	W	0.031	0.035	0.023	alanine scanning, binding assay	W479A decreases 2G12 binding to <50% of WT in strain JRCSF
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	158	gp120, V2	S	0.297	0.185	0.291	X-ray crystallography	PG16 contact with C clade strain ZM109 S158
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	160	gp120, V2	N	0.401	0.452	0.358	X-ray crystallography	PG16 contact with C clade strain ZM109 N160
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	163	gp120, V2	T	0.360	0.638	0.154	X-ray crystallography	PG16 contact with C clade strain ZM109 T163
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	166	gp120, V2	R	1.127	1.398	0.772	X-ray crystallography	PG16 contact with C clade strain ZM109 L166
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	167	gp120, V2	G	0.601	1.122	0.185	X-ray crystallography	PG16 contact with C clade strain ZM109 D167
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	168	gp120, V2	K	0.547	0.666	0.396	X-ray crystallography	PG16 contact with C clade strain ZM109 R168
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	169	gp120, V2	V	1.974	1.770	1.344	X-ray crystallography	PG16 contact with C clade strain ZM109 L169
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	170	gp120, V2	Q	1.458	1.423	1.428	X-ray crystallography	PG16 contact with C clade strain ZM109 Q170
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	171	gp120, V2	K	1.239	0.957	1.413	X-ray crystallography	PG16 contact with C clade strain ZM109 L171
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	172	gp120, V2	E	1.506	1.172	1.484	X-ray crystallography	PG16 contact with C clade strain ZM109 V172
535	PG16 contacts with clade C strain ZM109	V2-apex	Pancera2013	contacts	PG16	173	gp120, V2	Y	1.165	0.808	1.158	X-ray crystallography	PG16 contact with C clade strain ZM109 N173
536	O.1  linear epitope	V3-glycan	Spencer2021	binding	O.1	304	gp120, V3 loop	R	0.287	0.390	0.141	binding assay	O.1  linear epitope RKSIHI
536	O.1  linear epitope	V3-glycan	Spencer2021	binding	O.1	305	gp120, V3 loop	K	1.097	0.713	0.943	binding assay	O.1  linear epitope RKSIHI
536	O.1  linear epitope	V3-glycan	Spencer2021	binding	O.1	306	gp120, V3 loop	R	0.732	0.860	0.338	binding assay	O.1  linear epitope RKSIHI
536	O.1  linear epitope	V3-glycan	Spencer2021	binding	O.1	307	gp120, V3 loop	I	0.067	0.030	0.111	binding assay	O.1  linear epitope RKSIHI
536	O.1  linear epitope	V3-glycan	Spencer2021	binding	O.1	308	gp120, V3 loop	R	0.108	0.091	0.127	binding assay	O.1  linear epitope RKSIHI
536	O.1  linear epitope	V3-glycan	Spencer2021	binding	O.1	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	O.1  linear epitope RKSIHI
537	O.3  linear epitope	V3-glycan	Spencer2021	binding	O.3	304	gp120, V3 loop	R	0.287	0.390	0.141	binding assay	O.3  linear epitope RKSIHI
537	O.3  linear epitope	V3-glycan	Spencer2021	binding	O.3	305	gp120, V3 loop	K	1.097	0.713	0.943	binding assay	O.3  linear epitope RKSIHI
537	O.3  linear epitope	V3-glycan	Spencer2021	binding	O.3	306	gp120, V3 loop	R	0.732	0.860	0.338	binding assay	O.3  linear epitope RKSIHI
537	O.3  linear epitope	V3-glycan	Spencer2021	binding	O.3	307	gp120, V3 loop	I	0.067	0.030	0.111	binding assay	O.3  linear epitope RKSIHI
537	O.3  linear epitope	V3-glycan	Spencer2021	binding	O.3	308	gp120, V3 loop	R	0.108	0.091	0.127	binding assay	O.3  linear epitope RKSIHI
537	O.3  linear epitope	V3-glycan	Spencer2021	binding	O.3	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	O.3  linear epitope RKSIHI
538	O.4 linear epitope	V3-glycan	Spencer2021	binding	O.4	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	O.4 linear epitope IHIGPGR
538	O.4 linear epitope	V3-glycan	Spencer2021	binding	O.4	310	gp120, V3 loop	Q	1.564	1.479	0.283	binding assay	O.4 linear epitope IHIGPGR
538	O.4 linear epitope	V3-glycan	Spencer2021	binding	O.4	311	gp120, V3 loop	R	0.768	1.050	0.114	binding assay	O.4 linear epitope IHIGPGR
538	O.4 linear epitope	V3-glycan	Spencer2021	binding	O.4	312	gp120, V3 loop	G	0.189	0.362	0.008	binding assay	O.4 linear epitope IHIGPGR
538	O.4 linear epitope	V3-glycan	Spencer2021	binding	O.4	313	gp120, V3 loop	P	0.307	0.424	0.078	binding assay	O.4 linear epitope IHIGPGR
538	O.4 linear epitope	V3-glycan	Spencer2021	binding	O.4	314	gp120, V3 loop	G	0.053	0.095	0.014	binding assay	O.4 linear epitope IHIGPGR
538	O.4 linear epitope	V3-glycan	Spencer2021	binding	O.4	315	gp120, V3 loop	R	1.120	1.028	0.196	binding assay	O.4 linear epitope IHIGPGR
539	O.5 linear epitope	V3-glycan	Spencer2021	binding	O.5	304	gp120, V3 loop	R	0.287	0.390	0.141	binding assay	O.5  linear epitope RKSIHI
539	O.5 linear epitope	V3-glycan	Spencer2021	binding	O.5	305	gp120, V3 loop	K	1.097	0.713	0.943	binding assay	O.5  linear epitope RKSIHI
539	O.5 linear epitope	V3-glycan	Spencer2021	binding	O.5	306	gp120, V3 loop	R	0.732	0.860	0.338	binding assay	O.5  linear epitope RKSIHI
539	O.5 linear epitope	V3-glycan	Spencer2021	binding	O.5	307	gp120, V3 loop	I	0.067	0.030	0.111	binding assay	O.5  linear epitope RKSIHI
539	O.5 linear epitope	V3-glycan	Spencer2021	binding	O.5	308	gp120, V3 loop	R	0.108	0.091	0.127	binding assay	O.5  linear epitope RKSIHI
539	O.5 linear epitope	V3-glycan	Spencer2021	binding	O.5	309	gp120, V3 loop	I	0.921	0.359	0.965	binding assay	O.5  linear epitope RKSIHI
540	Mutations associated with resistance or susceptibility to 17b	CD4i	Wang2019	neutralization	17b	77	gp120	T	0.042	0.088	0.020	neutralization assay	Mutation A77T in SHIV-CNE40 decreased neutralization by 17b
540	Mutations associated with resistance or susceptibility to 17b	CD4i	Wang2019	neutralization	17b	658	gp41	Q	0.977	0.813	0.600	neutralization assay	Mutation of E658 to K, Q, or L in SHIV-CNE40 abrogated neutralization by 17b; mutation of K658 to E in other viruses was associated with increased neutralization by 17b
541	Mutation in SHIV-CNE40 associated with resistance to PGT121	V3-glycan	Wang2019	neutralization	PGT121	658	gp41	Q	0.977	0.813	0.600	neutralization assay	E658K in SHIV-CNE40 decreased neutralization by PGT121
542	Mutation in SHIV-CNE40 associated with resistance to 35O22	gp120/gp41 interface	Wang2019	neutralization	35O22	624	gp41	N	1.565	1.592	1.486	neutralization assay	N624D in SHIV-CNE40 decreased neutralization by 35O22
543	Mutation in SHIV-CNE40 associated with resistance to 10E8	MPER	Wang2019	neutralization	10E8	658	gp41	Q	0.977	0.813	0.600	neutralization assay	E658K in SHIV-CNE40 decreased neutralization by 10E8
544	Mutation in SHIV-CNE40 associated with resistance to 3BNC117	CD4BS	Wang2019	neutralization	3BNC117	276	gp120, Loop D	N	0.120	0.063	0.169	neutralization assay	N276D in SHIV-CNE40 abrograted neutralization by 3BNC117
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	85	gp120	V	2.208	1.797	1.418	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	87	gp120	V	1.538	1.611	1.463	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	241	gp120	N	0.169	0.183	0.134	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	520	gp41, fusion peptide	L	0.604	0.253	0.390	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	648	gp41	E	1.390	1.332	1.379	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
545	2C06 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C06	651	gp41	N	1.168	0.818	1.387	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	85	gp120	V	2.208	1.797	1.418	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	87	gp120	V	1.538	1.611	1.463	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
546	2C09 contacts with BG505	gp41 fusion domain	Wang2023	contacts	2C09	520	gp41, fusion peptide	L	0.604	0.253	0.390	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	85	gp120	V	2.208	1.797	1.418	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	87	gp120	V	1.538	1.611	1.463	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
547	A12V163-a.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-a.01	520	gp41, fusion peptide	L	0.604	0.253	0.390	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	85	gp120	V	2.208	1.797	1.418	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	87	gp120	V	1.538	1.611	1.463	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
548	A12V163-b.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	A12V163-b.01	640	gp41	S	2.068	1.971	1.834	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	85	gp120	V	2.208	1.797	1.418	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	241	gp120	N	0.169	0.183	0.134	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
549	VRC34.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	VRC34.01	520	gp41, fusion peptide	L	0.604	0.253	0.390	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	85	gp120	V	2.208	1.797	1.418	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	87	gp120	V	1.538	1.611	1.463	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	512	gp41, fusion peptide	A	0.175	0.260	0.110	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	514	gp41, fusion peptide	G	0.544	0.691	0.502	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
550	vFP16.02 contacts with BG505	gp41 fusion domain	Wang2023	contacts	vFP16.02	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	85	gp120	V	2.208	1.797	1.418	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	87	gp120	V	1.538	1.611	1.463	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	512	gp41, fusion peptide	A	0.175	0.260	0.110	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	513	gp41, fusion peptide	V	0.711	0.736	0.506	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	514	gp41, fusion peptide	G	0.544	0.691	0.502	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	515	gp41, fusion peptide	I	1.106	1.147	0.877	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	516	gp41, fusion peptide	G	0.091	0.038	0.048	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	517	gp41, fusion peptide	A	0.147	0.109	0.058	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	518	gp41, fusion peptide	L	1.201	1.110	0.718	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	519	gp41, fusion peptide	F	0.695	0.243	0.837	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	520	gp41, fusion peptide	L	0.604	0.253	0.390	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
551	0PV-c.01 contacts with BG505	gp41 fusion domain	Wang2023	contacts	0PV-c.01	535	gp41	M	1.200	1.414	0.742	molecular modeling, X-ray crystallography	contact with BG505; buried surface area >20A
552	mutation affects binding to BG505-SOSIP	gp41 fusion domain	Wang2023	binding	2C06	85	gp120	V	2.208	1.797	1.418	bio-layer interferometry	BG505 DS-SOSIP-H85V or H85E reduces binding to half or less of binding to BG505 DS-SOSIP
552	mutation affects binding to BG505-SOSIP	gp41 fusion domain	Wang2023	binding	2C06	241	gp120	N	0.169	0.183	0.134	bio-layer interferometry	BG505 DS-SOSIP-S241N reduces binding to half or less of binding to BG505 DS-SOSIP
552	mutation affects binding to BG505-SOSIP	gp41 fusion domain	Wang2023	binding	2C06	644	gp41	S	2.131	1.538	1.732	bio-layer interferometry	BG505 DS-SOSIP-G644R or G644T reduces binding to half or less of binding to BG505 DS-SOSIP
553	mutation affects binding to BG505-SOSIP	gp41 fusion domain	Wang2023	binding	2C09	85	gp120	V	2.208	1.797	1.418	bio-layer interferometry	BG505 DS-SOSIP-H85V or H85E reduces binding to half or less of binding to BG505 DS-SOSIP
553	mutation affects binding to BG505-SOSIP	gp41 fusion domain	Wang2023	binding	2C09	241	gp120	N	0.169	0.183	0.134	bio-layer interferometry	BG505 DS-SOSIP-S241N reduces binding to half or less of binding to BG505 DS-SOSIP
553	mutation affects binding to BG505-SOSIP	gp41 fusion domain	Wang2023	binding	2C09	644	gp41	S	2.131	1.538	1.732	bio-layer interferometry	BG505 DS-SOSIP-G644R or G644T reduces binding to half or less of binding to BG505 DS-SOSIP
554	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	V2-apex	Willis2022	contacts	PCT64-LMCA	160	gp120, V2	N	0.401	0.452	0.358	cryo-EM	N160 glycan forms hydrogen bonds
554	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	V2-apex	Willis2022	contacts	PCT64-LMCA	166	gp120, V2	R	1.127	1.398	0.772	cryo-EM	R166 likely forms cation-pi interactions
554	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	V2-apex	Willis2022	contacts	PCT64-LMCA	167	gp120, V2	G	0.601	1.122	0.185	cryo-EM	N167 forms hydrogen bonds
554	PCT64-LMCA contacts with germline-targeted BG505-based ApexGT2.2MUT Env trimer	V2-apex	Willis2022	contacts	PCT64-LMCA	169	gp120, V2	V	1.974	1.770	1.344	cryo-EM	R169 forms hydrogen bonds
555	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	V2-apex	Willis2022	contacts	PCT64-35S	123	gp120	T	0.033	0.028	0.038	cryo-EM	T123 forms hydrogen bond
555	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	V2-apex	Willis2022	contacts	PCT64-35S	156	gp120, V1	N	0.217	0.220	0.224	cryo-EM	N156 glycan forms hydrogen bonds
555	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	V2-apex	Willis2022	contacts	PCT64-35S	160	gp120, V2	N	0.401	0.452	0.358	cryo-EM	N160 glycan forms hydrogen bonds
555	PCT64-35S contacts with germline-targeted BG505-based ApexGT2 Env trimer	V2-apex	Willis2022	contacts	PCT64-35S	166	gp120, V2	R	1.127	1.398	0.772	cryo-EM	R166 forms cation-pi interactions and h-bonds
556	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	V2-apex	Willis2022	contacts	PG9-iGL	156	gp120, V1	N	0.217	0.220	0.224	cryo-EM	N156 glycan forms hydrogen bond
556	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	V2-apex	Willis2022	contacts	PG9-iGL	160	gp120, V2	N	0.401	0.452	0.358	cryo-EM	N160 glycan forms hydrogen bonds
556	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	V2-apex	Willis2022	contacts	PG9-iGL	168	gp120, V2	K	0.547	0.666	0.396	cryo-EM	K168 is a structural contact
556	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	V2-apex	Willis2022	contacts	PG9-iGL	169	gp120, V2	V	1.974	1.770	1.344	cryo-EM	R169 forms H-bonds and likely cation-pi interactions
556	PG9-iGL contacts with germline-targeted BG505-based ApexGT3 Env trimer	V2-apex	Willis2022	contacts	PG9-iGL	171	gp120, V2	K	1.239	0.957	1.413	cryo-EM	K171 forms hydrogen bond
557	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	V2-apex	Willis2022	contacts	PG9	156	gp120, V1	N	0.217	0.220	0.224	cryo-EM	N156 glycan forms hydrogen bonds
557	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	V2-apex	Willis2022	contacts	PG9	160	gp120, V2	N	0.401	0.452	0.358	cryo-EM	N160 glycan forms hydrogen bonds
557	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	V2-apex	Willis2022	contacts	PG9	167	gp120, V2	G	0.601	1.122	0.185	cryo-EM	N167 forms hydrogen bond, N167 glycan interactions
557	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	V2-apex	Willis2022	contacts	PG9	168	gp120, V2	K	0.547	0.666	0.396	cryo-EM	K168 is a structural contact
557	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	V2-apex	Willis2022	contacts	PG9	169	gp120, V2	V	1.974	1.770	1.344	cryo-EM	R169 forms H-bonds and likely cation-pi interactions
557	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	V2-apex	Willis2022	contacts	PG9	171	gp120, V2	K	1.239	0.957	1.413	cryo-EM	K171 forms hydrogen bond
557	PG9 contacts with germline-targeted BG505-based ApexGT3.2MUT Env trimer	V2-apex	Willis2022	contacts	PG9	172	gp120, V2	E	1.506	1.172	1.484	cryo-EM	R172 is a structural contact
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	156	gp120, V1	N	0.217	0.220	0.224	cryo-EM	LC glycan contact with CDRL3
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	160	gp120, V2	N	0.401	0.452	0.358	cryo-EM	HC glycan contact with CDRH3
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	163	gp120, V2	T	0.360	0.638	0.154	cryo-EM	side chain contact
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	164	gp120, V2	S	1.660	1.925	0.453	cryo-EM	side chain and main chain contact; H bond and salt bridge with LC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	165	gp120, V2	I	1.321	1.292	1.011	cryo-EM	side chain contact
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	166	gp120, V2	R	1.127	1.398	0.772	cryo-EM	side chain and main chain contact; H bond with HC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	167	gp120, V2	G	0.601	1.122	0.185	cryo-EM	side chain and main chain contact; H bond with HC and LC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	168	gp120, V2	K	0.547	0.666	0.396	cryo-EM	side chain contact; H bond with HC and LC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	169	gp120, V2	V	1.974	1.770	1.344	cryo-EM	side chain and main chain contactH bond with HC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	170	gp120, V2	Q	1.458	1.423	1.428	cryo-EM	side chain and main chain contact
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	171	gp120, V2	K	1.239	0.957	1.413	cryo-EM	side chain and main chain contact; H bond with HC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	173	gp120, V2	Y	1.165	0.808	1.158	cryo-EM	side chain contact; H bond with HC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	185	gp120, V2-hypervariable, V2	D	1.700	1.370	1.762	cryo-EM	side chain and main chain contact
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	186	gp120, V2-hypervariable, V2	N	1.871	1.592	1.819	cryo-EM	side chain and main chain contact; H bond with LC
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	187	gp120, V2-hypervariable, V2	D	1.817	1.813	1.638	cryo-EM	side chain and main chain contact
558	J038 contacts with clade C strain C1080	V2-apex	Gao2022	contacts	J038	188	gp120, V2-hypervariable, V2	T	1.874	1.618	1.850	cryo-EM	side chain contact
559	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J029	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
559	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J029	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
559	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J029	166	gp120, V2	R	1.127	1.398	0.772	neutralization assay	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
559	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J029	167	gp120, V2	G	0.601	1.122	0.185	neutralization assay	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
559	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J029	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
560	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J031	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
560	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J031	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
560	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J031	166	gp120, V2	R	1.127	1.398	0.772	neutralization assay	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
560	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J031	167	gp120, V2	G	0.601	1.122	0.185	neutralization assay	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
560	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J031	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
561	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J033	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
561	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J033	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
561	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J033	166	gp120, V2	R	1.127	1.398	0.772	neutralization assay	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
561	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J033	167	gp120, V2	G	0.601	1.122	0.185	neutralization assay	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
561	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J033	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
562	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J038	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
562	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J038	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
562	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J038	166	gp120, V2	R	1.127	1.398	0.772	neutralization assay	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
562	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J038	167	gp120, V2	G	0.601	1.122	0.185	neutralization assay	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
562	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J038	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
563	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J040	160	gp120, V2	N	0.401	0.452	0.358	neutralization assay	N160A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
563	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J040	162	gp120, V2	S	0.289	0.445	0.179	neutralization assay	T162A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
563	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J040	166	gp120, V2	R	1.127	1.398	0.772	neutralization assay	R166A makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
563	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J040	167	gp120, V2	G	0.601	1.122	0.185	neutralization assay	D167N makes CAP45 more sensitive to neutralization by J029, J031, J033, J038, and J040
563	Mutation affects neutralization of CAP45	V2-apex	Gao2022	neutralization	J040	169	gp120, V2	V	1.974	1.770	1.344	neutralization assay	K169E makes CAP45 more resistant to neutralization by J029, J031, J033, J038, and J040
